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Abstract 
The identification of surgical patients at higher risk of infection enables targeted 
allocation of critical care resources to improve patient mortality. The Complement 
cascade of the innate immune system is known to increase risk of infection if 
compromised and can be tested in vitro as a potential method for stratification of 
high-risk patients.  
Existing assays of Complement function are laboratory bound and require trained 
personnel to operate and interpret. This thesis describes the development of 
novel immunoassays for C3, C5a, TCC and TNFα, based on a multiplex 
biosensor platform with a duty cycle of <15 minutes. The assays for C3 and C5a 
were validated for use with serum samples with a CV of 23% and 21% 
respectively, within a dynamic range of 3.2-12.5 nM. When combined with 
automated data analysis presented here, the biosensor assays provide a step 
towards easy functional testing of Complement biomarkers at point-of-care. A 
new technique for assessing the monomeric purity of antibody samples is also 
presented for quality control in future immunoassay development.  
A hypothesis-driven selection of candidate biomarker tests, denoting a 
compromised immune state, is possible with a mathematical model. Prerequisite 
techniques for optimising nonlinear models with unknown parameters are 
presented in a systems biology study of IgG binding to protein A/G to determine 
reaction kinetics and stoichiometry. The same techniques were used to fit a 187-
parameter model of in vitro Complement activation to ELISA data from pooled 
human serum, with a mean absolute error of 14%. Sensitivity and flux analyses 
verified that the optimised model was consistent with existing knowledge of the 
system: regulation via Properdin and Factor H was predicted quantitatively.  
The optimised model predicted the effect of Complement depletion on the 
concentration-time profiles of proteins following activation: new phenotypes of 
immune state. Model predictions for the variation in C5a and TCC formation rate 
phenotypes in healthy adults showed no significant difference (P>0.05) from the 
serum data of 22 volunteers. The model and cohort data provide an initial 
estimate of effect size for future clinical studies investigating the ability of these 
Complement activation phenotypes to identify high-risk surgical patients or 
identify the onset of infection. 
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Plain Language Summary 
The risk of contracting an infection is increased when the body’s natural defences 
are compromised in the presence of disease-causing microorganisms. As such, 
infection often occurs as an undesired result of surgery and is associated with 
increased patient discomfort and risk of death. The precise level of infection risk 
depends on both the type of surgery and the health of the patient, which is 
currently assessed with blood tests of immune system activity before surgery and 
during recovery. Patients perceived to be at an elevated risk of infection can be 
allocated additional health care resources, such as increased observation during 
recovery but infection remains a leading cause of death or delay in recovery in 
patients following surgery. This thesis reports the development of a new test of 
the immune system to help identify patients at higher risk of infection due to a 
compromised immune state from an underlying condition or debilitation.  
Among the various components of the immune system that might be tested, the 
Complement cascade was chosen as the focus of the present study: a system of 
proteins which circulate in the blood to recognise and kill disease-causing 
microorganisms on a timescale of minutes. The Complement cascade is 
activated independently of cellular processes and involves the consumption of its 
components. Therefore, Complement protein levels can be measured to follow 
activation of the system over time and data from blood samples are largely 
representative of how the system behaves in the patient. As such, the 
Complement system of a patient can be sampled with existing blood collection 
methods and their Complement function tested quickly and accurately with 
minimal discomfort.  
There are two existing tests of Complement system function used in current 
clinical care, both reporting the ability of patient blood serum samples to destroy 
animal cells. These tests are typically only used when a genetic deficiency is 
suspected and must be performed in the laboratory by trained staff. It was 
recognised that a new test that is fast and comparatively easy to operate might 
allow more frequent Complement function testing before surgery and at the 
bedside of recovering surgical patients. The present work proposes a test of 
Complement cascade function in a routine blood sample by measuring the 
consumption of proteins in response to a stimulus. 
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The concentrations of Complement proteins in blood samples can be tested with 
a number of methods, many of which use antibodies. Antibodies are proteins 
which bind specifically to other molecules and can be used in sensors to detect 
the presence and abundance of Complement proteins. The Shaw lab where the 
present study was based, has developed an in-house sensor platform, LiScAR, 
to observe the rate at which proteins in liquid samples bind to proteins on a sensor 
surface in real time. The first experimental chapter of this thesis describes the 
LiScAR in detail and how the technology can be used to determine the 
concentration of a protein in a sample in under 10 minutes.  
Attempts to produce tests for Complement protein concentrations by immobilising 
antibodies on the sensor surface of the LiScAR proved more challenging than 
anticipated. Chapter 3 reports the results of testing a number of commercial 
antibodies, with many failing to produce working assays. The reasons behind 
failed assays were investigated and results point towards loss of antibody 
function following attachment to the sensor surfaces, as opposed to inadequate 
specificity or the orientation of antibodies. Fragmentation of antibodies during 
storage was also considered. The LiScAR was used to record the number of 
antigens bound by each antibody in a sample, with a theoretical limit of 1-2 
(depending on antigen mass) and decreasing with fragmentation of the antibody 
structure. The new technique can be used for quality control of antibody samples 
in future work to improve experimental reproducibility. A number of new LiScAR 
tests worked well for samples of purified proteins but showed a lack of specificity 
or insufficient sensitivity when tested with human blood samples. Two new tests 
for the concentrations of Complement proteins C5a and C3 were validated for 
use with serum samples and, along with the test for antibody fragmentation 
mentioned previously, represent a significant contribution to the range of LiScAR 
tests and the larger field of blood testing.  
Protein A/G (PAG) is a genetically engineered protein which binds to a common 
region on many antibodies and was used throughout the LiScAR studies to gauge 
instrument sensitivity and create antibody surfaces with directional control. PAG 
is known to have multiple binding sites for antibodies but a serendipitous result 
was recorded when mixing PAG and antibody in a known ratio: the initial reaction 
appeared to occur with 2 antibodies bound per PAG, contrary to the genetics 
literature which suggests 6 or 8. This observation prompted a detailed kinetic 
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analysis of the reaction, reported in Chapter 4. The study used the LiScAR to 
rapidly sample antibody concentration after mixing with PAG, to track the 
progress of the reaction every 5 minutes. This work was used to learn the 
fundamental systems biology techniques of fitting complex models to limited 
experimental data.  
The Complement cascade is a complex biological system and it was recognised 
that several variables would affect the ability of the aforementioned consumption 
test to identify Complement-depleted patients. These include the level of 
activation stimulus, the target proteins to measure and the delay between 
activation and measurement. It was also recognised that a mathematical model 
of the Complement system could be trained on a limited biological data set and 
then used to simulate a proposed Complement activation test for predicting the 
effect of Complement depletion on a test result. At the time of writing, a number 
of mathematical models for Complement are published in the literature but all 
either fail to consider all pathways of the system or lack relevant biological data 
for optimisation. Chapter 5 describes the construction and fitting of a new 
Complement system model to biological data from a pooled human serum sample 
following activation. The resulting model fitted well to the data and was verified to 
behave as expected according to the current understanding of the Complement 
cascade by simulating the effects of increasing the levels of proteins which are 
known to accelerate or inhibit activation.  
The model was then used to simulate a number of potential Complement 
consumption tests: the concentrations of certain Complement proteins following 
a given level of stimulus and delay before testing. The results of the new tests 
were expected to vary in the healthy adult population due to natural variation in 
starting Complement protein concentrations in blood and this variation was 
modelled by repeating the test simulations 250 times with random combinations 
of protein concentrations within their normal ranges. The tests were then 
performed on a cohort of 22 adults in Chapter 6, to assess the accuracy of the 
model predictions and record the true variation in the new Complement 
consumption tests for the first time. The results suggested that the pooled serum 
and freshly collected serum samples displayed similar total Complement 
activation properties but some differences were apparent in the early reactions of 
the system. As such, the model failed to predict the results of some tests and was 
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highly accurate for others, suggesting refinement of the model simulation is 
required. The data revealed that starting protein concentrations may not be 
entirely random as simulated in the model prediction. For example, individuals 
who had higher concentrations of a certain protein were likely to have higher 
concentrations of another protein. 
The model was used to predict the Complement consumption test results of a 
Complement-depleted patient. Interestingly, there was no predicted correlation 
between the value of a patient’s Complement consumption test scores in healthy 
and depleted states. However, all tests were predicted to be sensitive to 
Complement depletion. Both of these predictions need to be validated with future 
research, performing these Complement depletion tests on a second cohort of 
patients who develop infections after surgery. The model and cohort data provide 
a first estimate of effect size for future clinical studies investigating the ability of 
these Complement tests to identify surgical patients at higher risk of infection, 
whilst the novel LiScAR tests provide a means of measuring C3 and C5 protein 
consumption with greater ease than existing methods. Performing these tests 
post-operatively might allow the onset of infection to be detected, enabling faster 
treatment and improved patient outcome.  
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1 Introduction 
Nosocomial infections or healthcare associated infections (HAI) are those 
acquired in hospital (1), often resulting in prolonged patient hospitalisation, 
reoperation, readmission, and negatively impacting patient outcome (2, 3). HAI 
may also pose a risk to attending medical staff (4). The World Health Organisation 
estimates that 7% of hospitalised patients in First World countries develop a 
nosocomial infection (5). The pre-operative identification of patients at increased 
risk of post-operative complications has been identified as an effective method 
for guiding more effective care (6) and the early treatment of an initial post-
operative complication is the best opportunity to limit patient death (failure to 
rescue) (7). The present study investigates in vitro activation of the Complement 
cascade in a blood sample, as a measure of immune state that might: 1) aid the 
identification of patients at high risk of HAI and 2) track patient recovery to rapidly 
reveal the onset of infection post-operatively. 
The ability of a microorganism to cause disease is a function of host defence 
disruption, virulence and the immunologic competence of the host response (8). 
Invasive procedures which break the skin or enter a body cavity increase the 
likelihood of developing nosocomial infections (9) by providing a means of 
transmission for the microorganism to the host (10). Common types of 
nosocomial infection in patients include: central line-associated bloodstream 
infections, catheter-associated urinary tract infections, and ventilator-associated 
pneumonia (11). In Europe and the USA, the prevalence of nosocomial infections 
in patients admitted to the intensive care unit (ICU) is 9-37% (12) and is attributed 
to the immuno-compromised condition of these critically ill patients which 
increases their susceptibility to HAI (13). Figure 1.1 shows patient groups most 
at risk of HAI and the type of infections most prevalent in each group.  
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Figure 1.1 HAI statistics recorded by the European Centre for Disease Prevention and Control (ECDC). a) 
prevalence of HAI by patient group. b) prevalence of HAI types in each patient group. LRT: lower respiratory 
tract. Figure from ref (14). 
The data indicate that surgical patients have the second highest risk of 
developing nosocomial infections after ICU patients which may be attributed to 
the effect of surgery on the immune system (15, 16). Over 200 million people 
worldwide have surgery requiring inpatient stay every year (17) and the most 
common type of nosocomial infection in surgical patients is surgical site infection 
(SSI)  (3, 18, 19) predominantly caused by Gram positive bacteria (47%) and 
Gram negative Enterobacteriaceae (29%) (14). SSI rates depend largely on the 
type of surgical procedure and range from 0.04% for cataract surgery to 13.36% 
for high-risk abdominal hysterectomies (20). As with any type of infection, SSI 
can lead to sepsis as bacteria enter the bloodstream and the resulting 
inflammatory response causes damage to host tissues – a dysregulated host 
response (21). Sepsis is a major cause of death in surgical ICU (22, 23). 
Sepsis is defined by The Society of Critical Care Medicine and the European 
Society of Intensive Care Medicine as life-threatening organ dysfunction caused 
by a dysregulated host response to infection (24). Patients with septic shock are 
a subset of sepsis patients which develop low blood pressure and exhibit a 40% 
risk of mortality (24). Each year, sepsis causes the deaths of ~31,000 patients 
and costs the NHS in England ~£2 billion (25). According a 2015 report by the 
National Confidential Enquiry into Patient Outcome And Death (NCEPOD), 
sepsis is first recorded within one week of surgery in the majority of cases (26) 
and any delays in detecting and treating infections such as sepsis increase the 
odds of patient mortality (27). The NHS estimates that 11,000 lives could be 
saved every year through better diagnosis and treatment of sepsis in the UK 
alone (25). Ultimately, the occurrence of post-operative complications of any kind 
within 30 days of surgery is the single most important determinant of long term 
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patient survival (28) and therefore the prevention of post-operative infections that 
can lead to sepsis, such as HAI, is highly desirable. 
The implementation of certain care pathways has been shown to reduce rates of 
SSI (29, 30). A care pathway is an outline of anticipated clinical care of 
appropriate duration and is used to aid a patient with a specific condition or set 
of symptoms move to positive outcomes (31, 32). Stratification of patients based 
on their predicted risk of post-operative infection is a patient-tailored approach to 
deciding the most effective care pathway to minimise risk of infection (33, 34). 
For example, the outcome of high‐risk surgical patients may be improved by more 
intensive observation by medical staff (35) and pre-habilitation (personalised 
preparation for surgery) (36) - components of a care pathway which may be of 
little benefit to low-risk patients.  
A determining factor of the patient’s care is the pre-operative evaluation. All 
patients presenting for surgery undergo pre-operative evaluation to identify risk 
factors that may lead to post-operative complications (infectious or non-
infectious) (37). The pre-operative assessment includes a medical history and 
blood tests which are chosen based on the type of surgical procedure and the 
medical state of the patient. The National Institute for Health and Care Excellence 
(NICE) has published guidelines for the types of pre-operative tests 
recommended for different patients (38). For example, a full blood count tests the 
number of red blood cells, white blood cells and platelets and is not a 
recommended test for low-risk procedures such as excising a skin lesion but is 
recommended for comparatively high-risk procedures such as abdominal 
hysterectomy.  
Within the surgical population, ~15% are considered high-risk because of certain 
biological characteristics such as age and comorbid disease (co-occurrence of 
one or more disorders) or the complexity of the surgical procedure and these 
patients account for the majority (~80%) of peri-operative deaths (39). Biological 
characteristics used to group or identify populations are called “biomarkers” or 
“phenotypes” (40) and an ideal identifier of high-risk patients would lead to the 
high-risk group accounting for closer to 100% of avoided complications. A number 
of biomarkers can be measured pre-operatively to assess patient health (41) such 
as the inflammatory markers C-reactive protein (CRP) and white blood cell (WBC) 
count which are routinely used to test for existing inflammatory conditions (42). 
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Tests for other plasma biomarkers may also be requested pre-operatively, 
although the Atlas of Variation in NHS Diagnostic Services in England (2017) 
highlights large geographical variation in the use of diagnostic tests (43). 
Glomerular filtration rate estimated from serum creatinine (a muscle waste 
product), and cardiac troponins (released by damaged heart muscle) may be 
used to reflect levels of pre-existing conditions of the kidneys and heart 
respectively, that predispose a surgical patient to non-infectious post-operative 
complications (39). Furthermore, the hormone B-type natriuretic peptide (BNP) 
regulates blood volume and raised pre-operative BNP has been show to predict 
30-day cardiac death and major adverse cardiac events following vascular 
surgery (44). 
When a post-operative infection does occur, early treatment is the best 
opportunity to prevent patient death (failure to rescue) (7). To facilitate early 
recognition and treatment of a patient’s deterioration post-operatively, patients’ 
observations charts are used to record measurements of vital signs and calculate 
some form of early warning score (EWS) (45). The current EWS used in the NHS 
is the National EWS (referred to as NEWS) and is used to assess the severity of 
acute illness based on six physiological measures: respiration rate, oxygen 
saturation, systolic blood pressure, pulse rate, level of consciousness and 
temperature (46). NICE Clinical Guideline 50, on the recognition and response to 
acute illness in adults in hospital states that the physiology of all patients in acute 
hospital settings should be measured at least every 12 hours and the frequency 
of monitoring should increase if abnormal physiology is detected such as the 
symptoms of sepsis. NCEPOD reported that 85% of patients with sepsis in 2015 
were monitored using an EWS system performed at an appropriate frequency 
(26), suggesting improvements to the EWS would have a greater benefit to 
patient outcome than increased observation.  
A blood culture test for the presence of bacteria in the blood is commonly used 
for sepsis diagnosis but may fail and requires hours to days before positivity of 
the culture is observed (47) – time during which a patient’s condition may worsen 
significantly without antibiotic intervention. Impaired tissue oxygenation occurs 
during sepsis, leading to an increase in serum lactate as a biproduct of anaerobic 
respiration (48). Lactate testing is increasingly used to assess the severity of 
sepsis and is a key component of the Surviving Sepsis Campaign (SSC) 
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Guidelines, although the majority of patients with sepsis are reportedly not tested 
(49). CRP correlates with mortality in critically ill patients (50) and can be used to 
indicate sepsis (51, 52). However, CRP does not allow discrimination of survivors 
from non-survivors in septic patients (53, 54). CRP is released by the liver in 
response to cytokines IL-1 and IL-6 to activate Complement and enhance 
phagocytosis (55). IL-6 and Procalcitonin (PCT) levels are significantly lower in 
sepsis survivors (54). CRP and PCT have become the most widely used 
biomarkers in the management of infection and sepsis in Europe (56). 
Despite the existing measures presented here, post-operative recovery remains 
highly variable (57) and it is estimated that less than 30% of high-risk patients in 
the UK are admitted to critical care after surgery - highlighting difficulty in the 
timely identification high-risk patients despite EWS monitoring (58). Novel 
biomarkers of infection risk measured pre-operatively may guide cost-conscious 
approaches for patient stratification into high- and low-risk groups associated with 
care pathways appropriate for their level of post-operative infection risk (34). 
Furthermore, new and existing biomarkers might be measured post-operatively 
and at higher frequency in the care pathways of high-risk patients for timely 
identification of HAI to improve patient outcome  
1.1 Biomarkers  
Biomarkers are measurable indicators of medical state (59) and are used to 
indicate the current status of a patient or predict future risk of disease (60). 
Historic biomarkers included external indicators of physiological processes such 
as fever and swelling (61) and many tests in clinical practice are biomarkers: 
biochemical tests provide chemical or protein biomarkers, whereas physiological 
assessments provide anatomical biomarkers (62).  
Biomarkers can be classified by the type of molecule and mechanism of action 
involved: genetic (63), epigenetic (64) or proteomic (65) for example. Alternatively 
biomarkers are often classified based on intended use: Types 0, 1, and 2 which 
may not be mutually exclusive (66, 67). Type 0 biomarkers are direct measures 
of disease state and correlate with clinical outcomes, such as CRP concentration 
for the assessment of inflammatory conditions. Type 1 biomarkers determine the 
biological effect of therapeutic intervention, such asHbA1c (a measure of 
glycated haemoglobin) used to monitor the treatment of diabetes. Type 2 
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biomarkers are referred to as ‘surrogate endpoints’; indirect measures of clinical 
endpoints such as how a patient feels or functions (68).  
Surrogate endpoints are used when direct measurement of a clinical endpoint is 
more challenging: for example blood pressure is relatively easy to measure 
compared to direct measurement of heart function (with invasive 
echocardiography for example) (69). Surrogate biomarkers are not etiologic but 
are chosen based on their strong correlation with the clinical endpoint of interest 
and there are many examples where a favourable surrogate response to therapy 
is not indicative of a favourable clinical response. For example, although lowering 
blood pressure in patients with hypertension is a desirable surrogate endpoint to 
reduce risk of stroke, hypertensive patients who develop heart failure (an 
undesirable clinical endpoint) also show low blood pressure (69). Type 0 and 
Type 1 biomarkers are most appropriate for the present study as these would 
directly reveal pre-existing factors that influence patient risk of nosocomial 
infection and post-operative response to surgery or infection.  
Many existing biomarkers were identified on the basis of understanding the 
underlying biological mechanisms of a the condition for which a biomarker is 
sought (a deductive method) (62). However, modern ‘Omics’ technologies (such 
as genomics, proteomics, metabolomics) can be used to generate thousands of 
molecular biomarker candidates (70) which may be compared in parallel for 
correlations with disease state (an inductive method) (62). Such technologies 
include protein microarrays and mass spectrometry, discussed later. Although 
high-throughput omics technologies are often used for biomarker discovery (71), 
the approach can suffer from the “curse of dimensionality” (72) where the value 
of testing additional biomarkers is disproportionately smaller than the effort 
required to statistically validate results (73). Hence, hypothesis-driven 
approaches are preferred because biological understanding of the biomarker 
under study (origin and function) allows better control of variables that might 
confound measurements of the biomarker during the validation process (74).  
Ultimately, biomarkers chosen by either deductive or inductive approaches must 
be clinically validated by showing an acceptable discriminatory power between 
populations of cases and controls, as measured by a number of metrics from the 
contingency matrix in Table 1.1. 
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Table 1.1 Contingency matrix used to describe the possible outcomes of a biomarker test performed on a 
population of individuals with and without the condition of interest. The statistical performance metrics 
associated with the success rate of the biomarker are also shown.  
Total 
population 
Condition 
positive 
Condition 
negative 
Prevalence 
= 
condition positive 
total population
   
Accuracy 
= 
true positive+true negative 
total population
   
Test 
result 
positive 
True positive 
False positive, 
Type I error 
Positive predictive 
value (PPV), 
precision 
= 
true positive 
test result positive
   
 
Test 
result 
negative 
False negative, 
Type II error 
True negative 
Negative predictive 
value (NPV) 
= 
true negative 
test result negative
   
 
 
True positive 
rate (TPR), 
recall, 
sensitivity 
= 
true positive 
condition positive
   
True negative 
rate (TNR), 
specificity, 
selectivity  
= 
true negative 
condition negative
   
  
 
Sensitivity describes the probability of obtaining a positive test result when the 
condition is positive but the metric favours a test that always reports a positive 
result regardless of condition (ignores false positives). In contrast, PPV describes 
the probability of a given positive test result occurring due to a true condition but 
the metric favours a test which fails to identify many condition positive cases 
(ignores false negatives). Only by considering both sensitivity and specificity or 
PPV and NPV can a thorough understanding of biomarker performance be 
obtained, although when the consequences of Type I error are low, a test with 
higher sensitivity is preferred.  
Results of biomarker testing are often described using a receiver operating 
characteristic (ROC) curve, in which the sensitivity (TPR) is plotted as a function 
of 1-specificity at different decision threshold values of the biomarker. A test 
decision made due to chance alone would display as a straight line with a gradient 
of 1 and an area under the curve (AUC) of 0.5. In contrast, an ideal biomarker 
would have ROC curve displaying 100% sensitivity (no false negatives) and 
100% specificity (no false positives) with an area of 1. The Yuden Index, J, 
provides a single statistic which considers both sensitivity and specificity, J = 
sensitivity + specificity -1, the maximum vertical distance between the ROC 
curves of the biomarker and chance alone (75).  
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The ROC curve assessment allows the diagnostic performance of multiple 
biomarkers to be compared - a useful tool considering the plethora of published 
biomarkers. In 2017, a search of the PubMed database for publication titles 
containing the term “biomarker” revealed 3581 articles published that year and 
more than 100 different molecules have been suggested as useful biomarkers of 
sepsis (76). The increasing attention to biomarker research is evident in the 
growth in the number of yearly biomarker publications, Figure 1.2. 
 
Figure 1.2 Number of publications per year returned by a PubMed query for publication titles containing the 
word “biomarker”, showing an increasing trend. 
It has been estimated that at ~100,000 different biomarkers have been described 
in the literature but the number of biomarkers applied in clinical practice is 
significantly lower (77) and only 4 (9.1%) of 44 original proteomic biomarker tests 
published in 2006 made progress toward clinical application after 10 years (78).  
The apparent bottleneck between biomarker discovery and adoption in clinical 
practice might be attributed to the challenges of biomarker validation (77). A 
clinical-grade assay must be available for the biomarker to be adopted in clinical 
practice (70) and biomarker validation testing is comprised of several steps (79): 
1) assessment of assay performance characteristics (analytical validation); 2) 
assessment of assay performance regarding correlation with clinical endpoint of 
interest (clinical validation); and 3) assessment of assay impact on clinical 
outcome (clinical utility). A new biomarker must therefore reliably indicate a 
clinical endpoint and provide demonstrable benefit to the patient, either through 
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improved patient management decision making or improved patient experience 
compared to existing practice (80).  
Clinical validation studies can fail to show acceptable biomarker performance for 
a number of reasons (77). Firstly, discovery studies can overestimate the effect 
size of a given biomarker as a result of poor selection of case and control patients 
which should be matched for age, gender and other diseases. The use of different 
assays with different performance characteristics is also a challenge for 
biomarker validation in different laboratories. Consequently, follow-up studies in 
other laboratories may fail to replicate results, particularly if the function of the 
biomarker is incompletely understood. Poorly defined intended use of the 
biomarker can also lead to poor selection of case and control patients and new 
candidate biomarkers should be proposed based on their ability to support a well-
defined clinical decision.  
As such, a substantial effort is required to demonstrate the effectiveness of a 
biomarker. It has been suggested that the penetration of new biomarkers into 
clinical practice would be improved if discovery and validation studies considered 
the common reasons for biomarker validation failure discussed above and 
involved a single optimised assay used across multiple clinical studies (77). 
Furthermore, the ability of individual new biomarkers to outperform existing tests 
is not necessarily required, because the combination of several test results may 
provide more discriminatory power. 
1.1.1 Biomarker Panels 
For clinical conditions with multiple etiologies, such as a compromised immune 
system, combining the results from a panel of biomarkers may permit a better 
characterisation of patient condition. For example, multiple risk factors for 
cardiovascular disease chosen based on biological insight have been combined 
into equations which better predict the risk of developing heart conditions than 
any individual risk factor alone (81). A pre-hospital NEWS value (46) is associated 
with death within 48 hours of hospital admission  (82).  A further example is the 
Acute Physiology and Chronic Health Evaluation (APACHE) score, which is 
calculated at the beginning of admission to ICU to predict a patient’s mortality risk 
using a number of biomarkers such as WBC count, creatinine, sodium and 
potassium concentrations (83). Similarly, Apgar scores are used to track the 
health of newborn babies, using variables such as skin tone, heart rate and reflex 
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irritability (84) and there are multiple other examples of scoring systems based 
on panels of biomarkers to maximise predictive value of patient outcome (85, 86). 
The severity of organ failure in sepsis may be quantified by a panel of  tests 
including creatinine and bilirubin which make up the Sequential [Sepsis-Related] 
Organ Failure Assessment (SOFA) score (87). The change in SOFA score over 
time (SOFA) has been demonstrated to evaluate treatment progress (88), 
effectively converting type 0 to type 1 biomarkers. A combination of SOFA score 
and additional biomarkers has been shown to predict the development of acute 
kidney injury in sepsis (89), highlighting the utility of combining existing scores 
with new biomarkers.  
The use of biomarker panels may reduce the risk of incorrectly assessing a 
clinical endpoint compared to a single type 2 biomarker. For example, the 
APACHE score uses the worst values recorded for each biomarker in the first 24 
hours after admission to the ICU (90), meaning that an underlying condition which 
confounds the result of one test (such as a surrogate endpoint) may still be 
detectable based on the other biomarkers which contribute to the total score. 
However, the choice of biomarkers to include in a panel is critical, as inclusion of 
insensitive markers can confound the predictions of the panel, particularly when 
a single value or score is calculated. The serum protein profiles of pigs have been 
screened with mass spectrometry to obtain large numbers of markers which show 
potential for the detection and identification of infections before the onset of 
symptoms, although specificity is low and could be attributed to the variation in 
irrelevant markers among individuals (91).  
Biomarker candidates insensitive to the condition of interest can be avoided by 
deductively selecting type 0 biomarkers from the physiological system directly 
affected by said condition. Therefore, as dysfunction of the immune system can 
contribute to opportunistic disease (92), type 0 biomarkers indicating the efficacy 
with which the immune system protects the host can be deductively rationalised 
as candidates for a biomarker panel designed to predict nosocomial infection risk 
following surgery. The study in ref (34) supports the choice of immune system 
biomarkers and suggests that that pre-surgical immune state predicts the rate of 
post-operative recovery - potentially enabling patient stratification based on a 
predicted recovery profile. Patient immune state might also be monitored 
following surgery as a form of EWS to detect the onset of infection at the bedside 
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(93). Understanding the host response to infection offers insights into hypothesis-
driven selection of candidate biomarker panels to predict the risk of nosocomial 
infection in surgical patients (94). An overview of the host immune response will 
now be presented.  
1.2 The Host Immune Response  
The host immune response is the defence mechanism which protects the host 
against invading pathogens and promotes wound healing and tissue repair (95). 
The immune system also responds to other immune challenges including medical 
devices and surgical trauma. The immune system may be divided into two 
components, each with a distinct protective role: the adaptive immune system 
provides highly specific host-protection from pathogens and is essential for an 
efficient immune response (96) but requires 3-5 days to respond to a previously 
unencountered pathogen (92) and hence the innate immune system is required 
as a first line of defence against infection (97). A critical attribute of both the innate 
and adaptive immune systems is the ability to distinguish self from non-self 
material. 
The appearance of non-self biological patterns associated with pathogens 
(PAMPs) (98) is recognised rapidly by the innate immune system. Examples of 
PAMPs include bacterial peptidoglycan, lipopolysaccharide (LPS) (99) and 
surface flagellin proteins (100). Double stranded RNA is associated with viral 
infection (101), whilst complex carbohydrates such as zymosan and chitin are 
recognised from the cell walls of fungi (102). Parasitic pathogens are also 
identified by PAMPs in the form of glycolipids (103). PAMPs are bound by pattern 
recognition receptors (PRRs) of the innate immune system which, unlike the 
adaptive immune system, are genetically inherited rather than acquired. PRRs 
may be soluble or expressed on the surface of host cells such as phagocytes, 
which engulf and destroy pathogens, a process called phagocytosis. The 
Complement cascade represents an important source of soluble PRRs (104, 
105), which directly induces cell lysis, opsonises pathogen surfaces to stimulate 
phagocytosis and recruits immune cells to the site of infection via 
chemoattraction. There are several families of cellular PRRs which differ in 
cellular location, structure and signal transduction. Cellular PRRs are located 
both inside the cell to detect intracellular pathogens such as viruses and on the 
external cell membrane to continuously monitor for PAMPs in extracellular fluids. 
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Toll-like receptors (TLRs) are a major PRR expressed on the surfaces of WBC’s 
such as phagocytic cells. The variety of PRRs ensures the innate immune system 
responds rapidly to infection of the host by a range of pathogens.  
The innate immune system can also be activated by trauma (accidental or 
surgical), which is accompanied by the extracellular release of damage 
associated molecular patterns (DAMPs) (106) also known  as ‘alarmins’ (107). 
DAMPs include cellular components normally confined within the boundary of the 
cell membrane such as mitochondrial DNA (mtDNA) (108), high mobility group 
box-1 (HBGb1) (109), Cold-inducible RNA binding protein (CIRB) (110) and F-
actin (111). Formyl peptides (112) may also be released by dying cells or may be 
secreted by pathogens. The innate immune system responds rapidly to the 
presence of both DAMPs and PAMPs by inducing inflammation. At the site of 
infection or injury, the Complement cascade releases inflammatory mediators 
whilst phagocytic cells release cytokines, cell signalling molecules which induce 
behavioural changes in nearby immune cells and attract further phagocytes to 
the site of infection. Cytokines also induce local vasodilation and increased 
vascular permeability, which is observed as redness, heat and swelling. Anti-
inflammatory mediators are also released following inflammation in an attempt to 
restore homeostasis, as excessive inflammation causes damage to host-tissues 
(113). Impairment of the innate immune response is associated with increased 
susceptibility to infections, as is observed following sepsis (114), and hence 
biomarkers assessing innate immune system function could provide a measure 
of infection risk.  
The adaptive immune system can be activated by the innate immune system and 
is essential for an efficient immune response (96). The adaptive immune system 
is comprised of two parts: humoral and cellular. The cellular immune response 
clears infected cells, whilst the humoral immune response clears circulating non-
self material. In the humoral immune response, soluble immunoglobulin proteins 
(antibodies) bind to the surfaces of extracellular foreign molecules, marking them 
for destruction by WBCs. Antibodies are secreted by plasma cells and bind 
specifically to a small region (the epitope) on the surface of antigens. Antibodies 
contribute to host defence by binding to toxins and preventing their interaction 
with host cells. Antibodies opsonise pathogens for phagocytosis and activate the 
Complement cascade of the innate immune system. Critically, with the exception 
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of natural antibodies (115), a previous antigenic challenge is required in order to 
express antibodies to a pathogen via the immunological memory of the adaptive 
immune system. Impairment of the cellular or humoral immune responses 
increases patient susceptibility to opportunistic infections, as is seen in acquired 
immunodeficiency syndrome (AIDS) when human immunodeficiency virus (HIV) 
infects and kills WBCs by inducing apoptosis (116).  
Both innate and adaptive immune responses provide host-resistance to disease 
that is critical to survival. However, it is the innate immune system that provides 
the first line of defence against microbial pathogens (117) and biomarkers 
assessing the function of the innate immune response might therefore be used 
to predict risk of infection. Preoperative inflammation is known to correlate with 
postoperative infectious complications in surgical patients (118-120) and there is 
evidence to suggest that modulating preoperative inflammation could decrease 
the risk post-operative infectious complications (121). The suitability of the 
components from the innate immune response as candidate biomarkers of 
infection risk will now be discussed.  
1.2.1 Candidate Immune System Biomarkers 
The overview of the host immune response presented here reveals several 
immune system components which might be measured as biomarkers of a 
weakened immune system and might correlate with nosocomial infection risk or 
reveal onset of infection. To aid in the selection of candidate immune system 
biomarkers, each candidate can be compared to the characteristics of an ideal 
biomarker (122, 123): 
1. specific to the condition of interest 
2. sensitive to condition severity, correlates with prognosis  
3. recovers to a baseline following effective therapy for “biomonitoring” 
4. well defined intended use for “biomarker-guided therapy” decision making 
In addition to these characteristics, the ease of biomarker testing should be 
considered. Less-invasive tests requiring smaller sample volumes are preferred 
in order to minimise patient discomfort. 
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The intended use of biomarker candidates in the present study can be clearly 
defined: 
The biomarker would be measured pre-operatively to determine the 
personal baseline of the patient and compared to the reference range of 
the biomarker in healthy adults at typical risk of HAI. A biomarker value 
outside of the reference range might indicate a high-risk patient and enable 
the patient to be stratified into an alternative care pathway, designed to 
improve the outcome of high-risk patients.  
The biomarker might also be tested post-operatively as an EWS to profile patient 
recovery. Items 2 and 3 on the list of ideal biomarker characteristics require the 
biomarker to respond dynamically to a condition, ideally tracking condition 
severity with minimal lag as to avoid delays in clinical decision making.  
Elevated cytokine concentrations indicate systemic inflammation and are 
attractive candidate biomarkers which might indicate patient risk of infection due 
to a compromised immune state. Systemic concentration variations in cytokines 
are observed after tissue injury (trauma or surgical) and infection (124), allowing 
cytokine testing to be performed on a variety of fluid samples such as serum (125) 
and tears (126), requiring minimal invasiveness. Furthermore, testing of 
cytokines can be performed using existing multiplex assays (such as Luminex 
bead-based assays) using small sample volumes (124). The human endotoxin 
model, an in vivo model of systemic inflammation in which LPS (a TLR agonist) 
is injected or infused intravenously in healthy volunteers, mimics the acute 
inflammatory response in sepsis and other acute inflammatory conditions 
(trauma, burns, surgery) (127). Within the first hour after LPS administration, pro-
inflammatory cytokines TNFα, IFN and IL-6 appear in plasma and reach peak 
concentrations after 90, 120 and 120 minutes respectively (127). Anti-
inflammatory cytokines IL-10 and IL-8 reach their maxima after approximately 3 
hours and later (127). A continuous LPS infusion instead of a bolus intravenous 
injection extends the time to maximum in the cytokine response profiles (128), 
and the cytokine kinetics are dose dependent – markers of condition severity. 
Cytokines therefore display many characteristics of an ideal biomarker but some 
shortfalls are evident. 
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Firstly, the human endotoxin model is used as a direct measure of the cytokine 
response to infection but could not be used as a biomarker of pre-operative 
immune state because 1) the procedure causes significant discomfort to the 
subject and 2) immune state of the patient is altered as a consequence of the 
measurement – the observer effect. Instead, the standing concentrations of 
interleukins 6,8 and 10 as well as TNFα show greater promise for the diagnosis 
of inflammatory conditions such as sepsis (129). The persistence of TNFα and 
IL-6 in the serum following hypotension correlates with poor outcome (multiple 
system organ failure and death) in septic and non-septic, critically ill patients 
(130). IL-6 in synovial fluid has been demonstrated to identify periprosthetic joint 
infection after shoulder surgery with an optimal cut-off of 359.3 pg/mL (131) and 
statistically significant differences between IL-1 and TNFα have been used to 
identify patients with SSI following neck dissection (132). A cut-off value of an IL-
6 level above 300 pg/mL in SIRS patients has been shown to correlate with larger 
risks of complications, including pneumonia and death (133). Serum cytokine cut-
offs have also been demonstrated to identify neonatal sepsis (31 pg/mL IL-6, 
17 pg/mL TNF-α and 1 pg/mL IL-1β) with accuracy improving when multiple 
markers were combined (134) – further highlighting the advantage of biomarker 
panels discussed previously. However, a more recent study reported an optimal 
cut-off value of 18 pg/mL for IL-6 and 10 pg/mL for CRP best identified neonatal 
sepsis (135) and yet another study derived a cut-off value of 10.85 pg/mL IL-6 
(136), suggesting absolute cut-off values of cytokines are difficult to determine. 
The significant variation among individuals and the variety of factors influencing 
cytokine release such as menstruation (137) has hindered the definition on a 
‘normal’ cytokine profile (129) (138).  
Whilst the standing concentrations of cytokines may perform well for indicating 
an underlying condition, these biomarkers are released by immune cells only after 
the onset of a clinical condition or complication. Therefore, the standing 
concentrations of cytokines in healthy individuals are unlikely to indicate how 
effectively immune cells will respond to future infection. In contrast, antibody 
dependent cellular cytotoxicity by neutrophils is largely dependent on genetic 
variations in Fc receptor expression among patients (139) which influences the 
sensitivity of these cells. Testing for genetic biomarkers is becoming increasingly 
affordable with whole genome sequencing available as a service (140). However, 
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a study of monozygotic twin pairs highlighted that whilst genetic testing is 
effective for identifying abnormal genes, the predictive value of whole genome 
sequencing is low for common conditions such as coronary heart disease, 
cancer, and stroke (141). Furthermore, DNA testing cannot reveal physical 
properties of an organism which vary over time due to behaviour and 
environmental effects on the immune system. Instead, epigenetic studies 
measuring changes to gene transcription as a direct result of the immune 
response are indicators of immune state and can be performed in vitro using 
mass cytometry to isolate immune cell types from patient blood.  
Elevated transcription of the IL-1β gene (142, 143) can be used to monitor 
neutrophil priming, in which a priming agent such as TNFα induces enhanced 
phagocytosis and a more robust immune response to further stimulus. 
Correlations have also been found between signalling molecules controlling 
transcription of DNA in monocytes of post-operative patients and the speed of 
patient convalescence (144), suggesting that gene transcription in the cellular 
immune response to surgery could be used to predict recovery. Furthermore, 
approximately 10% of individuals infected with Mycobacterium tuberculosis 
develop active tuberculosis disease (TB) (145) and genetic testing of dendritic 
cells challenged with Mycobacterium tuberculosis in vitro has revealed 
differences in gene expression between resistant individuals diagnosed with 
latent TB and susceptible individuals that recovered from active TB (146). 
However, changes to gene transcription during sepsis are highly variable (147) 
and functional testing of a patient’s immune cells to an in vitro challenge is a more 
direct test of a patient’s potential ability to clear a future infection.  
Functional testing of neutrophil performance characteristics in vitro such as 
phagocytic activity has been shown to predict the risk of infection, organ failure 
and mortality observed in patients with cirrhosis (148) and alcoholic hepatitis 
(149) (diseases associated with an increased incidence of microbial infection). 
Furthermore, reduced phagocytosis upon admission is a negative predictor of 
survival of patients with sepsis (150). Ultimately however, in vitro testing of cells 
does not capture significant effector functions of the cellular immune system such 
as vascular permeability and does not account for external impacts on cellular 
activity such as hormones. In contrast, the Complement system is almost entirely 
confined to the blood and is largely independent of external influences such as 
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cellular activity. As such, the whole Complement system can be observed in 
serum and can be stimulated in vitro under conditions which closely approximate 
those in vivo.  
The Complement cascade is a system of proteins which circulate the blood as 
inactive precursors and become activated upon recognition of PAMPs and 
DAMPs (151). Complement activation results in the consumption of circulating 
proteins after 30 minutes of activation in vitro (152), releasing protein fragments 
that opsonise pathogen surfaces or directly induce pathogen lysis. Measurement 
of Complement zymogens and activation products can be readily achieved using 
low volume serum samples and existing immunoassays. For a given stimulus, 
the dynamics of the Complement system depend on the relative concentrations 
of its interacting proteins according to the laws of enzyme kinetics and hence 
Complement activation dynamics should be sensitive to Complement depletion 
as is observed following sepsis (153). Complement therefore represents an ideal 
system of potential biomarkers which are fundamentally sensitive to infection and 
recover to a baseline following effective therapy - type 1 and type 2 biomarkers. 
Patients with a deficiency in one or more Complement proteins, due to an 
underlying inflammatory or genetic condition, could be at higher risk of infection 
(154, 155) and might be identified with an in vitro functional test of Complement 
activation dynamics – new risk biomarkers. 
1.3 The Complement Cascade 
The Complement system is primarily viewed as a first responder to microbial 
infections (156) and is comprised of plasma proteins which mostly circulate as 
inactive zymogens (157, 158). In addition to the protective role of Complement in 
innate immunity, it is increasingly apparent that the system is also responsible for 
the modulation of several complex tissue regeneration processes including: 
removal of obsolete synapses in the brain (159); inhibition of angiogenesis (160); 
mobilization of hematopoietic stem/progenitor cells during transplantation (161) 
and lipid metabolism (162). There is also crosstalk between Complement and the 
coagulation cascade (163, 164). For example, kallikrein cleaves C3, C5 and 
factor B (FB). Liver cells (hepatocytes) are the major source of Complement 
components in plasma but many other cell types synthesise Complement 
proteins (165). A specific example of extrahepatic biosynthesis of Complement is 
in the central nervous system, which utilises Complement for host immunity and 
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obsolete synapse removal but is surrounded by the blood-brain or blood-spinal 
cord barrier and shielded from Complement proteins in the plasma (166). Whilst 
the diverse roles of Complement in vivo are still emerging, its mechanisms of 
activation as part of the immune response have been studied extensively since 
its discovery in the 19th century and are now well established (167).  
Excluding extrinsic activation via crosstalk with the coagulation cascade, 
Complement activation occurs primarily via one or all of three possible initiation 
pathways: the Classical pathway (CP), Lectin pathway (LP) and Alternative 
pathway (AP) which lead to activation of the Terminal pathway (TP), Figure 1.3.  
 
Figure 1.3 Simplified diagrammatic model of the Complement cascade. All three initiation pathways cleave 
C3 into the fragments C3a and C3b: inducing phagocytosis and inflammation. C3b further activates the AP 
in an amplification loop and initiates the TP which cleaves C5. C5a contributes to further inflammation whilst 
C5b results in the formation of the membrane attack complex to induce pathogen membrane lysis. 
All three activation pathways converge with the cleavage of the proteins C3 and 
C5 into their constituent fragments. C3a and C5a are anaphylatoxins which 
attract and activate WBCs by binding to G-protein-coupled receptors (C3aR and 
C5aR) (156). C3b from the upper cascade is an opsonin (168) which covalently 
binds to pathogen surfaces via a thioester domain (169) and marks them for 
destruction by interacting with CR1 on phagocytic cells (156). C5b from the lower 
cascade is the first building block of the membrane attack complex (MAC), 
otherwise known as the terminal cascade complex (TCC) which forms pores 
pathogen membranes and induces lysis (156). When formed in solution, TCC is 
often referred to as sC5b-9. Anaphylatoxins, opsonins and MAC are important 
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contributors to host defence against infection (156) and acquired or inherited 
Complement deficiency leads to increased risk of infection (154, 155). The 
Complement pathways will now be discussed in more detail.  
1.3.1 Classical and Lectin Pathways 
The CP and LP can be activated by specific pattern recognition molecules on 
exogenous material surfaces. C1q of the CP binds to CRP as well as immune 
complexes containing IgG and IgM (170), complementing the adaptive immune 
system (171). C1q also recognises PAMPs such as LPS (172) and non-immune 
self-ligands (173) such as membrane protrusions on apoptotic cells to aid in the 
clearance of dying cells (174). The equivalent pattern recognition molecule of the 
LP is mannose-binding lectin (MBL), which recognises sugars (including glucose, 
fructose and mannose) on pathogen surfaces (157, 175). Stable binding of C1q 
or MBL is achieved only when their ligands are clustered on a surface in a specific 
pattern.  
Serine proteases are associated with C1q (C1r and C1s) and MBL (MASP1 and 
MASP2) in a Ca2+ dependent manner and hence the addition of chelating agents 
such as ethylenediaminetetraacetic acid (EDTA) to serum samples is used to 
prevent CP or LP activation (157). The serine proteases are zymogens which 
become activated by a conformational change in the structure of C1q or MBL 
following binding. C1q binding to immune complexes leads to the activation of 
C1r which in turn activates C1s (176) and similarly, upon MBL binding to its 
substrates, MASP1 activates MASP2. A notable difference between the two 
activation events is that a C1r2C1s2 tetramer is always associated with C1q, whilst 
70% of MBL in blood is associated with a single homodimer of either MASP1 or 
MASP2 (177). The separation of MASP homodimers in different MBL molecules 
ensures that LP activation occurs only by colocalization and cross-activation of 
MBL containing different MASPs (178). Greater deposition of MBL therefore 
increases LP activation. MASP separation may also ensure the lack of 
spontaneous activation of the LP. Although the mechanism is unclear, there is 
evidence for spontaneous activity in the CP (179) in which its serine proteases 
are not separated. 
C1s and MASP2 cleave C4 into fragments C4a and C4b which can bind locally 
via its thioester domain to immune complexes or cell surfaces (180). The locally 
bound C4b then binds to C2 which is cleaved in-situ by C1s, MASP1 or MASP2 
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to form a C3 convertase and a fragment of C2 (181). The nomenclature of the C2 
fragments is inconsistent in the literature and should be addressed for clarity. 
Originally, C2a was used to indicate the fragment representing the activated form 
of the C2 proenzyme and proteolytic subunit of the C3 convertase (182). It was 
later discovered that this C2 fragment incorporated into the CP/LP C3 convertase 
is 70 kDa, whilst the other fragment is 30 kDa and the naming is inconsistent with 
the convention of denoting the smaller of two fragments with the earlier letter. The 
Complement Nomenclature Committee have published recommended names for 
many proteins (183) which will be used here, but C2b has not been universally 
adopted by the Complement community to denote the larger fragment of C2. The 
C3 convertase of the CP/LP is therefore referred to here as C4bC2a in agreement 
with the original work and the larger Complement community.  
1.3.2 Alternative Pathway 
Under normal physiological conditions, the AP is continuously active at a 
relatively low level, due to a process known as tick-over (184). Tick-over is the 
spontaneous hydrolysis of a labile thioester bond within C3 at a rate of 1×10-4 µM-
1 min-1 (185) to produce small quantities of C3(H2O). Gas bubbles and biomaterial 
surfaces are capable of increasing the rate of C3(H2O) formation (186) such that 
tick-over is sensitive to different levels of stimulus. The structural change 
associated with the formation of C3(H2O) exposes a binding site for factor B (FB), 
which binds in a Mg2+-dependent manner. FB in the C3(H2O)FB complex may be 
cleaved into fragments Ba and Bb by the serine protease factor D (FD). The result 
of tick-over is the continuous generation of the enzymatically active protein 
complex C3(H2O)Bb, a C3 convertase with a half-life of 77 seconds (187) which 
cleaves C3 to produce low standing concentrations of C3a and C3b. The thioester 
domain of C3b enables the protein to opsonise any surface with exposed hydroxyl 
groups. However, the C3b thioester is relatively short-lived, with a half-life of 60 
μs, ensuring that C3b binding occurs locally, within 60 nm of the C3 cleavage 
event (157). The low, sentinel concentration of short-lived C3b opsonin assures 
AP activation on any surface with exposed hydroxyl or amine residues. Notably, 
C3b has variable affinity for the hydroxyl groups of sugars (168), leading to 
variable AP activation by different surfaces. The term ‘Complement compatibility’, 
introduced by Tom Mollnes, describes the degree to which a material surface 
activates the complement system (188). 
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The AP is distinct from the CP and LP in that it lacks a well-defined recognition 
molecule. Instead, the AP serves to amplify any C3b produced by tick-over or the 
CP and LP. C3b typically binds in a Mg2+ dependent manner to FB, forming the 
C3 convertase C3bBb (189). There is evidence to suggest that FB binds to C3b 
via either Ba or Bb portions however only C3bBb and not C3bBa has the ability 
to cleave C3 (190), with consequences for negative feedback in the AP. The 
cleavage of C3 by C3bBb produces further C3b to form additional C3bBb: a 
positive feedback loop analogous to the chain reaction of neutrons in nuclear 
fission, Figure 1.4.  
 
Figure 1.4 The amplification loop of the AP. C3b binds to FB, which in the presence of FD produces a C3 
convertase capable of producing more C3b.  
The AP is further enhanced by positive feedback using Properdin (P) (191), a 
protein released from WBCs during inflammation in response to C5a (192) and 
the only known positive regulator in the Complement system. P binds to the AP 
C3 convertase and increases its half-life by up to 10 fold (193), leading to 
enhanced AP amplification and increased C5a production and neutrophil 
activation. Surface plasmon resonance studies have shown that P can bind 
multiple C3b molecules (194) and provide a platform with additional, stabilised 
sites for C3 convertase assembly (195). Furthermore, there is evidence to 
suggest P is capable of binding to specific target surfaces including bacteria 
(196), providing the possibility of C3 convertase assembly being C3b-directed or 
P-directed (197). The role of P as a pattern recognition molecule is controversial 
as studies have shown that P binding to zymosan and E. coli  is dependent on 
initial C3b deposition (198). 
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The formation of the C3 convertases by pattern recognition molecules sensitive 
to different molecular patterns provides the opportunity for differential activation 
of Complement according to the activating exogenous surface. For example, 
there is experimental evidence that non-encapsulated Crypotococci induce C3 
cleavage rapidly via IgG binding and activation of the CP, followed by the AP with 
a lag of order minutes (199). In contrast, encapsulated Cryptococci have been 
shown to activate exclusively the AP, characterised by a 4-6 minute delay in C3 
deposition following exposure to serum, attributed to the asynchronous and focal 
deposition of C3b (199). Measuring the dynamics of Complement activation might 
provide a means to identify the causative pathogen in sepsis – a differential 
diagnosis currently achieved using blood cultures which require hours to days of 
incubation and can fail. Irrespective of initiation pathway, Complement activation 
ultimately leads to activation of the TP.  
1.3.3 Terminal Pathway 
The bioactive C3b fragment is versatile. In addition to binding FB and hydroxyl 
groups on surfaces, C3b also binds to C4b and C3b of the CP/LP and AP C3 
convertases. The resulting complexes, (C4bC2a)C3b and (C3bBb)C3b are 
serine proteases which lose the ability to cleave C3 and gain the ability to cleave 
C5 (157, 200) into its constituent fragments: C5a and C5b. The molecular details 
of C5 convertase formation remain poorly understood although experiments have 
shown that high C3b densities are required for C5 convertase formation on a 
surface (201).  The dynamic equilibrium between C3 convertase and C5 
convertase formation due to competition for C3b has been observed as a flux 
control point of Complement activation, in which the upper cascade appears to 
reach a threshold concentration of C3b before triggering the TP (152). C5 
cleavage is the last enzymatic step in Complement activation and C5b 
sequentially binds to complement components C6, C7, C8 and C9 to form the 
cytotoxic MAC capable of lysing cell membranes (202).  
The Complement system responds rapidly to a variety of stimuli via the three 
initiation pathways and amplification loop providing positive feedback. However, 
Complement is not cell-specific and activation may induce opsonisation and 
damage of host tissues unless regulated (203). The amplification of the stimulus 
must be controlled to prevent excessive activation causing harm to the host as is 
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seen in systemic inflammatory response syndrome (SIRS) as a result of trauma 
(accidental or surgical) or infection (204-206).  
1.3.4 Complement Regulation 
Complement activation has been described as a ‘double edged sword’, as whilst 
the system is effective at protecting the host from infection, excessive activation 
in otherwise healthy individuals causes severe injury to host tissues. In addition 
to the rapid half-lives of many activated intermediates, the Complement system 
is regulated at multiple points to prevent excessive activation (157). Host cells 
are protected from Complement activation by expressing a collection of 
membrane regulators. These include CR1, membrane cofactor protein (MCP) 
and decay accelerating factor (DAF) which deactivate C3 and C4 convertases. In 
addition, MAC inhibitory protein (CD59) prevents MAC formation by blocking the 
binding of C9 to C8. Expression of cell surface Complement regulators is not 
always desired and confers protection of tumour cells against Complement-
induced lysis (207).  
Understanding Complement regulation in vitro is important to rationalise the 
choice of biomarkers. Soluble regulators of Complement include vitronectin (Vn) 
which prevents soluble sC5b-7 membrane insertion (208) and clusterin (Cl) which 
also prevents membrane insertion of TCC and its precursors (209). Furthermore, 
plasma carboxypeptidase enzymes cleave the C-terminal arginine from C3a to 
produce C3adesArg (210) which cannot bind to C3aR and activate WBC’s (156). 
The same enzymatic cleavage occurs on C5a to produce C5adesArg which 
shows reduced affinity for C5aR. Assays for such Complement activation 
products should ensure the ‘desArg’ forms of these proteins are also measured.  
Complement regulation significantly perturbs activation of the initiation pathways. 
In the CP, an average of 4 C2 molecules and 35 C4 molecules are cleaved per 
activated C1 complex due to rapid inhibition by the serpin, C1-inhibitor (C1-INH) 
(211). C1-INH also regulates MBL activation of the LP (212). C4 binding protein 
(C4BP) accelerates the natural decay of C4bC2a by binding to C4b and 
encouraging the dissociation of C2a (213). Subsequently, in the presence of 
C4BP in the fluid phase, the serine protease factor I (FI) cleaves C4b into inactive 
fragments C4c and C4d. The soluble form of Complement receptor type 1 (sCR1) 
(214, 215) also induces dissociation of C4bC2a and serves as a cofactor for the 
FI-mediated proteolysis of C4b. sCR1 has more diverse functions than C4BP and 
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also plays a role in AP deactivation. In the presence of sCR1, FI cleaves C3b into 
iC3b which is unable to bind FB, preventing C3 convertase formation (193). 
However, the master regulator of the AP is factor H (FH), which directly blocks 
the binding of FB to C3b (216). FH also accelerates AP C3 convertase 
dissociation and acts as a cofactor for FI in deactivation of C3b. Critically, FH is 
able to bind C3(H2O) to regulate both tick-over and AP C3 convertase formation 
but FH cannot bind to C3 as the binding site only becomes exposed after 
hydrolysis or cleavage. The impact of regulatory proteins on Complement 
activation is significant and deactivated proteins such as iC3b may provide 
sensitive measures of Complement activation in addition to their activated forms. 
The end products of regulation pathways in particular, may be good biomarkers 
of Complement activity due to their fundamentally long half-lives – these will not 
be consumed by further reactions.   
Continual dysregulation of Complement activation can contribute to chronic 
inflammatory and degenerative conditions (217) including: systemic lupus 
erythematosus (SLE) (218), age-related macular degeneration (AMD) (219), 
atypical hemolytic uremic syndrome (aHUS) (219) and paroxysmal nocturnal 
hemoglobinuria (PNH) (220). A number of therapeutic inhibitors designed to 
control Complement activation are being developed (221, 222). Berinert (CSL 
Behring), Ruconest (Salix Pharmaceuticals) and Cinryze (Shire Pharmaceuticals) 
are preparations of C1-INH approved for treating hereditary angioedema (severe 
swelling) due to insufficient functional C1-INH (222). Lampalizumab 
(Roche/Genentech) is a monoclonal antibody (mAb) designed to inhibit FD 
activity, although recent phase III clinical trials in AMD patients showed no benefit 
(223). Cp40 (Amyndas), APL-1 and APL-2 (Apellis Pharmaceuticals) are 
preparations of Compstatin, a synthetic peptide which sterically hinders the 
binding of C3 to convertases (224); Comptstatin has been shown to improve the 
outcome of trauma-induced hemorrhagic shock in non-human primates (225).  
Reduced Complement activation is sought during shock and certain autoimmune 
diseases (226). However, long-term suppression of the complete Complement 
system may increase risk of infection and additional antimicrobial prophylaxis is 
used to counter this risk (224). C5 is an attractive target for therapeutic inhibitors 
as negative regulation of the Complement system at this point preserves the 
chemoattractant and opsonisation functions of C3a and C3b, whilst preventing 
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C5 cleavage and the formation of TCC. Eculizumab (Soliris; Alexion 
Pharmaceuticals)  (227) is a humanized monoclonal antibody that inhibits C5 
binding and is approved for the treatment of PNH and aHUS. Despite a plethora 
of targets for inhibition, development of Complement drugs has been considered 
relatively slow (217), possibly due to the complexity of Complement activation 
and its diversity of functions which may confound in vivo studies. The 
development of therapeutics for Complement regulation may be aided by a 
systems level understanding of Complement activation, discussed later.  
Complement activation is an important factor for effective clearance of infection 
and results in the consumption of circulating proteins. However, C3 depletion to 
a cut-off value of <0.578 mg/mL during sepsis strongly correlates with increased 
mortality (sensitivity 78.4% and specificity 99.8%) (153), exemplifying how 
Complement activation can be both protective and harmful to the host. C3 
depletion relative to a personal healthy value pre-operatively (percentage 
consumption) might be used to better assess Complement activation in 
individuals with personal healthy protein concentrations at the extremes of the 
normal ranges. For example, a patient with a personal healthy C3 value in the 
90th percentile would exhibit greater Complement activation, compared to a 
patient in the 10th percentile for C3 concentration, before achieving a given 
absolute cut-off value for C3 concentration. Patients considered to be 
Complement-depleted relative to their personal healthy values could be provided 
with antimicrobial prophylaxis if considered to be at a high risk of infection. To 
sustain C3 levels, exogenous supplementation of C3 has been demonstrated to 
enhance bacterial clearance and improve survival in septic mice (228). Sepsis 
survivors exhibit a higher mortality risk compared with age-matched non-septic 
critical care survivors (229) and individuals with chronic medical conditions are 
also at increased risk of future sepsis events (230). A recent review of 
Complement polymorphisms describes combinations of risk alleles whose 
aggregate effect on disease risk is significant: a ‘Complotype’ (231). These 
potentially high-risk patients are ideal candidates for stratification into the high-
risk care pathway described previously. 
The Complement response of a patient is a phenotype and likely an important 
factor in determining the course and severity of HAI (203). A Complement test 
might be used to identify patients with atypical Complement activation 
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phenotypes which might indicate greater risk of developing infectious 
complications: type 0 biomarkers. As with the SOFA score, a Complement 
activation test could be used repeatedly to assess Complement exhaustion over 
time and track condition severity with therapeutic intervention: type 1 biomarkers. 
Interestingly, the standing concentration of C3 does not correlate with the 
APACHE II or SOFA scores of septic patients (153), highlighting that 
Complement activation in sepsis is variable and relies on factors other than C3 
concentrations. A better measure of Complement activation potential would 
include additional proteins of the system including activation products in a 
biomarker panel. Ideally, this panel of biomarkers would be measured on a rapid 
and multiplex assay platform to allow repeated evaluation of Complement 
activation phenotypes at point-of care. The trajectory of Complement activation 
phenotypes from pre-operative to post-operative immune states could reveal the 
impact of surgery on the immune system and provide evidence for the onset of 
nosocomial infection. Existing assays of Complement will now be discussed. 
1.4 Existing Assays of Complement Activation  
Assays for Complement proteins are increasingly important for initial diagnosis of 
disease, tracking progression of a condition and the patient response to 
complement-targeted therapies (203). There are four major classes of 
Complement diagnostic approaches: detection of opsonin deposition, 
measurement of zymogen concentrations, measurement of activation product 
concentrations and functional tests of Complement activity (203).  
Detection of Complement proteins deposited on cells membranes can provide 
information about the type and localization of Complement activity in tissues 
(203). For example, localised Complement deposition has been observed on 
lesions in the brains of multiple sclerosis patients (232) and in joint tissues of 
those with rheumatoid arthritis (233). Immunohistochemistry is often used to 
observe antigen distribution over tissue sections and relies on Complement 
protein detection by antibodies conjugated to labels. The labels can be observed 
via a range of methods and are used to visualise the location of antibody binding 
on a tissue sample (234). Antibody labels include enzymes which induce colour 
changes, fluorescent markers (235), radioactive isotopes (236) and nanoparticles 
(237) which will be discussed later. Whilst immunohistochemistry is effective for 
showing Complement deposition, results cannot indicate the extent of 
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Complement depletion in healthy individuals with adequate surface regulators 
protecting the host tissues. In contrast, Complement proteins circulate in the 
blood of all individuals and are readily measured from routine blood samples. 
The standing concentrations of inactive Complement precursors such as C1q, 
C1-INH, C4, C3, or FB are measured in clinical practice to detect Complement 
deficiency and so have validated assays and standards (238). Protein 
concentration is commonly measured by immunoprecipitation assays in which 
primary antibodies form complexes with proteins in the sample expressing 
specific epitope targets. Secondary antibodies, specific to the primary antibodies, 
may be added to increase the mass of the formed complexes which scatter light 
passed through the sample. The relationship between antibody-antigen 
complexes and the extent of light scattering is calibrated to determine the total 
concentration of antigen in the sample (239). However, immunoprecipitation 
gives no information about the conformation or activation state of the protein, and 
protein concentrations may appear normal in patients with dysfunctional proteins 
(240).   
Activation products, such as protein fragments, directly indicate Complement 
activity may be more sensitive markers of dysregulation (241). For example, C3a 
has been measured alongside PCT to distinguish between SIRS and sepsis (242) 
– two conditions which present following surgery with similar symptoms of 
excessive inflammation (204). Complement activation products exhibit different 
properties to their parent proteins and these are exploited in assays for 
Complement activation. Firstly, many protein fragments from as a result of 
Complement activation are low molecular weight and their larger parent proteins 
may be filtered from solution (using polyethylene glycol for example) before 
immunoprecipitation analysis (243). Secondly, neo-epitopes on the surface of the 
protein fragments may be targeted by antibodies in immunoassays. Enzyme 
linked immunosorbent assays (ELISA) have been used extensively to quantify 
Complement activation in fluid samples (244) (245) but the epitope specificity of 
the antibody is important, highlighted by the recent finding that Eculizumab-C5 
complexes express a C5a neoepitope resulting in false positives in some assays 
for C5a (246). 
There are commercially available ELISA kits for Complement zymogens and 
fragments and several variations of the ELISA method. The most sensitive (by 2-
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5 fold) is the sandwich ELISA (247). Antibodies are immobilised on a solid 
support, such as polystyrene or polypropylene, are used to capture antigens in a 
sample over time. Antigen concentration in the sample is proportional to the rate 
at which antigens bind to the capture antibodies. The assay surface is washed to 
remove unbound proteins and covered with detection antibodies which bind to 
epitopes on captured antigen. The epitopes of each antibody should ideally be 
on opposite sides of the antigen to avoid steric hinderance between antibodies 
binding to the antigen. The detection antibodies are conjugated to enzymes that 
produce a coloured product following interaction with a substrate which is added 
as the penultimate step in the procedure. A commonly conjugated enzyme is 
horseradish peroxidase (HRP) which oxidises chromogenic substrates such as 
tetramethylbenzidine (TMB) into coloured products. Peroxidase enzymes 
catalyse the reduction of hydrogen peroxide to water using two hydrogen atoms 
from TMB, which is oxidised from a colourless diamine to a blue diimine (248). 
The reaction is stopped in a final step via the addition of acid which reduces the 
pH of the solution outside the optimal working range of the enzyme. In a ‘double-
sandwich’ ELISA, the detection antibody is not conjugated and a conjugated 
secondary antibody (specific to the Fc region of the detection antibody) is used 
to induce colouration. The extent of colouration is dependent on the number of 
antigens bound to the assay surface which is calibrated to derive the 
concentration of antigen in the sample.  
Plasma protein concentrations vary among individuals (C3a concentration range 
= 29.7–173.8 ng / mL (249)) which confounds the use of strict cut-off points 
denoting Complement depletion. In addition, small activation fragments are 
removed by the kidneys such that C5a concentration measured in the plasma of 
healthy donors has been shown previously to be no different from septic patients 
(250). Higher mass biomarkers of Complement activation such as TCC would 
have low serum concentrations before elective surgery and rise post-operatively 
depending on the concentration of DAMPs produced by the procedure, further 
confounding the use of in vivo cut-off concentrations. Therefore, the best test of 
Complement activation potential is with a functional test: challenging patient 
serum in vitro and observing the Complement activation response. Such an 
approach was taken in a recent study of Complement activation after polytrauma 
(251).  
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Activation of the CP may be quantified using the CH50 test, which determines 
the dilution of serum required to lyse 50% of a known quantity of sheep 
erythrocytes (252). The sheep erythrocytes are sensitised to Classical 
Complement activation by pre-coating with anti-sheep antibodies. Serum for 
CH50 testing is diluted in buffer containing the divalent cations Mg2+ and Ca2+ 
required for Complement activation: the structure of the C1 complex is dependent 
on Calcium (253) and C4b binding to C2 is dependent on Magnesium (254). The 
test is an end-point assay and the protocol requires 50 minutes to complete (255).  
Activation of the AP may be quantified via the AH50 test, a similar method to 
CH50. The binding of MBL to mannan requires Ca2+ (256) and the calcium-
dependence of the CP and LP may be used to inhibit these pathways by reducing 
the bioavailability of Ca2+ with the chelating agent ethylene glycol tetraacetic acid 
(EGTA). The serum for AH50 testing is diluted using buffer containing only Mg2+ 
ions which ensures all haemolysis occurs as a result of AP activation, as the AP 
requires only magnesium for activation in the binding of C3b to FB (257-259).  
The CH50 and AH50 tests are sensitive to several sources of error (255). Firstly, 
spontaneous lysis of erythrocytes may occur independently of Complement 
activity and the batch to batch variation of antibodies used to sensitise the cell 
membranes can lead to systematic errors. Secondly, a serum standard of known 
haemolytic activity is required to account for these errors. The CH50 results of 
the adult population exhibit a normal distribution with a factor of ~2 between 
minimum and maximum values (260, 261), highlighting significant variation in 
Complement activity in the healthy population.  
Functional activity tests of all three initiation pathways in serum can be performed 
using ELISA, wherein the assay surface is coated with either antibody, mannan 
or LPS and the concentration of soluble TCC (sC5b-9) is recorded (262). 
Functional tests using TCC as an endpoint minimise the number of tests required 
to diagnose Complement deficiency (263); only if all Complement components 
are present in a serum sample and function correctly will the AH50 and CH50 (or 
equivalent ELISA assays) induce normal production of TCC (when compared to 
a standard reference range). An alternate functional activity test would involve 
activating all initiation pathways simultaneously and observing the response in 
each pathway with assays for specific activation products: biomarkers of the 
system response.  
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Owing to the reactivity of the Complement system in vitro, the assays of 
Complement discussed here may be influenced by pre-analytical factors such as 
sample preparation and handling.  Activation markers can be rapidly produced in 
samples before analysis and confound results of activation studies. Freezing 
samples at -80 oC after mixing with the divalent cation chelating agent EDTA is 
often used to slow activation of all three initiation pathways, however, quantifiable 
activation still occurs (264). Furthermore, Complement can also be activated by 
sample thawing (241) and cation chelation only inhibits certain steps in the 
system which may induce flux bottlenecks and confound protein concentration 
studies. Ideally, Complement activity should be assessed immediately after 
sampling – achievable with minimal sample preparation and a rapid assay at 
point-of-care.  
When sampling is performed correctly, the kinetics of Complement activation can 
be recorded accurately. EGTA serum and a synthetic pathway of purified FD, FB, 
FH, FI, C3, and P at physiological concentrations yield the same kinetics of C3 
deposition on encapsulated Cryptococci (265) and Bacteroides (266). 
Furthermore, a synthetic pathway of 11 Alternative and Terminal cascade 
proteins (including negative regulatory protein FH) is capable of lysing sheep 
erythrocytes with a similar dose response curve to C4-depleted serum (267). The 
observation has two major implications. Firstly, extrinsic activation of the AP does 
not appear to contribute significantly to C3 opsonisation of bacterial surfaces. 
Secondly, the kinetics of Complement activation may be closely approximated 
using a well-defined set of proteins and equations for chemical kinetics in a 
mechanistic mathematical model of the system. 
Complement is a complex system involving a balance of activating and 
deactivating reactions and many intermediates with short half-lives. The 
complexity of the system makes the hypothesis-driven selection of biomarkers 
challenging – which analytes should be measured following activation and when? 
Experimental data describing all Complement components following activation 
would provide a thorough characterisation of the system response in vitro but this 
would be a technical challenge due to the number of proteins involved. 
Mathematical models can be trained on limited data to help researchers to 
understand non-linear and emergent properties of biological systems, 
quantitatively predict the effects of perturbations, generate hypotheses and guide 
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future studies (268). Non-linear features of systems can occur as a result of 
positive feedback such as the amplification loop in the Complement cascade for 
example. The emergent properties of a system are those which occur as a 
consequence of, but are not shared by, the interacting system components (269). 
For example, cells are self-assembled structures of molecules that when studied 
individually are considered ‘non-living’ but together display emergent, ‘living’ 
properties such as self-repair, reproduction and evolution via a complex system 
of interactions. Such a system is considered irreducible: unlikely to be fully 
understood studying each reaction in isolation (268). Systems biology models are 
used to understand and predict non-linear and emergent behaviour in complex 
systems such as the Complement cascade (270). 
A mechanistically complete Complement activation model could be used to guide 
hypothesis driven selection of candidate biomarkers most sensitive to 
Complement depletion and patient risk of HAI. Complement is a suitable 
biological system for mechanistic modelling because the proteins and 
interactions of the system are largely well-defined as described previously. 
Complement activation can therefore be mathematically represented using 
differential equations, discussed in Chapters 2 and 4 to describe the 
concentration change of each species over time. Furthermore, the binding 
kinetics of some reactions in the Complement system have been derived by 
studying reactants in isolation. A fully mechanistic approach to Complement 
modelling is possible due to the existing biological understanding of the system. 
Existing Complement models have been used to investigate therapeutic inhibition 
of certain interactions to guide drug design (271) and the effect of starting protein 
concentrations on bactericidal action (185). However, no existing Complement 
models are both fully mechanistic and consider all pathways of the system, 
preventing predictions of system behaviour based on any protein or interaction 
described in section 1.3. Inadequate biological data has been cited as the major 
limiting factor in the training and validation of complete Complement models 
(271).  
In summary, the identification of surgical patients at higher risk of nosocomial 
infection is challenging but enables targeted allocation of critical care resources 
to improve high-risk patient mortality. The Complement cascade is a fundamental 
component of the innate immune system and responds rapidly to infection, which 
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if compromised increases risk of HAI. The hypothesis of this thesis is that a direct 
measurement of Complement function might help identify surgical patients at 
higher risk of HAI. The best test of Complement activation potential is a functional 
test: challenging patient serum in vitro with an activation stimulus and observing 
the Complement activation response in each pathway. The in vitro response of 
Complement to a standard challenge can be profiled over time by measuring 
activation product concentrations (such as C5a) or the consumption of zymogens 
(such as C3) in serum with existing immunoassays. A depleted Complement 
cascade should exhibit a different activation response compared to a ‘healthy’ 
system because activation kinetics depend upon both the stimulus and relative 
concentrations of the circulating proteins. Properties of the concentration-time 
profiles of Complement proteins following activation such as initial rate and total 
change in concentration are patient phenotypes, observable physical properties 
where values outside of the healthy reference range might indicate that a patient 
is at higher risk of nosocomial infection. The proposed test of Complement 
activation potential is shown in Figure 1.5. 
 
Figure 1.5 The proposed test of Complement activation potential: a possible measure of post-operative risk 
of nosocomial infection. A serum sample is collected from a patient either pre-operatively, with the intention 
of predicting infection risk, or post-operatively, with the intention of detecting the onset of Complications. All 
initiation pathways of the Complement system are activated in vitro and the response profiles of Complement 
activation products measured over time with immunoassays. Alternatively, Complement activation can be 
predicted using a mechanistic mathematical model which considers the starting concentrations of all 
proteins. Properties of the measured or predicted concentration-time profiles, such as initial rate and 
absolute change in analyte concentrations, are then compared to the reference range. Deviation from the 
reference range of patients at low risk of post-operative infection may suggest a patient is high-risk and 
inform clinical decision making such as the choice of care pathway.  
56 
 
Repeating the Complement function test after surgery would allow a patient’s 
response to be compared to their pre-operative condition, wherein a significant 
relative decrease in Complement activation potential might indicate increased 
vulnerability to infection. Repeated testing over time as part of an EWS might 
enable early recognition of infection and track condition severity.  
Studies of Complement in patients are currently limited by laboratory bound 
assays which require trained personnel to operate. Complement activation 
potential is occasionally assessed with functional tests such as CH50 and AH50 
to identify genetic deficiencies but is not tested routinely in a clinical setting. The 
ease of studying Complement activation potential could be improved with a point-
of-care biosensor for specific Complement protein concentrations. Ideally the 
biosensor would be multiplex, allowing a panel of biomarkers to be tested, and 
the assay would enable real time measurements of protein concentrations with 
minimal sample preparation to avoid the need for sample storage and allow the 
test to be performed with ease.  
The protein concentration profiles most sensitive to a depleted Complement 
response are challenging to predict due to the highly non-linear change in protein 
concentrations during Complement activation (185). Complement activation in 
vitro should be fully characterised to enable a hypothesis-driven approach to 
identifying the most sensitive phenotypes of Complement depletion. A fully 
mechanistic model of Complement activation, describing the change in 
concentration of all species over time could be used to quantitatively predict 
phenotypes which are sensitive to Complement depletion. The identified 
phenotypes could then be tested in a clinical study comparing the phenotype 
distributions of healthy patients and those who develop nosocomial infection. An 
accurate in vitro Complement activation model might also be used to predict 
patient phenotypes based on a single measurement of the starting Complement 
protein concentrations in a serum sample. Use of a model prediction would 
reduce time for patient stratification into high- and low-risk groups. Such an 
approach would require both a multiplex assay of critical protein concentrations 
and a validated mathematical model of in vitro Complement activation – neither 
of which are currently available.  
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1.5 Thesis Aim and Objectives 
This thesis will report the characterisation in vitro Complement activation 
phenotypes as potential biomarkers of immune state denoting a patient’s risk of 
post-operative nosocomial infection. The same phenotypes should also reveal 
the onset of infection post-operatively and their measurement requires a 
quantitative assay platform capable of measuring Complement activation 
products over time. The phenotypes may also be predicted using a mechanistic 
model of the system considering the starting concentrations of proteins in a serum 
sample. Ultimately, the intended utility of the phenotypes is stratification of 
patients into care pathways to improve outcome. 
The first objective was to establish a reproducible assay platform on which tests 
for Complement activation can be developed, with potential for multiplexing, 
miniaturisation and use at point-of-care – not possible with existing clinical assays 
of Complement function. Chapter 2 describes the development of a microarray 
biosensor platform, the Light Scattering Array Reader (LiScAR), inherited as an 
existing device for studying protein-protein interactions with the potential to be 
used as a multiplex immunoassay for serum proteins (272).  
The second objective was to screen antibodies for sensitivity and specificity 
against analytes of interest using the LiScAR biosensor platform. Chapter 3 
describes the development and performance assessment of novel multiplex 
immunoassays for Complement proteins A rapid test for antibody monomeric 
purity was developed to support the new assays, enabling quality control testing 
of antibody samples from different batches. A rapid and multiplex biosensor 
platform and validated assays for a number of Complement proteins allowed 
rapid kinetic data of cascade activation to be collected for the optimisation of a 
mathematical model of the Complement system.  
The third objective was to produce a mathematical model of Complement 
activation. Chapter 4 describes a systems biology approach to developing kinetic 
models of a simple system. Chapter 5 describes the use of techniques discussed 
in Chapter 4 to train a fully mechanistic mathematical model of the Complement 
system. The optimised model was used to predict the response of the 
Complement system from different starting conditions. Quantitative Complement 
activation characteristics, system phenotypes, were explored using the model as 
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metrics to indicate Complement depletion and possibly risk of nosocomial 
infection. 
The fourth and final objective was to establish the distributions of in vitro 
Complement activation phenotypes for the healthy adult population. Chapter 6 
presents the first measurements of in vitro Complement activation phenotype 
distributions in healthy adults and compares the results to modelled predictions 
for model validation. The phenotype variation was used to estimate the power of 
each phenotype to discriminate healthy from compromised Complement 
systems: a necessary prerequisite to future clinical studies investigated in vitro 
Complement activation phenotypes for patient stratification.  
This thesis details the research journey from conceptualisation of a new 
biomarker, through development of a new assay and training of a new 
mathematical model, to recording biomarker values in a cohort of healthy 
individuals. This work therefore aims to provide all necessary prerequisites for 
further research into Complement response testing as a means to gauge immune 
state and infection risk.  
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
2 Development and Performance Assessment of a 
Biophotonic Protein Biosensor: LiScAR 
2.1 Introduction 
The biosensor platform around which a significant portion of this thesis is based 
was inherited as an existing device designed for observing protein-protein 
interactions using light scattering (272). The biophotonic instrument, hereby 
referred to as the light scattering array reader (LiScAR), has been described 
previously in several publications and utilised for a broad range of experiments 
including: antibody affinity studies (273-275), serum antibody screening (276-
278), lectin-fibrinogen affinity studies (279) and antibody epitope mapping (275). 
Previous research indicated that the LiScAR might be used as an immunoassay 
for serum proteins, such as those of Complement cascade, with significant 
potential for miniaturisation and eventually use at point-of-care. This chapter will 
first introduce the main properties of biosensors and show why the LiScAR is an 
appropriate platform on which to develop assays for studying the Complement 
cascade.  
Biosensors are analytical instruments designed to produce a signal in response 
to the presence of a specific analyte or set of analytes (280). Conventional 
analytical techniques such as mass spectrometry (MS) and ELISA assays are the 
gold standard for quantitatively determining biomarker concentration in a sample 
but require trained personnel to operate and are laboratory bound – hindering 
their use for biomarker profiling of patients at point-of-care (281). In contrast, 
biosensors often surpass conventional analytical techniques with respect to ease 
of use and portability (282) by combining the specificity of biochemical 
interactions with a microprocessor into a single instrument with a small form factor 
(appropriate for use at point-of-care) where all data analysis is automated for the 
user. Biosensors may also enable more rapid sampling rates and lower running 
costs compared to MS or ELISA, making these devices attractive instruments for 
research use. Biosensors have many applications in fields such as food safety 
(283), medical diagnostics (284), drug discovery (285), and environmental 
monitoring (286) but regardless of application, all biosensors consist of the 
following common components (287):  
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• Bio-receptor – a biomolecule that generates a response upon interaction 
with analyte, in a process termed bio-recognition. The response may be 
observed as variations in temperature, colour, charge, etc. The part of the 
response that contains useful information is termed signal (288). 
• Transducer – a device that converts the energy of the bio-recognition 
signal into another form, typically electrical energy.  
• Electronics – the transduced signal is systematically processed and 
interpreted to make the data meaningful for the user.  
• Display – the results of electronic processing are reported to the user 
graphically, typically by a computer screen.  
The International Union of Pure and Applied Chemistry (IUPAC) recommends 
that a biosensor is classified according to the bio-receptor mechanism or mode 
of signal transduction (289).  
2.1.1 Bio-receptors and signal transduction 
Once a target analyte has been identified, a major task in developing a biosensor 
involves selection of a suitable bio-receptor. There are two major categories of 
bio-receptors: bio-ligands and bio-catalysts (290). Molecules capable of simply 
binding to a target analyte are considered bio-ligands and antibodies (282), 
nucleic acids (291) and lectins (292) are common examples. Bio-catalysts are 
also capable of binding analytes but have an additional activating role in biological 
reactions - converting bound substrates to products. Typical examples of bio-
catalysts include enzymes (293) and whole cells (294). The range of available 
bio-receptors requires a variety of signal transduction technologies to convert the 
initial stimulus into electrical signals that can be analysed by a computer 
processor. The transducer element of a biosensor is not selective for the analyte 
but greatly influences the sensitivity of the instrument because signal 
transduction is a potential bottleneck in the transfer of information from bio-
recognition stimulus to electrical output. Common modes of signal transduction 
include: electrochemical (295), thermometric (296), piezoelectric (297), optical 
(298) and magnetic (299).  
The performance of biosensors, with varying bio-receptors and modes of signal 
transduction, may be compared using standardised instrument characterisation 
metrics.  IUPAC strongly recommend that the performance criteria of a biosensor 
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should be reported using the following metrics: calibration characteristics, 
selectivity, measurement duration, reproducibility, stability and lifetime (289). 
2.1.2 Calibration Characteristics 
An important analytical characteristic of a biosensor is the relationship between 
analyte concentration and the signal produced by the bio-recognition event: the 
calibration curve (300).  Calibration curves are often plotted as signal with respect 
to analyte concentration on a log scale, and typically show deviation from linearity 
at the extremes of the concentration range, Figure 2.1. 
 
Figure 2.1 A typical calibration curve for a biosensor, showing the relationship between analyte concentration 
and signal. The curve is most sensitive to analyte concentration within a linear range (purple), over which 
the gradient is effectively constant and may be fitted to a straight line. The gradient of the linear portion of 
the curve (black) provides a measure of instrument sensitivity. The curve is typically sigmoidal and the 
inflection point (red) defines the position at which the sign of curvature changes and the gradient is steepest. 
The curve shown is asymmetrical and hence the inflection point is not in the centre of the linear range. 
The sensitivity of a biosensor is in part determined by the slope of the calibration 
curve. All else being equal, a greater absolute change in signal for a given change 
in analyte concentration enables greater measurement resolution - the ability to 
distinguish between smaller differences in analyte concentration. A non-zero 
signal in the absence of analyte is common in analytical techniques and is termed 
background: a non-specific contributor to the analyte signal which must be 
included in the calibration curve to prevent artificially high readings at low analyte 
concentrations. Performing the standard instrument analysis procedure on a 
sample containing zero analyte is referred to as a blank measurement and 
provides an estimate of the background. Absolute signal magnitude (above the 
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background) is not however, the sole contributor to instrument sensitivity and 
signal noise has an equally critical impact on calibration performance.  
Noise is defined as any fluctuations in the instrument response that are 
independent of analyte concentration and hence greater noise reduces 
instrument performance (288). There are several sources of instrument noise 
which may or may not be avoidable. For example, environmental sources of 
noise, such as physical vibration from nearby electric motors or electromagnetic 
interference from power cables, may be avoided by isolating or insulating the 
analytical instrument from these signals. In contrast, thermal noise is unavoidable 
in electric circuits as this occurs due to the random motion of discrete charge 
carriers regardless of applied voltage. Similarly, the shot noise of a camera 
sensor occurs due to the discrete detection of photons emitted randomly from a 
light source.  
Noise is a major source of variation between identical measurements on the 
same instrument, termed intra-assay variation or analytical noise. The Gaussian 
(or normal) distribution describes how repeated measurements cluster 
symmetrically around a mean value. The random variation among measurements 
in a normal distribution can be estimated using the sample standard deviation 
(SD) (301). The SD is the square root of the sample variance and a measure of 
the typical difference of a measurement from the mean of the sample: 
 𝑆𝐷 =  √
∑ (𝑥𝑖 − ?̅?)2
𝑛
𝑖=1
𝑛 − 1
 2.1 
where xi represents an individual measurement, ?̅? is their mean value and N is 
the number of repeats. The n-1 term is Bessel’s correction, which improves the 
closeness of the estimated SD to the true standard deviation of the population 
(σ). One SD either side of the mean measurement value describes a region 
containing 68% of all individual measurements, whilst 95% of all measurements 
have values within an interval 2SD to either side of the mean. Not all distributions 
are normal and should be tested before attempting to calculate SD. Normality 
testing is discussed in Chapter 6.  
A related statistic to SD is standard error (SE) (301), which estimates the 
standard deviation of a sampling distribution: a distribution of values where each 
is derived from multiple observations such as a distribution of mean values 
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achieved in repeated experiments. In a distribution of mean values, the standard 
error of the mean (SEM) is used to estimate the average difference of each 
experiment’s mean from the mean of the sampling distribution: 
 𝑆𝐸 =  
𝜎
√𝑛
 2.2 
where σ is the standard deviation of the population and n is the number of values 
in the sampling distribution. For infinite populations where the true value of σ is 
unknown, SD is used as an estimate – highlighting the importance of Bessel’s 
correction. The 95% confidence interval (CI) provides the information about a 
range within which the 95% sample means will fall: 2SEM either side of the 
sampling distribution mean. Notably, a normality test is not required before 
calculating the SEM because according to the Central Limit Theorem: the 
distribution of mean values is closely approximated by a normal distribution, even 
if the distributions of the measurements in each sample are not normally 
distributed.  
The low gradient regions of the calibration curve are most affected by analytical 
noise and have worse measurement resolution than the linear region. For 
example, when repeatedly sampled, the measured brightness of a light source 
(the number of photons emitted per unit time) will vary significantly if a relatively 
low number of photons are detected during the time frame of each measurement. 
In contrast, the brightness of a more intense light source (or the same light source 
recorded over a longer period of time) will produce more consistent estimates of 
brightness because the random variations in photon emission will be smaller 
relative to the recorded value: the measurement has a better signal to noise ratio.  
The repeatability of an instrument is quantified by repeating the analytical 
procedure on a standard sample of analyte. The relative variability in apparent 
analyte concentrations (derived from reading off the standard curve) can be 
measured using the coefficient of variation (CV) (302) with the result often 
reported as a percentage: 
 
𝐶𝑉 =
𝑆𝐷
µ
× 100 
 
2.3 
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where µ is the sample mean value and SD is the sample standard deviation. It is 
evident that lower concentration samples will show higher CV for a constant SD: 
a lower signal to noise ratio.  
During the design of biosensor platforms, it is advantageous to identify the 
sensitivity requirements of the instrument (303), which could be decided by the 
range of analyte concentration in samples of interest. For instance, a biosensor 
designed to measure C3 in serum would ideally be sensitive to the lowest 
concentration of the C3 distribution found in serum, else the instrument must 
simply report that the derived concentration is below its detection threshold. 
Furthermore, it is often advantageous for the dynamic range of the standard curve 
to encompass the analyte concentration range, as differential dilution of samples 
can lead to matrix effects (304), discussed later. The concentration ranges of 
Complement proteins should be considered for biosensor design and are shown 
in Figure 2.2. 
 
Figure 2.2 Concentrations of circulating Complement proteins in normal human serum. a) concentration 
ranges ordered by lower range limit. b) distribution of median Complement protein serum concentrations. 
Values from Table 6.1.  
The majority of Complement protein concentrations in serum range between 100-
3000 nM and their medians approximate a log normal distribution. The LiScAR 
should therefore have nanomolar sensitivity in order to be appropriate for 
studying the response of the Complement cascade.  
To compare the lowest concentration of analyte that can be reliably measured on 
analytical instruments with varying analytical noise and calibration curve 
gradients, detection limits are defined, Figure 2.3. Detection limits are expressed 
in units of analyte concentration after converting the detection signal threshold to 
concentration using a calibration curve (288). Three types of detection limit are 
65 
 
typically defined for analytical instruments and are designed to account for 
analytical noise which is random and normally distributed: 
• Limit of blank (LoB) – the highest apparent analyte concentration when 
replicates of a blank sample are measured, defined mathematically as µ + 
xSD of the derived blank replicates. The value of x is chosen based on the 
required confidence in analyte detection; 1.645×SD is recommended and 
contains 95% of the blank values as described previously (305).  
• Limit of detection (LoD) – the minimum concentration of analyte required 
to produce a statistically significant signal compared to the analytical noise 
derived from replicate blank samples. Traditionally LoD is defined as µ + 
2×SD of the derived blank replicates. However, the method is overly 
optimistic and does not consider the analytical noise of the samples 
containing the LoD concentration of analyte. For example, a protein 
solution may induce more analytical noise than the blank solution 
containing only buffer. Therefore, a superior approach is to measure the 
analytical noise for a low concentration of analyte and define LoD as LoB 
+ xSD of the low concentration replicates. The value of x is again chosen 
based on the required confidence and 1.645×SD is recommended to 
ensure 95% of samples at LoD concentration will produce values 
exceeding the LoB (305).  
• Lower / Upper limit of quantitation (LLoQ / ULoQ) – the lowest or highest 
concentration of analyte which can be determined from the calibration 
curve with desired analytical precision, such as a certain CV value (305). 
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Figure 2.3 Graphical representation of LoB, LoD and LoQ metrics. The distribution of apparent 
concentrations of several blank replicates enables LoB to be defined (solid black). 5% of blank samples have 
apparent concentrations greater than the LoB (α), representing Type I error. The distribution of samples at 
a concentration of LoD (dashed black, red) is calculated from the SD of low concentration replicates. 5% of 
samples at LoD concentration have apparent concentrations below the LoB (β), representing Type II error. 
The apparent concentration of replicate samples at LoQ concentration (dot dashed black, blue) must show 
a required CV. 
The overall analytical method is typically more complex than analysing pure, 
standard samples of analyte and the imprecision associated with additional steps 
such as dilution or mixing with reagents provides opportunities for error to 
accumulate. Therefore, in addition to the previous definition of LoD, the method 
detection limit (MDL) considers  the preparation and matrix of the measured 
samples when calculating LoD (306). For instance, blood samples may need to 
be diluted before use with an assay to lower the analyte concentration in the 
sample into the dynamic range of the standard curve. The matrix of the sample 
may have a significant effect on LoD and should be controlled for by one of two 
ways in a standard operating procedure: 
• The standard samples which are measured to produce the standard curve 
may be produced in the same matrix as the samples of interest. The 
standard curve can directly determine the analyte concentration in test 
samples, but preparation of the standards may be complicated.  
• The standard samples measured to produce the standard curve may be 
produced in a different matrix to that of the samples of interest, simplifying 
standard production. A sample of known analyte concentration in the same 
matrix as the samples of interest (termed a spike) is then measured. The 
difference between the known concentration of the spike and the 
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biosensor reading defines a property called percentage recovery and can 
be used to adjust the readings of unknown samples.  
Importantly, detection limits only measure the ability of a biosensor to distinguish 
between background and signal. Proving that biosensor signal is due to the 
presence a certain analyte is a question of selectivity, which requires additional 
experiments.  
2.1.3 Selectivity 
In theory, a biosensor is described as specific when a single analyte is 
responsible for the signal that is measured and no other (307). However, bio-
receptors often fall short of being truly specific, instead simply exhibiting a degree 
of preference for the target analyte: selectivity (308).  The phenomenon of 
selectivity is often due a high degree of similarity (chemical and structural) 
between analytes. For instance, there is a high degree of structural homology 
between IgG of sheep, goats and cows. Antisera raised against IgG from one 
species may contain antibodies capable of binding to the IgG of other species 
(309). Furthermore, selectivity for a protein is complicated if the target analyte 
can be incorporated into a larger structure. A monoclonal antibody specific for C3 
of the Complement cascade may bind to C3, C3b and any other complexes 
containing C3b so long as the epitope remains and is sterically available. Herein 
lies a major challenge of developing antibody-based assays as the epitope 
targets are not commonly reported (310). Many biosensors in use rely on a single 
highly selective bio-recognition element, but an alternate approach is to 
incorporate several sensor elements into a single device: multiplex platforms. 
Chemometrics is a data processing technique that uses mathematical and 
statistical methods to correlate patterns in multiplex or large analytical data sets 
with the physical properties of a sample. Published examples of chemometrics 
include determining the origin of medicines  (311) and consumables (312) and a 
method for the detection of extra-terrestrial life (313) – all based on characteristic 
chemical ‘signatures’. Chemometric methods such as principal component 
analysis can combine data from arrays of sensor elements which react 
differentially with analytes of interest to create a ‘chemical fingerprint’, allowing 
samples to be compared in multidimensional parameter space. Chemometric 
analysis is therefore analogous to combining taste and smell to distinguish 
between foods and is sometimes referred to as a ‘chemical nose/tongue’ 
68 
 
approach (308). The advantage of such an approach is that the variety of 
analytical data can make up for low selectivity of individual assay elements. 
Ideally all sensor elements of a multiplex biosensor will be highly selective and 
operate simultaneously -reducing both the sample volume required and the 
measurement duration compared to if the assays were operated individually. A 
disadvantage of chemometrics is the potential effect irrelevant data which may 
confound the analysis. As discussed in Chapter 1, a panel of validated, high-
quality biomarkers is most desirable.  
2.1.4 Sampling Rate and Measurement Reproducibility 
The rate at which the concentration of analyte in a sample can be determined is 
a critical metric when reporting biosensor performance. For samples which are 
chemically stable, assays providing high accuracy but longer operation times are 
ideal. An example would be using an ELISA plate to measure the analyte 
concentration in 96 samples simultaneously over several hours. However, a 
significant challenge for biosensor development is providing a sampling rate that 
is sufficient to distinguish the kinetics of rapid biological processes.  
High frequency sampling is particularly important for studying the Complement 
cascade as the system is activated on timescales of minutes rather than hours, 
and so sample collection, storage and measurement should be performed with 
minimal delay to achieve accurate results. As discussed in Chapter 1, activated 
Complement samples are typically stored with EDTA to halt activation by 
sequestering divalent cations required for certain protein-protein interactions. 
However, chemically halting a cascade at only certain points in the system is 
likely to cause bottlenecks of flux and provide misleading kinetic data. Therefore, 
Complement activation kinetics would ideally be studied using fresh serum 
sampled on a timescale capable of defining the rate of change in concentration 
of each protein of interest. Such an approach requires an instrument capable of 
measuring a sample rapidly and ideally repeatably at a high frequency to 
minimise cost - rather than using multiple single use assays such as ELISA 
plates. Not all biorecognition elements are appropriate for repeated use, often 
because the reaction with the target analyte is irreversible. Repeated 
measurements of stable samples must produce similar values, and the 
performance metric of the similarity is termed reproducibility and can be 
measured with CV.   
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As discussed, the variation in biosensor technology, sensitivity and sampling rate 
is significant. It is therefore unsurprising that biosensors also vary in terms of 
reproducibility over time: the ability of the biosensor to generate identical 
responses for a repeated experiment (287). A critical factor in determining the 
reproducibility of a biosensor is the stability of any biological components and 
reagents, which often degrade over time with repeated use and under storage 
conditions – hence the expiration dates accompanying commercial 
immunoassays. The half-life of any tethering chemistry involved in the 
construction of the biosensor is a further source of biosensor performance 
variation over time. Biosensor sensitivity loss due to bio-receptor degradation and 
tethering half-lives must be determined experimentally by repeated 
measurements of an analytical calibration standard. Understanding the lifetime 
of a biosensor ensures repeatable experiments and may enable signal loss to be 
corrected for, if well characterised. 
2.1.5 Labelled and Label-free Techniques 
Two classes of biosensors may be defined based on how the binding of analyte 
is detected by the sensing element: labelled where the detection event detects 
the presence of the label (assumed to be bound to the target with known 
stoichiometry) and label-free techniques where the native species is detected 
(314). Labelled techniques include surface-based assays such as ELISA and 
bead-based assays such as the Luminex platform, whilst label-free techniques 
include mass spectrometry (MS) and surface plasmon resonance (SPR) devices 
(315). 
Detecting analyte directly according to physical properties such as mass or 
charge in a background of other species is often challenging. Therefore, many 
biological assays use a high affinity receptor such as a monoclonal antibody to 
bind analyte with high selectivity, before labelling the receptor with a signal-
generating reagent that is more easily observable (316), Figure 2.4. Common 
labels include nanoparticles, fluorescent proteins and element isotopes (317), 
which are detected by measuring the light or radiation emitted by these labels 
when bound to the analyte of interest. A typical example of a labelled technique 
is ELISA, in which no signal is generated by the binding of analyte to the assay 
surface. Instead, a detection antibody conjugated to an enzyme is used to 
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produce a coloured substrate and reveal the quantity of bound analyte via a 
secondary binding step in the assay protocol. 
 
Figure 2.4 Origin of measurable signal in labelled and label-free techniques. Bio-recognition elements 
(green) bind to analyte (pink). a) Analyte may be detected based on the recognition event only in a label free 
biosensor. b) Analyte may be detected based on a readout of label activity (yellow). Figure adapted from ref 
(316). 
Labelled assays such as ELISA typically exhibit LOD values two orders of 
magnitude lower than their label-free counterparts, with the most sensitive 
labelled techniques using conjugated secondary antibodies for signal 
amplification (318). However, the synthesis of labels may be complex or low yield 
and requires quality control to prevent sources of error leading to systematic inter 
assay variation. Furthermore, in the case of sandwich immunoassays, finding an 
antibody pair with compatible epitope locations and acceptable selectivity is 
challenging. Another disadvantage of using labels is that these techniques may 
have relatively low temporal resolution, particularly if the incubation time required 
for analyte detection with the labelling step is significant – highlighting the 
importance of high affinity antibodies as bio-recognition and detection reagents, 
discussed later. For consistency, label-based assays such as ELISA make a 
single measurement after a fixed time period and are known as end-point assays. 
In contrast, label-free biosensors enable the direct detection of many biological 
and chemical analytes (298) and may derive analyte concentration from the rate 
of binding observed in real time: kinetic assays.  
Label-free biosensors often enable faster sampling speeds than labelled endpoint 
assays and may be broadly divided into two categories: optical (298) and non-
optical (314). Non-optical techniques include electrochemistry (319), acoustic 
resonance (320), microcantilever (321), isothermal titration calorimetry (322) and 
quartz crystal microbalance technology (323). Most commercial analytical 
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platforms use optical techniques (324) including SPR (325), optical waveguides 
(326) and disk resonators (327). Optical biosensors have benefited from progress 
in nano-technology which has enabled the production of cost-effective and small 
form factor devices with the potential to be used for biomarker measurements at 
point-of-care in a clinical setting (298, 328).  
2.1.6 SPR-based Biosensors 
The most extensively employed optical biosensors are those based on SPR 
(329). SPR is also one of the most prominent optical biosensor technologies used 
for pharmaceutical research (330) and a significant proportion of research papers 
report SPR-based assays for clinically relevant biomarkers with appropriate 
detection limits in a range of biological fluids (331). SPR-based sensors, such as 
the LiScAR, can detect the binding of biomolecules to a sensor surface 
functionalised with complementary proteins which can be reused. SPR-based 
sensors therefore offer rapid, repeatable, label-free measurements of binding 
kinetics from a single sample – a significant advantage over conventional clinical 
chemistry techniques such as ELISA.  
SPR-based biosensors are not without disadvantages and the major drawback is 
that detection limits are fundamentally reliant on the mass of analyte. Labelled 
techniques such as ELISA assays can achieve picomolar LoD values (332), 
whilst the typical LoD for SPR methods is 1−10 nM for a 20-kDa protein (333). 
SPR detection limits are similar to those of ELISA for larger molecules (334) and 
labelling techniques are available for SPR to improve sensitivity (335), but at the 
cost of sampling speed. A further disadvantage of conventional SPR-based 
biosensors is the requirement for protein immobilisation on a sensor surface, 
which may limit mass transfer and has been attributed to the under-estimation of 
binding rate constants compared to the same reactions in solution (336, 337). 
The rate constants of a simple antibody-antigen interaction at a surface and in 
solution are compared using the LiScAR in Chapter 4. 
In order to be adopted in a clinical setting, the advantages of SPR-based 
biosensors over conventional end-point assays must be demonstrated for the 
detection of biomolecules in clinical samples from patients. However, only 1% of 
research articles report the use of patient samples and the median number of 
patients in these studies is small (~10) (331). Instrument calibration using pooled 
biofluids is useful for technique development but may not be appropriate for 
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actual clinical samples due to differences in protein adsorption profiles between 
patients (338).  
For studying the Complement cascade, both labelled and label-free techniques 
have their place. Quantifying binding kinetics and rapidly sampling analyte 
concentrations are tasks most appropriate for a label-free biosensor platform, 
such as the LiScAR, whilst high precision estimates of low concentration proteins 
could be performed with labelled techniques such as ELISA. The characteristics 
of existing biosensors have been discussed and those most appropriate for 
measuring Complement activation in a clinical setting have been identified. The 
LiScAR platform described here is an SPR-based kinetic assay platform which 
when combined with a well-chosen bio-receptor and tethering chemistry should 
provide rapid, repeatable and low volume sampling of complex biological fluids 
with nanomolar sensitivity. The basic principles of SPR in relation to the signal 
generation in the LiScAR will now be described, before the construction and 
development of the device is presented in detail.  
2.1.7 Surface Plasmon Resonance  
Plasmons are oscillations of free electrons at the surface of metals, induced by 
the oscillating electric field of incident electromagnetic (EM) radiation (339). In 
particles smaller than the wavelength of incident EM radiation, such as metallic 
nanoparticles, all electrons in the volume of the particle experience a similar 
electric field and displace coherently from one side of the particle to the other: a 
localised surface plasmon (LSP) (339). The displacement of the negatively 
charged electrons from the positively charged metal lattice generates a restoring 
force that attracts the electrons back to the lattice – inducing an oscillation with 
direction parallel to the electric field of the incident EM radiation (340). The 
frequency at which a plasmon can oscillate is a function of particle size, shape, 
and composition. Furthermore, the lifetime of the oscillation is limited by energy 
loss (dephasing times for gold nanoparticles are of 2–50 fs depending on particle 
characteristics) but can be sustained by radiation with a wavelength matching the 
oscillation frequency (or resonance frequency) of the plasmon, in a process 
known as resonance, Figure 2.5. 
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Figure 2.5 Illustration of a localised surface plasmon on a metal sphere with diameter smaller than the 
wavelength of incident EM radiation. Figure adapted from ref (341). 
LSP resonance (LSPR) results in wavelength selective absorption at visible 
wavelengths for noble metal nanoparticles, which may be observed with a UV-
visible spectrometer (315). Gold nanoparticles are commonly used in the 
construction of LSPR-based sensors (342) and the absorption spectrum of gold 
colloid reveals an absorbance peak corresponding to the resonance frequency, 
Figure 2.6. 
 
Figure 2.6 UV-visible absorption spectrum of 3–4 nm gold nanoparticles. The colloid was produced using 
the synthesis described in ref (343).  
The spectrum suggests higher absorbance for shorter wavelengths but this is an 
artefact due to Rayleigh scattering of EM radiation by molecules and particles in 
the solution with smaller diameter than the wavelength of incident radiation. 
Rayleigh scattering is inversely proportional to wavelength and hence shorter 
wavelengths are scattered more and prevented from reaching the detector of the 
spectrometer (344). The width of the absorbance peak indicates the size 
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distribution of the gold colloid whilst the position of the maximum shifts with 
particle size (larger particles red-shift) as well as particle shape and material 
(329). Furthermore, the amount of light scattered and absorbed (the extinction) 
of the nanoparticles changes with properties of the surrounding medium such as 
increasing refractive index (RI) (329). 
RI is the ratio of the speed of light in a vacuum to the speed of light in a specified 
medium and is dependent on molecular structure, molecular weight and 
temperature (345). When proteins in solution bind to nanoparticles functionalised 
with complementary bio-receptors, the local refractive index of the nanoparticles 
increases and causes a red-shift and an increase in extinction at the resonance 
frequency of the LSP (329). The increase in scattering of monochromatic light by 
nanoparticles can be recorded to show the RI increase associated with analyte 
binding to the nanoparticles in real time: the basis of the LiScAR platform.  
Single nanoparticles have been used to detect biotin with an LoD of 10 nM (346) 
and the high potential for miniaturisation is a key advantage of LSPR-related 
sensors as this reduces the required sample volume – an important issue for 
clinical testing. Miniaturisation also enables multiple sensors to be combined into 
a multiplex assay platform. The LiScAR is therefore an ideal platform for the 
development of a multiplex assay for Complement proteins in a clinical setting. 
2.2 Aims and Objectives 
The aim of this chapter is to describe and explain the principles behind the 
construction and operation of the LiScAR biosensor platform. This chapter will 
also present optimised methods to maximise performance of the biosensor, 
ahead of attempting antibody immobilisation for assays Complement proteins in 
Chapter 3.  
The first objective was to study the fundamental methods behind assay surface 
fabrication, signal generation and instrument operation which were inherited from 
the research group (276).  
The second objective was to investigate effect of changing several variables 
throughout the fabrication process and develop optimised standard operating 
procedures (SOPs) for assay construction. The operation the biosensor was 
made faster and more user-friendly by developing automated data processing 
routines.  
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The final objective was to demonstrate the procedure for kinetic analysis of 
analyte binding at the sensor surface and calibration of the instrument to derive 
analyte concentration. 
2.3 Materials 
The fundamental methods and SOP for the LiScAR were inherited from the 
research group and published in reference (276). The following materials are 
used for the construction of the LiScAR sensor surface. Auric chloride (#254169), 
sodium citrate (#W302600), glycerol (#G9012), hexadecyltrimethylammonium 
bromide (#H5882) and ascorbic acid (#A4403) were obtained from Simga Aldrich. 
The linker (HS-C11-EG6-OCH2-COOH) and spacer (HS-C11-EG3) self 
assembled monolayer components were purchased from Prochimia Surfaces. 
Pierce recombinant protein A/G (#21186) was obtained from Thermo Scientific. 
Human serum albumin and bovine serum albumin were obtained from Sigma-
Aldrich. NIST RM 8671 was purchased from the National Institute of Standards 
and Technology. Standard instrument running buffer, also used in preparation 
and dilution of the samples, was phosphate-buffered saline (PBS) supplied in 
tablet form by Sigma-Aldrich. Ortho-phosphoric acid (85%) was obtained from 
Fluka and a 0.01 M aqueous solution used as regeneration buffer. Silane-prep 
slides were obtained from Sigma Aldrich and the COC, COP and amino 
microscope slides were obtained as bespoke materials from Scienion AG. 
2.4 Gold Nanoparticle Array Production SOP 
Gold nanoparticle colloid was synthesised following the methods described in ref 
(343). Auric chloride (200 µL, 50 mM) and sodium citrate (100 µL, 0.1 M) were 
added to 40 mL deionised water in a Duran bottle. NaBH4 (0.151 g) was dissolved 
in 40 mL of deionised water to produce a 0.1 M solution and cooled in an ice bath 
to 0 oC. The cooled NaBH4 (2.4 mL) was added quickly via pipette to the auric 
chloride solution with stirring. A colloid of gold nanoparticles was formed with an 
orange / red colour. The reaction mixture was stirred at room temperature for 10 
minutes before incubation at 40 oC in a water bath with periodic stirring of <5 
seconds every minute. The reaction mixture was allowed to stand at room 
temperature for 2 hours and gradually darkened to a ruby red colour – associated 
with a shift in the resonance frequency of the nanoparticles as they matured. A 
dark purple solution and the presence of black particulates would have indicated 
aggregation of nanoparticles requiring the synthesis to be repeated. The gold 
76 
 
colloid is stable for several months at 4 oC and is referred to as a ‘seeds’ solution. 
The absorbance spectrum of the seeds solution was checked with 
spectrophotometer for quality control as described previously in Figure 2.6.  
The seeds solution was diluted in a solution of sodium citrate and glycerol was 
added. The optimal seeds dilution factor and glycerol content were determined 
by previous optimisation experiments on the given substrate surface, as 
described in sections 2.7.2 and 2.7.3. Sodium citrate concentration was 
maintained during dilution of the seeds to prevent the colloid crashing out of 
solution. The diluted seeds solution was then printed as liquid droplets in an array 
format onto the chosen substrate surface using an inkjet printer 
(sciFLEXARRAYER S3 from Scienion AG, Berlin, Germany). Unless otherwise 
stated, all LiScAR experiments in the thesis were performed using arrays 
produced on an aminated glass microscope slide, referred to as the ‘amino’ 
substrate by the supplier (Scienion AG, Berlin, Germany) with best results 
achieved from printing a seeds solution at 1/10th the concentration of the 
synthesis solution and containing 20% glycerol (by volume). Printed arrays were 
incubated at 70% humidity for 2 hours to allow the gold nanoparticles to bind to 
the aminated surface. The printed arrays were washed under flow with deionised 
water from a tap or wash bottle and dried with N2 gas. 
Auric chloride (500 µL, 50 mM) was added to 50 mL of deionised water. Aqueous 
hexadecyltrimethylammonium bromide (CTAB) solution (0.2 M) was warmed to 
30 0C with stirring until fully dissolved (the solution is above the limit of solubility 
at room temperature). The dissolved CTAB (50 mL, 0.2 M) was added to the auric 
chloride solution to produce a solution with a brown/orange colour. Ascorbic acid 
(450 µL, 0.1 M) was then added to the solution which turns colourless and is 
referred to as growth solution.  
The printed arrays were incubated in the growth solution for 30 minutes at 28 oC 
- allowing the seed nanoparticles to grow into efficient light scattering particles. 
The nanoparticle arrays were washed immediately with deionised water under 
flow from a wash bottle or tap before standing for 2 days in deionised water. 
During this time, 3 water changes were performed to ensure all CTAB is removed 
from the array surfaces. The nanoparticle arrays were dried with N2 gas and may 
be stored dry at 4oC for several months.  
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2.5 LiScAR Instrument Configuration 
The component layout of the LiScAR is shown in Figure 2.7. When installed into 
the LiScAR, the nanoparticle array was surrounded by a parafilm gasket and a 
glass cover window is placed on top. The glass cover window had two holes 
which housed microfluidic tubing with a push fit. The nanoparticle array, parafilm 
and cover window were assembled in layers to create a flow cell with the input 
and output holes of the cover window located at opposite sides of the nanoparticle 
array surface. The flow cell was clamped to a dove prism with index matching 
fluid between the rear of the nanoparticle array surface and the prism. A 100 mW 
LED illuminated the dove prism (and hence the nanoparticle array also) with 660 
nm red light through a small aperture. Light leaving the prism was captured and 
dissipated by felt baffles. A monochrome video camera (Lumenera Lu13M) was 
positioned normal to the array surface to observe changes in the scattered light 
from the nanoparticles associated with local refractive index changes. The video 
camera had a ½ inch, progressive monochrome CCD sensor with 1392x1040 
pixels (with 2×binning to 696x520) and a dynamic range of pixel brightness levels 
of 0-4095. The LiScAR components were contained in a blackout hardboard 
structure to insulate the components from external light sources that would 
contribute to background noise. 
 
Figure 2.7 Component layout of the LiScAR biosensor platform. Components 1 and 2 were new additions to 
the inherited setup. Component 1 was used to reduce the form factor of the instrument and ensured the 
diameter of the light beam is within the cross section of the prism. Component 2 was a felt light trap. Both 
new components reduced the amount of reflected light returning to the prism which was a source of 
background noise. Figure adapted from ref (274). 
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The nanoparticle arrays could be installed in the LiScAR for observation and 
quality control. The array could be checked visually for signs of non-uniformity 
which would indicate a discontinuous substrate surface before printing or array 
damage after printing. The printed volume and hydrophobicity of the substrate 
surface are factors which, for a given seed solution, determined the size of the 
printed nanoparticle spot. A homogenous substrate surface should produce spots 
of a single diameter and brightness, although small variations were often 
observed. A typical nanoparticle array is shown in Figure 2.8.  
 
Figure 2.8 False colour image of gold nanoparticle spots as seen by the video camera of the LiScAR 
biosensor platform ((Lumenera Lu13M). Nanoparticle spots were developed on the amino substrate surface 
as described in section 2.4. 
The brightness of the camera pixels focused on each assay spot were recorded 
at a frame rate of 30 frames per second (FPS). As discussed previously, the 
sensitivity of the instrument was improved by maximising the signal to noise ratio. 
The noise of the brightness signal from each assay spot was reduced by 
averaging video frames and can be estimated by the equation: 
 𝑛𝑜𝑖𝑠𝑒 =
𝑦
√𝑛
 2.4 
 
where n is the number of measurements and y is the noise without averaging. 
The effect of frame averaging on the magnitude of noise in the brightness signal 
of the nanoparticles spots was investigated and results are shown in Figure 2.9. 
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Figure 2.9 The effect of frame averaging on the noise of the nanoparticle spots signal recorded by the LiScAR 
biosensor platform. Nanoparticle spots were developed on the amino substrate surface as described in 
section 2.4. Data were collected at 30 FPS for 30 seconds at six frame averages: 1, 2, 4, 8, 16 and 30. The 
data are fitted to equation 2.4 with R2=0.99. Error bars are 2SD from n=3 technical replicates.  
The data fit well to equation 2.4, showing a 6-fold reduction in noise when 30 
frames were averaged compared to no averaging. As anticipated, noise reduction 
showed limiting returns with further averaging – indicating that the inherited 
protocol averaging 30 frames every second is a good compromise between 
measurement duration and signal to noise ratio.  
The established protocol for characterising array spot sensitivity was performed 
by measuring the brightness change associated with a known change in RI 
between PBS and double concentrated PBS (2×PBS). When the LiScAR was 
active, PBS buffer was continuously pumped into the flow cell. The sample loop 
(Figure 2.7) was loaded with sample and the buffer flow was redirected to push 
the contents of the sample loop across the array surface. After a period of time, 
the original flow configuration was restored to fill the flow cell with PBS once 
more. A sample injection of 2×PBS buffer can be seen as a step change in the 
brightness of each spot, Figure 2.10. 
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Figure 2.10 The change in spot brightness over time for a typical array of n=150 spots in response to a PBS 
to 2×PBS switch. Nanoparticle spots were developed on the amino substrate surface as described in section 
2.4. a) raw data showing the variation in starting intensity of each individual spot. b) data processed by 
dividing each data point by the first so that each time course has a starting value of 1 (baseline 
normalisation). The data show that the signal change associated with the PBS to 2×PBS switch is typically 
~1%.  
The RI associated with the PBS to 2×PBS switch can be measured with a 
refractometer and has a value of 1.6 mRIU at room temperature. One established 
measure of RI sensitivity for the LiScAR is nRIS, the percentage change in 
brightness per RIU, calculated using the equation: 
 𝑛𝑅𝐼𝑆 = 100 ×
signal
𝑠𝑖𝑔𝑛𝑎𝑙𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 × RI
 2.5 
 
where signalbaseline is the mean signal under PBS and signal is the change in 
brightness in response to the known RI. The signal was determined by 
subtracting signalbaseline from the mean value of the plateau signal (array in 
2×PBS). The PBS to 2×PBS switch was not instantaneous and data were also 
recorded from a transition period with duration dependent on the rate at which 
the volume of the flow cell is replaced with the sample of 2×PBS.  
2.6 Signal Processing Routine for Refractive Index Sensitivity 
Calibration 
To avoid user bias in deciding which regions should be averaged to determine 
baseline and plateau in the calculation of nRIS, the present study developed an 
automated signal processing routine to standardise the procedure. The workflow 
of the routine was applied to the response data of each and every assay spot and 
was comprised of several phases: 
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1. The first and last 10 data points were averaged and the gradient between 
the two was calculated by fitting the data to a linear equation. 
2. The x values of each data point were substituted into the fitted linear 
equation (with the derived values of gradient and y axis intercept) to 
produce a theoretical linear baseline across the time range of the data.  
3. The theoretical linear baseline was subtracted from the data to correct for 
signal drift over the time-course of the measurement, which can occur due 
to small changes in temperature or lamp intensity oscillations. 
4. The response range of the data was determined and the data were split 
into two populations: those with brightness values above half of the 
response range (the plateau population) and those with brightness values 
below half of the response range (the baseline population). 
5. The baseline population was split into a pre-plateau population and a post-
plateau population – identified by a gap in the time values greater than 2 
seconds (corresponding to the plateau population). 
6. The pre-plateau and post-plateau data were trimmed one data point at a 
time, starting from the last and first time points respectively, until the data 
point to be removed had a brightness value lower than the mean of the 
remaining values. 
7. The pre-plateau and post-plateau population were combined to form the 
overall baseline population. 
8. The plateau population data was trimmed from both the start and end time 
points alternately, until the data point to be removed had a higher 
brightness value than the mean of the remaining plateau population. 
9. The mean and standard deviation of the baseline and plateau populations 
was calculated. 
The output of the automated analysis routine for an array of 150 spots is shown 
in Figure 2.11.  
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Figure 2.11 Output of the automated PBS switch analysis software performed on the mean signal from a 
typical array of n=150 spots. Nanoparticle spots were developed on the amino substrate surface as 
described in section 2.4. a) the change in brightness over time, in response to a PBS to 2×PBS switch. The 
baseline (purple) and plateau (green) regions are determined. b) a histogram of brightness values rotated 
to match the data of the PBS to 2×PBS switch in (a). The mean values (orange) are determined from data 
of the baseline (purple) and plateau (green) regions.  
The nRIS metric is a noise-independent measure of assay signal but as 
mentioned previously, it is the signal to noise ratio that must be optimised to 
maximise assay sensitivity. The signal was calculated by subtraction of 
𝑠𝑖𝑔𝑛𝑎𝑙𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 from 𝑠𝑖𝑔𝑛𝑎𝑙𝑝𝑙𝑎𝑡𝑒𝑎𝑢 and hence the noise of signal can be calculated 
using quadrature: 
 𝜎signal = √(𝜎𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒2 + 𝜎𝑝𝑙𝑎𝑡𝑒𝑎𝑢2) 2.6 
 
where 𝜎𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 and 𝜎𝑝𝑙𝑎𝑡𝑒𝑎𝑢 are the standard deviations of the baseline and 
plateau signals. The values of 𝜎𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 and 𝜎𝑝𝑙𝑎𝑡𝑒𝑎𝑢 are assumed to be the same 
and so equation 2.6 can be simplified: 
 𝜎signal = √2𝜎2 = √2 × 𝜎 2.7 
 
where 𝜎signal is the minimum signal which can be observed with a statistical 
significance of 1 standard deviation. Converting the value of 𝜎signal to RIU gives 
the LoB for RI change and is a noise-dependent measure of refractive index 
sensitivity, RIS: 
 𝑅𝐼𝑆 = √2 × 𝜎 ×
RI
signal
 2.8 
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A further output of the automated PBS switch analysis routine was a visualisation 
of relative array spot performance. The RIS of each array spot could be visualised 
in the dimensions of the printed array, to observe effects of spatial spot location 
on RI sensitivity such as heterogeneity in the aminated substrate. The RIS of 
each array spot in a typical array is visualised as a function of print order in Figure 
2.12. 
 
Figure 2.12 The RI sensitivity of each assay spot in a typical array of n=150 spots on a single array. a) RIS 
dependence on spot location on the array. Nanoparticle spots were developed on the amino substrate 
surface as described in section 2.4. Each bar represents a spot and highlights any variations due to the 
aminated substrate surface. b) RIS dependence on the order of printing with R2=0.05 showing no effect of 
spot number on RIS.  
The homogenous distribution of RIS values across the geometry of the array 
indicated a uniform substrate surface. Furthermore, a lack of correlation between 
spot number and RIS indicated no time-dependent change in the gold colloid 
whilst in the printer nozzle.  
As will be discussed later, the signals from subsets of spots are typically averaged 
to produce a single assay channel with lower noise. Ideally all array spots would 
show identical RI sensitivity but in practice a distribution is observed, Figure 2.13.  
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Figure 2.13 Histogram of RIS values for a typical array of n=150 spots on a single array. Nanoparticle spots 
were developed on the amino substrate surface as described in section 2.4. A normal distribution function 
(blue) fits the data with R2=0.94. 
The range of RIS values across an array was typically <35% above and below a 
mean of 1-10×10-5 RIU after optimising print conditions for the substrate material 
and batch number, discussed subsequently. For comparison, the commercially 
available SPR-based instruments from BIAcore may achieve detection limits 
below 3×10−7 RIU although the instruments typically use temperature controlled 
sensors to reduce noise (347).  
Ideal arrays displayed a normal distribution of RIS values but many arrays 
showed skewed distributions with subsets of array spots exhibiting poor values 
of RIS, as discussed later. Spots with RIS values deviating significantly from the 
normal distribution (>3×SD) were routinely removed from further analyses by the 
automated analysis software to avoid reducing the response of an averaged 
signal from a group of spots.  
2.7 Refractive Index Sensitivity Optimisation 
Ultimately, the RIS of a given nanoparticle spot depends upon a number of 
variables during sensor surface manufacture which can be explored easily with 
the automated signal processing routine. A series of experiments were performed 
to assess the growth of the seed nanoparticles and optimise the established SOP 
using the RIS performance metric. Quantitative pass/fail limits for quality control 
(QC) of each array can then be derived. 
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2.7.1 Seeds Growth Time 
The time over which the printed seed particles are grown determines the size of 
the resulting nanoparticles. The PBS switch analysis routine was used to assess 
the scattering properties of nanoparticle spots grown for different periods of time 
using the established SOP in section 2.4. The time dependence of several spot 
characteristics was investigated and results are shown in Figure 2.14. 
 
Figure 2.14 The effect of growth time on nanoparticle spot characteristics. Nanoparticle spots were 
developed on the amino substrate surface as described in section 2.4. a) noise and brightness. b) RIS and 
nRIS. Noise is defined here as 2SD of the background signal. The central mark of each box indicates the 
median of n=150 spots on a single array and the bottom and top edges of each box indicate the 25th and 
75th percentiles respectively. The whiskers extend to the most extreme values. Best fit lines are shown to 
track the trends in the medians. 
As the nanoparticles grew over time, the brightness of the printed spots 
increased. As shown previously, a negative relationship was observed between 
spot brightness and signal noise due to the number of photons collected by the 
camera sensor for a given exposure. The relatively unchanging nRIS and 
decreasing noise as the nanoparticles grew over time, lead to a proportional 
decrease in RIS with limiting returns after 25 minutes. The temperature of the 
growth solution was not investigated but is likely to correlate with growth time and 
should be investigated in future work for effects on nanoparticle shape. The nRIS 
did not appear to change significantly over time and may be determined 
predominantly based on characteristics of the printed seeds such as surface 
density which must also be optimised.  
2.7.2 Nanoparticle Size and Surface Density 
The seeds concentration and print viscosity should have a significant effect on 
the surface density of the nanoparticle spots. High concentrations of seeds 
should have an increased collision frequency with the substrate surface, 
increasing the rate of binding and hence the density of immobilised nanoparticles. 
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In contrast, viscosity is a measure of the friction between molecules of a fluid and 
higher concentrations of glycerol increase the viscosity of the solution and should 
reduce the rate of seeds binding to the substrate surface according to the Stokes-
Einstein relation (348): 
 𝐷 =
𝑘𝐵𝑇
6𝑟𝐻
 2.9 
 
where 𝑘𝐵 is the Boltzmann constant (1.38×10
-23 J K-1) and T is the temperature 
of the solution. The hydrodynamic radius, 𝑟𝐻, is the radius of an equivalent sphere 
which would diffuse at the same rate as the particle in solution.  is the viscosity 
of the solvent and 𝐷 is the diffusion coefficient, a constant of proportionality 
between the movement of a particle due to molecular diffusion and movement 
due to a concentration gradient. Decreasing the temperature and increasing the 
viscosity or size of the seeds will slow the diffusion of the nanoparticles. 
Furthermore, the addition of glycerol to the seed solution prevents the printed 
droplet from evaporating, which would increase the seeds concentration in each 
printed droplet and the seeds would be deposited onto the substrate surface in 
their entirety upon complete drying. 
The nanoparticle spots were characterised using scanning electron microscopy 
(SEM) images to observe the physical properties of the nanoparticle spots which 
may be responsible for variations in RIS. An SEM image of a typical nanoparticle 
spot on the amino surface is shown in Figure 2.26. 
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Figure 2.15 Scanning electron microscopy images of nanoparticles grown on an aminated substrate surface. 
The nanoparticles were developed on the amino substrate surface as described in section 2.4. a) image 
showing a typical array spot ~200 µm in diameter. b) image showing the edge of an array spot with the 
surface density of nanoparticles decreasing from centre to edge. c) high resolution image showing 
nanoparticles grow into a variety of shapes: plates, rods and spherical particles.  
The seed nanoparticles grew into a variety of shapes including plates, rods and 
spherical nanoparticles. Some structures had sharp features (truncated 
polyhedral and the tips of rods) which may produce plasmons more sensitive to 
RI. The known magnification of the SEM images enables the dimensions of the 
nanoparticles to be derived from a given image.  
SEM images of nanoparticle spots printed from solutions containing a variety of 
glycerol and seeds concentrations were analysed systematically with an 
automated image processing routine. The workflow of the routine was comprised 
of several stages: 
1. A binary version of the original image file was created (all pixels either 
black or white) based on a brightness threshold set by the user.  
2. A flood fill operation filled ‘holes’ in the image. Pixels designated as ‘holes’ 
were those that could not be reached by filling starting from the edge of 
the image. 
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3. Pixels were grouped into objects by an algorithm that looked for 8-
connected pixels of the same colour. The pixel coordinates of each object 
were recorded. 
4. The pixels of each object were counted and converted into an equivalent 
circular diameter (ECD) according to the equation: 
 𝐸𝐶𝐷 = 2 × √
𝐴

 2.10 
 
where A is the area of the object in pixels. 
5. Objects within the upper and lower ECD thresholds set by the user were 
recorded as a list of ECD values. 
The routine was tested using an image of 1000 white squares on a black 
background and counted the correct number of squares. A typical analysis of a 
SEM nanoparticle image is shown in Figure 2.16. In the example shown, 136 
objects were counted from a total of 63818 objects identified, highlighting the 
requirement for user-defined ECD thresholds for accurate results and a 
systematic brightness threshold for all images.  
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Figure 2.16 Analysis of nanoparticle size and density in a typical SEM image of an array spot. Nanoparticle 
spots were developed on the amino substrate surface as described in section 2.4. a) original SEM image of 
nanoparticles. b) individual objects in the image are highlighted in different colours. c) histogram of ECD 
values showing the sizes counted according to the ECD limits set by the user. d) original image with counted 
object numbers overlaid. Overlapping particles which produce ECD values higher than the upper ECD limit 
are discounted and shown with yellow asterisks. The object labelled 102 in red is below the upper ECD 
threshold and counted, despite being a cluster of nanoparticles – a source of error in the routine.  
Overlapping particles were a source of error in the analysis routine and may be 
counted as a single large particle. However, large groups of indistinguishable 
nanoparticles were removed from the analysis by the upper ECD threshold. 
Clusters of small particles could be counted if the ECD of the cluster was within 
the ECD limits, but the original image was overlaid with the counted particle 
numbers which allowed visual inspection of the results. Nanoparticle clusters 
represent ~3% of the nanoparticle objects identified in Figure 2.16.  
The analysis routine was used to assess images of array spots printed from 
solutions containing varying concentrations of glycerol and seeds, Figure 2.17. 
Due to the variation in nanoparticle density across the spot, images were 
captured from the centre and the edge of each spot. 
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Figure 2.17 Effect of glycerol concentration and seeds solution concentration on the size and density of array 
spot nanoparticles. Nanoparticle spots were developed on the amino substrate surface as described in 
section 2.4. a) mean ECD of nanoparticles at the centre of an array spot. b) mean ECD of nanoparticles at 
the edge of an array spot. c) nanoparticle density at the centre of an array spot. d) nanoparticle density at 
the edge of and array spot. Glycerol concentration is expressed as percentage volume of the solution and 
seeds concentration is expressed as a percentage of the seeds solution described in section 2.4. Error bars 
are 2SD of nanoparticles counted (n>100) in images of array spots (n=1) developed on a single array. 
In agreement with the Stokes-Einstein relation, nanoparticle density increased 
with seeds concentration - attributed to higher collision numbers and binding at 
higher concentrations. However, the effect of glycerol concentration on surface 
density was not obvious. Nanoparticle density was also greater in the centre of 
the spot compared to the edge, which may be attributed to droplet deformation 
after printing. The exposure of the substrate at the edge of the spot to printed 
seeds solution may be brief upon initial landing a flattening of the droplet and 
subsequent evaporation.  
The ECD of the nanoparticles ranged from 24 to 93 nM, with surface densities of 
6 to 170 µm-2. The ECD of nanoparticles was visibly reduced by seeds 
concentration but glycerol concentration did not have a visible effect. The centre 
of each nanoparticle spot had a higher particle density and smaller mean ECD, 
which suggests nanoparticle size may be limited by the available surface area in 
high density regions. Figure 2.18 shows the effect of seeds and glycerol 
concentrations on RIS for a single assay spot.  
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Figure 2.18 Effect of glycerol concentration and seeds solution concentration on nanoparticle spot 
characteristics. Nanoparticle spots were developed on the amino substrate surface as described in section 
2.4. Four spot parameters are reported by the signal processing routine: a) brightness, b) noise, c) nRIS and 
d) RIS. Data points are derived from the mean response of n=7 assay spots and 2 experimental repeats. 
Glycerol concentration is expressed as percentage volume of the solution and seeds concentration is 
expressed as a percentage of the seeds solution described in section 2.4. 
As was observed in the nanoparticle diameter and density data, the effect of 
seeds concentration was greater than the effect of glycerol concentration within 
the tested ranges. The viscosity range covered by the solutions tested (0-20% 
glycerol) is approximately 1.01-1.88×10-6 m2 s-1 according to the calculation in ref 
(349), based on initial work in refs (350, 351). Higher glycerol concentrations 
generally appeared to produce brighter, less noisy, and more sensitive spots, 
although a RIS minimum the in the box search surface was not identified. Glycerol 
concentrations above 20% were challenging to print due to the viscosity of the 
droplets and were not investigated. An optimum region for seeds concentration 
was found between 1-50% 
The lowest RIS for the aminated substrate was achieved at 20% glycerol and 
10% seeds with a value of (2.1±0.5)×10-5 RIU per spot. The RIS minimum 
corresponds to densities and ECD values in the ranges 4.8-7.9 µm-2 and 59-72 
nm respectively (range between mean values for edge and off-centre particles).  
The fabrication process in section 2.4 is designed to synthesise gold 
nanoparticles on any substrate surface and a variety of substrates were explored 
in an attempt to further improve the RI sensitivity of the LiScAR.  
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2.7.3 Substrate Material 
Plastic substrates such as polypropylene (PP), Cyclic olefin copolymer (COC) 
and Cyclic olefin polymer (COP) are desirable as LiScAR assay surfaces 
because of the cost benefit over aminated glass, although an aminated glass 
substrate is available from Sigma Aldrich at ~10% the cost of the typically used 
amino substrate described in section 2.4. The viscosity and seeds concentration 
parameters were box-searched to optimise the printing conditions on the plastic 
and sigma substrates, Figure 2.19. 
 
Figure 2.19 Box search of glycerol concentration and seeds solution concentration to optimise RIS on 
various substrate surfaces. Nanoparticle spots were developed 4 substrates as described in section 2.4: a) 
PP, b) COP, c) COC and d) Sigma. Glycerol concentration is expressed as percentage volume of the solution 
and seeds concentration is expressed as a percentage of the seeds solution described in section 2.4. Data 
points are derived from the mean response of n=7 assay spots. 
The substrate onto which the nanoparticle array was printed had a demonstrable 
effect on the refractive index sensitivity of an array and the optimum combination 
of seeds and glycerol concentrations varied for different surfaces. The plastic and 
glass substrates are compared to the amino substrate in Figure 2.20.  
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Figure 2.20 RIS values of nanoparticle spots developed on five substrates. Nanoparticle spots were 
developed using glycerol and seeds solution concentration variations to the printing protocol described in 
section 2.4 as shown in Figure 2.19. n=150 spots on a single array surface.  
The plastic substrates produced arrays with higher variation and worse RI 
sensitivity compared to glass substrates. The PP substrate in particular displayed 
a large variation in RIS values, which could be attributed to nonlinear effects of 
glycerol and seeds concentration on baseline noise or nRIS of the nanoparticle 
spots. The mathematical relationship between RIS and nRIS can be derived by 
multiplying both sides of the nRIS equation by RIS: 
𝑛𝑅𝐼𝑆 × 𝑅𝐼𝑆 = 100 ×
signal
𝑠𝑖𝑔𝑛𝑎𝑙𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 × RI
× √2 × 𝜎 ×
RI
signal
 
Solving for RIS gives: 
𝑅𝐼𝑆 = 100 ×
signal
𝑠𝑖𝑔𝑛𝑎𝑙𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 × RI × nRIS
× √2 × 𝜎 ×
RI
signal
 
Simplifying by cancelling RI and signal terms gives: 
𝑅𝐼𝑆 = 100 ×
1
𝑠𝑖𝑔𝑛𝑎𝑙𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 × nRIS
× √2 × 𝜎 
Rearranging the equation gives: 
 𝑅𝐼𝑆 = 100 ×
√2
nRIS
×
𝜎
𝑠𝑖𝑔𝑛𝑎𝑙𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
 2.11 
 
Figure 2.21 shows equation 2.11 fitted to nRIS and RIS data from the 
nanoparticle spots grown on different substrates. 
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Figure 2.21 The relationship between RIS and nRIS. Nanoparticle spots were developed on a  number of 
substrates using glycerol and seeds solution concentration variations to the printing protocol described in 
section 2.4 as shown in Figure 2.19. n=150 spots on a single array surface. The mathematical relationship 
fits the data (red line) with R2=0.72.  
The R2 of the fit in Figure 2.21 suggests that equation 2.11 accounts for 72% of 
the variance in RIS. The estimated parameters of equation 2.11 reveal a 
fundamental property of the LiScAR setup: the ratio of baseline noise (σ) to spot 
brightness (𝑠𝑖𝑔𝑛𝑎𝑙𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒) with a value of (1.69±0.04)×10
-4 (95% confidence). 
When smaller, the ratio scales the nRIS vs RIS curve vertically such that smaller 
values of RIS are achieved for a given nRIS: the ratio is minimised when spots 
are brighter with lower baseline noise.  
Plotting brightness against σ shows that spot noise decreased with the square 
root of sampling number (in this case the number of photons captured by the 
video camera, apparent brightness) as described previously in equation 2.4,  
Figure 2.22. 
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Figure 2.22 Effect of spot brightness on spot noise. Nanoparticle spots were developed on a number of 
substrates using glycerol and seeds solution concentration variations to the printing protocol described in 
section 2.4 as shown in Figure 2.19. Spot noise is 1SD for each of n=150 spots on a single array surface. 
The data fit to equation 2.4 with R2=0.19 showing noise decreasing with the square root of brightness.  
The R2 of the fit in Figure 2.22 is relatively poor which may be due to the lack of 
brightness data between zero and 100 AU – the region of the curve where noise 
is expected to change most significantly. Importantly, Figure 2.22 does not predict 
which substrate produced the lowest RIS: the worst performing substrate in terms 
of RIS was PP, despite producing bright spots with low noise - highlighting the 
contribution of nRIS to RIS variation. nRIS is strongly influenced by the opacity 
of the substrate which if scratched or contains impurities can scatter light and 
contribute to absolute background signal - reducing the percentage brightness 
change caused by the nanoparticles.  
In summary, the fabrication procedure for the nanoparticle surfaces was 
optimised for RI sensitivity on five substrate materials. Optimal results were 
achieved with a nanoparticle density and ECD of 4.8-7.9 µm-2 and 59-72 nm, 
using 20% glycerol and 10% seeds solution concentrations, the standard amino 
surface and a growth time of 30 minutes. The optimised SOP derived from the 
box search produced spots with nRIS = 770±26 % RIU-1 and RIS = (2.1±0.5)×10-
5 RIU per spot. The RIS from the mean response signal of 7 spots (a single 
column on a typical 10×14 array) was 1.4×10-5 RIU. Variation between print 
batches on amino and sigma substrates lead to typical nRIS values in the range 
650-850 and RIS values of 1-10×10-5 RIU per spot.  
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The array format of the sensor surface and the automated data analysis routines 
improved the speed of data collection and sensitivity optimisation, allowing new 
batches of substrate surfaces to be optimised via box search before printing a 
new batch of gold array surfaces. Future work might investigate the ratio of 
different shaped nanoparticles on RIS and the temperature of the growth solution. 
Furthermore, the pH of the printed seeds solution might also be studied for its 
effect on nanoparticle surface density.   
The optimised and calibrated gold nanoparticle array surface can be used to 
determine the RI of various solutions and this was demonstrated using binary 
mixtures of isopropanol (IPA) and water, Figure 2.23. 
 
Figure 2.23 RI dependence on the mass fraction of isopropanol in a binary mixture with water. Literature 
values for the RI at 25 oC (red) and 20oC (blue) are in good agreement with the RI derived from the 
nanoparticle data (green). Nanoparticle spots were developed on the amino substrate surface as described 
in section 2.4. Error bars are 2SD from n=3 technical repeats.  
The data are in good agreement with published values (352) for binary mixtures 
of IPA and water, validating the nanoparticle array as a reliable technique for 
measuring changes in RI. The transducer, electronics and display elements of 
the LiScAR have now been discussed and subsequent sections of the chapter 
will focus on the bio-receptor element – enabling the LiScAR to record the RI 
change associated with protein binding interactions. 
2.8 LiScAR Bio-Receptor Tethering 
The LiScAR is sensitive to RI changes associated with protein binding reactions 
within 93 ± 10 nm of spherical gold nanoparticles of diameter 90 ± 13 nm (353). 
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Therefore, analyte sensing in complex samples can be achieved by tethering of 
the bio-receptors to the gold nanoparticles. 
Gold nanoparticles are negatively charged and will adsorb proteins with positively 
charged residues. The formation of protein corona around nanoparticles is a 
complex process (354), however it is widely accepted that surface adsorption can 
lead to structural changes in proteins, including denaturation (355). Proteins may 
have significantly reduced activity when adsorbed directly to the metal surface, 
leading to a reduction in assay sensitivity. The aim of protein immobilisation is 
therefore to maintain protein structure and accessibility of the relevant binding 
sites (356). Furthermore, many bio-sensors are limited by non-specific binding of 
background materials (fouling) when sampling complex mixtures such as human 
serum (357). The inherited LiScAR protocol uses a self-assembled monolayer 
(SAM) which insulates the gold surface from immobilised proteins and also 
serves as an anti-fouling layer.   
SAMs are mixtures organic molecules which spontaneously form ordered layers 
on surfaces (358). SAMs on planar gold surfaces are widely used in the 
construction of a variety of surfaces for use in biosensors and nanomedicine 
(359). The SAM used in the studies reported here bound to the gold nanoparticles 
via thiol groups in a complex process, involving the dissociation of the S–H bond 
followed by the formation of the Au–S covalent bond (360). There were two 
components to the SAM, termed linker and spacer. The linker component 
terminated with a carboxylic acid group, which was used to immobilise proteins 
with a covalent peptide bond. The spacer component terminated with a hydroxyl 
group and formed an antifouling layer on the gold surface. The ratio of linker to 
spacer could be used to control the density of immobilised proteins. Repeated 
ethylene glycol (PEG) groups were common to both linker and spacer elements 
which prevented the non-specific adsorption of proteins (361).  PEG is also an 
amphiphilic polymer which is surrounded by an organised structure of water 
molecules when hydrated, leading to hydrophilic surface passivation (362). A 
schematic of the SAM is shown in Figure 2.24. 
98 
 
 
Figure 2.24 Schematic of the self-assembled monolayer bound to a gold surface via thiol groups. The spacer 
component is capped with a hydroxyl group and provides an antifouling layer over the gold surface. The 
linker component is capped with a carboxylic acid group which may be activated for tethering to proteins. 
The linker has a larger number of repeated PEG units than the spacer, exposing the carboxylic acid group 
above the SAM surface.  
Most proteins contain an abundance of lysine amino acids with nucleophilic 
primary amines as R groups. Carbodiimide compounds are used for efficient 
crosslinking of these primary amines to the carboxylic acid terminus of the SAM 
linker component. Carbodiimides are considered zero-length crosslinkers 
because no portion of their chemical structure becomes part of the final bond,  
Figure 2.25. 
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Figure 2.25 Schematic of EDC/NHS coupling chemistry. SAM linker (1) is tethered to the primary amine of 
a protein (2). The O-acylisourea intermediate is readily hydrolysed and the synthesis typically includes N-
hydroxysuccinimide to extend the half-life of the intermediate. Image from ref (363). 
In the present work, the carbodiimide compound 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) was used to activate carboxyl groups 
on the SAM linker, forming an active O-acylisourea intermediate that was easily 
displaced by nucleophilic attack from primary amino groups on the protein 
structure. The O-acylisourea intermediate is unstable and is readily hydrolysed 
by water. Therefore, N-hydroxysuccinimide (NHS) was included in the reaction 
mixture to form a dry-stable NHS ester intermediate that is less readily hydrolysed 
but still reactive towards primary amines (363).  
2.8.1 Assay Method 
The method of immobilising proteins on the LiScAR sensor surfaces was 
inherited from the research group and is used for all LiScAR experiments in the 
thesis unless otherwise stated. Nanoparticle arrays were developed on the amino 
substrate as described in sections 2.4 before washing with ethanol. The SAM 
components were mixed in a 10:1 spacer to linker ratio at 2 mM in ethanol and 
the nanoparticle arrays were submerged in the solution for a minimum of 4 hours 
to allow uniform SAM formation. EDC (20 mg) and NHS (35 mg) were dissolved 
in 1 mL of dimethylformamide (DMF) before dilution with 20 mL IPA. SAM coated 
nanoparticle arrays were washed with IPA and left to stand in the EDC/NHS 
solution for 20 minutes. The nanoparticle arrays were washed rapidly with IPA 
100 
 
followed by water under flow and then dried with N2 gas. Protein solutions at >0.5 
mg/mL in PBS were printed on top of specific groups of nanoparticle spots using 
an inkjet printer (sciFLEXARRAYER S3 from Scienion AG, Berlin, Germany) and 
become tethered to the activated SAM surface. The arrays were left in the printer 
at room temperature for 2 hours at 70% humidity before storage at 4oC.  
A functionalised array may be enclosed in the flow cell configuration discussed 
previously and stored in PBS running buffer. A flow rate of 6 mL/hr was typically 
used for binding experiments to eliminate mass transport effects (276). The SOP 
of the LiScAR is the present study was as follows: 
1. The array was washed with 10 mM phosphoric acid solution to remove 
unbound proteins simply adsorbed onto the gold nanoparticle surface.  
2. The array was blocked for 300 s with 1 mg/mL BSA solution in PBS to 
fill any spaces of the gold surface that would otherwise enable 
nonspecific binding of sample proteins. 
3. The array was washed again with 10 mM phosphoric acid solution to 
remove BSA weakly adsorbed onto the gold nanoparticle surface.  
4. A 2×PBS switch was performed, enabling calibration of sensor 
response to RI and RIS to be determined by the automated signal 
processing routine described previously. 
5. A sample was injected to observe analyte association to the assay 
surface in real time: the association phase. 
6. The flow was switched back to PBS running buffer to observe analyte 
dissociation: the dissociation phase. 
7. A 200 nM sample of detection antibody (described in detail in 3.3.2) 
may be injected at this stage and the AUC may be calibrated for analyte 
concentration determination. 
8. The array was washed with 10 mM phosphoric acid solution to remove 
bound analyte. 
The array surface is reusable and steps 5-7 may be repeated in a duty cycle 
typically lasting 10 minutes in total. The brightness data were recorded for each 
spot and calibrated to RIU using the automated signal processing routine 
described in section 2.6. The response data from each spot were normalised to 
a starting value of zero and the data from multiple spots were averaged to 
produce a single kinetic trace of analyte binding with relatively low background 
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noise compared to the individual spot responses. The number of spots used for 
averaging was typically 14, corresponding to a single row of a 14×10 array. The 
surfaces may be tested using a standard IgG reference material from NIST which 
binds to array spots functionalised with the Fc binding protein A/G (PAG), 
described in Chapter 3. Data from a typical analyte capture experiment are shown 
in Figure 2.26, comprising of an association phase followed by a dissociation 
phase. 
 
Figure 2.26 Kinetic response curves of NIST IgG (3.2 nM in PBS) binding to PAG on the LiScAR sensor 
surface. PAG was immobilised using the assay method described in 2.8.1. a) the signal from n=27 individual 
assay spots. b) the averaged signal from the same n=27 assay spots.  
The data in Figure 2.26 show significant variation in the response of each assay 
spot. Inter-spot variation occurs as a result of variations in surface 
functionalisation which depends on the accuracy with which droplets of protein 
are printed onto the gold spots. Sub-optimal printing accuracy leads to gold 
nanoparticle regions with no functionalisation and hence no sensitivity to analyte, 
which results in a lower mean brightness change recorded by the LiScAR for 
each spot. Printing accuracy can be checked qualitatively by observing a newly 
printed array through a microscope lens. Alternatively, printing accuracy can be 
interrogated quantitatively by calculating the unresponsive pixels in a 
nanoparticle spot image as a percentage of the total spot pixels. 
The raw kinetic trace is sensitive to changes in temperature, physical 
disturbances of the surface supporting the instrument and variations in 
illumination intensity of the LED. To observe these effects, a group of control 
spots are always included on each assay, printed from a 1 mg/mL BSA solution. 
BSA is an appropriate control protein for healthy human serum samples due to 
its stability and lack of specific binding affinity for human proteins. However, 
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serum antibodies to BSA may develop as part of a patient’s immune response (at 
nanomolar concentrations) following exposure to BSA which is used as a surgical 
sealant in procedures such as vascular reconstructions (364). For serum samples 
containing anti-BSA antibodies, a different control protein could be used such as 
human serum albumin. As with the assay spots, the signals of the control spots 
were normalised and averaged into a single channel which showed all changes 
in signal that were not due to the binding of analyte. The signal of the control 
spots was subtracted from the signal of the assay spots, producing a kinetic trace 
which did not drift and responded predominantly due to specific analyte binding, 
Figure 2.27. 
 
Figure 2.27 The effect of subtracting the assay response signal from a reference channel. PAG and BSA 
were immobilised using the assay method described in 2.8.1. a) raw assay signal of the NIST mAb (3.2 nM) 
binding to PAG assay channel (blue) and BSA reference channel (black). b) assay signal after reference 
signal subtraction. Signals are the averaged response of n=27 assay spots.  
PAG spots and BSA spots were located randomly across the array to ensure 
these positive control and reference channels were representative of sensitivity 
and nonspecific signal changes respectively at all assay locations. The number 
of positive control and reference spots used for averaging was chosen to match 
the number of spots in each assay channel - ensuring the averaged signals from 
both assay and control spots displayed similar noise. The rate of analyte binding 
recorded by the assay spots can be analysed to derive the kinetics of the 
interaction and the maximum analyte load of the assay surface. 
2.9 Kinetic analysis of sensor response 
The competing processes of binding and dissociation of analyte at the assay 
surface are evident in the distinctive shape of the sensor response. The standard 
model for filling a biosensor surface is that of the Langmuirian adsorption 
isotherm (365), which describes a finite number of binding sites on the assay 
103 
 
surface being filled by analyte over time. The assumptions of the Langmuirian 
adsorption isotherm are: 1) all sites are assumed to be identical; 2) each site can 
hold a maximum of 1 analyte; 3) there is no interaction between neighbouring 
binding sites and 4) the adsorption process must represent a dynamically 
reversible process. Initially, in what is termed the association phase, the rate of 
analyte binding to an unfilled assay surface is high and decreases as the number 
of available binding sites are filled up by analyte: leading to a horizontal 
asymptote. The initial rate of analyte association is therefore dependent on the 
concentration of analyte and available surface sites: a second order reaction with 
rate constant, ka, having units of M-1 s-1. The rate of analyte dissociation from the 
assay surface is independent of analyte concentration: a first order reaction with 
rate constant, kd, having units of s-1. Analyte dissociation occurs simultaneously 
to binding during the association phase and the overall rate of assay surface filling 
may be described by a differential equation showing the balance between the 
association and dissociation rates: 
 
𝑑θ
𝑑𝑡
= 𝑘𝑎[𝑃](1 − θ) − 𝑘𝑑θ 2.12 
 
where θ is the surface coverage and 1-θ is the remaining unfilled binding sites as 
a fraction of total binding sites; P is the concentration of protein analyte in solution 
and ka and kd are the association and dissociation rate constants respectively. 
The positive term describes association of analyte, whilst the negative term 
describes dissociation. The surface coverage at a specific time during 
association, θ(𝑡), may be estimated by integrating equation 2.12 to give: 
 θ(𝑡) =
(𝑡)
𝑚
=
𝑘𝑎[𝑃]
𝑘𝑎[𝑃] + 𝑘𝑑
(1 − 𝑒−(𝑘𝑎[𝑃]+𝑘𝑑)𝑡) 2.13 
 
where (𝑡) is the experimentally observed change in signal at time t and 𝑚 is 
the signal that would be observed at surface saturation. 𝑚 is not attainable 
experimentally due to dissociation as shown in equation 2.13 and an equilibrium 
surface coverage is observed in practice. The relative values of ka and kd describe 
strength of the binding interaction and define the affinity constant, KD, via the 
equation: 
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 𝐾𝐷 =
𝑘𝑑
𝑘𝑎
 2.14 
 
KD is equal to the concentration of analyte required such that 50% surface 
coverage is maintained at equilibrium. Quantitative measures of protein-protein 
interactions are critical to understanding protein functions (366) and screening for 
new antibodies (367) for use as high affinity bio-receptors. Furthermore, 
investigating the relationship between binding affinity and protein structure is a 
fundamental component of drug design (366).  
2.9.1 Parameter Estimation for the Langmuir model 
The ka, kd and 𝑚 parameters of the Langmuir model can be estimated by fitting 
the model to RI data from the association and dissociation phases of a protein 
binding experiment on the LiScAR (368). The RI data are used to fit equation 2.15 
for the association phase (equivalent to equation 2.13 scaled by 𝑚) and equation 
2.16  for the dissociation phase: 
 (𝑡) = 𝑚
𝑘𝑎[𝑃]
𝑘𝑎[𝑃] + 𝑘𝑑
(1 − 𝑒−(𝑘𝑎[𝑃]+𝑘𝑑)𝑡) 2.15 
 
 (𝑡) = 𝑎𝑒
−𝑘𝑑𝑡 2.16 
 
where 𝑎 is the signal at the start of the dissociation phase. Model fitting 
techniques, parameter estimation and goodness of fit analysis are discussed in 
Chapter 4. Briefly, in order to estimate model parameters with good precision, the 
training data must represent the effects of all parameters of the model. For 
example, to best estimate the value of 𝑚, ideal fitting data would show analyte 
binding until maximum surface coverage is achieved. The data would constrain 
the model such that a good fit would only be achieved over a small range of 
possible 𝑚 estimates. Similarly, a poor estimate of kd will occur if the data used 
to the fit the model do not show significant analyte dissociation – a situation which 
can occur if the noise of the data exceeds the gradient of the dissociation phase. 
When the model is fitted to a single measurement of association and dissociation, 
the parameters of the model are poorly determined but the precision of parameter 
estimation is markedly improved by fitting the model to data from a range of 
analyte concentrations simultaneously: a global fit. A Langmuir model global fit to 
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LiScAR data of IgG binding to spots functionalised with PAG is shown in Figure 
2.28.  
 
Figure 2.28 Global fit of the Langmuir model (red) to kinetic data from IgG binding to immobilised PAG 
(black). PAG was immobilised using the assay method described in 2.8.1. Signals are the averaged 
response of n=20 assay spots. Duplicate concentrations of IgG were sampled (6.25, 12.5, 35 and 50 nM) 
and higher concentrations induce greater response signal. The association phase shown here begins at 20 
seconds and lasts 100 seconds in total. The dissociation phase shown here begins at 120 seconds and lasts 
200 seconds. The fit estimates for the interaction are: ka=3.26 ±0.03×105 M-1 s-1 and kd=3.01 ±0.37×10-4 s-1.  
The precision of parameter estimation in the global fit comes from the increased 
constraints by the data on the model parameters. The higher concentrations 
provide a better estimate of 𝑚, but increase the likelihood of collecting data 
which violates the assumptions of the Langmuir model such as cooperativity 
between binding sites and aggregation rather than 1:1 binding kinetics. In 
contrast, lower concentrations provide good quality kinetic data but may not show 
enough curvature during association to precisely define 𝑚. The global fit enables 
all parameters to be estimated with improved confidence over a single kinetic 
trace.  
Protein adsorption data often appear to be fit well by the Langmuir model (369). 
However, incorrect parameter estimates will be made if the data are collected 
from a process which violates any assumptions of the model. These limitations 
are important to understand before attempting to fit the Langmuir model to kinetic 
data. 
2.9.2 Limitations of the Langmuir model  
The assumption that all binding events on the surface are equal is easily violated 
by nonspecific binding. Whilst antibodies bind with affinity constants of 
106 
 
10−10 −10−11 M to specific epitopes (310), nonspecific binding of antibodies to low 
affinity targets is likely to occur at some binding sites at higher concentrations of 
analyte (~10-3 M) (370). When nonspecific binding occurs, the gradient of the 
association phase may be increased due to additional mass binding to the 
surface. The gradient of the dissociation phase is also typically increased initially 
as the nonspecific interactions often have rapid dissociation rates. Additional 
phenomena which occur at higher analyte concentrations are protein clustering 
and aggregation which will violate both the 1:1 binding assumption and the non-
cooperativity assumption. Protein clustering and aggregation are discussed in 
detail in Chapter 3. 
The effects of nonspecific binding, aggregation and clustering may or may not be 
evident in the shape of the kinetic data. Hence, to minimise nonspecific binding 
effects it is important to use the lowest concentrations of analyte that provide 
sufficient surface coverage to estimate all parameters of the Langmuir model. 
Nonspecific binding of analyte to the non-biological regions of the assay surface 
is also reduced by the incorporation of additional blocking steps during assay 
preparation. Step 2 of the standard operating procedure may be repeated to 
ensure hydrophobic and electrostatic interactions between analyte and the gold 
/ SAM surface are effectively blocked before complex solutions are sampled 
(371).  
Matrix effects are effects on an analytical technique caused by any elements of 
a sample that are not the analyte (304). Matrix effects account for the nonspecific 
effects mentioned previously and include the phenomenon of molecular crowding 
(372). The volume occupied by proteins in solution is unavailable to others 
because two molecules cannot occupy the same space at the same time. In 
crowded biological samples, the steric hinderance of large proteins effectively 
limits the volume available to smaller proteins, leading to discontinuous protein 
concentrations. Matrix effects may also affect binding rates by altering the rate of 
diffusion (mass transport) in the solution. For instance, a sample containing a 
relatively high concentration of albumin will exhibit a lower rate of diffusion onto 
the assay surface due to higher viscosity, as shown in 2.9. Matrix effects may be 
accounted for by diluting samples using a solution with a similar matrix to the 
sample - ensuring that any effect on the assay is consistent for all measurements 
regardless of dilution factor. Alternatively, matrix effects such as excluded volume 
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and diffusion limitations will be minimised at relatively high sample dilutions in 
PBS buffer.  
In theory, once the parameters of the Langmuir model are estimated using a 
global fit to kinetic data, the concentration of analyte in unknown samples may be 
estimated based on association and dissociation data. However, this approach is 
challenging due to errors in the estimated parameters of the Langmuir model and 
matrix effects of samples in complex mixtures. In practice, the area under the 
curve (AUC) of the association phase is calibrated to analyte concentration and 
used to construct a standard curve which is independent of the Langmuir 
assumptions.  
Because the assay response cannot be measured at every concentration of 
analyte within the dynamic range of the assay, a mathematical function must be 
fit to the data which enables interpolation between the standard concentration 
response values. Selection of the standard curve function is critical to achieve 
accurate assay result. For example, a linear function can be applied to the linear 
range of the assay shown in Figure 2.1 but will not fit well to the sigmoidal 
relationship exhibited by a larger range analyte concentrations. In contrast, over-
parameterised models may enable a perfect fit to the data but are subject to noise 
and may provide inaccurate interpolation between data points (known as 
overfitting) that does not represent the “true curve” (373). This is an example of 
the bias-variance trade-off commonly encountered in model fitting. The ideal 
standard curve function should fit well to the data with the smallest number of 
parameters and the 5-parameter logistic model is commonly applied to 
immunoassay data (373): 
 𝑦 = D +
A − D
(1 + (𝑥 𝐶⁄ )
𝐵
)
𝐸 2.17 
 
where A is the minimum asymptote (the response value at zero analyte), C is the 
inflection point and D is the maximum asymptote (the response value at infinite 
analyte concentration). Parameters B and E define the steepness and the 
asymmetry of the sigmoidal curve respectively. Figure 2.29 shows the calibration 
process for an IgG assay (based on nanoparticle spots functionalised with PAG) 
using the 5-parameter logistic equation.  
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Figure 2.29 Calibration data of IgG binding to immobilised PAG. PAG was immobilised using the assay 
method described in 2.8.1. Signals are the averaged response of n=20 assay spots. Duplicate 
concentrations of IgG were sampled (6.25, 12.5, 25, 50, 100 and 200 nM) and higher concentrations induce 
greater response. a) kinetic response data (black) showing association and dissociation phases and the 
AUC region (green).  b) standard curve of IgG standard concentration against AUC (green) which can be 
interpolated with a 5-parameter logistic standard curve (blue) to determine the concentration of IgG in an 
unknown sample. The CV at each concentration (orange) indicates the analytical precision across the curve. 
The data show good reproducibility in the relationship between IgG concentration 
and AUC. The standard curve was used to derive the IgG concentration of the 
standards based on their AUC as a measure of assay performance. A maximum 
CV in derived concentration of 16% occured at the lowest standard concentration 
(6.25 nM). The CV plot allowed the LLoQ to be determined which for the example 
shown was 12.5 nM - based on a chosen CV threshold of 5%. For comparison, 
Enzo ELISA kits state that intra-assay CV should be less than 10% (374). The 
CV in derived concentration should increase as the IgG concentration 
approaches the ULoQ, which for the example shown was >200 nM IgG. In 
practice a new standard curve is performed for each LiScAR assay but in future 
batch calibration may be possible with highly reproducible assay surfaces.  
2.10 Conclusions  
These results show that the LiScAR is an appropriate biosensor platform on 
which to develop assays for studying the Complement cascade. The fabrication 
process of the LiScAR assay surfaces has been discussed and the inherited 
protocol was developed to improve the RI sensitivity of the nanoparticle spots.  
Furthermore, potential violations of the Langmuir model assumptions have been 
considered and solutions presented to ensure the validity of estimated kinetic 
parameters. The development of automated signal processing routines enabled 
rapid and standardised assay calibration and operation and is a first step towards 
enabling non-specialized technicians to operate the LiScAR - a major advantage 
for all biosensors. The optimised experimental methods and standard operating 
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procedures for the LiScAR were used to produce reliable data for the studies 
presented in the subsequent chapters. Chapter 3 presents the results of antibody 
tethering to the LiScAR sensor surface to develop novel protein assays specific 
to biomarkers of Complement cascade activation and reports a method for 
antibody sample purity testing using the PAG surface presented here. 
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3 Antibody Properties in the Development of New 
Biophotonic Assays of Complement Activation 
3.1 Introduction 
Chapter 2 demonstrated that proteins can be printed onto the LiScAR assay 
sensor surface in an array format and tethered using EDC/NHS coupling 
chemistry, one of the most commonly used strategies for crosslinking proteins to 
gold nanoparticles (375). BSA and PAG were routinely printed to produce control 
spots and a positive control assay for IgG concentration, respectively. In theory, 
the same methods for protein immobilisation could be applied to immobilise any 
commercially available antibody to produce an assay for its antigen. The 
frequency of lysine amino acids in proteins is ~7% (376), suggesting that a 
number of amines are available for EDC/NHS tethering on most proteins. The 
structure of IgG is shown in Figure 3.1.  
 
Figure 3.1 Structure of IgG. a) spacefill model coloured by chain showing heavy chains (light blue and red) 
and light chains (dark blue and orange); and  b) spacefill model coloured by amino acid. Image created with 
NGL Viewer (377). Protein data bank ID: 1IGT.  
The IgG structure is comprised of four major regions: two fragment antigen 
binding regions (Fab), the fragment crystallisable region (Fc) and the hinge region 
(378). The Fc region interacts with cell surface receptors and is connected via the 
hinge region to two Fab regions which bind to antigen. It is therefore the Fab 
regions which provide bio-recognition in immunoassays such as the LiScAR 
platform. There are typically 80 lysine residues present in IgG with ~50% 
accessible for tethering (379). Trastuzumab emtansine (trade name Kadcyla) and 
ibritumomab tiuxetan (trade name Zevalin) are examples antibody-drug 
conjugates (ADCs) in which antibody is conjugated via its lysine residues to 
‘cytotoxic payloads’ (380) allowing targeted delivery to cancer cells (381).  
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The single flow cell of the LiScAR platform exposes all assay elements of the 
biophotonic sensor surface to a given sample, allowing multiple assays to be 
performed simultaneously as a multiplex biosensor. Fundamentally, the 𝑚 of the 
biophotonic assays is proportional to the mass of analyte bound to the surface 
and by extension the sensitivity of analyte capture is also dependent on analyte 
mass. The PAG-functionalised surface produces a strong signal during IgG 
capture but multiplex assays of Complement activation require proteins of 
different masses to be measured. Low-mass analytes such as C5a (10.4 kDa) 
and high-mass analytes such as TCC (1030 kDa) will exhibit different responses 
upon analyte capture. The sensitivity of assays may be improved with an 
additional (labelling) step in the SOP: detection.  
Following analyte capture and preceding surface regeneration, an antibody 
sample may be injected over the assay surface which binds to epitopes on the 
captured analyte. A calibration curve is constructed from the AUC of the detection 
step only and somewhat standardises assay sensitivity because the masses of 
detection antibodies are similar. Notably, there will be some variation in detection 
step response due to varying binding ratios between analyte and detection 
antibody if polyclonal antibodies are used. The inclusion of a detection step 
increases the duty cycle time of the assay but can improve assay sensitivity if the 
total mass of detection antibody on the sensor surface is greater than the mass 
of captured analyte. Signal amplification with the detection step does not limit the 
biophotonic assays to analytes above a minimum mass threshold, allowing 
Complement activation biomarkers to be chosen without restriction by mass 
limits. Furthermore, the detection step occurs after any nonspecific binding 
effects between the sample and the sensor surface, allowing complex mixtures 
to be analysed that would otherwise perturb the signal of the capture step.  
The first step in the development of a new assay is to identify analyte targets 
based on the information they provide. This study aims to develop assays of 
Complement activation which can be achieved by two strategies: 1) the 
consumption of circulating inactive proteins and 2) the release of activation 
products. C3 is consumed as a result of activation in all Complement pathways 
and patients with C3 glomerulopathy (a kidney disorder caused by dysregulated 
Complement activation) present with increased C3d and low C3 levels, reflecting 
ongoing Complement activation in these patients (382). Severely burned patients 
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also show low C3 concentrations initially but C3 recovers to normal levels during 
treatment for survivors whilst non-survivors show diminished C3 recovery (383). 
C3 cleavage is therefore a good biomarker of Complement activation.  
Proteins consumed or released by the CP and LP may also be used as measures 
of Complement activation. C4 is common to both pathways and C4d deposition 
on certain brain tumours has been associated with worsened patient outcome 
(384). C4 and C3 concentrations typically show a positive relationship and a 
C3/C4 ratio above 4.53 has been identified as a risk biomarker for cardiovascular 
events in acute coronary heart disease (385). A significant correlation has also 
been found between MBL concentration and MBL-associated C4 consumption in 
plasma from healthy individuals (386), potentially explaining why lower peri-
operative MBL levels are associated with an increased occurrence of post-
operative infections (387, 388). However, there is contrasting evidence 
suggesting MBL and MASP-2 levels in serum do not affect the clinical outcome 
in cystic fibrosis patients (389). The conflicting evidence in different patient 
groups further highlights that the best measure of Complement activation 
potential is with a functional test rather than inferring system properties from a 
given protein concentration.  
The correlation between the concentration of AP or TP proteins and patient 
outcome has been investigated for many conditions, although the reasons for the 
correlation are often unclear. Patients with heart failure display significantly 
increased levels of FD and TCC, whilst low levels of FH and P are associated 
with adverse patient outcome (390). It has also been shown that sC5b-9 (fluid 
phase TCC) concentration predicts future cardiovascular events in type 2 
diabetes patients with myocardial infarction (391). Furthermore, the relationship 
between C5a and sC5b-9 concentrations and patient death has been 
investigated during acute episodes of thrombotic thrombocytopenic purpura 
(TTP) – a blood clotting disorder (392) for which sC5b-9 concentration might also 
distinguish patients with TTP from those with aHUS  (393). In addition, Bb and 
sC5b-9 concentrations in early pregnancy are strongly predictive of adverse 
outcomes in patients with SLE (394). These examples suggest that proteins 
consumed or released by the AP and TP are good biomarkers of Complement 
activation and are likely to show the greatest sensitivity due to the amplification 
loop of the AP. 
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Once analytes have been identified, the selection of antibodies with appropriate 
epitope targets is critical. Assays of Complement activation must be specific to 
either intact proteins or their activated fragments and two assay designs are 
proposed in Figure 3.2. 
 
Figure 3.2 Types of sandwich immunoassay for measuring Complement activation. a) A protein fragment 
(blue) is captured by an antibody (green) via a neo-epitope (red) which is exposed only after cleavage. A 
detection antibody binds to an epitope elsewhere on the fragment. Complement activation is observed as 
an increase in assay signal due to the increase in neo-epitope concentration. b) The capture antibody binds 
to an epitope present on both the blue fragment and the intact protein. A detection antibody binds to an 
epitope on both the orange fragment and the intact protein. Complement activation is observed as a 
decrease in assay signal because the detection antibody cannot bind when the epitopes are separated.   
The specificity of the assay in in Figure 3.2a is primarily due to the capture 
antibody which binds a neo-epitope exposed on the analyte of interest after 
cleavage from its parent protein. Assay response is subsequently enhanced by 
using a detection antibody which if polyclonal may enable multiple antibodies to 
detect a single captured analyte – maximising assay sensitivity.  
The specificity of the assay in Figure 3.2b relies on both capture and detection 
antibodies binding to epitopes on the surface of the intact protein which are 
separated upon activation. A disadvantage of the assay in Figure 3.2b is that the 
captured epitope is not unique to the target analyte and cleaved protein fragments 
will compete with the intact protein for binding sites on the sensor surface. 
Competition for surface binding sites will be greatest when the ratio of intact 
protein concentration to fragment concentration is lowest. Therefore, this type of 
assay will overestimate protein consumption to a greater extent during in vitro 
experiments which cause greater consumption of Complement proteins. If the 
competing fragments are below the 30-50 kDa molecular mass filtration cut-off of 
the kidneys (395) they will be cleared from the plasma and any assay perturbed 
by these fragments in vitro may be better suited for assessing in vivo Complement 
activation. 
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Several antibodies have been reported in the literature to produce immunoassays 
for Complement activation products, some of which are commercially available. 
An ELISA for Ba has been used to profile the half-life of Ba in human plasma 
using anti-Ba mAb D22/3 (specific for a neo-epitope on Ba) and anti-factor B as 
an antibody pair (245) but these antibodies are no longer available to purchase. 
An ELISA for C5a has been used to profile Complement activation in septic 
baboons using anti-C5a mAb C17/1 (specific for a neo-epitope on C5a) and a 
polyclonal anti-C5 detection antibody (244). In addition, an ELISA for TCC has 
been used to quantify TCC in human plasma using mAb aE11 (specific for a neo-
epitope on polymerised C9) (396) and polyclonal anti-C6 detection antibody 
(244).  
Monoclonal antibodies specific to epitopes which are separated upon protein 
cleavage may be used for capture and detection antibodies in assays of protein 
consumption. The mAb K13/16 has been shown to bind both C3a and intact C3 
(397), implying that the epitope of K13/16 is located on the outer surface of C3 
which becomes part of the C3a fragment upon cleavage. Detection antibodies 
which bind to the C3b surface of intact C3 should produce a C3 activation assay 
where detection signal will decrease with C3 cleavage.  
3.2 Aims and Objectives 
This Chapter reports investigations into antibody properties in the development 
of novel assays of Complement activation. 
The first objective was to test of a panel of candidate capture and detection 
antibodies for Complement proteins using the optimised assay production 
methods described in Chapter 2.  
The second objective was to investigate the effects of changing the inherited 
protocol for surface functionalisation described in 2.8.1 in an attempt to optimise 
the sensitivity of the successful sandwich assays.  
The third objective was to assess the performance of the novel Complement 
assays according to the metrics discussed in Chapter 2, such as sensitivity and 
specificity.  
Owing to the variability in antibody properties encountered, the fourth objective 
was to develop a novel quality control test of antibody samples which could 
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improve the reproducibility of future assay development on the LiScAR biosensor 
platform.  
3.3 Antibody Screening 
3.3.1 Capture Antibody Screening 
A panel of candidate capture antibodies was immobilised on the amino substrate 
surface described in section 2.4 using the assay method described in 2.8.1. The 
antibodies tested are listed in Table 3.1. A polyclonal antibody for TNFα, a 
cytokine discussed in Chapter 1 as a biomarker of sepsis, was included in the 
panel. A polyclonal antibody for CRP was inherited from the research group as a 
working CRP capture antibody and was included in the antibody screen for 
reference. A monoclonal IgG from NIST was also included in the antibody screen 
as a well characterised reference material and will be discussed later in the 
chapter.  
Table 3.1 Antibodies immobilised on the LiScAR sensor surface and tested for their ability to capture the 
listed antigens. Antibodies were immobilised and tested using the assay method described in 2.8.1. 
Clone 
name 
Product 
code 
Supplier Reactivity Antigen 
tested 
Product 
code 
Supplier 
unknown A252 Pathway 
Diagnostics 
Bb (neo) Bb A155 CompTech 
K13/16 GAU 013-
16-02 
Thermo 
Fisher 
C3a/C3 C3 A113c CompTech 
013III-1.16 MA1-
82814 
Thermo 
Fisher 
C3b/C3 C3 A113c CompTech 
unknown A209 Pathway 
Diagnostics 
iC3b (neo) iC3b A115 CompTech 
polyclonal NBP1-
31229 
Novus 
Biologicals 
C4b/C4 C4 A105c CompTech 
unknown A251 Pathway 
Diagnostics 
C4d/C4 C4 A105c CompTech 
C17/5 GAU 025-
05-02 
Thermo 
Fisher 
C5a (neo) C5a A145 CompTech 
unknown A239 Pathway 
Diagnostics 
TCC (neo) TCC A127 CompTech 
polyclonal AHP1212 Bio-Rad TNFα TNFα PHP051 Bio-Rad 
NIST mAb 8671 NIST RSVF RSVF 11049-
V08B 
Sino Biological 
 
In each antibody screening experiment a minimum of 14 array spots were 
functionalised with BSA to provide a negative control channel for baseline 
subtraction. A number of spots were also functionalised with PAG as a positive 
control according to the standard operating procedure. Target analytes were 
diluted to 25 nM in PBS (with the exception of large molecular mass antigens C3 
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and TCC which were diluted to 15 nM) and injected into the LiScAR for 200 
seconds, with a regeneration step of 100 seconds between samples.  
Six antibodies were found to be successful in capturing their antigen from 
solution. The array format of the LiScAR assay surfaces allows cross-reactivity 
to be directly observed and the 6 capture antibodies were printed onto multiplex 
assay surfaces for specificity testing. Assays were considered adequately 
specific only if their array spots produced significantly more signal than the 
controls (3SD). Successful antigen capture experiments for all analytes are 
shown in Figure 3.3, compared to the polyclonal antibody for CRP which was 
inherited from the research group as a previously working antibody for CRP 
capture on the LiScAR sensor surface.  
 
Figure 3.3 Signal response of LiScAR sensor surfaces to antigen samples. A number of proteins were 
immobilised using the assay method described in 2.8.1: PAG (blue), anti-C5a (green), anti-TCC (purple), 
NISTmAb (red), anti-TNFα (pink) and anti-CRP (orange). Each panel shows the array response to a 25 nM 
sample of antigen from Table 3.1: a) 15 nM C3; b) 25 nM C5a; c) 15 nM TCC; d) 25 nM RSVF; e) 25 nM 
TNFα and f) 25 nM CRP. Signals are the averaged response of n=15 assay spots. 
Five novel assays were demonstrated for the detection of C3a, C5a, TCC, RSVF 
and TNFα in <5 minutes. All assays produced a specific response when exposed 
to purified solutions of their target antigen.  
The capture antibody screening revealed that not all antibody samples tested 
were suitable for antigen capture after immobilisation on the LiScAR surface, with 
a success rate of <50%. The RI change associated with antigen capture 
correlated positively with antigen mass as expected but the success of assay 
production does not relate to a particular analyte mass range, Figure 3.4. For 
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example, C5a (9 kDa) capture was observed whereas Ba (33 kDa) capture was 
not despite a three-fold increase in analyte mass. 
 
Figure 3.4 Effect of analyte mass on LiScAR signal following 150 seconds of association at 15 nM. 
Experiments were performed using the assay method described in 2.8.1. Data points were derived from the 
averaged response of n=15 assay spots. Analytes are labelled and fit to a straight line with R2=0.97. 
Deviation from the linear trend between analyte mass and assay response may 
occur as a result of differences in binding kinetics and the number of binding sites 
on the sensor surface. For example, a rapid association rate would enable 
maximum surface coverage to be achieved within a shorter period of time, whilst 
a lower number of binding sites on the assay surface would reduce m.  
3.3.2 Detection Antibody Screening 
The use of a detection antibody can be used to improve the sensitivity of the 
biophotonic assays, as discussed previously. For a given assay, the number of 
available binding sites before analyte capture is constant. Within the dynamic 
range of the assay, the surface coverage achieved during analyte capture varies 
based on analyte concentration when the duration of association phase is fixed. 
The number of binding sites available for the detection antibody is determined by 
the surface coverage of captured analyte and hence precision of the detection 
step improves as m is approached. Detection step association rate cannot be 
used to determine the concentration because analyte surface coverage is 
uncertain. Therefore, a relatively high concentration of detection antibody must 
be used, compared to the concentration of analyte standards, to maximise 
detection antibody surface coverage whilst minimising the duty cycle of the assay. 
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A panel of candidate detection antibodies were diluted to 200 nM in PBS for 
testing on the capture assays for C3, C5a, TCC and TNFα. The antibodies tested 
are listed in Table 3.2. The polyclonal antibody for CRP capture was inherited 
from the research group as a working CRP detection antibody and was included 
in the antibody screen for reference. 
Table 3.2 Antibodies tested for their ability to detect the listed antigens captured by antibodies immobilised 
on the LiScAR sensor surface. Antibodies were immobilised and tested using the assay method described 
in 2.8.1. 
Description Product code Supplier Reactivity Antigen 
tested 
monoclonal MA1-82814 Thermo Fisher C3b/C3 C3 
monoclonal MCA2606 Bio-Rad C3d/C3 C3 
anti-sera AHP1752 Bio-Rad C3 C3 
polyclonal PA5-35000 Thermo Fisher C5a C5a 
monoclonal LF-MA0231 Thermo Fisher C6 TCC 
polyclonal 32034-05111 Assay Pro C9 TCC 
polyclonal 32556-05111 Assay Pro TCC TCC 
monoclonal ABIN112002 Antibodies Online TCC TCC 
polyclonal AHP1212 Bio-Rad TNFα TNFα 
 
A capture step of 200 seconds was performed for each antigen at 15 nM. A 
detection step of 200 seconds was then performed using each candidate 
detection antibody at 200 nM (or anti-sera diluted 500-fold). 100 seconds of PBS 
running buffer between capture and detection is used as a reliable measure of 
the pre-detection signal for AUC analysis and could be used to estimate kd of the 
capture step. Successful detection steps following analyte capture are shown in 
Figure 3.5 compared with the assay for CRP that was inherited from the research 
group. The anti-C3d/C3 monoclonal antibody MCA2606 was also able to bind 
captured C3 but the signal was weak, Appendix 1. 
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Figure 3.5 Signal response of LiScAR sensor surfaces to antigen capture and detection. A number of 
proteins were immobilised using the assay method described in 2.8.1: PAG (grey), anti-C5a (green), anti-
TCC (purple), anti-TNFα (red) and anti-CRP (orange). Antigen capture (15 nM) and detection (200 nM) for 
a number of assays (Table 3.2) are shown: a) C3 and AHP1752; b) C5a and PA5-35000; c) TNFα and 
AHP1212; d) CRP and its detection antibody inherited from the research group. Signals are the averaged 
response of n=15 assay spots shown for n=2 duplicate experiments performed on the same assay surface. 
Following the capture step, all assay channels exhibited a specific detection step 
response to their respective analytes only. TCC was the only analyte for which 
detection antibodies were sought but not found. Antigen detection was achieved 
for C3, C5a and TNFα. All detection steps showed significant curvature, 
suggesting maximum detection antibody coverage is approached within 200 
seconds. Furthermore, the RI of all detection steps was greater than the capture 
step – suggesting that the detection step increased assay sensitivity for these 
analytes in the duty cycle described here.  
3.4 Optimisation of Biophotonic Assays 
To achieve optimal analyte sensitivity, protein immobilisation should achieve a  
high surface density of antibodies in an orientation that does not hinder 
accessibility of the Fab region binding sites (398). Furthermore, covalent 
attachment of antibody to a solid support can lead to a change in the structural 
configuration of the protein resulting in reduced binding ability (399). A number of 
parameters of the assay fabrication process were investigated here for their effect 
on assay sensitivity: 1) concentration of printed antibody; 2) the delay between 
SAM activation and functionalisation; 3) the buffer in which the antibody is printed 
and 4) the orientation of immobilised antibody.  
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3.4.1 Print concentration 
A large proportion of the cost associated with the fabrication of the LiScAR arrays 
is the protein or analyte used for functionalisation. The cost of each print is 
reduced by diluting the concentration of printed protein but may reduce the 
surface density and sensitivity of the resulting array spots. The effect of print 
concentration on assay performance was investigated by printing an anti-CRP 
polyclonal antibody sample (inherited from the research group) at a range of 
concentrations and recording the AUC of the CRP capture step, Figure 3.6. 
 
Figure 3.6 The effect of print concentration on response of the LiScAR CRP assay. Experiments were 
performed using the assay method described in 2.8.1. The AUC from several CRP injections is shown: 
3.1nM (green) 6.3 nM (purple), 12.5 nM (yellow), 50 nM (orange) and 100 nM (blue). Data points were 
derived from the averaged response of n=15 assay spots on a single array surface. 
The relationship between antibody print concentration and assay response was 
more significant at higher analyte concentrations. The standard printing protocol 
used 1 mg/mL print concentration and these data indicate that optimal sensitivity 
may be achieved with print concentrations in the range 0.5-2 mg/mL - offering a 
potential materials savings. At printed concentrations greater than 2 mg/mL, the 
response of the CRP assay did not improve. Other antibodies should be 
investigated to determine whether all proteins show a similar trend when printed 
under the same conditions.  
3.4.2 NHS Ester Hydrolysis  
A potential source of inter-assay sensitivity variation is the time delay between 
SAM drying and protein printing, which provides an opportunity for hydrolysis of 
the NHS ester intermediate. For best results, arrays were printed as soon as 
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possible after removal from the EDC/NHS solution and dried with N2 gas. The 
time required to prepare different numbers of arrays before printing may vary 
significantly if slides are dried with a gas hose individually as was the case in the 
present work: a single printed substrate could be printed in <5 minutes, whereas 
20 substrates required up to 15 minutes to dry before printing. Water in the air is 
in vast excess to that of the NHS ester intermediates on the activated SAM 
surfaces before printing. Therefore, the rate of NHS ester hydrolysis is 
proportional only to the concentration of the ester and the rate equation becomes 
pseudo first order: 
 𝑟𝑎𝑡𝑒 = 𝑘[𝐴] 3.1 
 
where k is the rate constant and [A] is the concentration of the NHS ester. First 
order reactions have a constant half-life: 
 𝑡1
2⁄
=
ln (2)
𝑘
 3.2 
 
where t1/2 is the half-life of the reaction and k is the rate constant. The relationship 
between assay response and printing delay may be written: 
 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑡 = 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠𝑡𝑎𝑟𝑡 × 0.5
𝑡
𝑡1
2⁄  
3.3 
 
where responset is the response of the assay following a printing delay of t and 
responsestart is the response with no delay before printing.  
The effect of NHS ester intermediate half-life on assay performance was 
investigated by delaying the time between SAM activation and printing of anti-
CRP polyclonal antibody at 1 mg/mL onto an array surface. The detection step 
response of the anti-CRP array spots to CRP samples are shown as a fit to 
equation 3.3 in Figure 3.7. The fitted responsestart was allowed to vary for each 
analyte concentration whilst the half-life parameter was fitted globally.  
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Figure 3.7 The effect of crosslinker half-life on LiScAR CRP assay performance. Experiments were 
performed using the assay method described in 2.8.1. Data points were derived from the averaged response 
of n=15 assay spots on a single assay surface. Duplicate determinations of analyte concentration are shown: 
0.78 (green), 1.56 (purple), 3.13 (yellow), 6.25 (orange) and 12.5 (blue) nM. Equation 3.3 is fit globally to 
data from assay response data when capture antibodies are printed with a delay following SAM activation. 
The half-life of the crosslinker in air at 70% humidity and 20 oC was determined to be 2.8 ±0.7 hours.  
The half-life of the NHS ester intermediate was estimated to be 170 ± 45 minutes. 
As expected, the half-life estimate in air is greater than the literature value of >120 
min for the hydrolysis half-life of PEG-NHS in solution at pH 7.4 (400, 401). For 
the data shown, the first substrate was printed as fast as possible following 
removal from the EDC/NHS solution with a benchmark time of 2 minutes and the 
data indicate that the assay response decreases by ~10% over a subsequent 30 
minutes delay to printing. In the present work, the time delay between SAM 
activation and protein printing was typically up to 10 minutes for a batch of <10 
substrates and limited mainly by the time required to dry arrays removed from the 
EDC/NHS solution. The duration of the drying step was therefore not significantly 
detrimental to the sensitivity of small batches of functionalised arrays but should 
be considered for mass production, where the drying step should be automated 
to dry multiple arrays simultaneously.  
3.4.3 Print Buffer 
Antibody samples are typically stored in PBS with sodium azide and occasionally 
BSA. The BSA minimises loss of antibody from binding to the plastic container 
surface and the sodium azide is bactericidal. Ideally, antibodies would be printed 
for EDC/NHS coupling from purified solutions of PBS only because as the sodium 
azide and BSA compete with IgG for the activated SAM linkers: leading to lower 
surface functionalisation and reduced assay sensitivity.  
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BSA competition for SAM linkers was investigated for its effect on assay 
performance by printing solutions of anti-CRP polyclonal antibody containing 
BSA. The capture step response of the CRP assay to 50 nM CRP is shown in 
Figure 3.8. The effect of BSA competition at different ratios of linker to spacer 
SAM components was also tested. 
 
Figure 3.8 The effect of SAM linker availability on LiScAR CRP assay performance. Experiments were 
performed using the assay method described in 2.8.1. The response of the CRP assay to 50 nM CRP is 
shown for assay spots functionalised with 0 mg/mL BSA (green) and 1 mg/mL BSA (orange) at 3 linker : 
spacer ratios. Error bars are 2SD from n=3 experimental repeats recording the averaged response of n=15 
assay spots. 
The ratio of linker to spacer SAM components had no effect on the response of 
the CRP assay for the range of ratios shown in Figure 3.8. However, when 
competition for linker components was introduced, via the inclusion of BSA in the 
printed antibody solution, assay response was significantly reduced. The result 
highlights that for optimum results, commercially available antibodies supplied 
with BSA should be buffer exchanged to remove BSA before printing.  
Additional properties of the printed antibody solution may affect assay sensitivity. 
The pI of an antibody is the pH at which the antibody will not migrate in an electric 
field due to the zwitterion structure having a net charge of zero. The isoelectric 
point (pI) of antibodies has been shown to vary significantly between samples 
(402), typically in the range 6-12 (402). Antibodies at pH<pI are positively charged 
and will be electrostatically attracted to the negatively charged gold nanoparticle 
surface (403) although their amine groups may react less readily with the SAM 
linker. Antibodies at pH>pI are negatively charged but their amine groups will be 
neutral and react more readily with the activated SAM linker. Print solution pH 
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also has an effect on the hydrolysis half-life of PEG-NHS esters, which exceeds 
120 min at pH 7.4, but is <9 min at pH 9 (400). The effects of electrostatic 
attraction and increased NHS ester half-life (pH<pI) are likely to give a greater 
improvement to surface coverage when the concentration of protein is low and 
limited by molecular collisions. Conversely, when protein concentration is not 
limiting, the effect of improved nucleophilicity (pH>pI) may be more advantageous 
to maximise surface coverage, despite reduced NHS ester half-life. pH may also 
affect antibody orientation on the assay surface (404) leading to variation in steric 
availability of binding sites, discussed later. 
The effect of printed antibody pH on assay response was investigated 
experimentally using the CRP assay. The capture antibody was buffer exchanged 
using a dialysis spin column, from PBS (containing 0.05% sodium azide) into 
phosphate buffer (0.1 M) at a number of pH values and printed using the SOP. 
The capture and detection step responses of the CRP assay are shown in Figure 
3.9.  
 
Figure 3.9 The effect of pH and buffer exchange on the LiScAR CRP assay capture step. Experiments were 
performed using the assay method described in 2.8.1. Buffer exchange prints (blue) are compared to ‘pH on 
top’ prints (red). Data points were derived from the averaged response of n=15 assay spots. A line of best 
fit (quadratic) is shown in black. 
Assay response did not appear to vary significantly within the pH range tested – 
although pH 8 displayed the highest mean assay response. Buffer exchange of 
antibody samples using spin columns is not always possible due to the limited 
volumes of antibody samples. A second buffer printed immediately on top of 
printed assay spots in a 1:1 volume ratio was investigated for its ability to change 
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the pH of antibody tethering without the need for buffer exchange - referred to as 
the ‘pH on top’ method. Phosphate buffer at a number of pH values was printed 
immediately following a standard print of anti-CRP from PBS at pH 7.4 and results 
are shown in Figure 3.9. Assay sensitivity was consistent between the buffer 
exchanged and ‘pH on top’ groups, suggesting that either method may be used 
to investigate the effect of solution pH on assay performance. Furthermore, assay 
spots functionalised with antibody after the buffer exchange (removing sodium 
azide) did not display a higher mean response to antigen than the ‘pH on top’ 
group. A limitation to the ‘pH on top’ method is the residual buffering capacity of 
the PBS antibody solution printed first, which will resist changes to pH associated 
with the second printed solution. A further limitation of the ‘pH on top’ method is 
the delay between printing the first and second buffers (~1 minute) during which 
time antibody tethering occurs as a function of the first buffer only. The error in 
estimated pH is minimised by printing 0.1 M solutions of the second buffer, which 
is an excess to the 0.01 M Na2HPO4 and 0.0018 M KH2PO4 found in PBS (the 
capture antibody buffer).  
The capture antibodies for the CRP and C5a assays were printed using the ‘pH 
on top’ method using phosphate buffer and borate buffer at pH values 5-7.4 and 
8-10 respectively. The capture and detection steps of the CRP and C5a assays 
were performed for a number of analyte concentrations to observe the effect of 
buffer and pH on assay sensitivity,  Figure 3.10. 
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Figure 3.10 The effect of printing buffer and pH on the LiScAR CRP and C5a assay calibration curves. 
Experiments were performed using the assay method described in 2.8.1. Data points were derived from the 
averaged response of n=15 assay spots from two assays. a) CRP capture step. b) CRP detection step. c) 
C5a capture step. d) C5a detection step. Borate buffer was used for pH 8-10 and phosphate buffer was used 
for pH 5-7.4.  
The data suggest that assay response was greatest when the antibodies are 
printed at pH 7.4-8. The results are in good agreement with literature showing 
reaction of NHS esters with amines is most efficient at pH 7.2–8.5 (405). 
Interestingly, assay performance appeared to rise from pH 9 to pH 10 in the 
capture step of both assays but not in the detection step. Experimental conditions 
such as pH can significantly affect the strength of individual thiol–gold contacts 
(360) and high pH values favour SAM dissociation from the gold surface (406) 
which reduces antifouling. The increase in capture signal relative to detection 
signal may therefore have occured as a result of nonspecific binding at higher pH 
values.  
The optimised buffer conditions: 1 mg/mL antibody without BSA or sodium azide, 
borate buffer pH8 ‘on top’ and minimum delay following SAM activation did not 
generate assays when applied to antibodies which failed the initial screen.  
3.4.4 Antibody Orientation 
It is unlikely that assays failed due to lack of assay surface functionalisation, 
owing to the high abundance of available lysine residues for tethering.  However, 
the covalent immobilisation of proteins has been shown to alter their primary 
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structure and antibody activity has been shown to reduce with tethering proximity 
to the active site (407). The range of available tethering locations using EDC/NHS 
coupling typically leads to high heterogeneity of products formed during the 
synthesis of (ADCs) (381) and a significant portion of antibodies on the 
biophotonic surface could be oriented such that the binding of antigen to the Fab 
region is hindered (398).  
 
Figure 3.11 Possible orientations of antibodies immobilised on an assay surface via random deposition. The 
“end on” and “side on” orientations are expected to allow antigen binding, whereas the “head on” and “lying 
on” orientations may sterically hinder antigen binding. The relative abundance of each configuration will limit 
the mass of antigen which can be captured by the assay surface and by extension, the LiScAR assay 
response.   
Tethering antibodies far from the Fab region minimises changes to the structural 
configuration of the Fab region which might reduce binding ability (399). 
Furthermore, the “end on” configuration is preferred due to minimal steric 
hinderance of antigen binding (398). Orientation control of antibodies on 
biosensor surfaces has been shown to improve assay sensitivity up to 200-fold 
compared to random deposition (408).  
Site-specific immobilisation of antibodies on a sensor surface is achievable by a 
number of methods (398, 409). Firstly, the isoelectric point of the Fab region is 
often larger than that of the Fc region for most antibodies, leading to antibodies 
with dipoles which may be oriented on a surface using an electric field (410, 411). 
The unique properties of the Fc region may also be targeted for site specific 
immobilisation. Antibodies pre-treated with HCl buffer at pH 2 before 
immobilisation mainly adsorb “end on” to hydrophobic surfaces, due to an 
increase the hydrophobicity of the Fc region which is less stable than the Fab 
region (404). The Fc region is also glycosylated and periodate oxidation of diols 
in the sugars generates aldehydes which can tether to SAM capped with amines 
(via imine bonds) (412). The high abundance of histidine residues on the Fc 
region can be used to orient antibodies via coordination to surfaces with cations 
presented on chelates (413). Reduction of disulphide groups in the hinge region 
128 
 
of IgG yields antibody fragments with exposed thiols which can be tethered to a 
maleimide surface (414). Biotin has been genetically incorporated into the Fc 
region of an antibody, leading to a 5-fold improvement in antigen detection limit 
when the antibody was immobilised on a streptavidin coated sensor surface 
compared to random deposition (415).  
The most common method for controlled orientation of antibodies on a biosensor 
surface uses the molecular recognition of Fc binding proteins (411, 416-418). The 
PAG-functionalised assay surface of the IgG assay, discussed in Chapter 2, 
binds IgG via the Fc region and generates an IgG layer in which Fab regions are 
most likely to be oriented away from the assay surface (419). Following non-
covalent binding of the antibody panel onto the PAG sensor surface, antigen 
capture was observed for antibodies which failed show antigen capture when 
crosslinked to SAM, Table 3.3.  
Table 3.3 Comparison of antigen capture by two antibody immobilisation methods: covalent crosslinking to 
SAM and reversible binding to PAG. Antigen capture events are noted as successful if a specific signal is 
observed which is >3σ of the control channel. 
 Antigen capture observed 
 
Antibody covalently bound to 
SAM 
Antibody non-covalently bound to 
PAG 
Anti-Bb no yes 
Anti-iC3b no yes 
Anti-C4d/C4 no no 
Anti-C3b/C3 no yes 
Anti-C4b/C4 no yes 
Anti-TCC yes yes 
Anti-C5a yes yes 
Anti-C3a/C3 yes yes 
 
The result suggests that the anti-Bb, anti-iC3b, anti-C3b/C3 and anti-C4b 
exhibited reduced antigen binding ability when crosslinked to the SAM surface 
due to either unfavourable tethered orientations or structural changes associated 
with covalent tethering.  
The disadvantage of noncovalent antibody immobilisation is that the capture 
antibody dissociates with elution of the antigen and must be reloaded onto the 
PAG surface before each measurement – increasing the duty cycle time, 
materials cost and sources of error. Furthermore, the PAG surface can capture 
detection antibodies non-specifically and increase the background signal of the 
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detection step. In the production of affinity columns for affinity column 
chromatography, antibody is allowed to bind to the PAG within the column before 
covalent crosslinking of the PAG-IgG complexes to generate reusable surfaces. 
The same technique is possible on the PAG functionalised biophotonic surfaces 
using an appropriate chemical crosslinker.  
Disuccinimidyl suberate (DSS) is a linear compound with NHS ester moieties at 
each end. As described in Chapter 2, NHS esters are susceptible to nucleophilic 
attack by primary amines to form stable amide bonds with lysine residues on the 
surface of proteins. In contrast to EDC, which is a zero length crosslinker, the two 
NHS esters of DSS are linked by a 8-carbon chain. DSS is therefore a ‘chemical 
stapler’ and an appropriate choice for crosslinking existing protein-protein 
interactions such as PAG-IgG. The structure of DSS and its mechanism of amine 
crosslinking are shown in Figure 3.12. 
  
Figure 3.12 Chemical structure of DSS and amine crosslinking mechanism. The carbonyl group of DSS is 
susceptible to nucleophile attack by amine groups which leads to substitution of the NHS group and the 
formation of an amide bond. Both NHS esters of DSS can react with amine groups on proteins within the 
spacer arm length of 11.4 Å to form a chemical crosslink. Unreacted DSS can be quenched by the addition 
of ethanolamine.  
The protocol developed for DSS crosslinking of IgG to PAG was as follows: 
1. Biophotonic array of BSA and PAG was exposed to a high concentration 
of capture antibody until maximal surface coverage is achieved. 
2. PBS running buffer was used to remove unbound IgG - ensuring a uniform 
2-dimensional layer of IgG. Results were improved by repeating steps 1 
and 2 several times to achieve a highly ordered and high density PAG-IgG 
surface. 
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3. 6.5 mg of DSS was dissolved in 0.5 mL DMF before mixing with PBS. The 
precipitate formed was removed with centrifugation for 5 minutes at 4.4 g. 
Failure to remove precipitate may block instrument tubing. 
4. The DSS solution (0.014 M) was injected into the biophotonic instrument 
for a period of time. 
5. An aqueous solution of ethanolamine (0.1 M) was used to quench the 
reaction for 10 minutes if the array was to be used immediately, otherwise 
the array was left in PBS overnight following step 6 to allow all NHS esters 
to hydrolyse. Use of an array expressing NHS esters leads to nonspecific 
and irreversible crosslinking of analytes. 
6. The assay surface is washed for 100 seconds in H3PO4 (10 mM) to remove 
unbound IgG.  
As with EDC/NHS coupling, a disadvantage of DSS crosslinking is the lack of 
specificity which may lead to biological activity loss when the crosslinker binds 
close to the Fab binding site. The duration of crosslinking is therefore a critical 
parameter in the protocol: assay sensitivity improves with antibody surface 
coverage but excessive crosslinking may lead to denaturing and a reduction in 
antigen binding ability. The fraction of PAG-IgG interactions which were 
successfully crosslinked was estimated by comparing the RI before and after the 
crosslinking and wash steps, Figure 3.13. 
 
Figure 3.13 PAG channel response to DSS crosslinking of IgG. PAG was immobilised using the assay 
method described in 2.8.1. A and B represent the RI before and after crosslinking and are used to estimate 
the extent of IgG crosslinking. Signal is the averaged response of 15 assay spots.  
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The percentage coverage of IgG retained following crosslinking was estimated 
by expressing A as a percentage B in Figure 3.13. DSS crosslinking time was 
optimised by recording the m of the CRP assay capture step for a 12.5 nM 
sample of CRP after different crosslinking times, Figure 3.14. 
 
Figure 3.14 The relationship between DSS crosslinking time and 𝑚  of the LiScAR CRP assay capture step. 
PAG was immobilised using the assay method described in 2.8.1. Data points were derived from the 
averaged response of n=15 assay spots. a) time dependence of coverage % (blue) and 𝑚 (orange). Error 
bars are 95% CI from the Langmuir model estimate of 𝑚  from single experiments. b) the linear relationship 
between coverage % and 𝑚  with R
2=0.93.  
The results show that that 90% surface coverage was retained after 100 seconds 
and antibody surface coverage is linearly correlated with assay response within 
range shown. Assay response is expected to show a decreasing trend with 
extensive crosslinking time but the data collected do not show the maximum.  
The anti-Bb, anti-iC3b, anti-C3b/C3 and anti-C4b antibodies showed antigen 
capture when non-covalently bound to PAG (Table 3.3) but failed to show antigen 
capture when covalently immobilised on PAG or the SAM surface, indicating their 
lack of antigen binding ability is a result of covalent immobilisation rather than 
immobilised orientation. The anti-C4d/C4 failed to capture antigen in any 
experiment, whether covalently immobilised or not, suggesting an inherent lack 
of antigen binding ability which was confirmed by immobilising antigens on the 
SAM surface and observing a lack of antibody binding. 
Antibodies which showed antigen capture when tethered directly to the SAM 
surface also captured antigen when crosslinked to PAG but the oriented surfaces 
displayed m values for antigen capture that were 30% lower than when the same 
antibodies were directly tethered to the SAM surface. The inferior performance of 
the oriented surfaces may be attributed to denaturing of the capture antibody (due 
to DMF or crosslinking) and/or a more favourable IgG surface density on the SAM 
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surface compared to the PAG surface. A lower surface density may limit the 
antigen binding capacity due to lack of immobilised Fab regions whilst high 
density packing of IgG may hinder the reaction between Fab regions and antigen 
(419). IgG loading times of 12 hours did not improve assay response. Future 
studies could attempt oriented crosslinking using water soluble crosslinkers such 
as sulfo-DSS to minimise denaturing of IgG and PAG.  
3.5 Novel Assays of Complement Activation 
The optimised assay fabrication processes, using EDC/NHS coupling, were used 
to produce four novel assays for C5a, TCC, C3 and TNFα. The assays use the 
antibody pairs shown in Table 3.4. Capture antibodies were immobilised on the 
amino substrate surface described in section 2.4 using the assay method 
described in 2.8.1. 
Table 3.4 Antibody pairs used in the production of four novel sandwich immunoassays. Assays were 
performed using the assay method described in 2.8.1. 
Target 
analyte 
Capture antibody 
target 
Supplier 
Detection 
antibody 
target 
Supplier 
C5a C5a neo-epitope 
ThermoFisher 
#GAU 025-05-02 
C5a/C5 
ThermoFisher 
#PA5-35000 
TCC 
Polymerised C9 
neo-epitope 
Quidel #A239 N/A N/A 
C3 C3a/C3 
ThermoFisher 
#GAU 013-16-02 
C3 
Bio-Rad 
#AHP1752 
TNFα TNFα 
Bio-Rad 
AHP1212 
TNFα 
Bio-Rad 
#AHP1212 
 
The specificity of the assay capture steps was established previously with 
mixtures of purified antigens in PBS (Figure 3.3) and the detection steps of each 
assay show a specific response following analyte capture from purified solutions 
of a single analyte (Figure 3.5). However, cross-reactivity was also tested in order 
to assess whether the assays could be performed simultaneously as a single 
multiplex assay.  
The cross-reactivity of the detection steps was tested by immobilising all analytes 
on an assay surface and observing their response to the capture and detection 
steps of all assays. A capture step of 200 seconds was performed for each 
antigen at 15 nM. A detection step of 200 seconds was then performed using 
each detection antibody at 200 nM (or anti-sera diluted 500-fold). As seen in 
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Figure 3.15, 100 seconds of PBS running buffer between capture and detection 
provides a reliable measure of the pre-detection signal for AUC analysis and 
could also be used to estimate kd of the capture step. Results of cross-reactivity 
testing are shown in Figure 3.15.  
 
Figure 3.15 Signal response of LiScAR sensor surfaces, functionalised with analyte, to assay capture and 
detection steps. Experiments were performed using the assay method described in 2.8.1 for n=2 
determinations of analyte: a) C5a, b) C3, c) TNFα and d) CRP. Signals are the averaged response of n=15 
assay spots. 
The RI associated with detection antibody capture by immobilised PAG showed 
significant variation despite consistent concentrations. The C3 detection step had 
a maximum signal of 3 mRIU in the PAG channel whereas the C5a detection step 
exceeded 5 mRIU in the PAG channel. The varying RI change associated with 
different IgG samples binding to the PAG surface is explored in detail later in the 
Chapter. 
All detection antibodies bound strongly to their respective immobilised analytes 
and the PAG positive control, indicating that few epitopes were denatured by 
surface tethering. Following analyte capture, the C5a detection step caused a 
response in the anti-C5a channel, the C5a channel and the PAG channel only – 
indicating that the detection antibody does not have affinity for the analytes of 
other assays (Figure 3.15a). The CRP channel appeared to respond to the TNFα 
detection step (Figure 3.15c) and the TNFα channel appeared to respond to the 
CRP detection step (Figure 3.15d) suggesting some cross-reactivity. However, 
the specific response of the anti-TNFα and anti-CRP channels to their respective 
analytes was significantly larger than the cross-reaction responses. The results 
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suggest that the assays for C5a, TCC, TNFα and CRP may be performed 
simultaneously due to the specificity of their detection antibodies. The C3 
detection step used antisera containing many different antibodies and appeared 
to exhibit affinity for all immobilised analytes (Figure 3.15b). Therefore, the C3 
detection step must be performed separately and after the detection steps of the 
other assays. The anti-C3d/C3 monoclonal antibody MCA2606 was also able to 
bind captured C3 and showed an adequately specific response (Appendix 1) 
although the signal was significantly weaker than detection with antisera. 
A multiplex array containing the assays for C5a, TCC, C3 and TNFα was used to 
assess the sensitivity of these new assays. The performance of the CRP assay 
is not presented here. Standard concentrations of each analyte were prepared at 
four-fold higher concentrations that desired for the standard curves and mixed 
equally, in random sequence before testing in duplicate. The detection steps of 
the C5a and TNFα assays were performed simultaneously first, followed by the 
detection step of the C3 assay. A 5-parameter logistic model was fit to the AUC 
data at each analyte concentration to produce standard curves. A CV analysis of 
the novel Complement assays is shown in Figure 3.16. Samples of inactivated, 
pooled human serum were diluted 30-fold and assayed for C5a and TCC as an 
initial test of assay susceptibility to nonspecific binding. The dissociation phase 
following analyte capture in serum was extended to 200 seconds to allow 
dissociation of non-specifically bound serum components until the signal baseline 
was stable. 
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Figure 3.16 Calibration of AUC dependence on analyte concentration for a multiplex panel of LiScAR assays. 
Experiments were performed using the assay method described in 2.8.1. Data points were derived from the 
averaged response of n=15 assay spots. The standard curves of 4 assays are shown: a) C5a, b) TCC, c) 
C3 and d) TNFα. A 5-parameter logistic model (black) is fit to the data from n=2 determinations of purified 
standards in PBS (green and orange). A sample of pooled human serum (black) serves as a control in the 
C5a and TCC assays. Intra-assay CV at each analyte concentration is shown for each assay (blue). 
The 5-parameter logistic model fits well to the data with R2>0.95 for all assays, 
confirming that the analytes tested did not cross-react and demonstrating a novel 
4-plex assay with a duty cycle of 15 minutes.  
The C5a assay produced a reading of zero for pooled serum as expected and 
suggests that the TP of the pooled serum was not activated. The C5a assay was 
used to profile the increase in C5a concentration following activation of the pooled 
serum and results are shown in Chapter 7. The non-zero TCC reading for 
inactivated serum implies that the assay experienced significant matrix effects 
from the serum, or the epitope target of the capture antibody was not specific to 
TCC. The TCC assay antibody may have some affinity for C9 that is not 
incorporated into TCC, rendering the assay inappropriate for use with serum 
samples.  
CV values were calculated across the range of the standard curves to show which 
analyte concentrations are derived most precisely by the assays. AUC values 
which exceed the limits of the standard curve model generated values of zero.  
Enzo ELISA kits state that intra-assay CV should be less than 10% (374) which 
is achieved for all three assays at an analyte concentration of 6.3 nM. The TCC 
assay exhibits the lowest CV values tested with a value of 2% at 6.3 nM and the 
performance is attributed to large AUC values associated with the mass of TCC 
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which exceeds 1 megadalton. The dynamic ranges of each assay and associated 
CV values are shown Table 3.5.  
Table 3.5 Performance assessment of the novel LiScAR Complement assays. 
 C5a TCC C3 TNFα 
LLoQ (CV) 3.2 nM (16%) 1.6 nM (16%) 3.2 nM (10%) 7.5 nM (35%) 
ULoQ (CV) 12.5 nM (41%) >50 nM (3%) 12.5 nM (48%) >30 nM (6%) 
Min CV 
(concentration) 
5% (6.3 nM) 2% (6.3 nM) 10% (6.3 nM) 6% (30 nM) 
Dynamic 
range CV % 
21 7 23 25 
 
The range of TNFα in healthy serum is 11 ± 7 pg/mL (420) and has a mass of 17 
kDa (higher for dimers and trimers), corresponding to a concentration range of 
0.66 ± 0.43 pM (lower for dimers and trimers) which is below the 7.5 nM LLoQ of 
the TNFα assay. As a result, the TNFα assay was not sufficiently sensitive for 
use with human serum and was not investigated further.  
The dynamic ranges of the C5a and C3 assays were similar and smaller than the 
range of possible analyte values in serum. Consequently, samples should be 
assayed for C5a and C3 at a number of dilutions to ensure the analyte 
concentration falls within the dynamic range of the assay. The upper limit of 
quantitation of the TCC assay was not apparent in the range of standard 
concentrations tested and was not investigated in further experiments due to the 
prohibitively expensive quantities of purified protein required for calibration.  
The specificities of the C5a, TCC, TNFα and C3 assays and their calibration 
characteristic were assessed here on a multiplex assay surface – demonstrating 
the ability of the LiScAR to record multiple biomarkers in a single test. However, 
before any assays can be used with confidence, the assays must be 
quantitatively validated with an existing analytical technique.  
3.5.1 Assay validation 
Validation of novel assays involves a comparison of the new technique to a gold 
standard (421) and the relationship between two variables (such as the 
measurements from two analytical techniques) is typically assessed with 
correlation and linear regression analysis (422). Correlation analysis quantifies 
the degree to which two variables are related by computing the Pearson 
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correlation coefficient, r, based on the covariance of the results of both assays. 
Sample covariance is calculated using the equation: 
 𝑐𝑜𝑣(𝑥, 𝑦) =
∑ (𝑥𝑖 − ?̅?)(𝑦𝑖 − ?̅?)
𝑛
𝑖=1
𝑛 − 1
 3.4 
 
where n is the number of paired measurements and ?̅? and ?̅? represent the means 
of each measurement respectively. The sign of the sample covariance depends 
on the sign of the correlation (positive or negative). The magnitude of the 
covariance depends on the magnitude of the data. Correlation between data of 
different magnitudes can be easily compared using the Pearson correlation 
coefficient, which is calculated from the covariance using the equation: 
 𝑟 =
𝑐𝑜𝑣(𝑥, 𝑦)
𝜎𝑥𝜎𝑦
 3.5 
 
where σx and σy are the standard deviations of the two measures (described 
previously in Chapter 2). The Pearson correlation coefficient, r, has a value 
between -1 and +1 with a sign dependent on sign of the correlation (positive or 
negative) and a magnitude corresponding directly to the strength of the 
correlation (zero if no correlation). As such, a strong positive correlation will 
always have an r value close to 1, regardless of the magnitude of the data. 
A further metric of correlation is linear regression, in which a straight-line model 
is fitted to a plot of one variable against the other. In contrast to covariance or 
Pearson correlation, linear regression enables the value of one variable to be 
predicted based on the value of the other. The regression line is obtained using 
the method of least squares (422), which finds the parameter values of a linear 
model that produce the smallest sum of the squared deviations between model 
and data, discussed further in Chapter 4. The goodness of fit (how closely the 
data match the fitted trend line) can be quantified with the coefficient of 
determination, R2, representing the ratio of the sum of squared residuals between 
the data and the regression line to the data and the mean. Correlation and linear 
regression may be used compare the results obtained using a novel assay to the 
results obtained using a gold standard technique.  
To assess the validity of the novel Complement assays, a number of analyte 
samples at a range of concentrations were measured on the novel biophotonic 
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assays and the equivalent gold standard assays. The gold standard for C5a and 
TCC measurement is ELISA, whilst the standard for C3 measurement in the 
clinical laboratory is an immunoturbidimetric assay. The C5a and TCC assays 
were assessed using PBS samples of purified proteins. The C5a and C3 assays 
were assessed using the results of serum samples from the clinical investigation 
presented in Chapter 6. Activated serum samples were diluted 20-fold for the C5a 
assay, whilst inactivated pooled serum samples were diluted to between 40% 
and 90% to produce a range of C3 concentrations before testing by diluting 
samples 640-fold. The dissociation phase following analyte capture in serum was 
extended to 200 seconds to allow dissociation of non-specifically bound serum 
components until the signal baseline was stable. A linear regression analysis of 
all three assays compared to their gold standards is shown in Figure 3.17. 
 
 
Figure 3.17 Correlation analysis of gold standard assays compared to the LiScAR Complement assays. 
Experiments were performed using the assay method described in 2.8.1. Data points were derived from the 
averaged response of n=15 assay spots. Three assays were assessed: a) C5a, b) TCC, and c) C3. PBS 
data (green) and serum data (gold) fit to a linear model with y intercept of zero (blue line) with R2 values of: 
0.96, 0.99 and 0.98 respectively. The ideal correlation, with a gradient of 1 and y intercept of zero, is shown 
for comparison (black dashed line). 
The C5a and TCC assays showed a strong linear correlation with ELISA whilst 
the biophotonic C3 assay displayed a significant offset from the results obtained 
using the turbidimetric assay - indicated by the large non-zero y intercept and low 
gradient of the linear regression model. The quantitative results of correlation and 
regression analysis using the equations and methods mentioned previously are 
shown in Table 3.6.  
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Table 3.6 Results of correlation and regression analysis for the comparison of novel LiScAR assays to their 
gold standards.  
 C5a TCC C3 
Sample 
covariance 
64.9 60.6 1.53×104 
Correlation, r 0.98 0.99 0.99 
Gradient of 
regression line 
0.90 1.2 0.35 
Intercept of 
regression line / 
nM 
-1.3 1.6 940 
 
The quantitative measurement of continuous variables always has some degree 
of associated error due to analytical imprecision and assessment of the 
agreement between two measures is therefore challenging. For example, the 
offset in the C3 assay is not reflected in the correlation and linear regression 
goodness-of-fit statistics as these analyses study the trend between two variables 
but do not value the differences in the pairs of results. The y-intercept of the 
regression line indicates poor absolute agreement but cannot distinguish 
between systematic error and nonlinear assay differences which is best assessed 
using a Bland-Altman analysis. 
A Bland-Altman analysis uses the mean and standard deviation of the differences 
between measures to define limits of agreement (423). The test result is 
subtracted from the gold standard result and the difference is plotted as a 
percentage of the mean of the two readings such that large positive values of 
percentage difference indicate that the new assay under-estimates the 
concentration compared to the gold standard. A Bland-Altman analysis of the 
novel assays and their respective gold standards is shown in Figure 3.18.  
 
Figure 3.18 Bland-Altman analysis of the LiScAR Complement assays. LiScAR experiments were performed 
using the assay method described in 2.8.1 and data points were derived from the averaged response of 
n=15 assay spots. Three assays were assessed: a) C5a, b) TCC, and c) C3. PBS data (green) and serum 
data (gold) define the mean (black line) and 2SD (red dashed lines) of assay differences.  
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Bias between the novel assays and their gold standards is observed as a non-
zero mean difference in the Bland-Altman plots and is apparent in all three assays 
to varying degrees. The bias is considered systematic if the distribution of the 
percentage difference is relatively constant across the range of the assay. The 
percentage difference is confounded by measurements approaching the LLoQ, 
where small absolute differences are perceived as large relative differences. For 
example, the blank serum reading of the C5a assay was excluded from the 
analysis as the value was lower than the LoQ of the assay.  
The C5a and TCC assays showed errors with no dependence on the mean 
reading and the associated bias appears to be systematic: on average the C5a 
assay under-estimated by 26 ± 27 % and the TCC assay over-estimated by 36 ± 
39 %. The bias could be accounted for in future assays to improve assay 
accuracy relative to the gold standard (for the analyte concentration range 
shown). The bias associated with the C3 assay was 55 ± 21 % and visibly 
worsened at greater analyte concentrations. The worsening error observed in the 
C3 assay is attributed to serum matrix effects induced by varying serum dilution. 
The turbidimetric assay for C3 suggests the pooled human serum had a C3 
concentration of 1420 mg/L (7.68 µM) and the offset in the biophotonic C3 assay 
results may have been due to a number of factors. Firstly, error in the standard 
C3 concentrations may have occured as a result of concentration error in the 
stock which was supplied as a solution rather than reconstituted from a solid. 
Errors may also have occured due to the instability of the C3 protein during 
sample preparation. Calibration of the assays is critical and highlights the need 
for high quality standards of precisely known concentrations. Future work should 
use spiked C3 serum samples, providing a broader range of C3 concentrations 
and enabling a constant dilution factor to be used for Bland-Altman validation 
analysis. The C5a and C3 assays were used for rapid sampling of in vitro 
Complement activation, shown in Chapter 7. 
The search strategy used here to find antibodies capable of capturing antigen on 
the LiScAR assay surface, involved printing of candidate capture antibodies and 
simultaneous testing with analyte samples. This approach is efficient for testing 
a panel of antibodies but is experimentally time consuming for individual 
antibodies as a new assay must be fabricated each time a new antibody becomes 
available for testing. Furthermore, the success rate of the search for capture 
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antibodies was <50%. Future LiScAR assay development would benefit from 
rapid assessment of antibody sample characteristics ahead of printing or use for 
detection because kinetic parameters and specificity information is rarely 
available for commercial antibodies.  
3.6 A Rapid and Quantitative Technique for Assessing IgG Monomeric 
Purity 
In nontherapeutic antibodies used for research, a link has been made between 
poor reproducibility of results and variability in antibody quality (424-426). 
Antibody samples are known to undergo degradation over time during storage 
(427) and the proportion of intact antibodies in a sample (the monomeric purity) 
is tested to ensure potency of therapeutic antibodies (428). Antibodies for 
research should also be assessed for monomeric purity to ensure reproducible 
experiments (429) and a rapid technique for assessing the monomeric purity of 
antibody samples could test the extent of degradation in samples immediately 
before use.  
Lot-to-lot comparisons of antibody samples should be performed with reference 
standards (430). NIST provide a monoclonal antibody, the NISTmAb, designed 
to support biopharmaceutical innovation by serving as reference standard for 
comparable evaluation of antibody-based techniques between different 
laboratories (431-433). The NISTmAb is a recombinant humanised IgG with a 
known sequence (434) specific to the respiratory syncytial virus protein F (RSVF) 
(435). The NISTmAb is well characterised with a known monomeric purity 
variation of 96.8-98.7% between batches, as characterised by comparing the 
relative peak areas of a non-denaturing size exclusion chromatogram (431, 432). 
Non-enzymatic fragmentation in monoclonal antibody samples is frequently 
observed at the hinge region disulphide bonds. In this region, a single polypeptide 
connects the Fab and Fc fragments and hence cleavage is followed by separation 
of these fragments (436). The most abundant antibody fragments and their 
respective masses observed by non-denaturing size exclusion chromatography 
SEC (427) are shown in Figure 3.19. 
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Figure 3.19 Fragmentation products typically observed in samples of IgG. Variable and constant domains 
are marked V and C respectively with subscripts for light and heavy chain marked L or H respectively. Heavy 
chain regions are numbered 1, 2, and 3 starting from the N-terminus and black lines indicate disulfide bonds. 
The most abundant antibody fragments recorded in IgG samples and their respective molecular masses are 
also shown. Heavy chain and Light chain fragments are labelled Hc and Lc respectively. The 50 kDa 
fragment may originate from the Fab region as shown or the Fc region. Similarly, the 25 kDa fragment may 
originate from the Lc as shown, the Hc of the Fab region, or Hc of the Fc region. 
SEC, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and mass spectrometry (MS) are the gold standard techniques used for 
characterisation and stability assessment of antibodies (427, 437, 438). Non-
reducing SDS-PAGE analysis of a papain digestion of the NISTmAb shows bands 
for Fab and Fc fragments at 50 kDa, whilst under reducing conditions, the 
disulphide bonds between heavy and light chains are separated to produce two 
species of 25 kDa (439). The primary amino acid sequence and PTM structure of 
antibodies are readily confirmed by  liquid chromatography and mass 
spectrometry (440) however there are no easy methods to establish the 
monomeric purity of a sample immediately before use. A plasmonic biosensor 
platform such as the LiScAR may enable rapid monitoring of monomeric purity in 
a research setting.   
Plasmonic biosensors are typically used to observe antibody binding kinetics and 
are fundamentally mass sensors, as described in Chapter 2. Accurate kinetic 
parameters may be derived using antibody samples of high monomeric purity and 
fitting the Langmuir binding interaction model to kinetic data in a global fit (368, 
369). However, kinetic analyses are fundamentally limited by unknown antibody 
concentration and monomeric purity because the presence of multiple binding 
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interactions in fragmented antibody samples invalidates the 1:1 assumption of 
the Langmuir model (369). 
The remainder of the present chapter describes a rapid technique to assess Fab 
specificity and monomeric purity using the LiScAR. Antigen or PAG were 
immobilised on the amino substrate surface described in section 2.4 using the 
assay method described in 2.8.1 to generate assays for Fab and Fc fragments.  
The technique described here is comprised of two steps, shown in Figure 3.20. 
 
Figure 3.20 Biophotonic assays used to characterise the monomeric purity of an IgG sample. Proteins were 
immobilised on the amino substrate surface described in section 2.4 using the assay method described in 
2.8.1. The Fab assay uses a sensor surface functionalised with antigen (orange) to confirm antibody 
specificity and derive antibody-antigen binding kinetics. The Fc assay uses a sensor surface functionalised 
with PAG (blue) to capture Fc fragments. Antibody captured by the Fc assay is used as an antigen assay to 
determine the antibody-antigen binding stoichiometry. Intact IgG may bind a maximum of 2 antigens (orange 
circles), whereas samples containing fragments lacking Fab regions will show a lack of antigen capture. The 
sensor response of the antigen surface (orange) and PAG surface (blue) to the NISTmAb is shown, with and 
without the inclusion of the antigen assay step (solid and dotted lines respectively) to highlight the signal of 
antigen capture. Signals are the averaged response of n=20 assay spots.  
In the first step, antibody binding to the Fab assay provides data for kinetic 
analysis of the antibody-antigen interaction and the mass of antibody binding to 
the Fc assay is recorded simultaneously. For a constant number of binding sites 
on the Fc assay surface, an initial estimate of monomeric purity may be obtained 
by observing a mass deficit in degraded samples compared to the NISTmAb. In 
the second step, the mass of antigen which can bind to the antibodies 
immobilised on the PAG surface (an antigen assay) is recorded. The 
stoichiometry of the antibody-antigen binding reaction on the PAG surface is 
derived from the masses of antibody and antigen captured by the Fc and antigen 
assays. Samples with high monomeric purity should exhibit an average of 1-2 
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antigens bound per antibody, depending on antibody mass, whereas antibody 
fragments lacking Fab regions should display a lower mean stoichiometry. A 
panel of eight antibody samples was tested: the NISTmAb, a therapeutic 
Infliximab biosimilar and six commercially available monoclonal and polyclonal 
samples for research use. Results are validated with native ESI-QTOF mass 
spectrometry – a gold standard technique for assessing the relative abundance 
of antibody fragmentation products in a sample (441).  
3.6.1 Materials and Methods 
Pierce recombinant protein A/G (#21186) and anti-C5a C17/5 (#GAU025-05-02) 
were obtained from Thermo Scientific. Bovine serum albumin (BSA) (#A7030) 
was obtained from Sigma-Aldrich. NIST RM 8671 was purchased from the 
National Institute of Standards and Technology and respiratory syncytial virus 
protein F (RSVF, #11049-V08B) was obtained from Sino Biological Inc. C5a 
protein (#A145) was purchased from Complement Technologies Inc. Anti-CRP 
monoclonal, anti CRP polyclonal, anti-thyroxine-binding globulin (anti-TBG), 
TNFα, CRP and TBG were all obtained from a major research reagent provider 
whilst the Infliximab biosimilar was obtained from clinical storage, reflecting the 
conditions of therapeutic antibodies before use (both sources of antibody 
samples are made anonymous to enable publication of monomeric purity 
measures). Standard instrument running buffer and sample dilution buffer was 
phosphate-buffered saline (PBS) supplied in tablet form by Sigma-Aldrich. Ortho-
phosphoric acid (85%) was obtained from Fluka and a 0.01 M aqueous solution 
used as regeneration buffer. The absorbance of the NISTmAb and other antibody 
samples was measured at 280 nm with a NanoDrop instrument and converted to 
total protein concentration using Beer’s Law and a molar extinction coefficient of 
210,000 M-1 cm-1, (as recommended by the manufacturer). 
The binding kinetics and monomeric purity of 8 antibody samples were assessed 
using a multiplex array and the LiScAR platform. BSA, PAG and antigen were 
printed with from 1 mg/mL solutions and the array surface was blocked with BSA 
(1 mg/mL, 300 seconds) before use to minimise non-specific binding. The 
response of each assay to refractive index (RI) change was calibrated as 
described in Chapter 2. The mean limit of detection per individual sensor element 
was 6.6 ± 2.9 × 10-2 mRIU. 
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The NISTmAb was injected into the LiScAR at concentrations of 1.56, 3.23 and 
6.25 nM to provide NIST-RSVF and NIST-PAG binding data for kinetic global 
fitting as shown in Chapter 2. For monomeric purity testing, all antibody samples 
were diluted to 100 nM (based on manufacturer stated concentration) and 
injected over the assay surface for a fixed period of 300 seconds to monitor 
association kinetics to the Fab assay and Fc assay. The assays were washed in 
PBS running buffer for 500 s to monitor dissociation kinetics. Each antigen 
sample was prepared at 100 nM in PBS and injected over the assay surfaces for 
300 s to observe antigen capture by IgG previously loaded on the PAG surface.  
The sensor response to antibody or antigen binding at maximum surface 
coverage, m, was derived for all experiments with kinetic fitting of the Langmuir 
adsorption isotherm. For clarity, the mvalue of the Fab assay is written  m Fab 
and the mvalue of the Fc assay is written m Fc and the mvalue of the antigen 
assay is written m antigen.  To minimise experimental variation, all antibody 
samples were tested in duplicate and in random sequence on a single multiplex 
array.  
ESI-QTOF experiments were performed by the University of Bath to estimate 
monomeric purity using a gold standard technique, following 13.a.ii of the protocol 
list in ref (442). The MS experiments analysed native, intact forms of the 
antibodies. The degree of antibody degradation was expressed as a relative area 
ratio of fragments compared to intact protein in the deconvoluted mass spectra.  
3.6.2 Results   
A series of kinetic traces were recorded for each antibody sample with the Fc, 
Fab and antigen assays. The Langmuir model was fit to the data as described in 
Chapter 2. The m of the NISTmAb sample binding via the Fab region to its 
antigen (RSVF) immobilised on the sensor surface was determined as 1.73 
(±0.03) mRIU by fitting the Langmuir model to data from 100 nM antibody 
samples. The kinetic parameters for the NISTmAb–RSVF interaction were 
derived as ka = (8.9 ± 0.2) × 104 M-1s-1 and kd = (2.4 ± 0.6) × 10-4 s-1 by fitting the 
Langmuir model to 3 low concentration samples, Figure 3.21. The equilibrium 
constant was estimated to be KD = 2.7 (± 0.7) nM. The errors were derived from 
the covariance matrix of the fit and are stated at 95% confidence limits. 
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Figure 3.21 RI time dependence for the NISTmAb binding to its antigen, RVSF, immobilised on the sensor 
surface. RSVF was immobilised using the assay method described in 2.8.1. a) kinetic response curves 
obtained from 1.56, 3.23 and 6.25 nM NISTmAb samples (black), and global fit to the Langmuir adsorption 
model (red). Signals are the averaged response of n=20 assay spots and higher concentrations induce a 
greater response. b) residuals over the time course of the fit, showing consistent error between model fit and 
data. c) histogram of the residuals indicating the error between the model fit and data is normally distributed. 
From four repeated experiments at 100 nM, the m of the NISTmAb sample 
binding via the Fc region to its PAG immobilised on the sensor surface was 
determined as 6.66 (±0.96) mRIU. Complex binding kinetics and deviations from 
1:1 Langmuir kinetics are evident in the data however a global fit to four low 
concentrations, whilst enabling the m value to float, enabled the model to fit well 
and estimates the kinetics of the interaction as ka = (5.9 ± 1.1) × 104 M-1s-1 and 
kd = (1.96 ± 1.85) × 10-5 s-1. The error associated with the dissociation rate 
constant is large due to the apparently slow dissociation rate – a common source 
of error highlighted in Chapter 2. 
The responses of the Fab, Fc and antigen assays were recorded for all antibody 
samples at 100 nM, Figure 3.22.  
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Figure 3.22 Raw kinetic response curves of the PAG surface (blue) and antigen surface (orange) to antibody 
binding (0-300 seconds) and antigen binding (400-700 seconds). PAG and antigen surfaces were 
constructed Experiments were performed using the assay method described in 2.8.1. Signals are the 
averaged response of n=20 assay spots. Two types of antibody were tested: a-e) monoclonal antibody 
samples and e-h) polyclonal antibody samples.  
The m Fab, m Fc and m antigen values of all antibody samples were derived by 
kinetic fitting and are shown in Table 3.7. All values assume antibody 
concentrations stated in the product data sheets which are confirmed by 
absorbance at A280 nm. The CV of m Fc for the NISTmAb was 7%. 
Table 3.7 The 𝑚 𝐹𝑎𝑏, 𝑚 𝐹𝑐 and 𝑚 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 values derived from fitting the Langmuir model to kinetic data 
from all antibody samples in the panel. The mass of TNFα is shown as a monomer, but there is evidence for 
dimers and trimers in solution. Errors are 95% CI.   
Sample 
m Fab / 
mRIU 
m Fc / 
mRIU 
m antigen 
/ mRIU 
Antigen Mass / 
kDa 
NISTmAb 1.73±0.03 6.66±0.96 3.37±0.77 53 
Infliximab biosimilar 0.22±0.06 6.82±0.21 1.32±0.01 17* 
Anti-C5a mono 0.42±0.13 3.07±0.28 0.11±0.04 10.4 
Anti-CRP mono 0.02±0.02 3.57±0.13 1.44±0.68 125 
Anti-TNFα poly 2.34±0.13 3.23±0.88 0.42±0.06 17 
Anti-C5a poly 5.82±1.48 5.36±0.60 0.06±0.04 10.4 
Anti-CRP poly 0.76±0.30 4.33±0.09 1.18±0.45 125 
Anti-TBG poly 1.60±0.70 3.74±0.24 0.08±0.05 54 
 
The m Fab was consistently lower than the m Fc for all antibody samples tested, 
indicating that for a given surface area, more antibodies were adsorbed when 
bound via the Fc region to the PAG surface compared binding via the Fab region 
to the antigen surface. The therapeutic Infliximab biosimilar antibody had a 
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particularly low m Fab value indicating a low surface density or epitope 
presentation. 
An estimate of the relative binding site density differences between PAG surfaces 
and the antigen surfaces was obtained by comparing the m Fab / m Fc ratio of 
the NISTmAb (0.26 ± 0.04) to that of the panel of antibodies with a range = (0.004 
– 1.1) × 10-3. Furthermore, an estimate of antibody monomeric purity was 
obtained by comparing the m antigen / m Fc ratio of the antibody samples, after 
normalising for antigen binding mass: dividing m antigen and m Fc by the antigen 
masses and intact IgG masses respectively,  Figure 3.23. 
 
Figure 3.23 𝑚  analysis showing the 𝑚 𝐹𝑎𝑏 / 𝑚 𝐹𝑐 ratio (green) and the 𝑚 𝑎𝑛𝑡𝑖𝑔𝑒𝑛/𝑚 𝐹𝑐 ratio (orange). 
The 𝑚 values of the 𝑚 𝑎𝑛𝑡𝑖𝑔𝑒𝑛/𝑚 𝐹𝑐 ratio are normalised for the mass of the antigen and intact antibody. 
The stoichiometric limit of the 𝑚 𝑎𝑛𝑡𝑖𝑔𝑒𝑛/𝑚 𝐹𝑐 ratio is between 1 and 2 (dashed lines). Error bars are 2SD 
from n=2 determinations. 
To validate the m antigen / m Fc ratio as a measure of antibody monomeric purity, 
the biosensor results were compared with results from the ESI mass spectrum 
recorded for each antibody, Figure 3.24.  
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Figure 3.24 The deconvolved mass spectra of antibody samples. Eight samples are shown: a) the NISTmAb; 
b) Infliximab biosimilar, c) anti-C5a monoclonal, d) anti-CRP monoclonal, e) anti-TNFα polyclonal, f) anti-
C5a polyclonal, g) anti-CRP polyclonal and h) anti-TBG polyclonal. The data are the averaged signal from 
n=3 determinations. More information on these antibody samples is provided in section 3.6.1.  
The deconvolved mass spectrum of the NISTmAb is dominated by a species at 
148.2 kDa attributed to the pure, non-fragmented IgG structure. All samples 
showed varying intensities of intact IgG at ~150 kDa, often with multiple 
glycoforms and many antibody samples show additional lower mass proteins at 
varying abundances. The NISTmAb Fab fragment has a reported mass of 47 (±5) 
kDa (439) and the mass spectrum shows a low intensity mass peak at 48 kDa 
(not visible at the scale of Figure 3.24).  
The relative abundances of fragments relative to the intact antibody were 
determined from the AUC of regions in which masses are typically present: 140-
160 kDa, 90-110 kDa, 65-85 kDa, 40-60 kDa and 15-35 kDa, Figure 3.25. These 
regions of the mass spectrum correspond to the predicted fragmentation products 
shown in Figure 3.19. 
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Figure 3.25 The abundances of fragments in each antibody sample evaluated by taking the AUC of specific 
regions of the mass spectra corresponding to IgG fragmentation products. The percentage abundances of 
the most abundant peaks are plotted relative to the intact region (140-160 kDa): 90-110 kDa (light blue), 65-
85 kDa (gold), 40-60 kDa (pink) and 15-35 kDa (blue). All regions may contain Fc moieties. 
The HcLc fragment, expected at 75kDa, was the most abundant fragmentation 
product in all monoclonal antibody samples, whilst the Fc-Fab fragment, 
expected at 100 kDa, was most abundant in the polyclonal samples with the 
exception of anti-TBG. The AUC of impurities relative to the intact IgG AUC was 
<20% for monoclonal antibodies, whilst all polyclonal samples displayed 
impurities present at >20% relative to the intact IgG structure. The monomeric 
purity estimated by ESI was the peak area of the intact region expressed as a 
percentage of total peak area and is tabulated in Table 3.8. The monomeric purity 
of the intact NISTmAb was determined by ESI to be 94% compared with the 
reported value of 96.5% by NIST (431). 
3.6.3 Discussion 
Antibody sample monomeric purity is critical for immuno-kinetic assay 
development, binding kinetics studies and effective immunotherapy. Two 
potential assays of antibody sample fragmentation were assessed here. The first 
was based on the mass deficit observed for fragmented samples binding via the 
Fc region to PAG on a the LiScAR sensor surface, the Fc assay. The second 
assay assessed monomeric purity using the binding ratio of antigen to antibody 
on a PAG surface, the antigen assay. Affinity of antibody for antigen was 
confirmed with an antigen surface which captures antibody via the Fab region, 
the Fab assay. Monomeric purity estimates from the LiScAR assays were 
validated using native ESI-QTOF mass spectrometry. 
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ESI data suggest the most abundant glycoform of the intact NISTmAb had a 
mean molecular mass of 148.2 kDa and the sample displays a distinctive 
glycosylation pattern. The masses of NISTmAb glycoforms are in good 
agreement with published values (434), Figure 3.26.  
 
Figure 3.26 The deconvoluted mass spectrum of the NISTmAb intact IgG region. The highest intensity peak 
has a mass of 148.2 kDa and the glycosylation pattern is in good agreement with previously identified 
glycoforms in mass spectrometry studies. The data are the averaged signal from n=3 determinations.  
The homogeneity of the NISTmAb contrasts with the heterogeneity of intact IgG 
masses in the anti-C5a monoclonal, anti-CRP monoclonal and anti-CRP 
polyclonal samples, attributed to multiple N-deglycolsylated glycoforms (443). 
The ESI data validate the NISTmAb as a good standard antibody of high 
monomeric purity.  
From the ESI data, an effective mass of antibody, MESI, can be derived from the 
mass spectrum with the equation:  
 𝑀𝐸𝑆𝐼 = 
𝑎𝐴 + 𝑏𝐵 + 𝑐𝐶 + 𝑑𝐷
𝑎 + 𝑏 + c + d
 3.6 
 
where lowercase letters represent the percentage AUC of the mass spectrum 
relative to the intact peak area (140-160 kDa) from the regions: 90-110 kDa 
(predicted Fab-Fc complex), 65-85 kDa (predicted HcLc complex), 40-60 kDa 
(predicted Hc or Lc) and 15-35 kDa (predicted Lc or Hc monomer of Fc). 
Uppercase letters represent the mean mass of the integration region: 150 kDa 
(intact), 100 kDa (predicted FabFc complex), 75 kDa (predicted HcLc complex), 
50 kDa (predicted Hc or Lc) and 25 kDa (predicted Lc or Hc monomer of Fc). The 
derived MESI for each of the antibodies in the panel are shown in Table 3.8.  
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The monomeric purity of the NISTmAb (and reassuringly that of the therapeutic 
infliximab biosimilar) was high, which was not the case for the other commercially 
available samples that would be used for research applications. The reliability of 
experiments involving Western blots, immunohistochemistry, flow cytometry and 
immunoprecipitation is negatively impacted by variations in antibody purity as 
these techniques fundamentally rely on a connection between Fc and Fab 
regions of the antibody. The consequence of purity on kinetic analysis needs to 
be considered with the fundamental errors of the 1:1 binding model or 
Langmuirian kinetics conventionally used to analyse antibody binding events. 
Fitting a set of low concentrations in the global fit methodology for the NISTmAb 
produces and error of 15% for ka and 10% for kd  due to the uncertainties in the 
fit over the timescale of the experiments (368). Model fitting errors would 
dominate the analysis of the NISTmAb and Infliximab biosimilar samples but this 
would not be true for all members of the antibody panel tested here. For the case 
of the anti-TBG sample, any reported antibody kinetics analyses without a sample 
purity assessment may have an error of up to 46% due to low monomeric purity. 
The packing density of IgG around a protein is a property of epitope density and 
steric packing. Antibodies with identical masses should therefore achieve 
identical m values for a given antibody packing density, albeit after differing 
periods of time to allow variations in association kinetics. There was significant 
variation in the m Fab (Table 3.7) which may be explained by variation in 
availability of epitopes for antibody binding as evidenced by the larger m Fab of 
polyclonal anti-CRP compared to the monoclonal anti-CRP sample on the same 
CRP surface. In contrast, the m Fc showed less variation thanm Fab, attributed 
to the use of a common PAG surface for all antibody samples with a consistent 
number of binding sites. 
Variation in m Fc may occur due to differing mean IgG mass differences 
(monomeric purity differences) between IgG samples as observed with ESI. The 
Fc assay presented here will bind with high affinity to both intact IgG and the most 
abundant fragmentation products which contain the Fc region - a concern for PAG 
based affinity purification of antibodies but a potential antibody fragmentation 
assay when combined with surface plasmon technology. Any given m derived 
from fitting of the Langmuir equation may be related to the adsorbed mass on the 
surface, M, by de Feijter’s formula (444): 
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 𝑀𝑎𝑑𝑠𝑜𝑟𝑏𝑒𝑑 = 𝑑𝐴
∆𝑅𝐼
𝑑𝑛
𝑑𝑐⁄
 3.7 
 
where dA is the thickness of the adsorbed layer and dn/dc is the rate of change 
of refractive index with surface concentration (the refractive index increment) and 
RI is the change in the refractive index. The value of dn/dc has been measured 
for protein as 0.182 cm3 g-1 and shown to vary with buffer conditions (445) but 
the effect is negligible (444).  
The largest uncertainty in the estimate of M is the value of dA. IgG layers adsorbed 
onto a protein A and silica surfaces have been observed previously using  
ellipsometry with thicknesses of 4 nm to 16 nm respectively (446, 447). Neutron 
reflectivity measurements of IgG4 binding to a protein A / BSA surface report 
three sequential layers leading to total thicknesses between 6.1 nm and 25 nm 
depending on washing and blocking of the surface (448) because nonspecific 3D 
aggregation upon adsorption at high IgG concentrations can enable adsorbed 
layers to exceed the maximum length of a single IgG molecule, 16 nm (449). The 
mean cross section dimension of the IgG crystal structure (450) suggests a  dA 
of 10 nm, assumed constant for all antibody samples. The surface adsorbed 
mass density depends only on the difference in the refractive index (∆RI) as a 
result of adsorbed antibody.  
Substituting m Fc  of NISTmAb for ∆RI in equation 3.7 predicts the areal density 
of the NISTmAb when all Fc binding domains on the PAG binding sites are filled, 
Madsorbed = (3.66 ±0.53) × 10-8 g cm-2. By comparison, electrostatic adsorption of 
monoclonal antibodies onto a variety of surfaces has been reported at densities 
in the range 5 × 10-7 to 5 × 10-6 g cm-2 (451, 452). Electrostatic adsorption is 
expected to achieve a higher surface mass density compared with the ordered 
two-dimensional layer of IgG bound to a PAG surface. The Madsorbed values of 
each antibody studied are presented in Table 3.8. 
The ESI data indicate that effectively all protein in the NISTmAb sample was 
antibody monomer (93.5%) with a monomeric mass, Mmonomer, of 148.2 kDa. The 
NISTmAb data and the Avogadro constant, Na, can be used to calibrate the 
surface density of intact antibodies bound at saturation, NAb = (Madsorbed / Mmonomer) 
× Na = (1.49±0.21) × 1011 cm-2. Comparatively, the maximum number of 
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monoclonal antibodies in a monolayer has been determined by adsorption onto 
a silicon nitride surface as 1.2×1012 cm-2, although it was estimated that up to 
75% of the protein may be non-specifically adsorbed rather than covalently bound 
(453). The unknown purity of antibody samples in the literature is a potentially 
large source of error for published NAb values derived from protein mass density 
measurements whereas the NAb figure presented here is of known accuracy due 
to the monomeric purity estimate from ESI. 
The number of PAG binding sites on the surface was constant for the NISTmAb 
and if all antibodies bound to the surface with the same packing density then an 
estimate of effective mass at each binding site, MFc, may be estimated from 
asserting a simple ratio: 
 
𝑚
𝐹𝑐
𝑀𝐹𝑐
=
𝑚
𝑚𝑜𝑛𝑜𝑚𝑒𝑟
𝑀𝑚𝑜𝑛𝑜𝑚𝑒𝑟
 3.8 
 
where 𝑚
𝑚𝑜𝑛𝑜𝑚𝑒𝑟
 and  𝑀𝑚𝑜𝑛𝑜𝑚𝑒𝑟 are the m Fc and mass of the monomeric 
reference material, which in the present study is the NISTmAb with m Fc = 
6.66±0.96 mRIU and a mass of 148.2 kDa. When a sample has degraded, a 
fraction of Fc binding domains on the PAG will be occupied by fragments with a 
lower mean molecular mass than the intact IgG: a mass deficit producing a lower 
m Fc for constant number of occupied binding sites. The estimated monomeric 
purity from the Fc assay can be derived by expressing MFc as a percentage of 
Mmonomer, Table 3.8.  
Table 3.8 Experimental properties derived for the antibody panel. 
Sample ESI 
mass, 
𝑀𝐸𝑆𝐼 
/ kDa 
ESI 
Monomeric 
purity / % 
Fc areal 
density, 
Madsorbed / 
g cm-2 
×10-8 
Plasmonic 
mass, 
 𝑀𝐹𝑐 
/ kDa 
Plasmonic 
monomeric 
purity / % 
NISTmAb 145 93.5 3.7±0.5 148±21 100±14 
Infliximab biosimilar 146 94.7 3.8±0.1 152±5 103±3 
Anti-C5a mono 142 89.0 1.7±0.2 68±6 46±4 
Anti-CRP mono 141 87.4 1.96±0.07 80±3 54±2 
Anti-TNFα poly 123 61.1 1.8±0.4 72±19 49±13 
Anti-C5a poly 127 64.7 3.0±0.3 119±12 80±8 
Anti-CRP poly 132 72.4 2.38±0.05 96±2 65±1 
Anti-TBG poly 119 54.2 2.1±0.1 83±5 56±3 
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A weak positive correlation is observed between MESI and MFc, the estimates of 
mean antibody mass in a sample according to ESI or the LiScAR Fc assay,  
Figure 3.27.  
 
Figure 3.27 Correlation between the monomeric purity of antibody samples estimated by the LiScAR Fc 
assay and ESI. A linear fit to the data (blue) and perfect correlation (dashed black) are shown. R2=0.22. 
Error bars are 2SD from n=2 determinations. 
Several phenomena may account for lack of correlation observed. Firstly, NAb at 
m Fc  may be a fundamental property of a given antibody due to glycan variation 
and the locations of PAG binding domains on the structure, leading to some 
antibody monomers binding in orientations which favour closer packing on the 
surface (454). The m Fc will also be sensitive to nonspecific aggregation and 
clustering of IgG (448) although aggregates of the NISTmAb IgG are only 
observed following deliberate physical agitation for days at room temperature 
(455) and the antibody samples tested here are not expected to contain 
significant aggregates due to appropriate storage.  
The lack of correlation between m Fc and ESI monomeric purity may best be 
explained by the orientation and higher packing density of low mass antibody 
degradation products, which may have access to a greater number of binding 
sites on the PAG surface than monomeric IgG. Therefore, it is likely that the m Fc 
of the Fc assay is only sensitive to severe antibody degradation. 
A more sensitive measure of monomeric purity is to support antibodies on the 
PAG surface and measure the antigen binding ratio, m antigen / m Fc, which after 
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normalising for molecular mass, shows a strong dependence on monomeric 
purity estimated by ESI, Figure 3.28. 
 
Figure 3.28 The relationship between monomeric purity estimated from the ESI data and the mass 
normalised 𝑚 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 / 𝑚 𝐹𝑐 biosensor measurement. The NISTmAb and Infliximab biosimilar (green) are 
>90% pure according to ESI data and exhibit 𝑚 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 / 𝑚 𝐹𝑐 ratios within the expected limits of 1-2 
antigens per antibody. Other commercially available antibodies (red) are <90% pure and show less than 1 
antigen bound per antibody. A 5-parameter logistic curve fits well to the data (blue) is constrained by a 
maximum asymptote of 2 (the upper limit of the antigen-antibody interaction stoichiometry). The anti-TNFα 
polyclonal (orange) does not fit the trend line, likely due to a unique fragmentation pattern resulting in a 
majority of 100 kDa HcLc fragments which may pack tightly on the PAG surface and remain capable of 
binding 1 antigen. Error bars are 2SD from n=2 determinations. 
The m antigen / m Fc ratio measure of antibody integrity shows a strongly rising 
trend with the pure antibodies showing a ratio that falls within the expected 
stochiometric limits of 1 or 2 antigens binding to per antibody. The Infliximab 
biosimilar antibody binds to a relatively low mass antigen (TNFα with a monomer 
mass of 17 kDa) and displayed an antigen-antibody binding ratio of 1.71  0.16. 
The NISTmAb binds to a higher-mass antigen (53 kDa) and displayed a lower 
antigen-antibody binding ratio of 1.31  0.57 attributed to greater steric hindrance 
of antigens.  The m antigen / m Fc ratio is antigen-dependent for larger antigens 
but would always exceed 1 with adequate antibody spacing on a plasmonic 
surface. The NISTmAb performed well as a standard material for the antibodies 
shown, but calibration of the assay would likely be improved by comparing each 
tested sample to a high-purity reference standard of the same antibody.  
Of the commercially available research antibodies, anti-TBG antibody showed a 
relatively high m Fab / m Fc ratio but displayed the weakest m antigen / m Fc ratio. 
These two ratios indicate that both Fab and Fc regions of TBG were present in 
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the sample, but a significant proportion were separated due to degradation. The 
high fragmentation suspected in the anti-TBG antibody is supported by the lack 
of intact antibody in the ESI mass spectrum, Figure 3.24. 
The  m antigen / m Fc ratio is a measure of the biological activity of an antibody 
sample, whereas the ESI monomeric purity estimated from mean mass penalises 
any form of antibody fragmentation. The ESI data predicted a low monomeric 
purity in the anti-TNFα polyclonal but the sample displayed a relatively high 
m antigen / m Fc ratio. The result may be explained by the unique degradation 
pattern shown in Figure 3.25 which indicates that the most abundant species was 
the 100 kDa HcLc fragment which is capable of binding to PAG and one antigen. 
The fragmentation in the anti-TNFα polyclonal remains identifiable by comparison 
to the Infliximab biosimilar which shares the same antigen but exhibited a higher 
antigen-antibody binding ratio. 
Using the m Fab / m Fc ratio recorded by the LiScAR, the antibody panel readily 
divided into two types of samples: the high purity (>90%) samples (NISTmAb and 
Infliximab biosimilar) and the remainder of the panel with lower purity (<90%). 
The m Fab / m Fc ratio was significantly different for these two material types as 
evidenced by a two-sample t-test and two sample Kolmogorov-Smirnov (P=0.01 
and P=0.03 respectively). These statistical tests are discussed in Chapter 6. The 
assays developed here show the potential to test the specification of antibodies 
immediately before use as assay materials and other antibody-dependent 
techniques to prevent variability in experimental results caused by sample 
degradation.  
3.7 Conclusions  
The NISTmAb provides an important new benchmark material which enables the 
calibration of biosensors assessing monomeric purity of antibody samples with 
assays for Fab, Fc and antigen. Analysis of a panel of commercially available 
research grade antibodies using ESI-QTOF and the LiScAR highlighted 
significant variation in monomeric purity and raises accuracy concerns for 
previously reported ka, kd and KD measurements of similar materials in the 
literature. Without sample monomeric purity analysis (of both the antibody and 
the antigen) these measurements may have errors greater than 46% in highly 
fragmented samples. The antigen assay technique to estimate antibody 
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monomeric purity can be performed in 15 minutes and may be combined with 
additional rapid tests for IgG aggregates as described for the NISTmAb in ref 
(455). 
Four novel assays have also been presented here for the quantitative 
concentration determination of C5a, TCC, C3 and TNFα. The calibration curves 
of the four new assays are reproducible and can be performed simultaneously 
with purified PBS standards in a 4-plex assay. Of the new assays, the C5a and 
C3 assays were suitably sensitive and selective for use with serum samples and 
can be combined into a 2-plex assay with a duty cycle of <15 minutes.  The 
Complement assays represent a proof-of-concept for point-of-care Complement 
testing and are used in Chapter 7 to collect high frequency kinetic data of 
Complement activation in vitro.  
Chapters 2 and 3 have demonstrated how immobilisation of proteins and 
antibodies on the LiScAR surface enables binding kinetics to be studied. Chapter 
4 introduces fundamental systems biology modelling techniques and considers 
whether the binding kinetics measured for surface interactions under PBS 
conditions reflect the binding interactions that occur in complex mixtures such as 
the serum. The transferability of kinetic models is a critical consideration when 
constructing a complex systems biology model such as that of Complement 
activation.  
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4 Kinetic Modelling of Biological Systems 
4.1 Introduction 
The mathematical modelling approach of systems biology is becoming an 
established strategy for understanding complex biological systems (456). 
Computer modelling tools such as Systems Biology Markup Language (SBML) 
(457) and COPASI (458) are readily available and allow computer models to be 
constructed and shared between research groups. Four main types of models 
can be identified (459): verbal, diagrammatic, physical and formal. Verbal models 
are used to qualitatively represent a system in words and any ambiguity is then 
clarified by showing the system structure or interactions in diagrammatic form. 
Physical models may be used when the scale of a system is not relevant such as 
spatial models of proteins. Formal models represent quantitative knowledge of 
the system using mathematical equations and can be interrogated rapidly using 
a computer. Formal models must be constructed with care, with consideration 
given to the isolation of certain objects (compartmentalisation), the treatment of 
time as a continuous or discrete variable and whether similar objects are 
represented as individuals or by populations. To further increase the variety of 
models, the interactions of species in the model may rigidly follow a set of rules 
(deterministic) or occur via chance (stochastic).  
Systems biology asserts that since genes and proteins are molecules and exert 
their functions through other molecules, a thorough explanation of a biological 
system may be achieved by combining knowledge of all molecular interactions 
involved (460). Biochemical systems obey the same physical laws as physics and 
chemistry, such as mass balance and energy transfer. Biochemical interactions 
can therefore be represented by chemical reactions, which can be used to 
construct deterministic differential equation models describing each species in 
system (461). Differential equations concerned with a single independent 
variable, such as time, are referred to as ordinary differential equations (ODEs). 
A reversible bimolecular binding reaction between reactants A and B is shown in 
equation 4.1 as a molecular equation, whilst equation 4.2 describes the same 
reaction as an ODE for the rate of concentration change of A over time: 
 𝐴 + 𝐵
𝑘𝑎1
→  
𝑘𝑑1
←  
 𝐴𝐵 4.1 
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𝑑[𝐴]
𝑑𝑡
= 𝑘𝑑1[𝐴𝐵] − 𝑘𝑎1[𝐴][𝐵] 4.2 
 
where A and B could represent distinct proteins and AB is the complex formed 
when A and B bind together. As seen in previous chapters: ka and kd represent 
the association and dissociation rate constants respectively. The ODE describes 
the change in the concentration of A with respect to time, based on the 
concentrations of A, B and AB. The ODE has a positive term which describes the 
formation of A from the breakdown of AB and a negative term which describes 
the removal of A by the reaction with B. In a larger system where A might also 
bind to proteins other than B, additional negative terms would be included in the 
ODE for the consumption of A. By extension, all reactions in a larger network can 
be written as rates of change of concentration in time based on the formation and 
destruction of complexes. The ODE shows that a critical distinction is made 
between the concentration of A as part of the AB complex and unbound A which 
is free to react with B. Stoichiometry is conserved and the total quantity of a 
species is calculated by the sum of its unbound and bound forms: A + AB = Atotal.  
ODE models are widely used in systems biology to quantitatively predict the 
kinetic behaviour of complex systems because they are able to consider both 
structure and reaction kinetics of a system (461, 462). A systems biology 
approach could be used to test the hypothesised reaction mechanism between A 
and B shown above by substituting the starting concentrations (of A, B and AB) 
and rate constants (ka and kd) into an ODE describing each species in the system. 
An ODE solver iteratively calculates the concentration of each species in the 
system after distinct time steps and returns the corresponding concentrations at 
each time step. The model simulation can then be compared to experimental time 
series data where a good agreement between the model and the data provides 
evidence that the structure of the model, its kinetic constants and starting 
conditions may be correct.  
The process of predicting system outputs based on knowledge of the system 
interactions is known as the ‘forward problem’ (463). Such an approach is 
possible if the starting concentrations of all species in the model and the rate 
constants are known, but this is often not the case in biological systems. Some 
rate constants may not have been measured experimentally, and the 
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concentrations of certain species may be unknown. Furthermore, such integrated 
models may not fit well to biological data (464, 465). 
The ‘inverse problem’ is the systems biology approach used to estimate model 
structure or unknown parameters such as rate constants by fitting model outputs 
to data (466). Data fitting (also termed optimisation) is typically achieved with 
some variation of the routine shown in Figure 4.1. 
 
Figure 4.1 Process diagram of parameter estimation by model fitting to data. Agreement threshold to exit 
the loop is predefined before the process begins. The agreement is typically assessed with an objective 
function such as root mean square or relative absolute error. An escape from the loop may also be included 
to terminate the routine in the event that acceptable agreement is not reached - a maximum number of 
attempts for example.  
The parameters to be estimated (or floated) are given initial guess values which 
are iteratively changed until the agreement between model and data reaches a 
predefined threshold: an optimised model. The goodness-of-fit is evaluated for 
each new set of parameters with an objective function (also termed cost or merit 
function) whose minimum or maximum value is sought (depending on objective 
function) by an optimisation procedure (467). Typically used objective functions 
include root mean square error (RMSE) or mean absolute error (MAE) which 
indicate a better fit when their values decrease and hence the task of the fitting 
routine is to minimise these objective functions.  
The decision to terminate the fitting routine is performed based on predefined 
criteria. For example, the routine may stop upon reaching a parameter 
combination which produces an objective function below some threshold such as 
the confidence intervals of the data. More commonly, fitting routines may end 
regardless of the absolute objective function value when improvements to the fit 
are only achieved with very small changes to the parameters (a parameter 
precision tolerance). Finally, the fit may end after a certain number of parameter 
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combinations have been evaluated. Finding the optimal combination of 
parameters may be computationally expensive (requiring many iterations), 
especially when estimating large numbers of parameters which produce 
nonlinear trends in the objective function (468). It is very inefficient to grid search 
the parameter space of large models with many floated parameters and more 
efficient parameter estimation algorithms have been developed (462, 465). 
Many parameter estimation algorithms are available but may be categorised into 
two groups: local and global (469). Nonlinear functions may contain many local 
minima: parameter estimates which produce better objective function values than 
similar estimates but do not produce the single best solution. If several local 
minima exist, the solution which produces the smallest objective function value is 
referred to as the global minimum. Local parameter estimation algorithms find the 
lowest objective function value within the basin of attraction of the starting point. 
A basin of attraction is a set of starting parameter values which lead to a local 
minimum in the objective function when each parameter is varied in the direction 
associated with the favourable change in objective function value. The basins of 
attraction for a local and global minimum, due to the single floated parameter x, 
are shown in Figure 4.2.  
 
Figure 4.2 Sketch of a two-dimensional objective function surface, showing the objective function value, F(x), 
at different values of x. A starting value (black circle) and the basins of attraction for the local minimum 
(orange) and the global minimum (blue) are shown.  
Most systems biology data fitting problems are multi-dimensional and their 
objective function surfaces cannot be visualised graphically. However, basins of 
attraction are still present in higher dimensions and Figure 4.2 highlights the 
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importance of a good initial guess when using local solvers. If the initial guess for 
x was within the local basin of attraction, then a local solver would not find the 
global solution as this would involve increasing the objective function value before 
reaching the global minimum. Global solvers attempt to search more than one 
basin of attraction to improve the probability of finding the global solution. The 
search efficiency and confidence that the fit solution is global can be improved by 
the inclusion of a priori knowledge of the system under study. Many fitting 
algorithms use bounds to constrain the parameter values within theoretically 
plausible ranges, although such a priori information should be used with caution 
to avoid bias in the model.  
Given that the equations of the model are constant during parameter estimation, 
confidence in the modelled reaction network is essential. Mechanistic knowledge 
of the system under study is therefore required to produce an accurate model. 
Incorrect assumptions of stoichiometry and excluded system inputs / outputs will 
lead to estimated parameters with little or no physical relevance to the true 
process. If the structure of the model is uncertain, the modelling process often 
includes the construction of many alternative model structures which can be 
compared after data fitting (470). The structures of models which fit poorly to the 
data can be rejected, providing some mechanistic insight, however the true 
mechanism may still be unclear as a potentially infinite number of incorrect model 
structures could produce equally good fits to the data (471). For example, the 
model y=mx+c will fit well to data showing a linear relationship between x and y. 
The model y=mx+(d/e) will fit equally well to the data when d/e=c but an infinite 
number of equally well-fitting solutions for parameters d  and  e are possible. 
Parameters d and e are therefore referred to as being highly correlated and as 
such their values are poorly defined by the data because as one increases the 
other decreases proportionally to achieve the same fit result. A recent review of 
17 systems biology models showed that many of the obtained model parameters 
were ‘sloppy’, meaning not well-defined (472). At the fit solution, several 
techniques are available to assess how confidently the parameter values are 
determined by the data. 
Insensitivity of the cost function to variation in a parameter value leads to large 
confidence limits on the derived value of a parameter – low precision estimates. 
A sensitivity analysis is used to estimate the change of the cost function with 
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respect to a given model parameter. The sensitivity of a function with respect to 
each variable can be evaluated at each observation in a data set to generate a 
Jacobian matrix (473), Figure 4.3. The Jacobian matrix indicates the relative 
influence of each parameter on the goodness-of-fit at different regions of the data 
set and can be used to assess the correlation of model parameters . 
 
Figure 4.3 Estimation of the Jacobian matrix for the function y=mx+c. The function fits perfectly to the data 
(residuals = 0) when m=1 and c=0 (solid blue). Two variations of the fitted function are shown: a) parameter 
m is changed by 1; b) parameter c is changed by 1.  The change in function value at each observation (red) 
is recorded to produce c) the Jacobian matrix. 
The columns of the Jacobian matrix shown in Figure 4.3 do not show any 
correlation: a change to the gradient parameter, m, increasingly affects the 
goodness-of-fit at larger values of x, whereas a change to the intercept 
parameter, c, affects the goodness of fit equally at all observations. The lack of 
correlation (positive or negative) between columns in the Jacobian indicates that 
the estimated parameters are well-defined by the model fit to the data. In contrast, 
a Jacobian matrix from fitting parameters d and e in the model y=(d/e)x+c would 
show a perfect negative relationship between the columns for d and e 
parameters, indicating no unique solution to the optimisation problem due to the 
high correlation in these parameters.  
The relationship between two columns in the Jacobian can be assessed 
quantitatively using covariance. Performing a covariance analysis on all pairwise 
combinations of columns in the Jacobian matrix is used to generate the variance-
covariance matrix, where the off-diagonal elements are the covariance of two 
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parameters and the diagonal elements are simply the variances of each 
parameter. As described in Chapter 3, parameter relationships are more easily 
compared by normalising covariance to correlation. The process of converting of 
the variance-covariance matrix to the correlation matrix is shown as an example 
in Figure 4.4. 
 
Figure 4.4 Flow chart showing the generation of the correlation matrix from the covariance matrix. The 
variance-covariance matrix of parameters a, b, and c is used to generate the standard deviation of each 
parameter. The correlation matrix is generated by dividing the variance-covariance matrix by the product of 
the standard deviations for each parameter. The correlation matrix indicates that parameters a and c are 
more correlated with each other than with b.  
Parameter correlation during model fitting may be avoided by several strategies. 
Firstly, additional data may be included in the fit which is disproportionately 
sensitive to one parameter in a correlated pair. Secondly, the number of floated 
parameters may be reduced. This may be achieved by simplification of the model 
to include fewer parameters, fixing certain parameters or asserting that multiple 
parameters should hold the same value based on a priori knowledge (474). The 
first approach may prevent the deduction of physically representative parameters 
such as rate constants if the model structure does not represent the true 
mechanisms in the system under study. The latter approaches require 
mechanistic understanding of the system. 
The requirement for mechanistic understanding before parameters can be 
usefully estimated is a major concern for critics of systems biology who claim that 
the inverse problem is impossible to solve for such complex systems with unclear 
mechanistic pathways (475). A rebuttal to the sceptics of systems biology is the 
emergent field of synthetic biology in which systems biology has provided the 
knowledge necessary to develop effective synthetic biological systems (476). 
Examples include the prediction of genetic modifications for optimal succinate 
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production in E. coli (477) and control of metabolic flux with synthetic protein 
scaffolds based on systems level knowledge of the metabolic pathways (478). A 
systems level understanding must precede the construction of optimised 
synthetic systems and demonstrating a systems level understanding is possible 
with a validated kinetic model.   
Model validation is an essential step in the systems biology approach to 
modelling. A model must be able to predict the result of observations, but 
successful predictions cannot guarantee that a model is correct but rather fail to 
to provide evidence for rejection  (479). Published systems biology studies 
appear to use a common strategy for the development of kinetic models (461): 
1. The model structure is defined, often by ODEs, based on existing 
knowledge of the system under study. 
2. Unknown parameters such as rate constants are estimated by fitting the 
model to experimental data (training data), typically in the form of time 
series concentration data of one or more species in the model. 
3. The agreement between model and data is assessed for both training data 
and independent data under different experimental conditions which were 
not used for parameter estimation: model validation. 
Models intended for use as quantitative predictive tools should always be 
validated and predicting the behaviour of the system in a new experimental 
setting is the ultimate test of predictive kinetic models (461). Partitioning of the 
existing data into training and validation data sets is common practice but, as with 
model structure design, may be subject to bias (discussed in Chapter 6). One 
approach is to fit the model to all available data before repeated validation with 
new data as it is made available with successive studies.  
There are several reasons for the inability of a model to predict the outcomes 
described by a new data set despite fitting well to the training data set. The model 
structure may not be applicable to the conditions of the validation data and model 
parameters may be poorly defined during optimisation or incorrectly defined due 
to multiple local minima during the fitting process. For qualitative investigations, 
the precise value of a parameter is not always required to draw meaningful 
biological conclusions of system dynamics (480), but quantitative predictions 
require accurate and transferable model parameters. A reasonable modelling 
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approach is therefore to include relevant published rate constants where 
available (481) and fit the remaining parameters to experimental data (469). 
Ideally, the included published rate constants should be derived from a similar 
experimental setting to the data for model fitting and such a setting should be 
representative of the intended system setting for model predictions. For example, 
if predicting system behaviour in vivo is the intended use of a model, care should 
be taken so that the in vitro conditions used for model optimisation reflect the in 
vivo conditions as much as possible (482). Association rate and equilibrium 
constants have been shown to vary by an order of magnitude due to nonspecific 
interactions and molecular crowing in actual intracellular environments (483). 
Kinetic studies performed in vitro have the advantage that the experimental 
conditions can be more strictly controlled compared to in vivo and perturbations 
can be made to estimate parameter values even for detailed kinetic mechanisms 
(484).  
Equation 4.2 describes a reaction in a standard system setting such as PBS but 
the active or effective concentration of a species available in a different system 
setting, such as a surface, may be different. Models of protein binding reactions 
may be complicated by properties such as avidity, steric effects and interface 
activity (485, 486) which likely differ between system settings. Furthermore, the 
excluded volume effect of macromolecular crowding increases the effective 
concentration of macromolecules in a solution (487). The effective concentration 
of a species can be modelled as the product of the known concentration and an 
activity coefficient: 
 𝑎1 =  𝛾1[𝐴] 4.3 
 
where 1 is the activity coefficient of the species A and depends on the difference 
in protein activity between the observed system setting and the standard setting 
used for kinetic modelling - the difference between PBS and cytoplasm for 
example. Significant differences in the effective activity of a species observed in 
varying system settings may fundamentally limit the predictive usefulness of a 
deterministic model derived from a single setting (488). These transferability 
uncertainties of  highlight the difficulty in applying a model to different system 
settings. 
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Models of protein binding reactions are particularly important in the field of 
synthetic multivalent ligand binding which studies next-generation therapeutic 
agents and biomaterials (489). The architecture of synthetic protein scaffolds may 
be genetically designed to vary in size and valency, which control reaction 
kinetics and mechanism of action (490). The genetically-modified protein PAG 
has multiple binding sites with high affinity for mammalian immunoglobulins: a 
model multivalent binding system (491). There is genetic evidence for 8 binding 
domains on PAG which are derived from the binding domains of protein A and 
protein G (492). However, when purchased, PAG is described as having 6 
binding sites despite the genetic evidence for 8 and there is clearly an unknown 
fraction of binding sites available sterically, Figure 4.5.  
 
Figure 4.5 Structure of the PAG-IgG complex. PAG (purple) is shown binding to IgG (green). Each bound 
IgG will occupy a fraction of the available spherical surface area (yellow) and must reduce the solid angle 
available to further IgG molecules.  
PAG is widely used for ligand capture in affinity chromatography (493) where 
there is an assumption that the protein activity on a separation surface is the 
same as in solution and in large excess due to the number of binding sites and 
mass on the surface. The number of IgG binding sites on the PAG is unclear, with 
conflict between the value quoted by suppliers and the genetic modification data. 
Biochemical titration data and a kinetic model of the system may enable the 
binding ratio to be observed directly and provide data for kinetic modelling of this 
relatively simple system.  
169 
 
4.2 Aims and Objectives 
The aim of this chapter is to demonstrate a systems biology approach to 
mathematically modelling a multivalent ligand binding system (IgG binding to 
PAG with unknown stoichiometry) using the techniques described previously, 
ahead of the more challenging task of modelling the Complement cascade in 
Chapter 5. 
The first objective was to record experimental kinetic data of the system under 
study. The biophotonic assay for IgG, described in Chapter 2, was used to collect 
high-frequency data of IgG concentration following mixing with PAG.  
The second objective was to construct a mechanistic model of the PAG-IgG 
system. The model structure and rate constants were derived in the standard 
system setting of PBS by fitting the model to the experimental data. Parameter 
optimisation methods were considered to ensure a global minimum is found and 
parameter correlation is assessed and minimised based on the methods 
discussed previously.  
The final objective was to compare the reaction kinetics of the system in PBS to 
those in an alternate system setting where PAG is immobilised on a sensor 
surface, from which activity coefficients can be derived. The transferability of 
model parameters and structure between system settings is assessed.  
4.3 Materials and Methods 
Pierce recombinant protein A/G (5 mg) was obtained from Thermo Scientific 
(#21186). IgG antibody used was rabbit anti-sheep (1 mg/mL) obtained from Bio-
Rad (#5184-2304). Human serum albumin and bovine serum albumin were 
obtained from Sigma-Aldrich. Standard instrument running buffer, also used in 
preparation and dilution of the samples, was phosphate-buffered saline (PBS) 
supplied in tablet form by Sigma-Aldrich. Ortho-phosphoric acid (85%) was 
obtained from Fluka and a 0.1 M aqueous solution used as regeneration buffer. 
GAPSII aminated glass prep slides were obtained from Corning (#40006).  
The IgG test array was constructed using a different printer to that described in 
the SOP in Chapter 2 (AJ1000 from ArrayJet, Edinburgh, UK). Printing accuracy 
was improved by increasing the viscosity of printed solutions and hence glycerol 
was routinely included in the samples. The assay was constructed using 24 assay 
elements functionalised with PAG printed from a 2 mg/mL solution in PBS and 
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50% glycerol. 16 light intensity controls were printed from a 2 mg/mL solution of 
BSA in PBS. The control elements were used to remove the effect of refractive 
index variation with temperature, intensity changes in the lamp illumination and 
non-specific protein binding. Nonspecific binding sites on the array surface were 
blocked with human serum albumin (5 μM, 300 seconds) before assay operation.  
Standard solutions of IgG (2.5 nM, 25 nM, 50 nM, 100 nM, 200 nM) were injected 
over the assay surface for a fixed period of 100 seconds to monitor association 
kinetics to PAG and washed in PBS for 200s to monitor dissociation kinetics. 
Association and dissociation timescales were chosen to provide typical errors in 
estimated association and dissociation rate constants of <15% and <10% 
respectively (368), whilst allowing rapid sampling of 5 minutes per sample. The 
resulting immune-kinetic assay traces were fitted simultaneously for all 
concentrations to the Langmuir model, discussed in Chapter 2, to produce a 
global fit and derive the kinetic constants of the interaction.  
PAG-IgG reaction mixtures were prepared with PAG mole fractions of: 0.09, 0.14, 
0.2, 0.25, 0.3, 0.35, 0.43 and 0.5. The starting IgG concentration was 100 nM for 
each mole fraction. The IgG concentration in a 500 μL sample of each reaction 
mixture was measured at 50±30s after mixing (variation due to speed of operator) 
and every 5 minutes thereafter for 1 hour. 
4.4 IgG Assay Calibration and PAG-IgG Binding Kinetics at the LiScAR 
Sensor Surface 
The fitted Langmuir model, for the PAG-IgG binding interaction at the interface of 
the sensor surface, gave estimates of ka and kd of (3.26 ±0.03) ×105 M-1 s-1 and 
(3.01 ±0.37) ×10-4 s-1 respectively, Figure 4.6a. The estimated kinetic constants 
compare favourably with literature values (494).  
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Figure 4.6 IgG capture by PAG immobilised on the LiScAR sensor surface. PAG was immobilised on the 
amino substrate surface using the assay method described in 2.8.1. Signals are the averaged response of 
n=20 assay spots. a) Duplicate kinetic responses (grey) of the sensor surface to varying concentrations of 
IgG (6.25, 12.5, 35, 50, 100,200 nM). Higher concentrations induce greater response and data deviated 
significantly from the globally fitted 1:1 Langmuir model (red). AUC of the kinetic response curve was 
recorded over 100 seconds of IgG association (green). b) Standard curve of n=2 IgG concentration 
determinations against AUC. The data fit to a logistic model (blue) with R2=0.997. 
The IgG immune-kinetic assay was calibrated using the AUC of the association 
step, plotted against IgG concentration and fitted to a logistic standard curve as 
described in Chapter 2, Figure 4.6b. The IgG assay Limit of Detection (derived 
here as 3σ of the noise distribution of the PBS blank) was 4.7×10-5 RIU 
corresponding to 0.4 nM. The Limit of Quantitation, (derived here as 10σ of the 
noise distribution of the PBS blank) was 1.7 nM.  The typical assay error, 
estimated from 9 sample repeats at 100 nM, was 5 nM (2σ). The duty cycle of 
the IgG assay was 5 minutes, allowing for a surface regeneration step after each 
sample measurement which removes previously captured IgG in preparation for 
the next sample. 
4.5 PAG-IgG Binding Kinetics in Solution 
Binary solutions of IgG/PAG were prepared with different PAG mole fractions 
(xPAG) in the range 0 – 0.5 (corresponding to starting ratios in the range 1:0 to 
1:1 IgG:PAG). The solutions were sampled for unbound IgG using the rapid 
biophotonic assay over a period of 1 hour, Figure 4.7. From an initial IgG 
concentration of 100 nM, the antibody concentration is seen to fall rapidly within 
the first 50 seconds followed by further, slower decrease over the proceeding 
hour. 
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Figure 4.7 Time course analysis of IgG binding to solution phase PAG. a) Unbound IgG concentration is 
shown for varying ratios of antibody and PAG: control, 10:1, 6:1, 3:1, 1:1. The data were fitted to a kinetically 
distinct 3-binding site model (solid blue) and an 8-binding site model (dashed red). b) Titration of the free 
IgG against the mole fraction of PAG, sampled at the end of the first kinetic process 50±30 seconds after 
mixing. All data points represent single measurements with error bars of 5nM, the typical assay error (±2σ). 
A 3-site model (solid blue) and an 8-site model (dashed red) are overlaid for comparison. 
The decrease in available IgG after the first 50 seconds is shown in Figure 4.7b 
and has a zero asymptote (LoQ 1.7 nM) at mole fractions of PAG in the range 
0.35 - 0.43, corresponding to 1.6 ± 0.3 IgG molecules bound to PAG. The 
effective activity of PAG during the initial 50 seconds of association is the ratio of 
bound IgG to the genetic sequence maximum of 8 sites, 𝛾𝑃𝐴𝐺 = 
1.6 ± 0.3 
8
= 0.20 ±
0.04. The apparent cooperative binding effect observed in Figure 4.7b has been 
previously reported for protein A (495) and may be explained by fewer antibodies 
bridging two PAG proteins (by binding via two Fc epitopes) at higher mole 
fractions of antibody (454), although this is not modelled.   
The number of bound IgG molecules per individual PAG molecule after 1 hour is 
shown in Figure 4.8. The maximum IgG : PAG binding ratio was 2.8 ± 0.5, 
markedly similar to the published ratio of 2.5 - 3.1 for protein A (496) but 
significantly below the 8 binding sites suggested by the sequence: corresponding 
to an activity, 𝛾𝑃𝐴𝐺 = 
2.8 ± 0.5
8
= 0.35 ± 0.06.  
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Figure 4.8 Effective stoichiometry of antibody (IgG) bound per PAG at varying mole fractions of PAG. Data 
were derived from the mean of n=3 determinations at 55 minutes ±5 minutes after mixing with PAG. Error 
bars are ±2σ. A 3-binding site model (solid blue) and an 8-binding site model (dashed red) are overlaid.  
The steric blocking of neighbouring IgG binding sites on the genetically modified 
PAG appeared to be no better than for native protein A. Despite reports that the 
sum of weaker contacts in a flexible context around a central scaffold can be 
more efficient than precise design and strong individual interactions (497), steric 
hindrance between binding domains must be considered in ligand design. Future 
synthetic Fc binding proteins should include contacts around platforms with 
considered geometries able to better accommodate IgG in all binding sites. 
4.6 PAG-IgG System Modelling 
An ordinary differential equation (ODE) model is presented here for the sequential 
filling of 8 binding sites (the number suggested by the genetics literature) on the 
PAG molecule assuming sequential non-cooperative binding. The model is 
described by molecular equations 1a-8a and mathematically by differential 
equations 1b-8b with ka and kd representing the forward and reverse reaction rate 
constants respectively. All effective activity coefficients were assumed to be 1.  
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𝐼𝑔𝐺 + 𝑃𝐴𝐺
𝑘𝑎1
→  
𝑘𝑑1
←  
 𝐼𝑔𝐺1𝑃𝐴𝐺 1a 
𝑑[𝐼𝑔𝐺]
𝑑𝑡
= 𝑘𝑑1[𝐼𝑔𝐺1𝑃𝐴𝐺]
− 𝑘𝑎1[𝐼𝑔𝐺][𝑃𝐴𝐺] 
1b 
𝐼𝑔𝐺 + 𝐼𝑔𝐺1𝑃𝐴𝐺
𝑘𝑎2
→  
𝑘𝑑2
←  
𝐼𝑔𝐺2𝑃𝐴𝐺 2a 
𝑑[𝐼𝑔𝐺]
𝑑𝑡
= 𝑘𝑑2[𝐼𝑔𝐺2𝑃𝐴𝐺]
− 𝑘𝑎2[𝐼𝑔𝐺][𝐼𝑔𝐺1𝑃𝐴𝐺] 
2b 
𝐼𝑔𝐺 + 𝐼𝑔𝐺2𝑃𝐴𝐺
𝑘𝑎3
→  
𝑘𝑑3
←  
𝐼𝑔𝐺3𝑃𝐴𝐺 3a 
𝑑[𝐼𝑔𝐺]
𝑑𝑡
= 𝑘𝑑3[𝐼𝑔𝐺3𝑃𝐴𝐺]
− 𝑘𝑎3[𝐼𝑔𝐺][𝐼𝑔𝐺2𝑃𝐴𝐺] 
3b 
𝐼𝑔𝐺 + 𝐼𝑔𝐺3𝑃𝐴𝐺
𝑘𝑎4
→  
𝑘𝑑4
←  
𝐼𝑔𝐺4𝑃𝐴𝐺 4a 
𝑑[𝐼𝑔𝐺]
𝑑𝑡
= 𝑘𝑑4[𝐼𝑔𝐺4𝑃𝐴𝐺]
− 𝑘𝑎4[𝐼𝑔𝐺][𝐼𝑔𝐺3𝑃𝐴𝐺] 
4b 
𝐼𝑔𝐺 + 𝐼𝑔𝐺4𝑃𝐴𝐺
𝑘𝑎5
→  
𝑘𝑑5
←  
𝐼𝑔𝐺5𝑃𝐴𝐺 5a 
𝑑[𝐼𝑔𝐺]
𝑑𝑡
= 𝑘𝑑5[𝐼𝑔𝐺5𝑃𝐴𝐺]
− 𝑘𝑎5[𝐼𝑔𝐺][𝐼𝑔𝐺4𝑃𝐴𝐺] 
5b 
𝐼𝑔𝐺 + 𝐼𝑔𝐺5𝑃𝐴𝐺
𝑘𝑎6
→  
𝑘𝑑6
←  
𝐼𝑔𝐺6𝑃𝐴𝐺 6a 
𝑑[𝐼𝑔𝐺]
𝑑𝑡
= 𝑘𝑑6[𝐼𝑔𝐺6𝑃𝐴𝐺]
− 𝑘𝑎6[𝐼𝑔𝐺][𝐼𝑔𝐺5𝑃𝐴𝐺] 
6b 
𝐼𝑔𝐺 + 𝐼𝑔𝐺6𝑃𝐴𝐺
𝑘𝑎7
→  
𝑘𝑑7
←  
𝐼𝑔𝐺7𝑃𝐴𝐺 7a 
𝑑[𝐼𝑔𝐺]
𝑑𝑡
= 𝑘𝑑7[𝐼𝑔𝐺7𝑃𝐴𝐺]
− 𝑘𝑎7[𝐼𝑔𝐺][𝐼𝑔𝐺6𝑃𝐴𝐺] 
7b 
𝐼𝑔𝐺 + 𝐼𝑔𝐺7𝑃𝐴𝐺
𝑘𝑎8
→  
𝑘𝑑8
←  
𝐼𝑔𝐺8𝑃𝐴𝐺 8a 
𝑑[𝐼𝑔𝐺]
𝑑𝑡
= 𝑘𝑑8[𝐼𝑔𝐺8𝑃𝐴𝐺]
− 𝑘𝑎8[𝐼𝑔𝐺][𝐼𝑔𝐺7𝑃𝐴𝐺] 
8b 
 
The ODE solutions were propagated numerically in MATLAB with the function 
‘ode15s’ and fitted simultaneously to all data shown in Figure 4.7 with equal 
weighting, using a non-linear least squares method (498, 499). The initial guess 
values for the association and dissociation rate constants of the model were taken 
from the surface data shown in Figure 4.6. The model fit did not converge to a 
solution when all 16 rate constants were allowed to float, owing to the high 
correlations between the parameters. 
4.6.1 Parameter Reduction 
The first parameter reduction technique was to fix the PAG-IgG dissociation rate 
at the rate observed on the surface. The dissociation rate reflects how well bound 
the IgG is to the PAG and is least likely to vary between settings. There was little 
opportunity for surface avidity for the Fc region binding and constant half-life is a 
reasonable assumption. The dissociation rates for all PAG-IgGn complexes were 
set at the dissociation rate observed on the sensor surface, 3.01 × 10-4 s-1, and 
the association rates of all reactions were fitted to the data. The 8 association 
rate constants were determined with poor confidence and remained highly 
correlated. The correlation matrix and a node map of parameter correlation are 
shown in Figure 4.9. 
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Figure 4.9 Parameter correlation for the 8-binding site, 8-parameter fit of the association rate constant 
parameters. The initial guess values for the association rate constants of the fitting routine were taken from 
the Langmuir model fit to the LiScAR surface data. a) Heat map of the correlation matrix. b) Node map of 
absolute pairwise parameter correlation, showing two distinct groups of parameters. Every model parameter 
is represented by a node and is linked to another parameter node if their absolute pairwise correlation is 
greater than 0.2. The figure highlights the rationale for grouping ka1-2 into k-fast and ka3-8 into k-slow. 
The heat map of the correlation matrix shows a striking division into two 
parameter groups and the node map shows the connectivity of the rate constants. 
The parameters in the model may be grouped based on the correlation 
connectivity into a single fast association reaction (combining ka1 - ka2) and a 
single slow-kinetic association (combining ka3-ka8), which allowed the fit to 
converge with good root-mean-square-error (RMSE), reduced parameter 
correlation and improved parameter confidence.  
The 8-binding site ODE model may also be reduced to describe the sequential 
filling of 3 binding sites only: the number determined experimentally by titration, 
Figure 4.8, using the same parameter grouping as the 8-site model (k-fast = ka1-
2 and k-slow = ka3). The results of fitting the reduced models are shown in Table 
4.1. 
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Table 4.1 Results of fitting 8 and 3 binding site models to IgG-PAG binding time course data. 
Model Fit Property 
Biosensor 
Interface Value 
Least squares 
local minimum 
estimate 
Pattern search 
global minimum 
estimate 
8 
binding 
site 
model 
k-fast / M-1 s-1 3.26 × 105 1.90 ± 0.09 × 106 1.89 × 106 
k-slow / M-1 s-1 3.26 × 105 6.10 ± 0.01 × 103 6.10 × 103 
kd / s-1 3.01 × 10-4 - - 
RMSE / nM 27.0 3.46 3.46 
3 
binding 
site 
model 
k-fast / M-1 s-1 3.26 × 105 1.86 ± 0.08 × 106 1.85 × 106 
k-slow / M-1 s-1 3.26 × 105 1.24 ± 0.05 × 104 1.24 × 104 
kd / s-1 3.01 × 10-4 - - 
RMSE / nM 12.6 3.31 3.31 
 
The RMSE for the 8 site and 3 site models were not significantly different: 3.25 
nM and 3.31 nM respectively (typical assay error was 5 nM). Considering both 
goodness-of-fit and titration data, the reaction mechanism in solution is best 
described by 3 antibody binding steps, rather than 8 as predicted by the genetic 
evidence. The correlation coefficients between the k-fast and k-slow parameters 
for the 8 and 3 binding site models are -0.03 and -0.05 respectively. The low value 
indicates that the k-fast and k-slow parameter groups are kinetically distinct in the 
data.  
The k-fast and k-slow rate constants reduction demonstrates a persistent 
challenge for systems biology modelling. Kinetically distinct processes in a 
deterministic model must have significantly different rates to be determined 
experimentally, highlighting that kinetic data need to be recorded at a sufficiently 
rapid sampling rate. Similar fast or slow kinetic processes may never be 
distinguishable and may only be studied in isolation. Furthermore, even with high 
quality data, there must be a global minimum in the fitted model if the kinetic 
parameters are to decouple sufficiently to allow the model to produce precise 
parameter estimates. The k-fast-k-slow parameter space in the current model can 
be explored in a box search and plotted in 3D with RMSE as the cost function of 
the fit, Figure 4.10. 
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Figure 4.10 Box-search parameter space of root mean square error at various combinations of k-fast and k-
slow for the 3-binding site model fit. The global minimum estimated by the pattern search global solver (green 
sphere) is within 95% confidence limits of the least squares fit result (red sphere). The least squares fit 
search path (red dashed line) and pattern search model evaluations (black crosses) originate from k-fast 
and k-slow initial guesses set at the surface studies value of 3.26×105 (outside plot range). 
The parameter space exploration allowed the depth of the global minimum from 
the starting point to be determined: 27.0 – 3.46 nM (RMSE) for the 8-site model 
and 12.6 – 3.31 nM (RMSE) for the 3-site model. Critically, two fitting routines, 
least squares and a pattern search method, find the same minimum and show 
good starting-point invariance, Table 4.1. Starting point invariance is a good test 
of model accuracy but is rarely checked so easily. There can be reasonable 
certainty in the purity of the two grouped rate constants, k-fast and k-slow, and 
that their resolution into kinetically distinct process is limited by the lack of data in 
the first 50 seconds of the titration time courses. Hence with some confidence, 
the PAG-IgG interaction is accurately described by two processes: an initial rapid 
binding of two IgG ligands followed more slowly by at most one further IgG.  
4.7 Discussion 
There are two observations in the results with consequences for spin-column 
separation science: 1) the surface excess of binding sites for IgG on the PAG 
surface may be significantly lower than expected and 2) loading times for the 
column may be as short as 50 seconds, rather than 10 minutes as indicated in 
some protocols. Both binding site models have the same fitted k-fast rate 
constant and predict that after 50 seconds, unbound IgG concentration is reduced 
by 50% and 99% at PAG mole fractions of 0.20 and 0.43 respectively, Figure 4.7. 
The antibody titration shows that ka1-2 dominate the reaction in early time and 
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complete antibody binding may be achieved rapidly with a sufficient PAG mole 
fraction. Over-loading of the column is probably the major concern if reliance on 
6-fold binding site excess (as sold) or 8-fold (as indicated by the genetic 
sequence) were critical in the adoption or modification of a protocol. 
The association rate of the IgG-PAG reaction differs significantly between 
solution and surface tethered PAG. The fitted 8-site and 3-site models have mean 
association rate constants that are 47 ± 8 % and 282 ± 20 % greater than ka 
derived from biosensor data of the IgG association to tethered PAG at a plasmon 
surface (3.26 ± 0.03) ×105 M-1 s-1.  The difference between the interface and 
solution-phase reaction rates may be attributed to several factors including 
differences in diffusion coefficients (limiting rate constants), reduced effective 
activity at the interface and limited transport across any interface that forms 
between the tethered proteins and the bulk solution. However, there is also a 
clear steric effect with the acceptance angle of the surface collision (Figure 4.5) 
likely limited, which will limit PAG binding activity when the reaction is confined to 
a surface.  The consequences of steric hinderance include reduced surface 
packing density (454) as seen in Chapter 3, enhanced cooperative binding (495) 
and potentially different surface complexes due to surface avidity (500). These 
latter effects are apparent as departures from the Langmuir model that are visible 
at high IgG concentrations in Figure 4.6.  All these effects can be grouped into an 
‘effective activity’ coefficient for a given experimental setting. Only if the effective 
activity of the experimental setting is known can a “pure” rate constant be 
determined which is transferable to other system settings.  
To derive the activity of a new experimental setting, the concept of a standard 
setting must first be considered for comparison. For protein-protein interactions 
the standard setting must capture the fundamental kinetics and thermodynamics 
of the interaction - minimising the effects of concentration perturbations such as 
hydrodynamic effects in the crowded environments of cell cytoplasm (501) which 
can be explored later. The rate constants determined in the standard setting 
provide the best understanding of association, dissociation and affinity of the 
ligand-protein interaction and define the standard number of binding sites. PAG-
IgG does not have 8 simultaneously functional sites as predicted by the genetic 
sequence. In this study, the number of kinetically active sites, 𝛾𝑃𝐴𝐺 = 
2.8 ± 0.5
8
=
0.35 ± 0.06, defines an effective activity for the PAG in PBS. 
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A model which fits well to in vitro data may not fully account for the added 
complexity of in vivo conditions (482). In the cytoplasm, as much as 40% of the 
total volume may be occupied by proteins (502), and crowding effects will 
generate several perturbations to protein-protein interactions and ligand binding 
(372). Reduced diffusion rate also changes the collision number within the 
environment. Interactions may be sterically favoured or hindered and 
concentrations of reactants may be enhanced or depleted by association with 
different components. The description of a second order reaction with the activity, 
, captures the effective concentration variations between the simple system 
settings observed but may not account for the addition of new pathways. Model 
transfer between system settings requires the contributing factors of the new 
setting to be understood or measured empirically. Models of the immune system 
may require the flexibility to be adapted for healthy and sick patients, where the 
patient’s response changes the viscosity and protein composition of the blood. 
Amplification of transferability uncertainties is likely to occur with larger reaction 
networks such as that of the Complement cascade and if not accounted for, could 
lead to a loss of any model predictability.  
4.8 Conclusions 
The issues of model transferability presented here, highlight the need for a model 
to be validated in every new system setting for which predictions are made. Model 
transfer to new system settings is possible using activity coefficients as presented 
here but such an approach may be challenging for large models such as those of 
Complement cascade activation. For example, research has shown that the 
assembly rate of the surface-bound AP C3 convertase is 80-fold greater in the 
presence of physiological Mg2+ (0.5 mM) than in 2 mM EDTA (a magnesium ion 
chelating agent), whilst in the fluid-phase the same reaction is estimated to differ 
less than three-fold under the same conditions (257). Ultimately, fitting a model 
to data in the most relevant system setting avoids the challenges of transferability. 
Complement activation studies are typically performed in serum and phenotype 
testing would likely occur in vitro for control over the conditions of activation. It is 
therefore logical that a Complement activation model for predicting patient 
phenotypes should also be developed using pooled human serum in vitro. 
Existing kinetic parameters of Complement protein interactions should be taken 
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from experiments performed in serum to develop a mechanistic model of 
Complement activation using the systems biology techniques presented here.  
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5 Kinetic Modelling of in vitro Complement Cascade 
Activation 
5.1 Introduction 
Chapter 4 showed that there are three major scientific applications of kinetic 
models of biological systems. Firstly, model construction enables the system 
response to be simulated by knowing the starting conditions and objects involved 
– challenging with diagrammatic models alone. Secondly, comparison of a kinetic 
model to data can provide evidence for system structure and model fitting can 
provide kinetic constants. Thirdly, the model predictions of system behaviour 
under different conditions can be used to generate hypotheses and guide new 
experiments to confirm any simulated effects. Ultimately, the goal of systems 
modelling is to achieve a refined model which accurately reproduces the 
relationship between any given starting conditions and the system response 
recorded in experimental data (459). It follows that a predictive model of 
Complement activation could be used to predict the Complement activation 
dynamics of patient serum and guide a hypothesis-driven approach to the 
selection of potential risk biomarkers of nosocomial infection.  
The Complement cascade is characterised by a series of rapid, consecutive 
kinetic processes with catalytic activity both positively and negatively regulated.  
C3 and C5 convertases are negatively regulated by a number of proteins in 
solution (FH, FI, C1-INH, C4BP and sCR1) and on the surface of host cells (157, 
158) as discussed in Chapter 1. The lifetime and catalytic activity of the C3 and 
C5 convertases controls the extent of Complement activation which can become 
dysregulated in conditions such as sepsis (503). The structures of most protein 
complexes and their interactions in the Complement system are well-known, 
allowing a mechanistic representation for Complement activation to be 
constructed following the recommended nomenclature for each protein (183), 
Figure 5.1. 
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Figure 5.1 Schematic of the mechanisms of Complement activation and inhibition. All complement pathways 
are highlighted: CP (blue), LP (yellow), CP/LP (green), tick-over (red), AP (purple) and TP (grey). Reversible 
reactions are indicated by double headed arrows. Reactions with known rate constants are shown in blue, 
whilst reactions with unknown rate constants are shown in red (all rate constants are tabulated in Appendix 
3 and Appendix 5). The protein species for which data were collected for model fitting are circled with dashed 
lines. The most sensitive reactions (accounting for 95% of model sensitivity) from the sensitivity analysis in 
section 5.3.4 are emboldened to show that system dynamics is controlled by reactions located throughout 
the system. 
Despite extensive study (167), some reactions of the Complement system are 
incompletely understood or remain contentious. For example, there is evidence 
to suggest that FB binds to C3b via either Ba or Bb portions (190) but the 
interaction is rarely mentioned in studies of the AP. A more recent study showed 
that the Ba portion of FB binds in a Mg2+ independent process followed by the 
slower binding of the Bb portion (504).  Furthermore, it is well reported that 
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Complement activation occurs ex vivo and complicates studies of Complement 
in serum and plasma samples, but the effect is typically attributed to tick-over in 
the AP, despite reports of spontaneous formation of C3 fragments in human 
plasma showing C1q dependence (505). Experimental evidence of spontaneous 
C1 activation is conflicting: one study estimated a first order rate constant of 0.173 
min-1 in purified solutions of C1 components which was suppressed in human 
serum (506), whilst other studies have shown that IgG oligomers (507) or immune 
complexes are required to activate C1 (508). A further study concluded that C1 
activation could be a result of unidentified proteolytic enzymes and can be both 
an intra- and intermolecular process impacted by experimental conditions (179) . 
LP tick-over has not been reported. Uncertainty in the mechanism of certain 
intermolecular binding reactions is a challenge when constructing of the 
Complement reaction network and previous studies have studied Complement 
activation dynamics using Complement models which focus on the well-known 
reactions. A list of existing Complement models and their properties is shown in 
Table 5.1. 
Table 5.1 Existing Complement models published in the literature. 
Model Year 
Pathways 
modelled 
Optimisation method 
Activation 
stimulus 
Hirayama et 
al. (509) 
1996 CP, TP 
Minimal protein 
consumption 
Spontaneous 
C1-C4 
complex 
Korotaevskiy 
et al. (185) 
2009 
CP, AP, 
TP 
Minimal protein 
consumption; in vitro 
bactericidal data 
Population of 
cells 
Liu et al. 
(510) 
2011 
CP, LP, 
TP, CRP 
crosstalk 
Fitting to CRP, C4, C3 
and C4BP time series 
data; in vitro bactericidal 
data 
CRP-C1 
complex and 
PAMPs 
Zewde et al. 
(511) 
2016 AP, TP None 
Surface for 
C3b deposition 
Sagar et al. 
(271) 
2017 LP, AP 
Fitting to C3a and C5a 
time series data 
Zymosan 
Zewde et al. 
(512) 
2018 
CP, AP, 
TP 
None 
Spontaneous 
C1 activation 
and surface for 
C3b deposition 
Present study 2019 
CP, LP, 
AP, TP 
Fitting to C3a, C5a, 
C4a, Ba and TCC time 
series data 
Zymosan 
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The present study requires a model that can predict the effects of starting protein 
conditions (such as depletion) on activation dynamics on the complete 
Complement system to deductively identify potential phenotypes of an immune 
state which is more vulnerable to post-operative nosocomial infection. The 
dogma of systems biology is that the qualitative mechanisms of Complement 
activation reported in the literature and represented in Figure 5.1, can only be 
investigated quantitatively through a mechanistic model of the system as a whole 
rather than isolated or simplified components (513). A thorough Complement 
model should therefore include each of the bimolecular reactions and consider 
the catalytic activity of each resulting enzyme and its inhibitors. 
All previous models of the Complement system have involved the use of ODEs 
but none have included mechanistic reactions for all pathways of the Complement 
system (none consider the LP for example), instead concentrating either on a 
subset of pathways or reducing model complexity by combining reactions into 
non-mechanistic equations. As discussed in Chapter 4, model simplification is 
driven by the major challenges facing an ODE model of a complex system: 1) 
insufficient quality data; 2) large numbers of kinetic parameters that are highly 
correlated and need to be optimised; 3) locating a global minimum in the 
parameter space and 4) data set invariance. Inadequate biological data has been 
cited as the major limiting factor in the optimisation of previous Complement 
models (271). Bimolecular rate constants of the Michaelis-Menten reaction 
scheme for enzymes (514) may not be experimentally accessible for all short-
lived intermediates and hence are often ignored in favour of reducing the 
parameters of the model. Non-mechanistic models are inherently unable to 
predict system behaviour beyond the context of the optimised model, such as the 
effect of additional inhibitory processes targeting an enzyme-substrate complex 
or different activation stimuli. As such, all previous models are inappropriate for 
use in the present study which aims to predict the effects of starting protein 
conditions on activation dynamics on the complete Complement system.  
A new model of Complement activation must therefore be developed and 
optimised specifically to predict system dynamics in the system setting studied 
here: in vitro activation of human serum. A previous model of Complement 
activation is optimised for in vitro zymosan activation of human serum (271) and 
used C3a and C5a time series data from the Shaw lab to fit model outputs. The 
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system setting of in vitro activation by a single stimulus is better suited to the 
present study than the system settings of other previous models which either 
consider activation via a growing population of cells, spontaneous activation  or 
are simply not optimised for a specific stimulus at all (see Table 5.1).  As 
described in Chapter 4, ODEs are widely used in biological modelling to capture 
the quantitative and dynamic nature of complex systems over time (462) and 
using ODEs in the present study allows the published rate constants compiled 
from previous models to be reused, although estimating the missing parameters 
remains challenging.  
Notwithstanding the modelling challenges, quantitative and mechanistic 
modelling of Complement activation should reveal the dynamics of the cascade 
and enable predictions to be made of therapeutic relevance, such as the effect of 
protein concentrations (deficiency) or system disruption by a drug on 
Complement activation dynamics. Of the 109 reactions shown in Figure 5.1, the 
kinetic constants of 34 have been reported previously (Appendix 3) but there is 
no prior information on the kinetics of the remaining reactions. As shown in 
Chapter 4, for a model to be quantitatively accurate, the model parameters should 
be known or estimated from fitting the model to experimental data. Model fitting 
is complicated by parameter correlation and the presence of multiple local minima 
- challenges which were overcome in Chapter 4 by grouping similar parameters 
using prior knowledge of their values and fitting using global optimisation 
algorithms. A starting value for parameter estimation within or close to the global 
minimum is beneficial.  
Despite a large range of recorded enzyme kinetics, a recent review of the enzyme 
kinetic parameters: Km, kcat and kcat/Km for ~2500 enzymes reveals that many are 
“moderately efficient” (515). For example, the relatively small range of kcat values 
within 1 – 100 s-1 accounts for 60% of all recorded enzymes. Median kinetic 
constants derived from the distribution of all known enzymes can be used as 
initial guess values for unknown kinetic parameters and a further reduction in the 
number of floated parameters can be achieved by assuming that all constitutive 
protein concentrations in pooled serum take the median values of their respective 
reference ranges. These two prior assumptions provide a biologically appropriate 
starting point for optimisation of a complete and mechanistic ODE model of 
Complement activation: referred to here as the C-ODE model.   
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5.2 Aims and Objectives 
The aim of this chapter is to describe the development of a fully mechanistic 
Complement model, based on the accepted reaction mechanisms in Figure 5.1. 
The purpose of the model is predicting Complement activation dynamics from 
specific starting conditions such as patient serum protein concentrations and the 
level of activation stimulus. 
The first objective was to study Complement activation markers (Ba, C4a and 
TCC) with ELISA, over 24 hours following the in vitro activation of pooled human 
serum with zymosan at several concentrations. The new data set was combined 
with data for C3a and C5a from previous activation studies using the same 
protocol (152) to produce a consistent data set of activation markers from all 
Complement pathways.  
The second objective was to construct an ODE model of Complement activation 
considering all bimolecular reactions and enzyme catalysis and incorporating 
available published rate constants. The optimisation strategies discussed 
previously were used to fit the model to the ELISA data and estimate unknown 
rate constants.  
Finally, parameter sensitivity and flux analyses were performed on the model to 
verify that the dynamics of Complement activation align with current 
understanding of the system. The C-ODE model predictions of new system 
phenotypes may then be validated in future studies. 
5.3 Materials and Methods 
5.3.1 in vitro serum activation  
Pooled Normal Human AB Serum was obtained from Innovative Research (IPLA-
SERAB-OTC). Phosphate buffered saline (PBS), EDTA and zymosan were 
obtained from Sigma Aldrich. ELISA assays were obtained from Quidel for Ba, 
C4a and TCC (#A035, #A033, #A020). All serum experiments were performed in 
a Level 2 laboratory following relevant risk assessments. 
Suspensions of zymosan in PBS (1 mL) were homogenised by vortex mixing and 
added to pooled normal human serum (24 mL) to give final zymosan 
concentrations of 0, 0.01, 0.1 and 1 mg/mL. The serum was maintained at 37 °C 
in an incubator with orbital shaking at 190 rpm during the experiment. Serum 
samples of 1 mL were collected by pipette from the reaction mixtures at time 
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points: −0.5, 0.5, 1, 2, 4, 8, 16 and 24 hours relative to the addition of zymosan. 
Samples were immediately mixed with aqueous EDTA (50 µL, 10 mM) to give a 
final EDTA concentration of 0.5mM and centrifuged for 30 minutes at 3000 g. The 
supernatant was removed, avoiding sampling fat deposits or the zymosan pellet, 
before freezing with liquid nitrogen and storage at -20 0C. The ELISA assay 
protocols were followed as detailed by the manufacturer. Before ELISA analysis 
of all samples, the first and final samples in the time courses were analysed at 
several dilution factors to ensure all samples fell within the dynamic range of each 
assay. Samples were diluted according to Table 5.2. ELISA calibration curves 
are shown in Appendix 2 with control samples exhibiting errors of <4%.  
Table 5.2 Dilution factors used with samples from each zymosan time series for use with ELISA.  Dilution 
factors include the dilution due to the addition of EDTA and zymosan solutions.  
Assay 0 mg / mL 
zymosan 
samples dilution 
factor 
0.01 mg / mL 
zymosan 
samples dilution 
factor 
0.1 mg / mL 
zymosan 
samples 
dilution factor 
1 mg / mL 
zymosan 
samples 
dilution factor 
C4a 272.5 272.5 381.5 381.5 
Ba 4375 6562.5 6562.5 13125 
TCC 87.5 164 246 820 
 
The ELISA data collected here were merged with the previously published data 
for C3a and C5a data (152) producing a dataset containing five markers of 
Complement activation sampled at eight time points over four different activation 
experiments of the same pooled serum sample. The final dataset (Figure 5.2) 
contains 160 data points with a mean ±2SD derived from at least two statistical 
repeats (C3a and C5a data from the previous work show biological repeats). The 
epitope decay observed previously in the C3a assay (152, 516) was corrected 
using the half-life equation 3.3 with a negative power: 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 = 𝑑𝑎𝑡𝑎 × 0.5
−
𝑡
𝑡1
2⁄  
where the half-life of the epitope decay was measured previously to be 28 hours 
(152).  
5.3.2 C-ODE Model Construction 
The C-ODE model is comprised of 85 distinct reaction mechanisms 
parameterised by 109 rate constants allowing for reversible reactions and 78 
ODE’s describe the concentration of each species over time. All reactions and 
species included in the C-ODE model are presented in Appendix 3 and Appendix 
4, respectively. The reaction network, shown in Figure 5.1, was developed into a 
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fully mechanistic model divided into three types of reactions. Firstly, simple 
bimolecular reactions and enzyme catalysis were constructed using the familiar 
Michaelis-Menten reaction scheme. Secondly, a new class of activation reactions 
was used to represent the complex activation of C1, MBL and C3 by zymosan, 
for which there was no kinetic data or mechanism. Lastly, a set of sink reactions 
was used to represent decay of activated species within the in vitro reaction 
mixture, removing these species permanently from the system.  
The Michaelis-Menten reaction type is exemplified in equation 5.1 with the 
formation of the tick-over C3 convertase: 
 𝐶3(𝐻2𝑂)𝐹𝐵 + 𝐹𝐷
𝑘𝑎
→ 
𝑘𝑑
← 
𝐶3(𝐻2𝑂)𝐹𝐵𝐹𝐷
𝑘𝑐𝑎𝑡
→  𝐶3(𝐻2𝑂)𝐵𝑏 + 𝐹𝐷 5.1 
 
where ka is the affinity constant, kd is the dissociation constant and kcat is the 
enzyme turnover number. Two spontaneous reactions were included in the 
model: C1 -> aC1 and C3 -> C3(H2O). The rate of spontaneous C3 hydrolysis is 
known and was assigned a value of 1×10-4 min-1 (184, 185). The rate constant of 
spontaneous C1 activation was considered to be unknown in the present study 
due to the contradictions in the literature discussed previously (179). The rate 
constants of the Michaelis-Menten reactions can be converted to enzyme kinetic 
constants: the affinity constant, kd /ka = KD; the Michaelis constant, (kcat + kd ) / ka 
= Km; and a measure of catalytic efficiency, kcat/Km. The enzyme kinetic constants 
may then be compared to the data in ref (515).  
Zymosan is reported to activate all Complement pathways but the mechanisms 
are complex with unknown rate constants. For example, the sequential activation 
processes of C1 and MBL by their associated serine proteases involves multiple 
proteins reacting simultaneously as described in Chapter 1. Furthermore, a 
recent review of the AP states that an active process rather than tick-over should 
be shown as the initiator of AP activation (517), with gas bubbles and biomaterial 
surfaces all known to increase the rate of C3(H2O) formation with an unknown 
mechanism (186). Considering the uncertain mechanisms of Complement 
activation, the model contains a minimal set of activation reactions which provide 
a simple means to express the complex Complement initiation processes in each 
pathway, Table 5.3.  
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Table 5.3 Activation reactions of the C-ODE model. Species ‘A’ represents the activating process, which in 
the present study is zymosan.  
Reaction name Reaction mechanism 
A1 A + C1 -> A + aC1 
A2 A + MBL -> A + aMBL 
A3 A + C3 -> A + C3(H2O) 
 
The zymosan in the reaction mixture had an unknown surface area but was 
prepared as a fine homogenous suspension which was well mixed to prevent 
settling during activation and is expected to behave as a solution phase reactant 
rather than a surface. Hence, the activation reactions were written as simple 
bimolecular reactions where zymosan is considered as having a constant 
concentration and any surface filling effects are ignored. The activation reactions 
enabled the familiar Michaelis Menten reaction scheme to be used for modelling 
the subsequent activity of the activated proteins: aC1, aMBL and C3(H2O).  
A final set of reactions are sink reactions, Michaelis-Menten reactions invoked to 
remove species from the reaction mixture when the activation products are inert 
to further reactions. The sink reactions therefore reduce model complexity by 
simplifying products of “dead end” metabolic pathways for which there is no data 
for model fitting (518). The full set of sink reactions is shown in Table 5.4. 
Table 5.4 Sink reactions of the C-ODE model. 
Reaction 
name 
Reaction mechanism 
d1 aC1 + C1inh -> C1inhC1 
d2 aMBL + C1inh -> C1inhMBL 
d3 C3(H2O)FHFI -> dC3(H2O) + FH + FI 
d4 C4BPC4bFI -> C4BP + dC4b + FI 
d5 sCR1C4bFI -> sCR1 + dC4b + FI 
d6 sCR1C3bFI -> sCR1 + iC3b + FI 
d7 C3bFHFI -> iC3b + FH + FI 
 
Sink reactions d1 and d2 permanently remove C1 and MBL from the serum 
respectively. C1-INH (also termed C1inh for modelling syntax) is a serpin and 
suicide inhibitor which irreversibly binds and inactivates C1r and C1s proteases 
in the C1 complex of the CP as well as the MASP-2 protease in the LP (519). 
C1inh therefore prevents the proteolytic cleavage of later complement 
components C4 and C2 by the activated forms of C1 and MBL. Reaction d3 
inactivates the spontaneously formed C3(H2O) using negative regulation from 
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FH and FI. Reactions d4 and d5 describe C4 deactivation mediated by C4BP, 
soluble CR1 and FI.  
Following dissociation from complexes or due to its natural half-life, C3b is 
converted to dC3b - considered to be inert to further reactions with FB and 
existing convertases. However, dC3b is not a sink species as it is further 
converted to iC3b by FI in the presence of a cofactor in sink reactions d6 and d7. 
Species for which there is no deactivated form (such as P, FB and Bb) are 
regenerated following dissociation from a complex, which simulates the natural 
equilibrium of these species in the serum. 
Of the 109 rate constants in the model, 34 were assigned published literature 
values, Appendix 3. Unknown rate constants of Michaelis-Menten reactions were 
given starting values equal to median enzyme values (515) of: ka = 6 µM-1 min-1; 
kd = 0.06 min-1; kD = 10 nM and turnover number, kcat = 840 min-1. The activation 
reactions in Table 5.3 are simplifications of complex processes and were 
assigned initial values of 1 µM min-1. The starting concentrations of the 78 
constituent proteins were set at their median physiological values in serum (the 
pooled-serum approximation) and all intermediate enzyme species formed as 
part of the cascade were assumed to have negligible concentrations before 
activation and are given starting concentrations of zero (Appendix 4). The ODEs 
were solved using a stiff solver, ‘ode15s’ in MATLAB R2017a software (520) with 
relative and absolute tolerances of 1×10-6 µM to produce a time series simulation 
of all 78 species in the model for a given zymosan concentration. 
5.3.3 C-ODE Model Parameter Optimisation 
The C-ODE model parameters were optimised by fitting the model outputs for 
C3a, Ba, C4a, C5a and TCC to the ELISA assay data at all zymosan 
concentrations: a global fit to 160 data points. The goodness-of-fit cost function 
was the square of the residuals (least squares) between the model and the data: 
ensuring outlying points had a disproportionate effect on the fit. The 
concentrations of each species in the dataset varied by two orders of magnitude 
and hence the data were normalised to values of 100 to ensure residuals for all 
data points were weighted equally by the cost function. Similarly, all floated 
parameters were normalised to values of 100 to ensure all parameter deviations 
were explored to equal extents by the step tolerance of the global optimisation 
routine. 
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The 56 unknown association rate constants and turnover numbers were allowed 
to vary in the fitting process whilst the 19 unknown dissociation rate constants, 
34 literature rate constants and 78 constituent protein concentrations were fixed. 
The unknown dissociation rate constants were fixed at a median kd value to 
remove high correlation with the ka and kcat parameters. The ka and kcat 
parameters of the Michaelis-Menten reactions were constrained in the fitting 
process by 15-fold above and below their starting values. The parameter search 
space encompassed 67%, 86% and 64% of the published values for Km, kcat/ Km 
and kcat in reference (515) respectively. The activation reactions (Table 5.3) were 
allowed to vary over a larger range of 1000-fold above and below their assigned 
initial values of 1 µM-1 min-1, as no prior information was known for these abstract 
reactions.  
The fit was performed with a gradient descent method implemented in MATLAB 
as ‘lsqcurvefit’ (498, 499). The fitting routine was stopped when the cost function 
changed by less than a tolerance of 1×10-3 relative to the previous value (0.1%). 
The converged fit at this tolerance defined a local minimum. Excursions away 
from the local minimum were generated by a global optimisation routine to initiate 
9 additional starting parameter values sampled randomly and uniformly from the 
fit bounds of the parameters before the gradient descent solver was executed. 
The fit solutions from all starting points were ranked in order of goodness-of-fit as 
judged by root mean square error (RMSE) and the best solution is presented here 
as the C-ODE model. RMSE serves as a multivariable function to combine the 
magnitudes of the residuals for all sample points into a single value measure of 
fit accuracy and penalises larger errors with the same bias as the least squares 
fitting routine. 
The gradient fitting routine provided the variance-covariance matrix, discussed in 
Chapter 4, was used to derive the correlation matrix and estimate 95% 
confidence limits of the fitted parameter values. The optimised C-ODE model was 
transferred to freely available COPASI software (458, 521) and software 
invariance demonstrated using a Bland-Altman comparison analysis as 
discussed in Chapter 3.  
5.3.4 Local Sensitivity and Flux analysis 
A major challenge when assessing large ODE models is to distinguish model 
features which are fundamental from those which are accidental or irrelevant 
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(522). Two key tests were used to assess whether the C-ODE model was 
consistent with published properties of Complement activation: 1) a local 
sensitivity analysis of model reactions to identify which kinetic parameters have 
the most effect on model output and 2) a flux analysis of model species to assess 
the activity of a particular pathway as a consequence of all related catalytic 
interactions (523). 
The local sensitivity analysis of the C-ODE model parameters was performed in 
MATLAB in the following sequence: 1) all model parameters were set to their 
values at the fit solution; 2) a single model parameter was perturbed by +1%; 3) 
the model was executed; 4) goodness-of-fit to the data was evaluated using the 
RMSE cost function; and 5) steps 1 to 4 were repeated for every parameter and 
ranked according to magnitude of change in RMSE.  
Flux represents the total turnover number for a given reaction, considering the 
concentration of the reactants and their respective rate constants. The C-ODE 
model was transferred to COPASI software (version 4.20.158) which was used 
to simulate the flux in events per minute through each reaction of the model using 
the following simulation settings: compartment volume = 1 L, duration = 1440 min, 
interval size = 1 min, relative tolerance = 1×10-6, absolute tolerance =  1×10-12, 
maximum internal steps = 1×104. The model is described entirely by Appendix 3, 
Appendix 4 and Appendix 5. 
5.4 Results 
The activation of pooled human serum by different concentrations of zymosan 
was profiled using Ba, C4a, C3a, C5a and TCC concentrations over 24 hours, 
Figure 5.2. The analytes Ba and C4a are markers of AP and CP/LP activation 
respectively, whilst C3a and C5a / TCC are measures of upper cascade and TC 
activity respectively.  
193 
 
 
Figure 5.2 Complement activation response to varying zymosan concentrations over time. A number of 
analytes are shown: a) C3a, b) C5a, c) C4a, d) Ba, and e) TCC. ELISA data (red) are interpolated with a 3D 
mesh to aid visualisation. Data represent the mean of n=2 technical replicates.  
All Complement activation markers measured in the pooled human serum 
increased in concentration over the 24-hour time course and the trend of a given 
analyte over time was similar for all zymosan concentrations, whilst the kinetics 
of each analyte were distinctly different. All markers of Complement activation 
appeared to reach a plateau after ~4 hours for all experiments, except for TCC 
which continued to rise gradually over 24 hours. The effect of zymosan on the 
CP/LP and AP activation is shown in Figure 5.3. 
 
 
Figure 5.3 Zymosan dependence of AP and CP/LP activation in pooled serum. The gradient of analyte 
concentration change between 0-30 (blue), 0-60 (red) and 0-240 (yellow) minutes following zymosan 
activation is shown. a) rate of Ba concentration increase. b) rate of C4a concentration increase. Error bars 
are 2SD from n=2 technical replicates. 
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The rate of C4a and Ba production showed zymosan dependence when judged 
by the gradient of concentration increase. Furthermore, there was evidence for a 
Z-independent production of C4a: in the absence of zymosan, the rate of C4a 
production over the 4 hours of serum incubation was (3.91±0.07)×10-3 µM min-1. 
This value for CP/LP activation may be compared to (2.7±0.4)×10-4 µM min-1 for 
Ba and (4.7±3.2)×10-4 µM min-1 for C3a in AP tick-over.  
C3a can be used a measure of total upper cascade activation and the C3a : C5a 
ratio has been used previously to identify a flux control threshold at 0.01 mg/mL 
zymosan (152), above which significant activation of the terminal cascade occurs. 
The C3a : TCC ratio is also a measure of flux between the upper and lower 
cascades and includes the effect of terminal cascade inhibition, Figure 5.4.  
 
Figure 5.4 Relative Complement pathway flux over time following zymosan activation. A number of zymosan 
activations are shown: control (blue), 0.01 mg/mL (orange), 0.1 mg/mL (yellow) and 1 mg/mL (purple). a) 
upper and lower cascade (C3a : TCC) and b) early and late lower cascade (C5a : TCC). Error bars are 2SD 
from n=2 technical replicates. 
The C3a : TCC ratio started at a value of 112±51 and evolved in time with strong 
dependence on zymosan concentration. During tick-over and at the lowest 
zymosan dose (0.01 mg/mL), the C3a : TCC ratio rose to a value of 243±29 at 24 
hours. In contrast, at 0.1 mg/mL zymosan the C3a : TCC ratio remained relatively 
constant at 78±24 and at the highest zymosan dose the C3a : TCC ratio fell to 
11±1 after 24 hours.  
The C5a : TCC ratio is a measure of lower cascade flux and started at a value of 
0.11±0.07, followed by a lag phase where the transient value correlated positively 
with zymosan dose. In contrast to the C3a : TCC ratio which was zymosan 
dependent after 24 hours, the C5a : TCC ratio converged at a value of 0.4±0.2 
for all zymosan activations after 24 hours, attributed to the linear system of 
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reactions between C5 and TCC. The expected ratio was 1 TCC produced per C5 
cleavage and may have been influenced here by the rising TCC assay response.  
Before any optimisation, the model fitted to the experimental data with a RMSE 
of 53% and mean absolute error (MAE) of 41%. The parameters in the model 
were then optimised using the global fitting strategy (Appendix 5) which reduced 
the RMSE to 19% and the MAE to 14%, approaching the experimental error in 
the ELISA repeats (21% RMSE and 12% MAE) Figure 5.5.  
 
Figure 5.5  C-ODE model fit to zymosan activation of pooled human serum over time, profiled using five 
Complement activation markers: a) C3a, b) C5a, c) C4a, d) Ba and e) TCC. Error bars are 2SD from n=2 
technical replicates. The global minimum fit to the data is shown in blue with a MAE of 14%. f) Bland-Altman 
analysis of the model fit residuals expressed as percentage error, with a mean of -2% (solid red) and 2SD = 
37% (dashed red). The model fits the data with R2=0.93. 
There was a good general correlation between the data and the fit with R2 = 0.93. 
The residuals of the model fit (excluding those at time = 0) may be expressed as 
percentage error and were distributed normally around a mean of -2% and SD = 
19.4%. The Bland-Altman plot in Figure 5.5f shows there was no apparent 
concentration bias in the C-ODE global minimum as the residuals were 
distributed evenly across the complete range of analyte concentrations. The fit 
residuals are explored in more detail in Figure 5.6. 
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Figure 5.6 Heat map of C-ODE model fit residuals as a percentage of each data point. The figure shows 
where the model fits best (white and yellow) and worst (red and black) in the data set. 
The fit deviated most from the data in early time, suggesting more data should be 
collected 0-2 hours following activation to better understand initial dynamics. The 
largest discrepancy between the model and data was for C5a at 30 minutes 
following activation, with an error of 70% and this region was explored further with 
the LiScAR assay for C5a in Chapter 7.  
The optimised model was transferred to COPASI software and the concentration-
time outputs were checked for agreement with the MATLAB output using a Bland-
Altman analysis, Figure 5.7. 
 
Figure 5.7 MATLAB solver output compared to COPASI for the C-ODE model fit. a) regression analysis with 
R2=1, intercept=0 and slope=1. b) Bland-Altman analysis showing relative differences between outputs. The 
relative tolerance of both ODE solvers was 1×10-6 relative to the state value (0.001%).  
The COPASI model output agreed with the MATLAB output within the tolerance 
of the ODE solvers, giving confidence to the use of COPASI for further analysis 
of the model.  
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Four basins of attraction (discussed in Chapter 4) were inferred from the fitting 
process by common minima in RMSE (19-20%, 26-29%, 37% and 50-53%) found 
by gradient descent from different starting parameter values, Figure 5.8. 
 
Figure 5.8 Local minima found by the global parameter optimisation routine for the C-ODE model fit. The 
initial guess is shown in black and the solutions are coloured by RMSE: 19-20% (red), 26-29% (green), 37% 
(blue) and 50-53% (purple). The global solution is also shown (dashed red). 
The starting point based on median enzyme kinetics produced a solution within 
the second-best basin of attraction with a RMSE of 27%, highlighting the 
importance of global optimisation when searching the parameter space of large 
non-linear models for a global minimum. 
The parameter estimates were constrained by bounds during the fitting process 
to reduce the parameter search space and the deviation of each parameter from 
its starting point is shown for the global solution in Figure 5.9.  
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Figure 5.9 Parameter estimates of the C-ODE model fit compared to the fit bounds. Floated model 
parameters were given canonical starting guess values (black crosses) and were allowed to float within the 
fit bounds (green bars). The global solution of the fitting routine (red circles) is also shown. 
The estimated parameter values at the fit solution were not at the limits of their fit 
bounds, indicating that the global minimum was wholly within the fit bounds and 
a different minimum would be required to improve the goodness-of-ft. The 
activation reactions detailed in Table 5.3 were not informed by median enzyme 
kinetics and were given larger fit bounds than the Michaelis-Menten reactions. 
The AP and LP activation reactions were changed by the fitting process from an 
initial guess of 1 to 0.1 and 2 µM-1 min-1 respectively, whilst the CP activation 
reaction was increased to a greater extent from an initial guess of 1 to 166 µM-1 
min-1. The change in rate constants by the fitting routine gives some indication as 
to the activity of each pathway although all have larger confidence intervals than 
their values due to over-parameterisation of the model fit to limited data.  
The distributions of the optimised C-ODE parameters are shown in Figure 5.10, 
compared to the distributions of kinetic constants for Complement reactions 
(adopted in the model) and all enzymes in ref (515). 
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Figure 5.10 Distributions of C-ODE model parameters: a) kd values, b) Ka values, c) KM values, d) kcat/KM 
values, and e) kcat values. Literature values in the model (blue) are compared to estimated values in the 
model (red) and the median values of all enzymatic reactions from supplementary data supplied by ref (515) 
(green). The value of the initial estimate before fitting (black line) and the fit bounds of the Michaelis-Menten 
reactions (dashed black lines) are also shown. 
Critically, the fixed dissociation constant for unknown reactions was within the 
range of the values published for complexes in the Complement cascade (Figure 
5.10a). The fit bounds for the fitted association constants covered the range of all 
published values for the Complement system (Figure 5.10b) with two exceptions: 
the formation of TCC (ka=170 µM-1 min-1) and the binding of FH to aC3b (ka=0.18 
µM-1 min-1). A single published turnover number for the reaction C3bFHFI -> iC3b 
+ FH + FI (kcat=5.8 min-1) was outside the parameter search region but within the 
range for all known enzymes (Figure 5.10e). 
As described in Chapter 4, poorly defined parameters can be identified by a 
correlation analysis. Pearson correlation coefficients for the derived parameters 
varied between 1 (high positively correlated) and -1 (highly negatively correlated) 
and the distribution of correlation coefficients is shown in Figure 5.11. 
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Figure 5.11 Distribution of parameter correlation from the correlation matrix of the C-ODE model fit. a) raw 
data showing a near-symmetrical distribution. b) absolute correlation values showing the majority of 
parameters are correlated <0.5.  
The correlation analysis shows a nearly symmetrical distribution around zero, 
with a mean of -9.9×10-3 and SD = 0.4. The median absolute correlation was 
0.29. Of the 1540 off-diagonal-pairwise parameter combinations, 258 (17%) and 
1193 (77%) had correlations with values below 0.1 and 0.5 respectively. 52 (3%) 
had parameter combinations with values greater than 0.8. As discussed in 
Chapter 4, the correlation matrix could be assessed in future work to group similar 
parameters and reduce the error in the parameter estimates, but such an 
approach is challenging for large models.  
Despite the low confidence in estimated parameters, the significance of each 
reaction on the model output can be explored with a local sensitivity analysis, 
Figure 5.12. 
201 
 
 
Figure 5.12 Local sensitivity analysis of C-ODE model rate constants. a) histogram of parameter sensitivity. 
b) sensitivity of ka, kcat and kd kinetic parameters. c) sensitivity of the activation (green) and sink reactions 
(gold) at the fit solution. d) sensitivity of all rate constants, including known kinetic values and all dissociation 
rates which are fixed in the fitting process (blue) and floated parameters (red). For clarity, the 23 most 
sensitive rate constants (accounting for 95% of total sensitivity) are shown from a total of 109.  
The distribution of sensitivity values for all model rate constants is shown in 
Figure 5.12a and is skewed towards higher values, suggesting a small number 
of reactions have little effect on the model fit. Figure 5.12b shows the relative 
sensitivities of the ka, kd and kcat parameters. Three kd values were highly 
sensitive outliers: the half-lives of the P-stabilised AP C5 convertase, C4bC2 and 
the CP/LP C5 convertase – deactivating reactions with literature values. The 
sensitivity of the activation reactions (Table 5.3) and sink reactions (Table 5.4) 
are shown in Figure 5.12c and indicate that CP and AP reactions were more 
sensitive that LP reactions.  
The 23 most sensitive rate constants (accounting for 95% of total rate constant 
sensitivity) are plotted in order of sensitivity in Figure 5.12d which shows the 
CP/LP convertase binding to C3 was more sensitive than the equivalent reactions 
of the tick-over and AP convertases. In contrast, the AP (P stabilised) C5 
convertase binding to C5 was more sensitive than the equivalent reactions of the 
CP/LP C5 convertase. The starting protein concentrations (fixed at their median 
serum values), known rate constants (fixed at literature values) and the unknown 
kd parameters (fixed at the median enzyme value) account for 70% of the 
parameters in the C-ODE model and induced 86% of the total change in RMSE 
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recorded during the analysis. The sensitivity analysis results for all model 
reactions and species are shown in Appendix 6 and Appendix 7 respectively. 
An inspection of the overall C-ODE model performance and the activity of 
reactions in the cascade was tested with a flux analysis. The time-dependent flux 
through the C3 and C5 convertases of all Complement pathways is shown in 
Figure 5.13.   
 
Figure 5.13 Time-dependent flux of substrates (in a 1 L compartment of serum) for the tick-over C3 
convertase (dot-dashed lines), AP convertases (dashed lines) and the CP/LP convertases (solid lines) at 
four concentrations of zymosan. The simulation was performed using the COPASI settings described in 
section 5.3.4. Plots a-d show the C3 convertases (red) and plots e-h show the C5 convertases (blue). The 
flux shown for the AP is from both forms of the convertase (associated with P or not).  
The maximum convertase activity in the C-ODE model occurs within 10 minutes 
of Complement activation by zymosan. The C3 convertases reach peak flux 
before the C5 convertases as anticipated, although the lag between upper and 
lower cascade decreases at higher zymosan concentrations. Furthermore, the 
C3 convertases display higher peak flux than the C5 convertases.  
Integration of the flux profiles provides an estimate of the substrate turnover in 
each Complement pathway for a given time period. The effect of zymosan on 1) 
flux maximum, 2) time to flux maximum and 3) substrate turnover is shown 
quantitatively in Figure 5.14. 
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Figure 5.14 Zymosan dependence of the flux of substrates (in a 1 L compartment of serum) through the 
convertases in each pathway: a) flux maximum; b) time to flux maximum; and c) the number of substrates 
converted over 10 minutes. The simulation was performed using the COPASI settings described in section 
5.3.4. 
The CP/LP C3 and C5 convertases display higher peak flux, earlier time to 
maximum and higher substrate turnover than the AP and tick-over convertases 
at higher concentrations of zymosan, whilst the opposite is true without zymosan. 
The transition in C3 and C5 flux from majority AP to majority CP/LP occurs at 
0.01-0.1 mg/mL zymosan in agreement with the data in Figure 5.4. 
5.5 Discussion 
The present study profiled Complement cascade activation by zymosan in pooled 
serum from the activation markers: Ba (AP), C4a (CP/LP) and TCC (TP). These 
data were added to existing activation data for C3a (total upper cascade) and 
C5a (early TP) to produce a data set totalling 160 data points from five analytes 
in four pathways. The experimental data are consistent with the existing 
understanding of Complement activation (such as linear flux in the TP, Figure 
5.1) and provide a quantitative insight into the stoichiometry of the response and 
pathway activation. The data were used to optimise the C-ODE model of 
Complement activation containing 109 rate constants and 78 species. The C-
ODE model was optimised based on two starting assumptions: 1) that the median 
values of all known enzyme parameters are good approximations for unknown 
kinetic constants and 2) that the respective median serum protein concentrations 
are good approximations for the values of the constitutive proteins in pooled 
serum. The optimised C-ODE model fitted the data within experimental RMSE 
and enabled pathway flux balance to be simulated under specific starting 
conditions, such as zymosan dose, to compare the activity in different 
Complement pathways. 
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5.5.1 Model Development 
The C-ODE model describes Complement using exclusively bimolecular 
chemical equations as have the previous Complement models shown in Table 
5.1, despite the current understanding that Complement initiation occurs on an 
activating surface, with zymosan providing a protected microenvironment for C3b 
(524). The kinetics of binding reactions confined to surfaces exhibit different 
kinetics to those in solution (525), as discussed in Chapter 4. The model might 
be made more accurate in future work by including equations such as the 
Langmuir equation in Chapter 2, for the interaction of proteins with a finite 
surface. Nevertheless, uniform activation of Complement throughout the reaction 
mixture is encouraged in the present study by continuous mixing of a fine 
suspension of zymosan which in previous work has been measured at a particle 
diameter of ~3 µm (526). Uniform Complement activation should more closely 
approximate bimolecular solution-phase kinetics than a continuous zymosan 
surface under serum without mixing, by minimising limitations of diffusion. A 
uniform reaction mixture also ensures that samples provide reliable estimates of 
concentration variations and the analytes chosen are not surface bound.  
There is no experimental data for the concentration variation over time for most 
species in the C-ODE model, which is a major source of high parameter 
correlation and starting point dependence of model fitting. Chapter 4 showed that 
parameter correlation can be reduced by fixing unknown kd values and a similar 
approach was taken here. The kinetic data from ∼2500 unique enzymes in ref 
(515) was used to fix the unknown kd values at the most highly probable median 
value, allowing the fitting process to control catalytic activity with ka and kcat 
parameters only. The median sensitivity of the kd parameters was lower than the 
median sensitivity of the ka and kcat parameters (Figure 5.12b) rationalising the 
fitting strategy of floating ka and kcat whilst fixing the kd parameters because errors 
in the assumed kd values will have comparatively lower impact on the model 
output. The fitting strategy resulted in only 3% of parameters being correlated 
with a Pearson correlation coefficient > 0.8 and a median value of 0.29. 
The parameter search space was limited by fit bounds to ensure estimated 
parameter values were within a biologically plausible range with the highest 
probability (Figure 5.10). The chosen fit bounds are somewhat supported by 
observing that the 31 of the 34 published kinetic constants for Complement are 
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wholly within the fit bounds and suggests that Complement is a system of 
“moderately efficient” enzymes. To ensure the best fit to the data was achieved 
within the fit bounds, multiple basins of attraction were explored in the parameter 
search space by running a gradient descent solver at multiple starting points 
(Figure 5.8). The best solution was chosen based on RMSE (Figure 5.9) and 
ensured that the specific combination of estimated rate constants best predicted 
the response of all analytes to zymosan, simultaneously (Figure 5.5).  
Of all parameters in the model, the optimised ka and kcat parameters accounted 
for only 14% of model sensitivity at the fit solution, highlighting the extent to which 
the fixed parameters shape the model. Despite the a priori biological constraints 
of the fixed parameters, the optimised model fitted well to the experimental data 
– evidence supporting the model structure. The starting point of the fit based on 
median biological values led to a local solution with the second best minimum 
and suggests that median kinetic constants of enzymes may be used a good 
starting point for constructing other systems biology models with many unknown 
parameters – although global optimisation is still essential to explore the 
parameter space for the best solution.  
5.5.2 Complement Activation Characteristics and Model Verification 
In the present study, zymosan was used to activate the Complement system in 
serum. Zymosan is a polysaccharide found in the cell walls of yeast and has been 
shown to directly activate the AP, inducing rapid C3 cleavage in mixtures of 
purified AP proteins by providing a surface for C3b binding and convertase 
formation (524). Zymosan activation of the LP has also been demonstrated (527) 
and CP activation occurs in serum due to natural antibodies against yeast cell 
wall components (199). The data in Figure 5.3 show Ba and C4a rates of 
formation were zymosan-dependent, an observation which is consistent with 
anticipated activation of the AP and CP/LP.  
Zymosan independent activation was observed in Ba as expected but also in 
C4a, supporting the previous reports of spontaneous activation in the CP/LP. 
Activation of the CP and LP was not distinguishable using the analytes shown 
because C4a is common to both pathways (Figure 5.1). However, C4BP 
reportedly regulates the assembly of LP convertases more strongly than the CP 
convertases because of a ∼7 to 13-fold greater affinity for C4b produced via the 
LP than the CP (528), suggesting the majority of C4bC2a production may have 
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been due to CP activity.  Normal human serum has been shown to reduce 
spontaneous C1 activation, observed in purified solutions of proteins, to a 
negligible effect (506), suggesting IgG oligomers (507) may have contributed to 
C1 activity in the pooled serum used here. The spontaneous C1 activation rate 
recorded here for pooled serum may be different to the rate observed in other 
serum samples and may limit the transferability of the C-ODE model to a different 
system setting, such as fresh serum or PBS.  
Before model validation with independent data, an intuitive test of the C-ODE 
model was to verify that model behaviour conformed to the existing 
understanding of the system. An equation for the spontaneous activation of C1 
allowed the C-ODE model to fit well to the data (Figure 5.5) and the fitted rate 
constant was 0.01 min-1 compared to 0.173 min-1 measured in purified solutions 
of C1 components (506). The C-ODE model does not distinguish between C4b 
produced by CP or LP but the sensitivity analysis indicates that CP activation was 
more sensitive than the LP activation reaction by 800-fold (Figure 5.12c), in 
agreement with evidence for CP dominance over LP.  
The sensitivity analysis suggests the CP/LP C3 convertase substrate binding and 
catalysis reactions were more sensitive than those of the AP C3 convertases, 
whereas the opposite is true for the C5 convertases. The peak flux values shown 
in Figure 5.13 are in agreement with the sensitivity analysis and show that a 100-
fold zymosan increase from 0.01 to 1 mg/mL triggers a 200-fold increase in the 
(peak) flux of C4bC2a compared to a 50-fold increase in C3Bb(P). The turnover 
analysis in Figure 5.14 suggests a more complex mechanism: the CP/LP 
dominates at higher zymosan concentrations, whilst the AP is more active at 
lower zymosan concentrations. The switch occurs between 0 and 0.1 mg/mL 
zymosan - identified previously as a flux control point in ref (152) and the data in 
Figure 5.4. Comparing CP/LP and AP activity following infection might provide a 
novel method for identifying pathogen load.  
The relative turnover in each pathway is also time-dependent. The maximum flux 
in the C-ODE model occurs at 0.2 seconds following 1 mg mL-1 zymosan 
activation in the cleavage of C4 by the activated C1 complex. However, CP/LP 
activity is short-lived and the total flux from upper cascade to lower cascade after 
20 minutes is predominantly due to the AP C5 convertases, which display higher 
turnover than the CP/LP C5 convertases over the 24 hours simulation at all 
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zymosan concentrations except 1 mg/mL where CP/LP and AP C5 turnover is 
similar. The result of minimal CP/LP activity after 20 minutes is consistent with 
evidence that AP amplification is responsible for 80% of TCC formation whether 
Complement is activated via the CP or LP (529, 530). 
The flux analysis shows that Complement activation of pooled serum by zymosan 
displays a characteristic pattern of pathway flux. Figure 5.14b reveals that the AP 
convertases reach peak flux 1-4 minutes later than those of the CP/LP and the 
lag decreases with zymosan concentration. The result is consistent with 
experimental evidence that non-encapsulated crypotococci induce C3 cleavage 
rapidly via the CP followed by the AP with a lag of order minutes (199). In contrast, 
uncapsulated cryptococci have been shown to exclusively activate the AP, 
characterised by a 4-6 minute lag in C3 deposition following activation due to the 
asynchronous and focal deposition of C3b (199). More early time data should be 
collected to observe the initial rate of C3 cleavage more precisely and this is 
attempted with the LiScAR assay for C3 in Chapter 7. Comparing CP/LP and AP 
activity following infection might provide a novel method for identifying pathogens. 
The deviation of the floated parameters from their (equal) starting values is shown 
in Figure 5.9 and can be compared to qualitative observations of reactions. The 
literature states that FB has a higher affinity for C3(H2O) than to C3b (157) and 
this is reflected in the fitted values for these association constants in the C-ODE 
model: 14.44 µM-1 min-1 versus 6.29 µM-1 min-1, leading to estimated affinity 
constants of 37 nM and 9.5 nM respectively. Furthermore, experimental evidence 
has shown the convertase activity of C3(H2O)Bb to be 50% lower than the C3bBb 
complex, as modelled here, whilst being more resistant to inhibition and 
remaining active significantly longer (186). The flux profiles are in good 
agreement, with C3(H2O)Bb dominating C3 turnover at low zymosan 
concentrations and persisting for longer but showing the lowest peak flux at 
higher concentrations of zymosan.  
The C-ODE model was used to assess species limiting Complement activation 
after 24 hours of activation with 1 mg/mL zymosan, Figure 5.15.  
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Figure 5.15 Model analysis of limiting species after 24 hours of Complement activation with 1 mg/mL 
zymosan. The simulation was performed using the COPASI settings described in section 5.3.4. The 
concentrations of model species after activation relative to their starting values are shown for: a) circulating 
activation proteins, b) circulating deactivation proteins and c) convertase complexes. MBL and C1 are 
completely depleted and C3 is depleted by >90%, whilst all other constituent protein concentrations remain 
at >50% of their initial values. The cascade is limited by the removal of C3 and C5 convertases by 
regenerated regulatory proteins. The only convertase remaining after 24 hours is the tick-over C3 convertase 
(at 2% of peak concentration).  
MBL and C1 are completely depleted and C3 is depleted by 97%, whilst all other 
constituent protein concentrations remain at >50% of their initial values. Before 
C3 is fully consumed, the C-ODE model suggests the cascade is predominantly 
limited by the removal of C3 and C5 convertases by regenerated regulatory 
proteins. The only convertase remaining after 24 hours is the spontaneously 
generated tick-over C3 convertase (at 2% of peak concentration).  
The duration of tick-over is predicted to exceed the 24-hour time-course of the 
data presented here, as although C1 is completely depleted, all other constituent 
protein concentrations including MBL, C3 and C4 remain at >50% of their initial 
values, Figure 5.16.  
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Figure 5.16 Model analysis of limiting species after 24 hours of Complement activation via tick-over. The 
simulation was performed using the COPASI settings described in section 5.3.4. The concentrations of 
model species after activation relative to their starting values are shown for: a) circulating activation proteins, 
b) circulating deactivation proteins and c) convertase complexes. As for activation with zymosan, C1 is 
completely depleted, although all other constituent protein concentrations, including MBL and C3, remain at 
>50% of their initial values. C4 is more depleted than C3. The CP/LP convertases are completely depleted 
whilst all other convertases remain at >10% of their peak values indicating that tick-over in vitro continues 
after 24 hours at 37oC.  
After 24 hours of tick-over all convertases remain at >10% of their peak values 
except for the CP/LP C3 and C5 convertases. Not until 25 days of tick-over is the 
tick-over C3 convertase reduced to <1% of its peak value and C3 reduced by 
>99%. All other convertases have negligible concentrations below 0.01% of their 
peak values, reaffirming the longevity and dominance of the tick-over convertase 
at low levels of stimulus.  
The C-ODE model indicates that the most sensitive reactions of the system are 
inhibitory rather than activating in agreement with a previous Complement model 
(185) and conforming to existing knowledge that Complement is highly 
suppressed under normal physiological conditions to prevent over-activation and 
damage to host cells. As discussed in Chapter 1, Complement inhibiting drugs 
are typically designed to target proteins responsible for activation: such as C5 
targeted by Eculizumab; FD targeted by Lampalizumab and C1 targeted by 
Berinert, Ruconest and Cynrise (222). Figure 5.12 shows the top three most 
sensitive rate constants are regulatory and had literature values: C1 inhibition by 
C1inh; the C3b thioester half-life and the half-life of the P-stabilised AP C5 
convertase. The sensitivity analysis suggests that enhancement of the existing 
regulatory mechanisms of the cascade may be a powerful strategy to treat 
patients with overactive Complement systems, whilst drugs designed to suppress 
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these inhibitory reactions might enhance the Complement response in 
immunocompromised patients. The sensitivity analysis in Figure 5.12 is also 
consistent with previous models of Complement activation in the reactions 
identified as being most sensitive. One model (510) identified C3b binding, C2 
cleavage, C4 cleavage and C4bC2a decay as the most sensitive reactions, whilst 
another model (511) identified FH binding to C3(H2O) and P binding as being the 
most sensitive reactions. All these reactions appear in the 23 most sensitive 
reactions of the C-ODE model in Figure 5.12.  
P is the only known positive regulator of AP activity and is secreted by neutrophils 
following stimulation by N-formyl-methionine-leucine-phenylalanine (fMLP) or 
tumour necrosis factor alpha (TNF-α) during infection (531) and endothelial cells 
produce P when induced by shear stress (532). Notably, the concentration of P 
is significantly decreased in sepsis patients on admission to intensive care but 
increased after clinical recovery to exceed levels observed in healthy volunteers 
(533). The effect of P concentration on model behaviour can be observed in the 
sensitivity analysis: the rate constants of C3 and C5 binding to P-stabilised 
convertases are more sensitive than their equivalent reactions in the absence of 
P (Figure 5.12). Furthermore, COPASI was used to quantitatively estimate the 
effect of P concentration on the flux of the AP C3 and C5 convertases according 
to the C-ODE model, Figure 5.17. 
 
Figure 5.17 Model prediction of time-dependent flux of substrates (in a 1 L compartment of serum) through 
the C3 convertases (red) and C5 convertases (blue) following 1 mg/mL zymosan activation. The simulation 
was performed using the COPASI settings described in section 5.3.4. The effect of P on the Alternative 
convertase flux is shown for un-stabilised convertase (solid lines) and P-stabilised (dashed lines). 
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The flux analysis is consistent with the current understanding of P function and 
the C3 and C5 convertases in the C-ODE model display significantly higher flux 
when stabilised by P. Notably, the relative flux increase due to P is greater for the 
C5 convertase than the C3 convertase, suggesting that P may have a greater 
effect on terminal pathway activation.   
Therapeutic recombinant P has been shown to confer increased resistance to 
infection (534) and the C-ODE model was used to predict the effect of doubling 
the concentration of P in the pooled serum, Figure 5.18.  
 
Figure 5.18 Model prediction of convertase flux (in a 1 L compartment of serum) following 1 mg/mL zymosan 
activation at median P concentration (solid lines) and twice-median P concentration (dashed lines) for C3 
(red) and C5 (blue) convertases. The simulation was performed using the COPASI settings described in 
section 5.3.4. 
Doubling P concentration is predicted to increase peak flux through the AP C3 
and C5 convertases by a factor of 10 and 2 respectively. The peak flux through 
the CP/LP C5 convertase was also increased by ~10%. Perhaps most 
interestingly, flux is decreased in the convertases that do not contain C3b (tick-
over and CP/LP C3 convertases), attributed to competition for the C3 substrate. 
The result highlights the utility of the model for predicting the complex behaviour 
of the Complement system to therapeutic interventions. In principle the prediction 
may be personalised for a given patient, by matching the profile of starting protein 
conditions which may be greater or lower than the median values studied here. 
Complement FH deficiency is a rare disorder which results in dysfunctional or 
undetectable concentrations of circulating FH, resulting in activation of the AP 
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and secondary depletion of C3 and other proteins of the AP (535). The plasma 
levels of FH are positively correlated with plasma C3 in mice (228) and mice with 
FH deficiency have 87-94% less C3 than healthy controls (536). Human FH levels 
influence the degree of C3 opsonization and killing of Phenuomococci with an 
optimal concentration of 300 µg/mL (1.9 µM) - the value adopted in the C-ODE 
model (537). FH-deficient patients are therefore more susceptible to infections, 
C3 glomerulopathy, and HUS (535). The C-ODE model was used to quantitatively 
estimate the effect of complete FH deficiency on the consumption of C3 and C5 
by observing the differences in C3 and C5 convertase flux, Figure 5.19. 
 
Figure 5.19 Model prediction of convertase flux (in a 1 L compartment of serum) following 0 mg/mL zymosan 
activation at median FH concentration (solid lines) and FH-deficient serum (dashed lines) for C3 (red) and 
C5 (blue) convertases. The simulation was performed using the COPASI settings described in section 5.3.4. 
The C-ODE model predicts that C3 and C5 consumption is increased significantly 
at 0 mg/mL zymosan in the absence of FH. Peak C3 convertase flux is increased 
~1000-fold, whilst peak AP C3 flux and CP/LP and AP C5 flux is increased ~100-
fold. Interestingly, the CP/LP C3 convertase flux is reduced to zero in the absence 
of FH - attributed to increased competition for the C3 substrate as seen with the 
P supplementation simulation in Figure 5.18. The CP/LP C5 convertase flux 
profile peaks at 5 minutes in the absence of FH which causes the rate of 
increasing AP C5 convertase flux to slow at 5 minutes before continuing to rise. 
The patterns of convertase flux are a new insight into the dynamics of 
Complement activation that would be difficult to measure experimentally due to 
the challenges associated with distinguishing between protein consumption due 
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to each pathway. The results further indicate that inhibiting one pathway in order 
to measure flux through the other would not capture the effects of substrate 
competition between convertases of different pathways.  
5.6 Conclusions 
The C-ODE model is the most comprehensive model of Complement activation 
to date: incorporating published rate constants and optimised with biological data 
from all pathways of the system at varying degrees of stimulus. The use of 
median enzyme kinetics and median serum concentrations produced a good 
starting point for model fitting and these values could be used as effective priors 
when constructing other systems biology models with unknown parameters. 
Additional priors might also be considered, such as reactions associated with 
pathways under higher selection pressure exhibiting higher values of kcat (515). 
There is evidence for the CP evolving from the LP to complement the adaptive 
immune system (216, 538), and the AP is hypothesised to be the evolutionarily 
oldest component (although this is contested (539) ). The mean kcat values 
published for the AP are 50% higher than those of the CP/LP, although the 
standard deviations indicate the difference is not statistically significant. The 
effect of substrate mass on Km (515) was not investigated but may also be 
considered to improve initial parameter estimates.  
The sensitivity and flux analysis of the C-ODE model revealed characteristics of 
the Complement cascade which have been previously reported, including: 
disproportionate upper and lower cascade activation (152); zymosan activation 
proceeding via CP followed by AP after a lag of several minutes (199); the 
importance of P for increasing AP convertase turnover and the importance of FH 
to limit activation (Figure 5.1). The model also highlighted the sensitivity of the 
system to its many inhibitory mechanisms, which may inspire novel strategies for 
therapeutic regulation of Complement. A logical progression of the present study 
would be to collect data to define the most sensitive unknown rate constants 
estimated by the sensitivity analysis. The ultimate validation of the model is to 
test predictions based on different starting conditions.  
The C-ODE model has the potential to be personalised for individual cases and 
substituting the starting protein concentrations for values across the physiological 
range may be used to predict the variation of in vitro Complement activation by 
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zymosan in the healthy population. The sensitivity of the C-ODE model to 
different surfaces could also be adjusted via the activation reactions which 
ultimately control the flux through each pathway but are currently optimised for a 
suspension of zymosan in PBS. Chapter 6 reports the results of in vitro 
Complement testing of healthy adult serum using the same zymosan activation 
protocol described here. The results provide a first look at the variation of 
Complement activation in the healthy adult population and provide independent 
data from the training data set with which to validate predictions of the C-ODE 
model. 
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6 in vitro Complement Activation Phenotype Variation in a 
Healthy Adult Population  
6.1 Introduction 
Complement activation dynamics in the fluid phase depend on the stimulus and 
the relative concentrations of Complement proteins and can be profiled over time 
using immunoassays for activation products such as TCC. The data shown in 
Chapter 5 indicate two characteristics of Complement activation that can be 
observed with minimal sampling: 1) the initial rate of activation marker 
concentration change and 2) the total activation marker concentration change (or 
capacity) following activation. These measures of Complement activation 
dynamics are phenotypes of immune state which may be useful in characterising 
host response to infection (34) as discussed in section 1.1 and are relatively 
simple to record using immunoassays as shown in section 5.4. Serum can be 
challenged in vitro with a standard concentration of zymosan and phenotypes 
measured after specific times – coined a ‘Z-test’. 
The C-ODE model, developed in Chapter 5, was optimised using data from 
pooled human serum and predicts the response of the Complement system in 
pooled serum to varying degrees of zymosan stimulus. As stated in Chapters 4 
and 5, predictive models must fit well to both the data used for parameter 
estimation and the results of independent experiments in a process known as 
model validation (540). Chapter 4 described an ODE-based model which fitted 
well to data in a solution setting but required adjustment via activity coefficients 
to be usefully predictive when the same interaction occurred at a surface. The 
intended utility of the C-ODE model is to accurately predict the Complement 
response to zymosan in patient serum samples with varying starting protein 
concentrations. Whether or not the C-ODE model can usefully be applied to 
different starting conditions must be tested (541). 
The importance of model validation is such that some studies publish model 
construction (structure selection and parameter estimation) and model validation 
independently, allowing the model to be repeatedly validated in new system 
settings (484, 542). As mentioned in Chapter 4, a common methodology applied 
by the modelling community for the analysis of biological models is partitioning 
the available data into two parts: a training dataset for model construction and a 
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‘hold-out’ validation dataset which is used to test the predictive power of the 
model (543). However, partitioning of a single dataset into training and validation 
sets can lead to incorrect conclusions about the validity of a model. For example, 
a validation dataset using the same dependent variables under very similar 
conditions to the training dataset is a poor test of model predictions. Similarly, a 
training data set which is very limited (failing to define key features of the fitted 
model) is unlikely to predict hold-out data of untrained dependent variables under 
extremely different conditions to the training data. Therefore, accurate biological 
knowledge of the system structure and parameter values is required in order to 
partition the data such that construction and validation is not biased – a 
paradoxical situation for complex models with uncertain structures and unknown 
parameters. To minimise bias in the development of models with uncertain 
structures, random and repeated partitioning of available data into training and 
validation sets (cross-validation) can be used (461). However, the structure of the 
C-DOE model is relatively well-known and is based on the accepted reaction 
mechanisms of 78 proteins. Of 109 rate constants, 34 have published values and 
unknown rate constants were constrained to physiological ranges and estimated 
during model fitting to experimental data of 5 activation products following 
zymosan activation of pooled serum. Therefore, the C-ODE model structure and 
a significant proportion of its parameters were not biased by the fitting process, 
making the model appropriate for validation with independent data without 
refitting or cross validation. 
The Complement phenotypes discussed here provide independent data for 
model validation and are functional tests of immune state which could be 
investigated for their ability to identify hospital patients at higher risk of 
nosocomial infection. As discussed in Chapter 1, prognostic models are 
commonly used combine two or more risk biomarkers to predict clinical outcomes 
but relatively few published prognostic models are adopted for clinical practice 
due to insufficient validation (544). The choice of sample size, statistical methods 
and inclusion criteria are important decisions in the design of clinical 
investigations and will be discussed briefly here.  
6.1.1 Sample Size  
Determining the optimal number of units of analysis to be included in a study is 
an essential component of study design. Larger sample sizes may require more 
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time and resources to collect the data, whilst smaller sample sizes reduce the 
power of the clinical study and risk that real differences will not be identified (545, 
546). Sample size planning ensures that the study is efficient: large enough to 
confidently answer the main research question but not excessively large to waste 
resources (547). The main research question of the present study is: are the 
distributions of Complement activation phenotypes observed in the healthy adult 
population significantly different from those predicted by the C-ODE model? 
The present study is a preliminary investigation which will be used to determine 
the distributions of Complement activation phenotypes. Preliminary studies are 
used to estimate a given effect size and facilitate the planning and conduct of 
pilot studies which precede full trials (548). The present study requires sufficient 
data to estimate the range and shape of the phenotype distributions which can 
then be compared to C-ODE model predictions. A sample size of 10-75 is 
recommended for pilot studies depending on the effect size identified in 
preliminary studies (549). 
6.1.2 Statistical Methods 
A number of statistical tests are available to determine whether two distributions 
are different but the choice of statistical test is important and depends upon the 
type of data being compared. Analytical data may be discrete or continuous and 
may be from a known or unknown distribution. Parametric tests assume data 
have come from a probability distribution which can be defined using an equation, 
such as a normal distribution (550). Parametric tests will therefore lead to 
erroneous conclusions when used to compare samples from distributions which 
violate the assumptions of the test. The present study will derive rate and capacity 
phenotype measurements from analyte concentration data on a continuous scale 
with no prior knowledge of the distributions. A normality test should be performed 
before choosing an appropriate statistical test to compare the datasets.  
The normality of data can be assessed visually using quantiles (also known as 
percentiles) (551). Quantiles are ‘cut points’ which split a distribution into equally 
likely ranges: the median is the ‘0.5 quantile’ (50th percentile) and splits a 
distribution into two groups with 50% of the data falling below the value of the 
median. A quantile-quantile plot is generated by plotting the ith smallest value of 
the test data against the 
𝑖−0.5
𝑛
 quantile of the standard normal distribution (mean 
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= 0, σ = 1). For example, the smallest value (i=1) in a sample of 10 values would 
be plotted against the value of the 0.05 quantile of the standard normal 
distribution, -1.64, below which 5% of the data fall. A quantile-quantile plot is 
shown in Figure 6.1.  
 
Figure 6.1 Quantile-quantile plot of 10 data points from a random normal distribution with a mean of zero 
and σ of 10. For any sample of n=10, the values of the x axis are unchanged. The data quantile values show 
a linear relationship with the standard normal distribution quantile values, indicating the data is normally 
distributed. 
The data in the quantile-quantile plot will fit well to a linear model if normally 
distributed. The quantile-quantile plot is valuable for observing where deviations 
from normality occur in the distribution. For example, in Figure 6.1 the data 
quantile value for the 0.05 quantile (x=-1.64) is lower than expected – although 
the result is known to be due to chance because the data were generated 
randomly. 
The Shapiro-Wilk (SW) test is a strongly recommended method for quantitatively 
testing the normality of a distribution (551) to produce the SW test statistic, W. 
The SW test is related to the quartile-quartile plot as the data are ordered by size 
and multiplied by coefficients derived from the expected values of the standard 
normal distribution quantiles (the x axis in Figure 6.1) during the calculation of W 
(552). The null-hypothesis of the SW test is that the population is normally 
distributed, with a test statistic of 1 for a perfectly normal distribution.  
The value of the test statistic will vary due to chance and by a larger amount for 
small sample sizes. Therefore, a measure of confidence in the test result 
considering the sample size is useful. The P value of a statistical test is the 
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probability of recording test statistic larger than a critical value expected for a 
given sample size when the null hypothesis is true (incorrectly rejecting the null 
hypothesis due to chance). As such, if the P value is lower than the desired 
significance level then there is evidence against the null hypothesis and a value 
of P<0.05 is often chosen (553) due to convention rather than any mathematical 
basis and no single index should substitute for scientific reasoning (554). Once 
normality of the data has been evaluated, additional comparative statistics must 
be applied to test whether the clinical and simulated data could be drawn from 
the same population.  
If the distributions being compared are normally distributed, the mean values may 
be compared using the two-sample t-test (555). The two-sample t-test is 
analogous to the signal to noise ratio discussed in Chapter 2: the difference 
between the sample means is divided by a measure of variation in the 
distributions. Hence, the value of the test statistic is maximised when the sample 
means are well determined by low variance and the distributions are well-
separated. There are two main variations of the two-sample t-test: the Student’s 
t-test is used when both samples have equal variances and Welch’s t-test is used 
when both samples have unequal variances (556). Statistically significant 
differences in variance may be assessed using the two-sample F-test (557). The 
null hypothesis of the two-sample F-test is that both samples come from normal 
distributions with the same variance whilst the null hypothesis of the two-sample 
t-test is that the data in the two distributions have equal means. The null 
hypothesis of each test may be rejected if the P value obtained for the test statistic 
is lower than a predefined significance level. 
If the distributions being compared are not both normally distributed, they may be 
compared using a cumulative density function (CDF) and the two-sample 
Kolmogorov-Smirnov (KS) test (558). A CDF evaluated at a given value in a 
distribution, is the probability of that value being less than or equal to the given 
value. The two-sample KS test simply calculates the largest difference in CDF 
value between two distributions and is therefore sensitive to any shape or 
magnitude differences between distributions – reminiscent of the Yuden Index 
statistic discussed in Chapter 1. The null hypotheses of the KS test is that both 
samples come from the same distributions and is rejected if the P value obtained 
for the test statistic is lower than a predefined significance level. An example of 
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different CDF plots and a graphical representation of the two-sample KS test 
statistic are shown in Figure 6.2. 
 
Figure 6.2 Empirical CDF plots. a) simulation using 10,000 samples of 3 random normal populations. Blue 
and orange distributions have equal means and unequal variances. Blue and yellow distributions have 
unequal means and equal variances; b) simulation using 20 values sampled randomly from 2 populations 
with equal means and variances. The largest difference in CDF value is the KS test statistic, labelled D, with 
a value of 0.2. The value of D is due to chance and will decrease with larger and more representative sample 
sizes. 
The Complement phenotype data collected in the present study were first 
assessed for normality before the most appropriate test for distribution 
differences was chosen: either the parametric t-test or the non-parametric KS 
test. The P values of any statistical test be reported so that the precision of model 
predictions can be judged on a continuous scale rather than arbitrary 
classification of results as “significant” or “non-significant” (559).  
6.1.3 Inclusion and Exclusion Criteria 
The power of a study may be increased by reducing the heterogeneity with strict 
inclusion / exclusion criteria. For example, serum samples could be excluded 
from the study before Complement phenotype testing if the concentrations of any 
proteins are outside the expected healthy ranges simulated by the C-ODE model. 
However, excessively strict inclusion criteria risk that conclusions drawn from the 
study do not represent the population to which the findings might be applied.  
There is no statistical association between the gender or age of individuals and 
the levels of C3 opsonisation (560) but other differences in Complement activity 
have been observed and significant variation has been reported (561). The aim 
of the present study is to establish the total variation in Complement activation 
between individuals and hence strict inclusion criteria would bias these results. A 
good recruitment criterion for the present investigation was self-certified healthy 
adults with no chronic inflammatory conditions that might influence Complement 
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activation due to illness. CRP can be screened in each sample by turbidimetric 
assay in the clinical chemistry laboratory to check for excessive inflammation as 
a post-recruitment exclusion criterion. In time, CRP testing could be performed 
on the LiScAR biosensor platform in parallel with the Complement assays as a 
point-of-care Z-test. 
6.2 Aims and Objectives 
The aim of this chapter is to report the variation of Complement activation 
phenotypes in the healthy adult population and test the accuracy of the C-ODE 
model in predicting the phenotype distributions.  
The first objective was to collect in vitro Complement activation data from healthy 
volunteers which provided reference distributions of certain Complement 
activation phenotypes. Two phenotypes of Complement activation were 
proposed here, based on zymosan activation in vitro: initial rate of analyte 
concentration increase (rate phenotype) and absolute change in analyte 
concentration (capacity phenotype).  
The second objective was to predict the variation in Complement activation 
predicted in the healthy population using the C-ODE model from Chapter 5. The 
clinical data and model prediction were then compared using an appropriate 
statistical test. The agreement between the measured phenotype distributions 
and those predicted by the model indicates the extent to which the model is 
predictive in the new system setting of fresh serum samples: model validation.  
The final objective was to predict how Complement depletion might affect the 
measured phenotypes, demonstrating the use of the C-ODE model and data to 
estimate an effect size with which future clinical investigations could be planned. 
Complement depletion is expected to be a risk factor for infection as discussed 
in Chapter 1. 
6.3 Materials and Methods 
The recruitment criteria for the study were adult volunteers self-reporting as 
healthy with no chronic inflammatory conditions that might impact their 
Complement protein concentrations and Z-test results. Volunteers were recruited 
through personal contact. The collection of blood samples was approved by the 
local University of Exeter Medical School Research Ethics Committee (UEMS 
REC reference number: May18/B/152Δ1). Informed consent was obtained from 
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the volunteers who were required to complete the consent form shown in 
Appendix 8 before the study could begin. All serum experiments were performed 
in a Level 2 laboratory following relevant risk assessments. CRP was screened 
in each sample by turbidimetric assay in a Clinical Chemistry Laboratory to 
assess for inflammation and was used as a post-recruitment exclusion criterion. 
C3, C4 and IgG concentrations were also tested to indicate whether the study 
cohort was well matched the reference ranges reported for these proteins – a 
potential source of error for model predictions.  
6.3.1 Modelling Predictions 
The C-ODE model and in vitro data from Chapter 5 were used to choose common 
sampling time points that would capture the initial rate and capacity of 
Complement protein concentration increase for a number of activation products. 
ELISA data for Ba, C3a, C4a, C5a and TCC concentration increase in response 
to varying zymosan dose were used to train the model and hence there is higher 
confidence in the predictions of these analytes than those without data for 
validation. A comparison of the C-ODE model fit to pooled serum data from a 1 
mg/mL zymosan activation and published data using a similar protocol (516) with 
10 mg/mL zymosan and heat-aggregated IgG are shown in Figure 6.3. 
 
Figure 6.3 Complement activation model fit (blue) to ELISA data (green) from section 5.4 showing sample 
points for the clinical investigation and cohort simulations (red targets). Sampling times were chosen based 
on their ability to determine initial rate and total capacity of concentration increase. Data from the literature 
following a similar protocol with heat aggregated IgG (516) are shown for comparison (gold). Error bars are 
2SD from duplicate determinations.  
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The timescale of analyte concentration increase was similar for all previously 
measured analytes and the sampling time points chosen to measure initial rate 
and capacity of concentration increase were: zero hours, 1 hour and 4 hours. 
Incidentally, the sampling times were the same as chosen by Bergseth et al. (516) 
in defining their human serum standard for Complement activation studies. The 
rate phenotypes were derived in units of concentration per minute using the 
formula: rate = (A1 - A0) / 60, where (A1 - A0) was the difference between the 
analyte concentrations at zero and 1 hour following zymosan activation. The 
capacity phenotype of each analyte was derived using the formula: capacity = A4 
- A0, the difference between the analyte concentrations at zero and 4 hours 
following zymosan activation.  
The rate and capacity phenotype distributions of each analyte were predicted by 
the C-ODE model using 250 starting conditions. Each starting condition was 
generated by sampling randomly from the published serum reference ranges 
(Table 6.1) of the 18 pre-activation proteins with circulating concentrations. 
Sampling was performed in MATLAB using the ‘betarnd’ function to generate a 
random sample from a beta distribution (shape parameters = 5,5) scaled to the 
limits of each reference range. The beta distribution is applied to model random 
variables in a number of fields including genetics to model allele frequency (562). 
The resulting sample distribution approximated normal random sampling 
(Shapairo Wilk, P<0.05). Beta random sampling has the benefit of being non-zero 
strictly within the set limits – unlike a continuous normal distribution, there is zero 
probability of randomly generating a protein concentration outside of its reference 
range.  
6.3.2 Clinical Investigation Protocol 
ELISA assays for Ba, C4a, C5a, iC3b and TCC were purchased from Quidel 
(#A033, #A035, #A021, #A006, #A020). Turbidimetric assays for IgG, C3 and C4 
were performed using the Cobas platform (Roche) at Royal Devon and Exeter 
Hospital Clinical Chemistry Laboratory. Phosphate buffered saline (PBS), EDTA 
and zymosan were obtained from Sigma Aldrich. Serum collection tubes 
(#367895), 21 guage needles (#360213) and adaptors (#364815) were 
purchased from Medisave.  
A new venepuncture performed by a phlebotomist was used to draw blood (10 
mL) from the volunteers into sterile serum collection tubes (Red BD vacutainer 
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with silica clot activator coating). The serum collection tubes were inverted 
several times and allowed to stand at room temperature for 30 minutes to allow 
clotting before centrifugation at 1,300 g for 10 minutes at room temperature, after 
which the serum supernatant was removed from the collection tubes for further 
centrifugation at 1,300 g for 5 minutes at 4oC as recommended elsewhere (563). 
Serum supernatant (3 mL) was removed and added to 7 mL Bijou flasks.  
Serum (1 mL) was sampled from the Bijou flasks into Eppendorf tubes (1.5 mL) 
containing EDTA (50 µL, 10 mM) to give a final EDTA concentration of 0.5 mM. 
The serum samples were centrifuged at 5,000g for 30 minutes (a necessary step 
to remove zymosan in subsequent samples and performed here for consistency). 
The supernatants were transferred to Eppendorf tubes (1.5 mL) and frozen with 
dry ice. The resulting time zero samples were stored at -80 0C.  
Zymosan (25 mg) was suspended in PBS (1 mL) by shaking overnight in a 1.5 
mL Eppendorf tube to ensure a fine suspension is achieved. The suspended 
zymosan solution (80 µL, 25 mg/mL) was added to the serum remaining in the 
Bijou flasks to give a total zymosan concentration of 1 mg/mL. The reaction 
mixtures were incubated at 37 0C with shaking at 190 RMP. After 1 hour and 4 
hours, 1 mL of serum was sampled from the Bijou flask and prepared for storage 
using the same protocol described for the time zero samples. Serum samples 
were thawed on ice as recommended elsewhere (241) before use with ELISA for 
Complement activation products. The turbidimetric assays for C3, C4, CRP and 
IgG were performed by the Clinical Chemistry Laboratory using standard 
operating procedures.  
6.3.3 Statistical Analysis  
The measured and predicted phenotype distributions are presented as 
histograms with 5 bins (quintiles) and normalised by probability from which a 
number of distribution properties were derived. Firstly, the percentage difference 
between the median predicted and measured phenotype values of each analyte 
is reported as a test of relative model accuracy. Secondly, the overlap 
(intersection) of the distributions is reported as a percentage of the total histogram 
area as an initial test of distribution shape differences. Finally, all phenotype 
distributions were tested for normality using a Shapiro-Wilk test with a 
significance level of P=0.05 as described previously. Normal distributions were 
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tested for equal variance using a two-sample F-test implemented using the 
‘vartest2’ function in MATLAB. Normally distributed samples with equal variances 
were compared using a two tailed Student’s t-test using the ‘ttest2’ function in 
MATLAB assuming equal variances. Normally distributed samples with unequal 
variances were compared using a two tailed Welch’s t-test using the ‘ttest2’ 
function in MATLAB assuming unequal variances. Non-normal distributions were 
compared using a Kolmogorov–Smirnov test using the ‘kstest2’ function in 
MATLAB. All test decisions were made using a significance level of P=0.05. 
The Complement activation model was constructed using differential equations 
and molar concentrations. For consistency, in the present study all assay results 
are also expressed in molar concentrations, rather than mass per unit volume as 
is commonplace for reporting protein concentrations in the literature. Correct 
conversion from mass to moles requires knowledge of the molecular mass of the 
protein used to calibrate each assay which is complicated by multimeric protein 
complexes. For example, the C1 complex is composed of a recognition 
subcomponent, C1q (460 kDa), and serine protease subcomponents, C1r (90 
kDa) and C1s (80 kDa) in a 1:2:2 ratio (564). As there are several serine protease 
subunits per C1 complex, using the total molecular mass of C1 (800 kDa) in the 
conversion of mass to molar concentration would under-estimate the molar 
concentration of purified C1q standards, highlighting the importance of 
understanding the true molecular mass of the assay calibration standards. The 
molecular masses of analytes used in all calculations are shown in Table 6.1. 
6.4 Results 
A cohort of 22 individuals was recruited self-reporting no chronic inflammatory 
conditions. The CRP concentrations were recorded in all patient samples: 15 
samples had CRP concentrations below the detection limit of the turbidimetric 
assay (1 mg/L) and the maximum recorded concentration was 4 mg/L. All CRP 
concentrations were below the upper healthy reference range limit of 10.5 mg/L 
(565). Consequently, no samples were rejected from the cohort due to chronic 
inflammation. The C3, C4 and IgG concentration distributions at time-zero are 
shown in Table 6.1 compared to the reference ranges from the literature.  
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Table 6.1 Analyte molecular masses used in concentration calculations, reference ranges used for model 
predictions and standing concentrations of serum proteins measured in cohort serum samples (n=22). *In 
serum the basic unit of MBL may oligomerise to higher-order molecules of varying mass. 
Analyte Molecular 
mass / kDa 
Modelled concentration 
range / µM 
Measured 
concentration median 
(range) / µM 
CRP 125 1.6-84×10-3 (565) 8.0(8.0-32)×10-3 
C3 185 (566) 6.9-8.9 (249)  5.8(4.5-7.5) 
C4 205 (566) 1.2-2.7 (567) 0.93(0.59-1.4) 
IgG 150 43-90 (568) 67(47-92) 
Ba 33 - 3.2(1.7-5.6)×10-2 
C4a 8.8 - 3.9(3.6-4.6)×10-3 
C5a 10.4 - 6.4(0.6-16)×10-4 
iC3b 176 - 8.0(3.6-14)×10-2 
TCC 1030 - 2.7(0.7-6.1)×10-4 
C1q 460 (566) 0.27-0.48 (569) - 
C2 93 (570) 0.12-0.38 (571) - 
C5 190 (566) 0.30-0.60 (572) - 
C6 105 (573) 0.51-0.69 (573) - 
C7 92 (574) 0.53-0.76 (574) - 
C8 151 (575) 0.33-0.53 (575) - 
C9 71 (576) 0.66-0.99 (576) - 
FB 93 (566) 0.80-3.1 (571) - 
FD 24 (566) 4.2-8.3×10-2 (577) - 
FI 88 (578) 0.23-0.45 (579) - 
FH 155 (580) 1.6-2.3 (579) - 
P 53 (581) 0.14-0.55 (582) - 
C4BP 540 (583) 0.28-0.56 (583)  
C1-INH 110 (584) 1.7-2.1 (249) - 
MBL 100* (585) 4.3-35×10-3 (586) - 
sCR1 200 (587) 1.1-2.2×10-4 (588) - 
 
The measured serum range for IgG was in good agreement with the reference 
range. The serum ranges for C3 and C4 varied by a factor 1.6 and 2.4 from 
minimum to maximum respectively, in good agreement with the modelled ranges 
of C3 and C4 which varied by a factor 1.3 and 2.3 from minimum to maximum 
respectively. The median C3 and C4 values measured in the cohort sera (5.8 µM 
and 0.93 µM) were 28% and 54% lower than the median values used for the 
optimisation of the C-ODE model (8.0 µM and 2.0 µM). 
The Complement system response to zymosan was profiled by ELISA over 4 
hours following activation of the fresh serum samples and is shown in Figure 6.4 
compared with the pooled serum data used for model fitting.  
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Figure 6.4 in vitro Complement activation in serum by 1 mg/mL zymosan. Z-test results from n=22 healthy 
volunteers (coloured) are compared to pooled human serum (black) profiled using 5 activation markers: a) 
Ba, b) C4a, c) C5a, d) C3 consumption and e) TCC. Error bars are 2SD from n=2 technical repeats. C3 
consumption is assessed by comparing iC3b data from the cohort serum to C3a data from pooled human 
serum used to fit the C-ODE model (species which are produced in a 1:1 ratio with each molecule of cleaved 
C3).  
All analytes showed an initial rise from their t = 0 concentrations and reached a 
plateau between 1 and 4 hours - similar concentration profiles to those observed 
for the pooled serum used to fit the C-ODE model in Chapter 5. The starting 
concentrations of most analytes were similar between pooled and cohort sera, 
although a significantly higher C4a concentration in the pooled serum suggests 
pre-analytical CP/LP activation. The mean rate of concentration increase for all 
analytes between 0 and 1 hours following activation (rate phenotype) was similar 
for pooled and cohort serum samples, although Ba and TCC rates appeared 
lower in the pooled serum. Furthermore, the total change in analyte concentration 
after 4 hours (capacity phenotype) appeared to be lower in the pooled serum for 
C5a and TCC.  
Excluding CRP (which was largely below the detection limit of the assay) all other 
measured analytes were normally distributed (Shapiro-Wilk, P > 0.05) except C4a 
which was not normally distributed (P=0.002). The normal distributions measured 
in the experimental phenotypes support the choice of normal random sampling 
from the of constituent protein reference ranges to generate the predicted 
phenotype distributions from the C-ODE model.  
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The C-ODE model was unmodified throughout the present study and the 
parameters were not re-fitted to the phenotype data measured here. The medians 
and ranges of the rate and capacity phenotypes, both experimental and 
theoretical, are tabulated in in Table 6.2 and histograms of the distributions are 
shown in Figure 6.5.  
Table 6.2 Comparison of phenotypes measured in the cohort serum (n=22) and predicted by the C-ODE 
model (n=250). 
Species 
Cohort Median 
Rate (range) 
/ nM min-1 
 
Cohort Median 
Capacity 
(range) 
/ µM 
Predicted 
Median Rate 
(range) / nM 
min-1 
Predicted 
Median 
Capacity 
(range) / µM 
Ba 15.4 (7.0-24.8) 1.01 (0.62-1.53) 4.25 (2.82-6.77) 
0.526 (0.370-
0.715) 
C4a 
4.59 (1.66-
11.63) 
0.480 (0.157-
0.873) 
13.9 (9.6-18.8) 
0.833 (0.575-
1.129) 
C5a 
2.97 (2.10-
4.48) 
0.243 (0.178-
0.288) 
2.17 (0.77-6.40) 
0.197 (0.067-
0.400) 
iC3b 
36.8 (19.2-
53.3) 
2.68 (2.14-3.38) 29.2 (20.1-42.2) 3.07 (2.33-3.89) 
TCC 
3.30 (1.82-
4.34) 
0.251 (0.160-
0.370) 
2.71 (0.77-6.40) 
0.197 (0.067-
0.400) 
 
The rate and capacity phenotypes of Ba and iC3b were significantly larger by a 
factor of 3-10 than the phenotype of C4a from the CP/LP and C5a or TCC 
phenotypes of the TP. The response profile of iC3b displayed the fastest rate and 
largest capacity of the analytes measured. Further, the C4a rate phenotype 
displayed the largest range and hence patient variability, varying by ~7-fold. The 
distributions of rate and capacity phenotypes for the cohort serum data are shown 
for each analyte in Figure 6.5.  
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Figure 6.5 Distributions of Complement system biomarkers: a-e) rate phenotype distributions for Ba, C4a, 
C5a, iC3b and TCC and f-g) capacity phenotype distributions for the same analytes. Biological data from 
n=22 healthy volunteers (blue) are compared to n=250 simulation data (red). 
The distribution comparison between the cohort phenotypes and the C-ODE 
predictions was tested using the percentage difference in the medians, the 
percentage histogram overlap and either a two tailed t-test or a KS test 
(depending on normality), Table 6.3. The median percentage difference between 
the phenotype medians of the prediction and the data was 21% and the median 
histogram intersection was 36%. The best agreement between measured and 
predicted phenotype distributions was for the rate phenotypes of C5a (KS test 
P=0.05) and TCC (KS test P=0.09). Notably, the iC3b rate and capacity 
phenotypes were also reasonably well predicted by the model with median 
percentage differences of -20% and 15% respectively. 
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Table 6.3 Results of statistical tests comparing rate and capacity phenotype distributions measured in the 
cohort serum (n=22) to the model predictions (n=250). Median percentage difference is difference between 
measured and predicted values as a percentage of the measured value. Histogram intersection is the 
overlapping histogram area as a percentage of the total histogram area. Distributions are tested for normality 
with the SW test (α=0.05) an appropriate agreement test is performed (t-test for normal distributions, KS test 
for non-normal distributions). The F-test determines if population variances are significantly different. P 
values > 0.05 indicate failure to reject the null hypotheses and are emboldened.  
Analyte 
Median 
percentage 
difference 
Distribution 
percentage 
intersection 
SW test 
P value 
F-test P 
value 
Agreement 
test 
P value 
Cohort Ba rate 
-72 7 
0.84 
 KS 3.9×10-19 
Predicted Ba rate 0.016 
Cohort C4a rate 
202 7 
0.11 
4.1×10-2 
Welch’s t-
test 
2.8×10-14 
Predicted C4a rate 0.73 
Cohort C5a rate 
-9 70 
0.55 
 KS 0.053 
Predicted C5a rate 3.6×10-7 
Cohort iC3b rate 
-20 34 
0.044 
 KS 5.5×10-9 
Predicted iC3b rate 0.013 
Cohort TCC rate 
-28 51 
0.63 
 KS 0.090 
Predicted TCC rate 3.6×10-7 
Cohort Ba capacity 
-48 7 
0.37 
1.2×10-35 
Welch’s t-
test 
2.7×10-8 Predicted Ba 
capacity 
0.32 
Cohort C4a capacity 
74 23 
0.30 
7.1×10-8 
Welch’s t-
test 
2.8×10-7 Predicted C4a 
capacity 
0.73 
Cohort C5a capacity 
-20 39 
0.27 
 KS 0.020 Predicted C5a 
capacity 
8.9×10-6 
Cohort iC3b 
capacity 
15 38 
0.69 
0.57 
Student’s t-
test 
9.2×10-6 
Predicted iC3b 
capacity 
0.079 
Cohort TCC 
capacity 
-22 44 
0.71 
 KS 8.2×10-4 
Predicted TCC 
capacity 
8.90E-06 
 
All measured phenotype distributions appeared normally distributed as judged by 
the SW test with P>0.05, with the exception of iC3b rate which had a marginal P 
value of 0.044. In contrast, many predicted distributions from the model were not 
normally distributed according to the SW test, despite normal random sampling 
of starting protein concentrations for each simulation.  
6.5 Discussion  
The variation of two new Complement phenotypes was investigated for the first 
time: 1) the initial rate of activation marker increase over 1 hour (rate phenotype) 
and 2) the total change in activation marker concentration over 4 hours (capacity 
phenotype) following a standard zymosan challenge of serum - the Z-test. The 
231 
 
experimental results from the cohort serum samples were used as an 
independent data set to test the accuracy and precision of the C-ODE model 
predictions of phenotype variation based on the concentration ranges of the 18 
circulating proteins and zymogens in the adult population. The comparison of 
measured and predicted phenotype ranges tests whether the C-ODE model 
optimisation captured the concentration-dependence of each pathway in the 
cascade without re-optimisation or fitting to the new data. 
6.5.1 Measured Phenotypes 
The response profiles of 5 Complement activation marker proteins to the Z-test 
were successfully measured in vitro, under the ethics protocol, in the serum of 22 
adult volunteers. The experimental data for the cohort in Table 6.2 point to 
significant variation in the C4a rate and capacity phenotypes which varied by 7-
fold and 5-fold respectively. The other rate and capacity phenotypes in the 
cascade indicated smaller variations. The Ba and iC3b rate phenotypes of the AP 
varied equally in range by 3-fold but AP activation is tightly regulated via 
degradation of C3b (measured with the iC3b phenotype), a process which 
appeared to respond twice as fast as AP activation (measured with the Ba 
phenotype). The iC3b capacity phenotype was also twice that of Ba, further 
highlighting the extent to which C3b is regulated. By comparison, the median C4a 
rate phenotype of the CP/LP was only 25% that of Ba and 13% that of iC3b, 
showing similar kinetics to the lower cascade phenotypes of C5a and TCC. For 
the first time, the variations in differential flux across the cascade pathways have 
been quantified by the Z-test protocol in a cohort of healthy individuals. 
To minimise pre-analytical activation of Complement in the Z-test protocol, 
samples were immediately mixed with EDTA to slow activation of all three 
initiation pathways during centrifugation before storage. Quantifiable 
Complement activation still occurs following addition of EDTA (264) and hence 
all samples were snap frozen and stored at -80oC. To minimise Complement by 
sample thawing (241) all samples were thawed slowly on ice before testing with 
ELISA. The Z-test protocol in the present study used the same sample 
preparation methods as the study pooled serum data, used to train the C-ODE 
model in Chapter 5. Consequently, any pre-analytical Complement activation 
should have been systematically consistent between experiments. The C3 and 
C4 concentrations in of the cohort sera exhibited similar relative ranges but 
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different absolute values to the reference ranges in Table 6.1. There are 
significant variations in reported reference ranges for C3 and C4 in serum which 
confounds the choice of a reference range: C3=660-1850 mg/L and C4=150-520 
mg/L in ref (589); C3=750-1650 mg/L and C4=200-650 mg/L in ref (590); 
C3=800-2100 mg/L and C4=150-500 mg/L in ref (591); C3=830-1770 mg/L C3 
and C4=150-450 mg/L C4 (592); C3=1280-1640 mg/L in ref (249) and C4=150-
450 mg/L in ref (593). Ultimately, the C3 and C4 concentrations measured in our 
cohort C3=840-1380 mg/L (4.5-7.5 µM) and C4=120-290 mg/L (0.6-1.4 µM) were 
within the total ranges reported in the referenced studies, 660-2100 mg/L (3.6-
11.5 µM) C3 and 150-650 mg/L (0.7-3.2 µM) C4, suggesting minimal pre-
analytical Complement activation and accurate phenotype data.  
Confidence in the value of a given protein concentration or phenotype is a 
function of assay error, sample dilution error and potentially variations in the mass 
and homogeneity of zymosan samples. A correlation analysis reveals that despite 
these potential sources of error, strong correlations were evident between protein 
concentrations and measured activation phenotypes, Figure 6.6. 
 
Figure 6.6 Heat map of correlation matrix showing Complement analyte standing concentrations and 
phenotypes (n=22). The plot is split according to parameter type (intact proteins, activation products, rate 
and capacity phenotypes). Boxes show notable high correlations and stars represent phenotypes with 
Pearson correlation coefficients <0.1. 
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The correlation analysis shows C3 and C4 concentrations were strongly 
correlated (Pearson correlation = 0.63) which is consistent with previous reports 
(594, 595) including a correlation with body mass index (596). IgG was found to 
be negatively correlated with C3 and C4 in the cohort serum (Pearson correlation 
= -0.45 and -0.49 respectively) which is also consistent with previous research 
(597). Correlations between observed protein concentrations might be 
considered to improve the accuracy of future models reliant on modelling protein 
concentration variations. Co-expression of genes could be considered also: the 
genes for C2, C4 and FB are coded for by genes on chromosome 6 (598) and 
the genes for C5 and C8 are located on chromosome 9 (595).  
The correlation coefficients of Complement activation products appear to show 
some dependence on molecular weight, Figure 6.7. High molecular weight 
Complement activation products Ba (33 kDa) and iC3b (176 kDa) show a strong 
positive correlation with TCC (>1 MD), whilst C4a (8.7 kDa) and C5a (10 kDa) 
below the mass cut-off of the kidneys (30-50 kDa) (395) do not. 
 
Figure 6.7 A matrix of plots showing correlations among pairs of analytes in µM (n=22). Lines of best fit are 
shown for each scatter plot and Pearson Coefficients displayed in red indicate significant correlation with P 
values <0.05.  
The correlation between the standing concentrations of high molecular weight 
analytes with TCC highlights the importance of using larger biomarkers to 
observe Complement activation in vivo. Indeed, the C5a concentration measured 
in the plasma of healthy donors has been shown previously to be identical to 
septic patients (250), whereas all markers of Complement activation are seen to 
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respond rapidly in the in vitro activations shown here, regardless of molecular 
weight. 
Considering the consistency of these results with previous observations of serum 
protein correlations, the correlation between serum proteins and the novel 
Complement activation phenotypes can be investigated with confidence. All 
Complement activation phenotypes were positively correlated as expected given 
that all are measures of the strength of the Complement response to activation. 
Furthermore, a strong positive correlation was evident between the rate and 
capacity phenotype pairs for each analyte, Figure 6.8. 
 
Figure 6.8 Linear regression analysis of the correlation between rate and capacity phenotypes in a cohort of 
n=22 healthy volunteers, measured for a number of activation products: a) Ba, b) C4a, C) C5a, d) iC3b and 
e) TCC. R2=0.67, 0.77, 019, 0.28, 0.15 respectively. Pearson correlation coefficients=0.82, 0.87, 0.44, 0.53, 
0.39, respectively with Ba, C4a and iC3b exhibiting P-values <0.05 indicating significant correlation.  
The linear regression analysis implies that the capacity phenotype may be 
predictable based on initial rate: analytes Ba and C4a capacity phenotypes show 
the strongest dependence on initial rate (linear R2=0.67 and 0.77 respectively). 
The TCC rate phenotype was least correlated with the other phenotypes (marked 
with stars in Figure 6.6), suggesting that a good estimate of Complement 
activation dynamics could be obtained by observing the minimal set of 
phenotypes: TCC rate, Ba rate, C4a capacity and iC3b capacity.  
The standing concentrations of C3 and C4 were positively correlated with all 
capacity phenotypes as expected – an intuitive result considering the role of these 
proteins as a source of components for the C3 and C5 convertases. Interestingly, 
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no single analyte was highly correlated with all the measured phenotypes. C3 
and C4 showed low mean absolute correlations with all phenotypes with Pearson 
correlation coefficients = 0.22 and 0.32 respectively, indicating that individual 
protein concentrations are poor predictors of Complement activation potential. 
Other proteins such as those used for positive and negative regulation of the 
system are highly sensitive reactants in the system according to the sensitivity 
analysis in Chapter 5 and a full profile of the constituent proteins for each patient 
would be required to classify protein combinations that are import to system 
performance. Indeed, only with a validated mathematical model and all starting 
protein concentrations can Complement function in serum be precisely predicted.  
6.5.2 Model Predictions 
A comparison of measured and predicted phenotypes, based on a measured set 
of starting protein concentrations, would be the ultimate model validation test but 
requires assays for all Complement proteins in all serum samples. In this study, 
the predictive accuracy of the model is tested not on the reproducibility of fitting 
data but on the variation of novel system properties which are the patient 
response phenotypes. The C-ODE model was used to predict the distributions of 
phenotypes based on varying the concentration combinations of the 18 
circulating proteins and zymogens that make up the cascade model. 
The complete profiling of the 18 constitutive proteins is a technical challenge and 
the C-ODE model was optimised previously based on published median serum 
values rather than measured concentrations. Optimisation based on median 
concentrations was a reasonable assumption for pooled serum but any errors 
between the concentrations used for model optimisation and their true values will 
have induced bias in the fitted rate constants. Considering the potential for model 
bias, the protein ranges used in the phenotype predictions were not matched to 
the C3 and C4 concentrations measured in the cohort serum. Because the model 
fits well to pooled serum data, an accurate model prediction for the mean 
phenotype values (of proteins in the training data set) would only occur if the true 
mean starting protein concentrations in the training and cohort sera were similar. 
If the true mean starting protein concentrations in the training and cohort sera 
were different, the C-ODE model predictions will fail, regardless of differences in 
the protein concentration values used in the model. Matching the numerical 
values of C3 and C4 concentrations in the model to those measured in the cohort 
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sera would risk producing a good median phenotype prediction due to chance. 
The validity of the model was therefore tested by comparing the variation in 
phenotype values which indicated whether the model reproduced the sensitivity 
of the Complement system to relative rather than absolute protein concentration 
variations. Table 6.1 shows that the relative variation in C3 and C4 concentrations 
measured in the cohort sera were in good agreement with the modelled variation. 
Furthermore, the consumption of C3 shown in Figure 6.4 was similar for both 
pooled and cohort sera (2.5-3 µM as measured by C3a and iC3b respectively), 
suggesting the C3 activation dynamics of the pooled serum were largely 
representative of the cohort serum for total cascade activity.  
A quantitative analysis comparing the model predictions to the cohort data (Table 
6.3 and Figure 6.5) revealed that the median percentage difference between 
measured and predicted phenotypes values was 21%, confirming that the pooled 
serum used for model training was reasonably representative of the cohort sera 
studied here. The measured and predicted phenotype distributions had a median 
histogram overlap of 32% for all phenotypes measured, suggesting reasonable 
precision considering high uncertainty in both the model parameters and model 
sensitivity to protein concentrations. Furthermore, iC3b was not a species present 
in the training data set, yet it’s rate and capacity phenotypes were reasonably 
well predicted by the C-ODE model. These results suggest that the data used for 
model training, particularly C3a, was somewhat effective in capturing the 
dynamics of other model species. 
Many of the predicted phenotype distributions exhibited SW test P values <0.05 
(evidence against normality) whereas all measured cohort phenotypes appeared 
normally distributed. Evidence for non-normality may be due to the large sample 
size of the simulation distribution which could allow trivial differences from 
normality to have been perceived as significant by the SW test. To investigate the 
bias associated with the sample size of the modelled phenotypes, all statistical 
tests were performed for different numbers of model simulations. The 250 values 
predicted by the model were sampled uniformly at random, with replacement, and 
compared to the experimental data for each phenotype. The procedure was 
repeated 50 times for each number of observations to determine the range and 
median P values, Figure 6.9. 
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Figure 6.9 Effect of modelled phenotype sample size on the median (solid lines) and range (dotted lines) of 
P values from the SW test for normality (blue) and the t-test or KS comparison tests (orange): a-e) rate 
phenotype distributions for Ba, C4a, C5a, iC3b and TCC; and f-g) capacity phenotype distributions for the 
same analytes. 
As expected, the median P value of the SW test for normality invariably 
decreased with sample size such that at n=20 all phenotype distributions 
appeared normal with P>0.05. The modelled phenotype distributions for Ba rate, 
Ba capacity, C4a capacity and iC3b capacity also appeared to be normally 
distributed at n=250 and as such were compared to their experimental 
distributions with a two-sample t-test. The phenotype distributions which for which 
there was evidence against normality at n=250 were compared to their 
experimental distributions with the KS test.  
The P values from the t-test and KS tests exhibited a larger range at n=20 as 
expected due to the effects of randomness on small samples. As such, the C5a 
capacity, iC3b capacity and TCC capacity phenotypes occasionally exhibited P 
values >0.05 at n=20. However, the median P values of the comparison tests did 
not vary sufficiently with n to alter the conclusions drawn from testing at n=250 in 
Table 6.2: the C5a rate (Figure 6.9c) and TCC rate (Figure 6.9e) phenotypes 
were the only phenotype predictions with median P>0.05 at all simulation sample 
sizes tested here.  
A further source of bias in the assessment of the C-ODE model’s ability to predict 
the Complement activation phenotypes was the choice of concentration ranges 
for modelling predictions, which show significant variation in the literature as 
discussed previously. To investigate the effect of starting protein concentration 
ranges on the C-ODE model predictions, the simulation was performed on 3 
variations of the reference ranges listed in Table 6.1. To capture the effect of 
using larger reference ranges, the limits of the concentration sampling ranges in 
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the model were extended by 20% of the median value. To capture the effect of 
using systematically different reference ranges the concentration sampling 
ranges in the model were translated by -20% and +20% of the median value. The 
minimum and maximum phenotype values, percentage difference of medians 
and percentage histogram overlap was recorded for all variations and is shown 
in Figure 6.10. 
 
Figure 6.10 Variation of C-ODE model phenotype predictions (n=25) and their agreement with the cohort 
data (n=22) with varying concentration sampling concentration ranges. Ranges were extended by 20% of 
the median, translated by -20% and +20% of the median and the most extreme values are shown here: a) 
phenotype ranges recorded from model predictions (red) and experimental data ranges (blue); b) percentage 
differences between predicted and recorded phenotype median values and c) histogram intersection 
between predicted and recorded phenotype distributions. 
With different concentration sampling ranges, the ranges of measured C5a, iC3b 
and TCC phenotypes were fully within the predicted ranges. Furthermore, the 
median phenotype values predicted for C5a, iC3b and TCC appeared robust 
and remained accurate to within 60% of the cohort data regardless of the 
reference range used for the simulation. The accuracy of the C-ODE model 
predictions for the iC3b, C5a and TCC phenotypes (common to all initiation 
pathways) indicates that model training using Ba, C3a, C4a, C5a and TCC 
concentration data from the pooled serum was effective for capturing total 
Complement activity. The KS test revealed no significant difference between 
measured and predicted distributions of the C5a and TCC rate phenotypes 
(P=0.05 and P=0.09 respectively) using the sampling ranges in Table 6.1. 
The measured ranges of Ba and C4a phenotypes remained only partially within 
the predicted ranges, regardless of the sampling ranges used for the simulation 
and the poor agreement is attributed to the differences observed between pooled 
serum and cohort serum for Ba and C4a despite similar C3 consumption. Figure 
6.5 shows that the AP (profiled using Ba) was more active in the cohort serum 
than predicted by the C-ODE model, whilst the CP/LP was less active than 
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predicted. Consistency between pooled and cohort data for late cascade markers 
indicates that regardless of the relative contributions of the AP and CP/LP, 
zymosan activation of Complement yielded consistent flux through the lower 
cascade. In future work, the C-ODE model should be re-optimised using data 
from serum where all concentrations are known and preferably using fresh serum 
due to differences is relative CP/LP and AP dynamics. The resulting model might 
yield precise predictions of Complement activation using specified starting 
concentrations and should be validated using pairwise comparisons of data and 
model prediction for each starting condition.   
Model validation is fundamentally performed to test whether a model is accurate 
enough to fulfil an intended purpose and a major goal of systems biology 
modelling is to develop a model that has sufficient accuracy to predict the 
response of a system to perturbation. The accuracy with which the C-ODE model 
predicted the distributions of iC3b, C5a and TCC phenotypes suggests that the 
model might also be used to predict the effect size of Complement depletion on 
these phenotypes. An optimal cut-off value of 0.578 mg/mL C3 has been 
identified as a good predictor of mortality in sepsis patients despite no correlation 
with APACHE II or SOFA scores (153) and corresponds to a consumption of 30-
70% from the C3 reference ranges discussed previously. 1 hour of 1 mg/mL 
zymosan activation was simulated by the C-ODE model, resulting in 31 ± 6 % C3 
depletion (2SD), to generate depleted starting conditions. The phenotype 
predictions from depleted starting conditions were compared to those of the 
healthy starting conditions to estimate the sensitivity of the phenotypes to pre-Z-
test Complement depletion, Figure 6.11. The model predictions suggest the C4a 
phenotypes are most sensitive to Complement depletion compared to the other 
activation markers.  
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Figure 6.11 Comparison of Complement activation phenotypes for cascade activation markers Ba, C4a, 
C5a, iC3b and TCC in healthy and Complement-depleted sera: a-c) rate phenotype and f-h) capacity 
phenotype. Box and whisker plots are shown for the n=250 model simulation values (grey) and suggest all 
phenotypes are sensitive to Complement depletion (pre-test deficit of 31 ± 6 % C3). The data from n=22 
healthy volunteers (orange) are shown for comparison. Selected simulations (n=5) with healthy phenotype 
values from above the upper quartile (green), below the lower quartile (red) and the interquartile range (blue) 
are tracked between healthy and depleted states showing no correlation. 
The position of each simulated phenotype value within the healthy and depleted 
phenotype value distributions was tracked and reveals that there is no correlation 
between healthy phenotype value and depleted phenotype values. The result 
suggests individuals may lose Complement activation potential at different rates, 
independent of their healthy phenotype value. The phenotype trajectories 
between healthy and depleted states suggest that some cascades make rapid 
transitions from super-median to sub-median phenotype values, which in 
principle would be predictable with a full cascade profile of all constituent proteins 
in a patient. Correlation between any of the 18 starting protein concentrations and 
the gradient between healthy and depleted phenotypes could be investigated in 
further studies to identify combinations of proteins which are most sensitive to 
Complement depletion.  
The simulation demonstrates the utility of the model in predicting patient response 
phenotypes and enables hypothesis-driven selection of biomarkers to test in 
future studies. The logical next step for investigations into these phenotypes is to 
collect data to validate the model prediction for the phenotypes in Complement-
compromised patients with a pilot study. The sample sizes required to assure 
adequate power to detect statistical significance can be estimated using 
Complement activation models such as the C-ODE model discussed here.  
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6.6 Conclusions 
The present study recorded the variation of 10 phenotypes of immune state in 
the healthy adult population and provided an independent data set with which to 
test the accuracy of C-ODE model. The model correctly predicted the variation 
for some phenotypes but the cohort data show that the pooled serum may have 
pre-analytical activation in CP/LP with a consequent bias in the model training 
which was observed in the validation process for Ba and C4a phenotypes. The 
accuracy of the analyte measurements might be improved by performing 
concentration analysis immediately after sampling with a rapid assay platform to 
minimise pre-analytical Complement activation. In time, the phenotypes 
presented here might be measured using the LiScAR biosensor platform at point-
of-care. The correlations between standing protein concentrations in the cohort 
serum reveal that the model predictions might be further improved by considering 
co-expression of proteins when simulating starting protein concentrations. 
The difference in phenotype values between the data for healthy individuals and 
the simulation of Complement depleted individuals was significant and highlights 
the utility of the model as a tool for power calculations in the design of future 
Complement activation studies. The C4a rate phenotype showed the largest 
variation in the cohort, varying by ~7-fold and is predicted to be the most sensitive 
phenotype to Complement depletion studied here. Identification of patients at 
high-risk of infection based on C3 and C4 concentrations may not be adequate 
as evidenced by the large reference ranges and lack of correlation between 
protein concentrations and patient phenotypes. The phenotypes are direct 
measures of Complement activation potential and are better suited to predicting 
patient response to infection. 
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7 Conclusions and Future Work 
This thesis began with the impact of nosocomial infections, particularly SSI, on 
the outcome of elective surgical patients and highlighted research showing that 
timely identification high-risk patients is beneficial but challenging (58). The use 
of ‘risk-biomarkers’ or ‘phenotypes’ measured pre- and/or post-operatively was 
identified as one method which could help healthcare professionals to stratify 
patients into high and low-risk groups and guide the allocation of additional peri-
operative care resources to high-risk patients and improve outcome (34). Several 
risk biomarkers are already in use, including CRP and WBC to gauge the immune 
states of patients (42). This thesis proposed that Complement activation 
phenotypes could provide a new source of risk-biomarkers and could be 
measured by activating Complement in patient serum in vitro and profiling the 
system response. Patients with Complement activation phenotypes, such as 
initial rate or absolute change (capacity) of analyte concentration, at the extremes 
of the distribution expected in healthy adults might be at higher risk of HAI and 
could be stratified into an appropriate care pathway based on this rapid 
assessment of immune state. Repeating the phenotype measurements post-
operatively might also be used to detect the onset of infection and improve patient 
outcome via timely therapeutic intervention.  
7.1 Summary of Research Findings 
Existing assays of Complement activation products, such as ELISA, are confined 
to the laboratory and require extensive training to operate. Therefore, it was 
recognised that a biosensor platform capable of rapidly measuring Complement 
activation products in serum samples with relative ease would be beneficial to the 
study of Complement phenotypes in a research or clinical setting. The LiScAR 
biosensor platform, developed by the Shaw Lab, can perform rapid and multiplex 
measurements of protein-sensor interactions and its performance was reviewed 
in Chapter 2. Automated signal processing routines were developed to 
standardise the calibration of the instrument as a protein assay and ultimately 
improve the ease of data collection. Chapter 3 reported the development and 
optimisation of LiScAR assays for C3, C5a, TCC and TNFα which could be 
calibrated simultaneously as a 4-plex assay with purified protein samples. The 
new LiScAR assays for C3 and C5a were validated with ELISA and turbidimetric 
assays and can be performed simultaneously and repeatedly in serum samples, 
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with a duty cycle of 15 minutes and a CV of 23% and 21% respectively, within a 
common dynamic range of 3.2-12.5 nM. It may be concluded that the LiScAR is 
a good platform for the development of assays required to track the progress of 
reactions with rapid and repeated measurements.  
A novel LiScAR assay for the monomeric purity of IgG samples was developed 
to accompany the new assays for quality control of assay materials. Both the 
LiScAR method and ESI-MS revealed that the commercial antibodies tested 
varied significantly in monomeric purity, with some as low as 54% intact. It may 
be concluded that careful quality control screening of antibody samples is 
required before use in reproducible research and the new monomeric purity 
assay provides a convenient new test for this purpose. The LiScAR assays could 
now be used to reliably measure in vitro Complement activation phenotypes in 
patient serum samples with a less complex and faster method than ELISA – a 
step towards Complement testing at point of care. The antigen array presented 
in Chapter 3 might also be used to screen for the presence of antibodies in serum 
against specific antigens to test the efficacy of vaccines, whilst the PAG-based 
IgG assay in Chapter 2 could quantify total IgG concentration. All assays may be 
included on a single multiplex array according to the research needs.  
An alternate approach to profiling in vitro Complement activation phenotypes with 
multiple measurements on multiplex assays is to predict the Complement 
response profile of a patient with a mathematical model, considering the starting 
protein concentrations measured in a single serum sample. Chapter 5 reported 
the development of a new mechanistic ODE model of Complement cascade 
activation, C-ODE. The C-ODE model is the most recent of 7 Complement 
models and is the only model optimised using biological data from all pathways 
of the system. The C-ODE model was optimised using the model fitting 
techniques described in Chapter 4 and ELISA data of Complement activation 
products in pooled human serum following zymosan activation. The C-ODE 
model was first verified by simulating the effect of FH deficiency and P 
supplementation on Complement activation, with results that were consistent with 
expectations of system behaviour in each condition. The mechanistic C-ODE 
model demonstrated its utility as a research tool by predicting significant 
competition for substrate among the initiation pathways in the FH-deficient and 
P-supplemented simulations – system behaviour that could not be quantitatively 
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predicted with a diagrammatic model alone. These simulations may benefit future 
investigations into Complement modulation therapy for drug design and the 
model is available as a COPASI file that can be shared among the research 
community. 
Following verification, the C-ODE model was used to estimate the variation in 
Complement activation phenotypes in the healthy population. The predictions 
considered the reference ranges of all 18 constituent protein concentrations in 
the model and results were compared with serum data from a cohort of 22 healthy 
volunteers in Chapter 6. The predicted distributions of C5a and TCC rate 
phenotypes were validated by observing no statistically significant difference from 
the experimental data, despite the challenges associated with model transfer to 
new system settings highlighted in Chapter 4. These challenges included 
increased pre-analytical CP/LP activity in the pooled serum data set as evidenced 
by a higher initial C4a concentration. It may be concluded that the mechanistic 
approach to modelling is useful for predicting system behaviour given sufficient 
training data and refinement of such a model is possible with iterative fitting to 
new experimental data as it becomes available.  Ultimately, a limited 
experimental dataset and a fully mechanistic mathematical model allowed the 
complex behaviour of the Complement system to be studied, even the behaviour 
of species that were not in the training data set. The same approaches described 
here, such as the assumptions of median enzyme kinetics as a starting point for 
model optimisation, could be usefully applied to other systems such as 
coagulation – a possible source of new phenotypes to predict infection.  
The cohort serum data revealed that the standing concentrations of individual 
proteins were not correlated with any of the measured rate and capacity 
phenotypes, highlighting the necessity for a direct test of Complement activation 
potential such as the standard Z-test described here. The cohort phenotype data 
provide a first estimate of the variation in Complement activation in healthy adults 
– a benchmark against which the serum of high-risk patients could now be judged 
in future studies. The model was used to predict the effect size of Complement 
depletion on the phenotype distributions, which supported the hypothesis that 
these tests would be sensitive measures of Complement depletion in patients. 
The model also predicts that there is no correlation between healthy and 
Complement-depleted phenotype values in terms of position in the simulated 
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distributions, suggesting highly personal transitions between these states. It may 
be concluded that Complement activation is a highly personal measure of 
immune state that should be investigated further for predicting patient risk of 
infection and detecting the onset of infection. The LiScAR shows potential to 
perform these tests at the bedside.  
7.2 Strengths and Weaknesses 
The C-ODE model was initially constructed using a bottom-up approach (599) by 
combining kinetic parameters measured in isolation in an established, complex 
reaction structure to predict systemic behaviour. This approach is distinct from 
top-down systems biology which looks for correlations between system behaviour 
and proteins or genes, in order to understand the effects of input on output (600). 
Top-down models often use ‘black-box’ models, such as artificial neural networks 
(601), which do not require mechanistic understanding of the system (602). 
Black-box models, are therefore an abstraction of the underlying physical 
processes of the system and can be optimised to fit well to experimental data and 
make predictions using a minimal set of parameters (602). However, their lack of 
physical interpretation is also the main disadvantage of black-box models, which 
often cannot investigate specific physical perturbations on the system without re-
training – the benefit of mechanistic kinetic models such as C-ODE. For example, 
the C-ODE model can be used to predict the effect of inhibitors at any reaction in 
the system and this is not possible using non-mechanistic models.  
Kinetic models are typically constructed for relatively small systems and of the 
462 models in the 2014 Biomodels database (603), the median number of 
reactions and species was 12 and 11 respectively (604). The C-ODE model is 
therefore significantly larger than most kinetic models and many of the 187 
parameters (concentrations and rate constants) were unknown, representing a 
significant optimisation challenge. The assumptions of median dissociation 
constants and starting concentrations allowed the model to be optimised by fitting 
56 unknown association rate constants and turnover numbers – a reasonable 
reduction in the dimensionality of the optimisation problem. However, the 
individual fitted rate constants of the fitted C-ODE model were poorly defined, in 
part due to a lack of experimental data and could not be used to construct 
accurate subsystem models containing the same reactions in an alternate 
structure - a model of the AP only for example.  
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In contrast, the Silicon Cell approach to modelling (464) aims to produce highly 
transferable models combining smaller models constructed based on 
experimentally determined structures and rate constants studied in isolation. 
Unlike the optimised C-ODE model, Silicon Cell models are not fit to datasets of 
system behaviour and any differences between model predictions and 
experimental data are instead used to identify new effectors of the system (464). 
As a result, Silicon Cell models do not necessarily describe systemic behaviour 
accurately but ensure all model parameters can be transferred between systems 
which is useful when simulating modular synthetic metabolic pathways. A Silicon 
Cell approach to modelling the complete Complement system could be 
considered in future work as more kinetic parameters become available.  
Metabolic networks containing easily isolated enzymes are ideal for studying 
using the Silicon Cell approach and a model of yeast glycolysis based entirely on 
in vitro data from the isolated enzymes has been used to describe in vivo data, 
albeit with additional system branches (482). Notably however, Silicon Cell  
model parameters are limited to models of similar system settings, as discussed 
in Chapter 4, and hence the conditions of study should be carefully considered to 
allow parameter transfer to future systems. Future work could study the isolated 
pathways of the Complement cascade, as discussed in Chapter 1, to provide 
missing rate constants in the C-ODE model. A protocol for such an experiment is 
presented in at the end of this chapter.  
“All models are wrong, but some are useful” is a common expression in the 
modelling community. The phrase captures the idea that no model can fully 
capture the complexity of physical phenomena and a model should be judged on 
its ability to fulfil a purpose. In the present study, the C-ODE model was 
developed to predict the concentration-time profiles of all species in the 
Complement system following activation by zymosan in vitro. The C-ODE model 
therefore allowed the hypothesis driven selection of candidate biomarkers that 
might predict patient risk of infection. The model predictions of C5a and TCC rate 
phenotype variation were somewhat validated in Chapter 6 and further 
refinement of the model is required to improve predictions of the other 
phenotypes measured.  Because the C-ODE model is mechanistic and contains 
all species in the system, refitting would be relatively straightforward if new time 
course data became available. 
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Many of the Complement activation products observed with the pooled human 
serum time course study in Chapters 5 and 6 were produced rapidly following 
activation. Accurate measures of reaction rates were therefore challenging to 
derive with assays such as ELISA which require samples to be stored before 
testing – introducing sources of error as described in Chapter 6. These sources 
of error might be overcome with real-time measurements of Complement 
activation. The present study demonstrated automated analysis of data from 4 
LiScAR assays performed simultaneously on a single sample in 15 minutes – 
eliminating the need for sample storage. Operating the LiScAR is also relatively 
simple and enables significantly faster data collection compared to four ELISA’s 
or the multiplex Complement assays offered by Merck’s Luminex platform. The 
LiScAR could now be used to collect data to refine the C-ODE model, particularly 
in early time, although a number of improvements to the technology can be 
identified and are discussed here. 
Firstly, to be adopted as a commercial instrument, the LiScAR instrument would 
need to be redesigned to pass the European Union health and environmental 
safety requirements (CE marking) required for all in vitro diagnostic devices sold 
in Europe. This would be a significant design challenge considering the 
microfluidic requirements of the instrument. A disadvantage of the LiScAR 
Complement assays developed here is the volume and concentration of detection 
antibodies required - which lead to a higher cost of each test compared to ELISA. 
The C5a assay, for example, used 450µL of 200 nM detection antibody to ensure 
a detection step of 200 seconds occured without dilution of the antibody in the 1 
mL sample loop at the 6 mL hour-1 (1.7 µL s-1) flow rate used in the LiScAR setup. 
At the time of writing, the detection antibody retails at £576 per 200 µL (1.07 mg 
mL-1) - enough for 13 tests at a resulting cost of £44 per test or £88 for an estimate 
of either rate or capacity phenotype, discussed in Chapter 6. For comparison, the 
96-well C5a ELISA used in Chapter 6 retails at £500 and can perform 80 tests 
(losing 2 columns to duplicate standard curve measurements and 
controls/blanks) at a resulting cost of £6 per test. Future work could minimise 
assay costs by re-designing the LiScAR platform to reduce the sample volumes 
required. This could be done by minimising the volume of the flow cell and the 
diameter of all tubing.  
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A further limitation of the LiScAR assay platform is the complex fabrication 
process of the assay surfaces, requiring tight control over a number of processes 
which impact assay sensitivity. A common issue encountered was variability in 
the synthesis of the gold nanoparticle seeds due to the nature of the method itself 
which was performed by hand. Cooled NaBH4 was injected via syringe into the 
auric chloride / sodium citrate solution and the reaction proceeded rapidly. 
Thorough mixing was required to ensure a uniform population of seed 
nanoparticles was produced but mixing must not be so vigorous as to cause 
aggregation of the nanoparticles in the colloid – referred to colloquially as 
“crashing out” and observed as black / purple flakes in the solution. The use of 
magnetic bars to stir the mixture was attempted to reduce experimental variation 
but appeared to encourage nanoparticle aggregation. The seeds solution is 
stable at 4 oC and a well-performing stock of nanoparticle seeds was used for all 
experiments in the later stages of this project to minimise variations in seeds 
synthesis. In time, synthesis of the gold nanoparticle seeds could be automated 
with a liquid handling device for the highest possible reproducibility.  
A further issue in the array fabrication process is variability in substrate surfaces 
which, as shown in Chapter 2, significantly impacts the growth and RI sensitivity 
of the printed gold nanoparticles. As such, the protocol for printing and growing 
the seed nanoparticles required re-optimisation with each new batch of 
substrates from the same manufacturer. The accuracy of printing also varied 
significantly between experiments. The printing technology is outside the scope 
of this thesis but is highly sensitive to sample viscosity and required extensive re-
optimisation (target practice) for each protein or antibody sample - involving 
significant waste of antibody samples and substrates. Both substrate quality 
control and printing accuracy are engineering challenges that should be 
addressed before large-scale manufacture of the LiScAR assay surfaces but 
careful experimental design allowed the complex fabrication process of the 
LiScAR assay surfaces to be performed with good reproducibility and minimal 
waste. In the current project, nanoparticle arrays on new batches of substrate 
were tested for sensitivity (as judged by the metrics RIS and nRIS) before 
tethering of proteins to prevent wasted batches. Other properties of the substrate 
might also be tested ahead of nanoparticle printing, such as hydrophobicity, to 
quickly estimate the quality of substrate batches without the need to test 
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nanoparticle arrays. Printing accuracy variations can be minimised by diluting 
samples in a common diluent such as PBS.  
The Bland-Altman analysis in Chapter 3 revealed errors in the calibration of the 
C5a, TCC and C3 assays. The bias associated with the C3 assay was 55 ± 21 % 
and not systematic but visibly worsens at greater analyte concentrations. These 
errors could be accounted for in future assays to improve assay accuracy relative 
to the gold standard (at least for the analyte concentration range and conditions 
tested) but ultimately must be addressed. Appendix 1 shows the results of testing 
an alternative assay for C3, using monoclonal rather than polyclonal detection 
antibody, although the use of a neo-epitope capture antibody is preferable.  
On average, the C5a assay systematically under-estimated by 26 ± 27 % and the 
TCC assay systematically over-estimated by 36 ± 39 %. The systematic 
calibration errors of all assays may be improved with the use of common protein 
standards of precisely known purity and concentration, such as the IgG reference 
material from NIST used to calibrate the monomeric purity assay in Chapter 3. 
The Bland-Altman analysis in the present study allows systematic calibration 
errors to be corrected for, providing a better agreement with the Gold Standard 
tests as demonstrated for the C5a assay later in this chapter.  
A visual representation of all factors influencing measurement uncertainty is 
shown in Figure 7.1. To maximise reliability of measured Complement activation 
phenotypes, additional experiments might be performed in future work to 
understand the effects of factors not investigated here. 
 
Figure 7.1 Feather diagram of the contributing factors for Complement phenotype measurement uncertainty, 
adapted from ref (605). Factors in green are controlled or measured in the present study, whereas factors 
in red should be investigated further.  
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Biological uncertainty stemming from variation among individuals was explicitly 
investigated in the present study of Complement activation phenotypes, using 
both model predictions and data from a cohort of healthy individuals. However, 
diurnal or circadian variations in plasma protein concentrations are a concern for 
the reliability of measurements and are observed for several proteins (e.g. 
bilirubin) (606) and hormones (e.g. cortisol) (607). Circadian variations in 
Complemented-mediated solubilisation of immune complexes have been 
reported in rheumatoid arthritis patients, suggesting blood could be sampled at 
the same time of day for increased reliability of Complement testing (608). 
However, the influence of diurnal variation on Complement activation has been 
studied using C3dg, showing no significant variation in plasma samples (609). 
Variation for an individual over time could be investigated in future work to 
understand the lifetime over which Complement phenotype test results are 
representative of immune state and inform the ideal measurement frequency 
during recovery. The model predictions in Chapter 6 predict that the studied 
activation phenotypes could change rapidly during infection, suggesting that 
these could be used to track condition severity and response to emerging 
therapeutic strategies such as supplementation with P (534) or C3 (228) – type 1 
and type 2 biomarkers.  
Analytical and pre-analytical factors were not specifically investigated in the 
present study of Complement activation phenotypes but were minimised with the 
use of commercial serum collection tubes and ELISA assay kits, as well as a 
consistent and established sample preparation protocol from ref (152). Many 
procedures in the experimental protocol were time dependent, meaning that 
results had the potential to be affected by variations in incubation and sampling 
times. In the Complement activation phenotypes study, samples were collected 
over a period of several weeks and labelled in chronological order. Sample 
aliquots were also defrosted and diluted in preparation for analysis in 
chronological order, which presents a potential source of non-systematic error. 
However, the concentrations of Complement activation markers showed no 
dependence on sample number, as judged by the data at 1 hour following the 
zymosan challenge in Figure 7.2. The samples measured at 1 hour following the 
zymosan challenge were used to measure the rate of analyte increase, making 
these data the most sensitive to variations in analytical timing. It may be 
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concluded that the method of serum sample preparation described here had 
minimal effect on the phenotype results.  
 
Figure 7.2 Dependence of analyte concentration (at 1 hour following zymosan challenge) on sample number. 
Sample number represents multiple effects including the age of experimental materials such as zymosan 
and the inverse of defrost time before dilution and analysis. No common trends are observed, indicating that 
the assay procedure did not influence the relative results.  
The choice of sampling time was a source of bias in deriving the Complement 
activation phenotypes. The protocol shown in Chapter 6 used the same sampling 
times for all analytes but the model indicates that more accurate measures of rate 
and capacity could be achieved with different sampling times for each analyte, 
due to different times to maximum. For example, Figure 6.3 shows that sampling 
at 0, 1 and 4 hours provided a good estimate of initial rate and total change in 
C5a and TCC but C4a reached a maximum before 1 hour, whilst Ba and iC3b 
reached their maxima after 4 hours. Using different sampling times for each 
analyte would complicate the method of data collection for the rate and capacity 
phenotypes, although the correlation between these phenotypes in Figure 6.8 
suggests the rate phenotypes alone may be a sufficient measure of Complement 
activity. Automated sampling and a rapid assay such as the LiScAR could 
measure different activation products at different times, from a single sample, 
following activation in real-time. Lack of sample preparation and storage would 
significantly reduce experimental complexity. 
An additional factor which was not investigated in the present study of 
Complement activation phenotypes was the effect of sampling location. However, 
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a new venepuncture of a vein in the arm was used throughout the study to collect 
all samples to minimise any effects. Furthermore, no significant difference has 
been found between protein biomarker concentrations in venous and arterial 
blood (610) suggesting sampling location is unlikely to affect results of systemic 
serum markers in the current work.  
The effects of gender, age or sex on Complement activation phenotypes were 
not explored in the present study due to ethical restrictions enforcing data 
anonymity but are known to impact Complement activity (561). Many volunteers 
were young adults which may go some way to explain why the recorded C3 and 
C4 concentration distributions cover a comparatively narrow region of the total 
ranges reported in the literature. A broader range of test-subjects could be 
explored in future work to achieve a data set more representative of the general 
population.  
Ultimately, although the ability of the Complement activation phenotypes to 
identify high-risk patients was not tested experimentally, the C-ODE model 
suggests a significant difference in phenotype values between healthy and 
Complement-depleted individuals. The C-ODE model accurately predicted the 
distribution of C5a and TCC rate phenotypes giving some confidence to the 
predictions. The C-ODE model predicts no correlation between the phenotype 
value before and after Complement-depletion – an interesting result supporting 
the initial hypothesis that repeated monitoring of these phenotypes would be 
useful to track patient immune state post-operatively to detect the onset of 
infection. The healthy cohort phenotype data and C-ODE model provide good 
preliminary data of an effect size, which could be used to plan a future clinical 
investigation of phenotype values from patients who develop infections following 
surgery.  
7.3 Future Work 
The present study developed two new assays for Complement activation, which 
in time could enable in vitro Complement testing in a clinical setting and measure 
Complement function with a less complex protocol than ELISA or the CH50 or 
AH50 tests mentioned previously. The new assays also allow rapid sampling of 
Complement activation to provide additional data for refinement of the C-ODE 
model. Preliminary data from the new assays in section 3.5 are presented here, 
253 
 
complete with protocols, to inspire future studies using these assays as research 
tools. 
7.3.1 High-Frequency Sampling of C5a in Human Serum 
Preliminary data were collected to demonstrate use of the LiScAR platform for 
high-frequency (HF) sampling of C5a in serum following Complement activation. 
Pooled human serum was activated with 1 mg/mL zymosan as described in the 
protocol as described in section 5.3.1. 50 µL of serum was sampled from the 
reaction mixture, diluted 10-fold with 450 µL PBS and injected into the LiScAR 
following centrifugation at 1,300 g for 2 minutes. The response of the LiScAR to 
the measurement sequence (described in Chapter 3) is shown in Figure 7.3. 
 
Figure 7.3 Response of anti-C5a assay spots (green) during the measurement sequence of an activated 
serum sample. The C5a assay is described in section 3.5 and was performed using the assay method 
described in 2.8.1. Signals are the averaged response of n=15 assay spots. a) The capture step at 20-220 
seconds, followed by a PBS wash at 220-320 seconds and a detection step at 320-520 seconds with 200 
nM polyclonal anti-C5a. b) The original detection step (green) is corrected for drift (blue) by subtracting a 
linear model (red) fit to signal drift data recorded by testing a serum sample and omitting the detection step 
(black). 
The kinetics of the association phase, during which C5a capture occurs, were 
masked by non-specific binding of 10-fold diluted serum (20-200 s). Non-specific 
binding to the BSA reference spots was revealed by a PBS wash step which 
shows rapid dissociation from the reference spots: causing a rapid increase in 
the apparent response of the C5a assay spots at 220 s - an artefact of reference 
subtraction. The PBS wash step described in Chapter 3 was shortened from 200 
s to 100 s to minimise the assay duty cycle and increase sampling frequency. 
100 s of PBS washing allowed the majority of non-specifically bound material 
from the assay surface but performing the measurement sequence on a serum 
sample without performing the detection step revealed that the baseline 
continues to drift after 100 s – a potential source of error considering that the 
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calibration curve used PBS samples which did not suffer from this effect. The 
signal drift in the HF data was corrected for by fitting a linear model to the drifting 
baseline and subtracting the linear model from the detection step data as shown 
in Figure 7.3. An alternate approach would be to calibrate the assay using C5a 
standards diluted using a matrix of pooled human serum. 
The C5a concentration in the serum sample was derived as per the standard 
operating procedure in section 2.8.1 and comparing the AUC of the corrected 
detection step data to the standard curve using purified human C5a in PBS, as 
described in Chapters 2 and 3. The HF sampling method and the standard 
sampling method described in Chapter 3 (with PBS washing between capture 
and detection steps for 200 s until baseline stability) were used to profile pooled 
serum activated by 1 mg/mL zymosan, Figure 7.4. All serum experiments were 
performed in a Level 2 laboratory following relevant risk assessments. 
 
Figure 7.4 C5a concentration profile in pooled human serum following incubation with 0 mg/mL zymosan 
(blue) and 1 mg/mL zymosan (red). Data from the novel C5a assay developed in section 3.5 using a PBS 
wash step of 200 seconds (circles) are in good agreement with HF data from the same assay using a shorter 
wash step of 100 s and drift correction (triangles). LiScAR data points were derived from the averaged 
response of n=15 assay spots. The Bland-Altman analysis in section 3.5 suggests that, on average, the C5a 
assay systematically under-estimates the C5a concentration compared to ELISA by 26% (likely due to errors 
in the concentrations of the calibration standards) and this was corrected for in the data shown. The C-ODE 
model fit (solid curves) from Chapter 5 joins the ELISA data (black circles) and the LiScAR data in a 
continuous trend. Error bars are 2SD from n=2 technical repeats.  
The LiScAR data for C5a collected using the standard and HF duty cycles show 
a similar trend in C5a production rate, although a thorough Bland-Altman analysis 
should be performed to determine the accuracy of the HF assay compared to the 
standard sampling routine. After correction for the 26% systematic error observed 
for the LiScAR C5a assay in Chapter 3, the LiScAR data closely match the ELISA 
data used to fit the C-ODE model at 60 minutes and 120 minutes following 
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activation. The HF LiScAR data provide a first look at the C5a response profile 
within 30 minutes of activation and the real-time sampling allows Complement 
activation to be studied without using EDTA and freeze-thawing of samples - 
avoiding pre-analytical activation. The real-time LiScAR data indicate that the 
model over-estimates C5a production rate in early time. Future work could repeat 
the serum activation experiments in Chapter 5 with LiScAR assays to obtain HF 
C5a data for all zymosan activations for further refinement of the C-ODE model 
in early time. 
7.3.2 Isolated Complement Pathways 
Complex fluids such as human serum present a number of challenges for 
quantitative assays of analytes, such as matrix effects of excluded volume and 
diffusion limitations, as discussed in Chapter 2. These effects may also impact 
the transferability of model parameters derived in different solutions, as 
discussed in Chapter 4. Matrix effects can be eliminated entirely by reconstructing 
the system under study with purified proteins in the same matrix used for assay 
calibration. Furthermore, subsystems of isolated proteins can be studied to 
provide missing rate constants of complex systems, as mentioned previously in 
the context of the Silicone Cell approach to modelling.  
Preliminary data were collected to demonstrate the use of the LiScAR to measure 
C3 consumption in an isolated AP of the constituent purified proteins. The fluid-
phase association of FB to C3b is known to involve Mg2+ ions, but research using 
excess EDTA has shown that the requirement for Mg2+ is not absolute and in the 
absence of divalent cations, the fluid-phase reaction rate is reduced 3-fold (257) 
allowing AP activation to proceed in PBS. An isolated AP was produced 
according to Table 7.1 in PBS, containing proteins at 1/10th of their physiological 
concentrations in serum. 
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Table 7.1 Concentrations and volumes of AP components used to produce an isolated system in PBS. 
 
C3 FB FD FH P 
stock concentration / 
mg mL-1 
5 1 1.56×10-4 1 8.04×10-2 
volume added to 
reaction mixture / µL 
14.8 9 450 15 11.2 
concentration in 
reaction mixture / mg 
mL-1 
0.148 1.80×10-2 1.4×10-4 3.00×10-2 1.80×10-3 
physiological 
concentration / mg 
mL-1 
1.48 0.180 1.40×10-3 0.300 1.8×10-2 
 
The reaction mixture was activated using zymosan as described in section 5.3.1 
and profiled with the LiScAR assay for C3, calibrated with C3 standards in PBS 
as described in section 3.5. There is a possibility of hydroxyl groups on the SAM 
spacer binding to C3b in activated serum samples and the effect on assay 
performance should be evaluated in future work. Furthermore, the capture 
antibody tethered to the sensor surface in the C3 assay is monoclonal and known 
to bind an epitope on the C3a portion of C3. The effect of C3a competition for C3 
on the LiScAR C3 assay was not tested and must be performed in future work to 
achieve accurate quantitative results. However, C3a has a mass of 9 kDa which 
should accommodate the binding of fewer polyclonal C3 detection antibodies 
than C3 (185 kDa) to produce a visible decrease in assay response. The aim of 
this experiment was to demonstrate a functional isolated AP and the C3 
consumption for the isolated AP is shown in Figure 7.5, in response to zero and 
1 mg/mL zymosan. 
257 
 
 
Figure 7.5 C3 consumption following activation of isolated AP proteins (in PBS at 1/10th of their serum 
concentrations) with zero (blue) and 1 mg/mL zymosan (red). C3 concentration data was recorded using the 
LiScAR biosensor platform and presented as a percentage relative to the starting value. The C3 assay is 
described in section 3.5 and was performed using the assay method described in 2.8.1. Data points were 
derived from the averaged response of n=15 assay spots. 
Despite the unknown contribution of C3a to the assay response, 1 mg/mL 
zymosan activation showed greater C3 consumption compared to the control 
experiment, suggesting the isolated AP was functional and activated in PBS. 
Future work on the isolated AP described here could include Mg2+ and major 
serum proteins (albumins, globulins and fibrinogen) in the reaction mixture to 
better approximate the conditions in serum and provide accurate data for 
refinement of unknown AP parameters C-ODE model. Alternatively, the isolated 
AP demonstrated here could be used to quantitatively investigate the effect of 
different constituent protein concentrations on the system response – the effect 
of doubling Properdin or removing FH for example, as simulated in the C-ODE 
model. 
The LiScAR biosensor platform is well suited to studying the isolated AP: the 
assays are quantitative, fast (<15 minutes), repeatable, multiplex and require 
small sample volumes (<1 mL). The selectivity of any novel assays should be 
thoroughly investigated in order to achieve physically relevant kinetic parameters 
and the anti-C3d/C3 antibody in Chapter 3 shows the ability to detect C3 captured 
by the anti-C3a/C3 capture antibody used for the existing assay, Appendix 1. The 
use of this antibody should provide a more selective C3 activation assay due to 
the specificity of the detection step, although the sensitivity and specificity of this 
assay requires further development and validation.  
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7.4 Conclusions 
This present work has progressed from conceptualisation of a new biomarker, 
through development of new assays and training a new mathematical model, to 
recording the biomarker values in a cohort of healthy individuals. Furthermore, 
preliminary experiments have been proposed, using the new assays to provide 
more data for refinement of the model and hypothesis testing. The combination 
of new assays and model provides a powerful new tool for studying Complement 
activation in a clinical setting: the assays enable rapid profiling of Complement 
proteins in patient serum samples outside of the clinical chemistry laboratory with 
minimal user training, whilst the C-ODE model can be continuously refined with 
new data to improve predictions of Complement response phenotypes, based on 
starting protein concentrations in patient serum. Phenotype data from 
Complement-depleted patients could now be collected in a clinical investigation 
to validate the effect size of Complement depletion predicted by the cohort data 
and C-ODE model. The present study has made demonstrable progress towards 
the pre-operative identification of patients at higher risk of nosocomial infection 
and rapid detection of infection post-operatively.  
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Appendices 
 
Appendix 1 Signal response of array surfaces to 100 nM C3 (capture step) and 100 nM anti-C3d/C3 
(detection step). The assay is described in section 3.3.2 and was performed using the assay method 
described in 2.8.1. This alternate detection antibody for intact C3 shows affinity for captured and immobilised 
C3 and exhibits no cross-reactivity with the assays for C5a and TCC. The detection step should not detect 
captured C3a. The detection step signal is significantly weaker than when C3 antiserum is used. 
 
 
Appendix 2 Standard curves of ELISA assays. Three assays are shown: a) Ba, b) C4a and c) TCC. Data 
are the mean of duplicate determinations (black). The data fit to a 5-parameter logistic curve with R2>0.999 
for all assays. High and low controls are shown in green and blue, respectively, displaying errors of <4%.  
 
Appendix 3 Table of published rate constants adopted in the C-ODE model. The majority of rate constants 
are taken from a publication describing a previous kinetic model of Complement activation in ref (185). Units 
for first order and second order rate constants are min-1 and µM-1 min-1respectively.  
Reaction Rate constant Reference / Notes 
'aC1C4 -> aC1 + C4a + C4b 300 (185) 
C4b + C2 -> C4bC2 2.5 (185) 
C4bC2 -> C4b + C2 2 (185) 
aC1 + C1inh -> C1inhC1 3.6 (185) 
C4bC2a -> C4b + C2a 0.35 (185) 
C4bC2aC3 -> C4bC2a + C3a + 
aC3b 
190 (185) 
C3 -> C3(H2O) 0.0001 (185) 
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C3(H2O)FB -> C3(H2O) + FB 0.54 assumed same as Bb 
C3(H2O)BbC3 -> C3(H2O)Bb + 
C3a + aC3b 
55 
(186) half the rate of 
alternative convertase 
C3(H2O)Bb -> C3(H2O) + Bb 0.54 (185) 
C3(H2O)FH -> C3(H2O) + FH 0.00069 
(185) Inferred from C3bFH 
-> dC3b + FH 
C3bBbC3 -> C3bBb + C3a + 
aC3b 
110 (185) 
C3bBbPC3 -> C3bBbP + C3a + 
aC3b 
190 (185) 
C3bBb -> dC3b + Bb 0.37 (185) 
C3bBbP -> dC3b + Bb + P 0.028 (185) 
aC3b + FH -> C3bFH 0.18 (185) 
C3bFH -> dC3b + FH 0.00069 (185) 
C3bFHFI -> iC3b + FH + FI 5.8 (185) 
aC3b -> dC3b 192.5 (157) t1/2=60 µs 
C4bC2a + aC3b -> 
(C4bC2a)C3b 
96 (185) 
(C4bC2a)C3b -> C4bC2a + 
dC3b 
0.28 (185) 
(C3bBb)C3b -> C3bBb + dC3b 0.23 (157) t1/2=3 min 
(C3bBb)C3bP -> C3bBbP + 
dC3b 
0.023 (157) t1/2=30 min 
(C3bBb)C3bC5 -> (C3bBb)C3b 
+ C5a + C5b 
290 (185) 
C5b + C6 -> C5bC6 3.6 (185) 
C5bC6 -> C5b + C6 5.40E-06 (185) 
C5bC6 + C7 -> C5bC6C7 44 (185) 
C5bC6C7 -> C5bC6 + C7 7.00E-05 (185) 
C5bC6C7 + C8 -> C5bC6C7C8 66 (185) 
C5bC6C7C8 -> C5bC6C7 + C8 0.000315 (185) 
C5bC6C7C8 + C9 -> TCC 170 (185) 
TCC -> C5bC6C7C8 + C9 5.20E-05 (185) 
C4BP + C4b -> C4BPC4b 12 (185) 
C4BPC4b -> C4BP + C4b 0.96 (185) 
 
Appendix 4 Table of starting concentrations for all species in the C-ODE model. Activation products were 
given starting values of zero unless measured in section 5.4.  
Species name Starting concentration / uM Reference / Notes 
(C3bBb)C3b 0 activation product 
(C3bBb)C3bC5 0 activation product 
(C3bBb)C3bP 0 activation product 
(C3bBb)C3bPC5 0 activation product 
(C4bC2a)C3b 0 activation product 
(C4bC2a)C3bC5 0 activation product 
A 0-0.02 activation stimulus 
Ba 0.124 measured 
Bb 0 activation product 
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C1 0.38 (569) 
C1inh 1.9 (249) 
C1inhC1 0 activation product 
C2 0.25 (571) 
C2a 0 activation product 
C2b 0 activation product 
C3 8 (249) 
C3(H2O) 0 activation product 
C3(H2O)Bb 0 activation product 
C3(H2O)BbC3 0 activation product 
C3(H2O)FB 0 activation product 
C3(H2O)FBFD 0 activation product 
C3(H2O)FH 0 activation product 
C3(H2O)FHFI 0 activation product 
C3a 0.685 measured 
C3bBb 0 activation product 
C3bBbC3 0 activation product 
C3bBbP 0 activation product 
C3bBbPC3 0 activation product 
C3bP 0 activation product 
C3bFB 0 activation product 
C3bFBP 0 activation product 
C3bFBFD 0 activation product 
C3bFBFDP 0 activation product 
C3bFH 0 activation product 
C3bFHFI 0 activation product 
C4 2 (593) 
C4BP 0.42 (611) 
C4BPC4b 0 activation product 
C4BPC4bFI 0 activation product 
C4a 0.801 measured 
C4b 0 activation product 
C4bC2 0 activation product 
C4bC2a 0 activation product 
C4bC2aC3 0 activation product 
C5 0.34 (566) 
C5a 0.001 measured 
C5b 0 activation product 
C5bC6 0 activation product 
C5bC6C7 0 activation product 
C5bC6C7C8 0 activation product 
C6 0.61 (566) 
C7 0.61 (566) 
C8 0.36 (566) 
C9 0.85 (566) 
MBL 0.014 (586) 
P 0.35 (533) 
TCC 0.006 measured 
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aC1 0 activation product 
aC1C4 0 activation product 
aC1C4bC2 0 activation product 
aC3b 0 activation product 
aMBL 0 activation product 
aMBLC1inh 0 activation product 
aMBLC4 0 activation product 
aMBLC4bC2 0 activation product 
dC1 0 activation product 
dC3(H2O) 0 activation product 
dC3b 0 activation product 
dC4b 0 activation product 
dMBL 0 activation product 
FB 1.9 (571) 
FD 0.058 (566) 
FH 1.94 (579) 
FI 0.34 (579) 
iC3b 0 activation product 
sCR1 0.00017 (588) 
sCR1C3b 0 activation product 
sCR1C3bfI 0 activation product 
sCR1C4b 0 activation product 
sCR1C4bfI 0 activation product 
 
Appendix 5 Table of reactions in the C-ODE model with unknown kinetic constants. The results of model 
fitting are shown, constrained within upper and lower bounds and starting from an initial guess value 
corresponding to median enzyme kinetics. Units for first order and second order rate constants are min-1 and 
µM-1 min-1respectively. 
Reaction Initial guess 
Lower 
bound 
Upper 
bound 
Fitted 
value 
C1 -> aC1 0.01 6.67E-04 0.15 7.26E-03 
A + C1 -> A + aC1 1 0.001 1000 166.42 
aC1 -> C1 0.06 na na 0.06 
aC1 + C4 -> aC1C4 6 0.4 90 8.85 
aC1C4 -> aC1 + C4 0.06 na na 0.06 
aC1 + C4bC2 -> 
aC1C4bC2 
6 0.4 90 24.86 
aC1C4bC2 -> aC1 + 
C4bC2 
0.06 na na 0.06 
aC1C4bC2 -> C4bC2a + 
C2b + aC1 
840 56 12600 911.04 
A + MBL -> A + aMBL 1 0.001 1000 1.87 
aMBL -> MBL 0.06 na na 0.06 
aMBL + C4 -> aMBLC4 6 0.4 90 4.57 
aMBLC4 -> aMBL + C4 0.06 na na 0.06 
aMBLC4 -> aMBL + C4a + 
C4b 
840 56 12600 100.76 
aMBL + C4bC2 -> 
aMBLC4bC2 
6 0.4 90 48.46 
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aMBLC4bC2 -> aMBL + 
C4bC2 
0.06 na na 0.06 
aMBLC4bC2 -> C4bC2a + 
C2b + aMBL 
840 56 12600 225.34 
aMBL + C1inh -> 
aMBLC1inh 
3.6 0.24 54 12.69 
C4bC2a + C3 -> 
C4bC2aC3 
6 0.4 90 2.27 
C4bC2aC3 -> C4bC2a + 
C3 
0.06 na na 0.06 
sCR1 + aC3b -> sCR1C3b 6 0.4 90 45.99 
sCR1 + C4b -> sCR1C4b 6 0.4 90 9.65 
sCR1 + C4bC2a -> 
sCR1C4b + C2a 
6 0.4 90 12.74 
C4BP + C4bC2a -> 
C4BPC4b + C2a 
6 0.4 90 6.21 
sCR1C3b + fI -> 
sCR1C3bfI 
6 0.4 90 17.48 
sCR1C4b + fI -> 
sCR1C4bfI 
6 0.4 90 4.64 
C4BPC4b + fI -> 
C4BPC4bfI 
6 0.4 90 3.44 
sCR1C3bfI -> sCR1 + 
iC3b + fI 
840 56 12600 311.72 
sCR1C4bfI -> sCR1 + 
dC4b + fI 
840 56 12600 727.20 
C4BPC4bfI -> C4BP + 
dC4b + fI 
840 56 12600 2988.82 
C3(H2O) + FB -> 
C3(H2O)FB 
6 0.4 90 14.44 
C3(H2O)FB + FD -> 
C3(H2O)FBFD 
6 0.4 90 23.48 
C3(H2O)FBFD -> 
C3(H2O)FB + FD 
0.06 na na 0.06 
C3(H2O)FBFD -> 
C3(H2O)Bb + Ba + FD 
840 56 12600 395.52 
C3(H2O)Bb + C3 -> 
C3(H2O)BbC3 
6 0.4 90 19.29 
C3(H2O)BbC3 -> 
C3(H2O)Bb + C3 
0.06 na na 0.06 
C3(H2O) + FH -> 
C3(H2O)FH 
6 0.4 90 4.28 
C3(H2O)FB + FH -> 
C3(H2O)FH + FB 
6 0.4 90 3.89 
C3(H2O)Bb + FH -> 
C3(H2O)FH + Bb 
6 0.4 90 5.29 
C3(H2O)FH + FI -> 
C3(H2O)FHFI 
6 0.4 90 9.26 
C3(H2O)FHFI -> 
dC3(H2O) + FH + FI 
840 56 12600 730.03 
A + C3 -> A + C3(H2O) 1 0.001 1000 0.09 
aC3b + FB -> C3bFB 6 0.4 90 6.29 
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C3bFB -> dC3b + FB 0.06 na na 0.06 
C3bFB + FD -> C3bFBFD 6 0.4 90 14.15 
C3bFBFD -> C3bFB + FD 0.06 na na 0.06 
C3bFBFD -> C3bBb + Ba 
+ FD 
840 56 12600 77.35 
C3bBb + P -> C3bBbP 6 0.4 90 23.59 
aC3b + P -> C3bP 6 0.4 90 30.01 
C3bP -> dC3b + P 0.06 na na 0.06 
C3bP + FB -> C3bFBP 6 0.4 90 18.71 
C3bFBP -> C3bP + FB 0.06 na na 0.06 
C3bFBP + FD -> 
C3bFBFDP 
6 0.4 90 20.99 
C3bFBFDP -> C3bFBP + 
FD 
0.06 na na 0.06 
C3bFBFDP -> C3bBbP + 
Ba + FD 
840 56 12600 735.42 
C3bBb + C3 -> C3bBbC3 6 0.4 90 2.98 
C3bBbC3 -> C3bBb + C3 0.06 na na 0.06 
C3bBbP + C3 -> 
C3bBbPC3 
6 0.4 90 5.37 
C3bBbPC3 -> C3bBbP + 
C3 
0.06 na na 0.06 
sCR1 + C3bBb -> 
sCR1C3b + Bb 
6 0.4 90 3.68 
sCR1 + C3bBbP -> 
sCR1C3b + Bb + P 
6 0.4 90 4.37 
C3bBb + FH -> C3bFH + 
Bb 
6 0.4 90 5.62 
C3bBbP + FH -> C3bFH + 
Bb + P 
6 0.4 90 6.65 
C3bFH + FI -> C3bFHFI 6 0.4 90 5.01 
C3bBb + aC3b -> 
(C3bBb)C3b 
6 0.4 90 14.52 
C3bBbP + aC3b -> 
(C3bBb)C3bP 
6 0.4 90 47.79 
(C4bC2a)C3b + C5 -> 
(C4bC2a)C3bC5 
6 0.4 90 47.60 
(C4bC2a)C3bC5 -> 
(C4bC2a)C3b + C5 
0.06 na na 0.06 
(C4bC2a)C3bC5 -> 
(C4bC2a)C3b + C5a + 
C5b 
840 56 12600 831.45 
(C3bBb)C3b + C5 -> 
(C3bBb)C3bC5 
6 0.4 90 6.76 
(C3bBb)C3bC5 -> 
(C3bBb)C3b + C5 
0.06 na na 0.06 
(C3bBb)C3bP + C5 -> 
(C3bBb)C3bPC5 
6 0.4 90 47.97 
(C3bBb)C3bPC5 -> 
(C3bBb)C3bP + C5 
0.06 na na 0.06 
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(C3bBb)C3bPC5 -> 
(C3bBb)C3bP + C5a + 
C5b 
840 56 12600 59.50 
dC3b + FH -> C3bFH 6 0.4 90 1.13 
dC3b + sCR1 -> sCR1C3b 6 0.4 90 42.72 
 
Appendix 6 Table of reactions in the C-ODE model ordered by sensitivity (the effect on the RMSE of the 
model fit). 
Reaction Sensitivity ( RMSE per 1% increase) 
aC1 + C1inh -> C1inhC1 2.19E-02 
aC3b -> dC3b 2.02E-02 
(C3bBb)C3bP -> C3bBbP + dC3b 1.24E-02 
C3bBbP + FH -> C3bFH + Bb + P 9.47E-03 
aC1 + C4 -> aC1C4 8.39E-03 
C3 -> C3(H2O) 8.18E-03 
(C3bBb)C3bP + C5 -> 
(C3bBb)C3bPC5 
6.60E-03 
C3bBbP + aC3b -> (C3bBb)C3bP 5.44E-03 
C3(H2O)Bb + FH -> C3(H2O)FH + 
Bb 
3.78E-03 
A + C3 -> A + C3(H2O) 3.77E-03 
C4BP + C4b -> C4BPC4b 3.20E-03 
C4bC2a + C3 -> C4bC2aC3 3.16E-03 
C4BP + C4bC2a -> C4BPC4b + 
C2a 
3.10E-03 
aC1 + C4bC2 -> aC1C4bC2 3.10E-03 
C4b + C2 -> C4bC2 3.05E-03 
C3(H2O)FB + FD -> 
C3(H2O)FBFD 
2.98E-03 
C4bC2 -> C4b + C2 2.84E-03 
(C4bC2a)C3b -> C4bC2a + dC3b 1.90E-03 
C3(H2O)FB + FH -> C3(H2O)FH + 
FB 
1.73E-03 
C4BPC4b + FI -> C4BPC4bfI 1.67E-03 
aC3b + P -> C3bP 1.52E-03 
C3(H2O)Bb + C3 -> 
C3(H2O)BbC3 
1.43E-03 
C3bBb + FH -> C3bFH + Bb 1.14E-03 
(C3bBb)C3bPC5 -> (C3bBb)C3bP 
+ C5a + C5b 
1.10E-03 
C3bBb + P -> C3bBbP 1.02E-03 
C4BPC4b -> C4BP + C4b 7.25E-04 
A + C1 -> A + aC1 7.05E-04 
C4bC2a + aC3b -> (C4bC2a)C3b 6.23E-04 
C3(H2O) + FB -> C3(H2O)FB 6.12E-04 
aC3b + FB -> C3bFB 5.37E-04 
(C4bC2a)C3b + C5 -> 
(C4bC2a)C3bC5 
4.64E-04 
C3bBbP + C3 -> C3bBbPC3 3.38E-04 
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C3(H2O) + FH -> C3(H2O)FH 1.78E-04 
C3bFH + FI -> C3bFHFI 1.67E-04 
C1 -> aC1 1.44E-04 
C3bFHFI -> iC3b + FH + FI 7.67E-05 
C3(H2O)Bb -> C3(H2O) + Bb 7.20E-05 
aC1C4 -> aC1 + C4a + C4b 7.13E-05 
C3bFB + FD -> C3bFBFD 5.98E-05 
C3bFBP + FD -> C3bFBFDP 5.20E-05 
C3(H2O)FH + FI -> C3(H2O)FHFI 4.40E-05 
aC1 -> C1 3.86E-05 
C3(H2O)BbC3 -> C3(H2O)Bb + 
C3a + aC3b 
3.55E-05 
C3bBb -> dC3b + Bb 3.46E-05 
C3bBb + C3 -> C3bBbC3 2.48E-05 
aMBL + C4 -> aMBLC4 2.46E-05 
C3bFB -> dC3b + FB 2.33E-05 
C3(H2O)FB -> C3(H2O) + FB 2.33E-05 
dC3b + FH -> C3bFH 2.13E-05 
C4bC2aC3 -> C4bC2a + C3a + 
aC3b 
2.04E-05 
aC3b + FH -> C3bFH 1.90E-05 
aMBL + C1inh -> aMBLC1inh 1.67E-05 
C5b + C6 -> C5bC6 1.54E-05 
C3bBbP -> dC3b + Bb + P 1.45E-05 
A + MBL -> A + aMBL 8.08E-06 
(C3bBb)C3bPC5 -> (C3bBb)C3bP 
+ C5 
7.76E-06 
C3bP -> dC3b + P 6.95E-06 
C3bP + FB -> C3bFBP 6.51E-06 
C4bC2a -> C4b + C2a 6.36E-06 
aMBL + C4bC2 -> aMBLC4bC2 5.11E-06 
C5bC6C7 + C8 -> C5bC6C7C8 4.29E-06 
(C3bBb)C3b -> C3bBb + dC3b 2.83E-06 
C3bBb + aC3b -> (C3bBb)C3b 2.08E-06 
(C3bBb)C3b + C5 -> 
(C3bBb)C3bC5 
2.01E-06 
C3bFBFD -> C3bBb + Ba + FD 1.96E-06 
C3(H2O)BbC3 -> C3(H2O)Bb + 
C3 
1.48E-06 
C5bC6 + C7 -> C5bC6C7 1.11E-06 
sCR1 + C4b -> sCR1C4b 1.07E-06 
C3(H2O)FBFD -> C3(H2O)Bb + 
Ba + FD 
9.76E-07 
aMBLC4 -> aMBL + C4a + C4b 7.35E-07 
sCR1 + C4bC2a -> sCR1C4b + 
C2a 
6.41E-07 
C4BPC4bfI -> C4BP + dC4b + fI 5.49E-07 
sCR1 + aC3b -> sCR1C3b 4.36E-07 
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sCR1 + C3bBbP -> sCR1C3b + 
Bb + P 
3.98E-07 
C3bBbC3 -> C3bBb + C3a + aC3b 3.75E-07 
C3bFBP -> C3bP + FB 3.75E-07 
aMBLC4bC2 -> C4bC2a + C2b + 
aMBL 
3.19E-07 
dC3b + sCR1 -> sCR1C3b 2.93E-07 
C4bC2aC3 -> C4bC2a + C3 2.93E-07 
aC1C4bC2 -> C4bC2a + C2b + 
aC1 
2.87E-07 
C3bFBFDP -> C3bBbP + Ba + FD 2.65E-07 
C3(H2O)FHFI -> dC3(H2O) + FH 
+ FI 
2.38E-07 
sCR1C4b + FI -> sCR1C4bFI 2.34E-07 
C5bC6C7C8 + C9 -> TCC 1.88E-07 
sCR1C3b + FI -> sCR1C3bfI 1.81E-07 
(C4bC2a)C3bC5 -> (C4bC2a)C3b 
+ C5a + C5b 
1.74E-07 
C3(H2O)FH -> C3(H2O) + FH 1.60E-07 
C3bBbPC3 -> C3bBbP + C3a + 
aC3b 
1.57E-07 
C3(H2O)FBFD -> C3(H2O)FB + 
FD 
9.23E-08 
(C4bC2a)C3bC5 -> (C4bC2a)C3b 
+ C5 
7.27E-08 
aMBL -> MBL 7.10E-08 
sCR1 + C3bBb -> sCR1C3b + Bb 6.29E-08 
C3bBbPC3 -> C3bBbP + C3 4.09E-08 
C3bFBFD -> C3bFB + FD 3.64E-08 
aC1C4bC2 -> aC1 + C4bC2 3.04E-08 
aMBLC4 -> aMBL + C4 1.91E-08 
C3bFH -> dC3b + FH 1.02E-08 
aC1C4 -> aC1 + C4 8.67E-09 
sCR1C3bFI -> sCR1 + iC3b + FI 7.44E-09 
sCR1C4bFI -> sCR1 + dC4b + FI 5.64E-09 
aMBLC4bC2 -> aMBL + C4bC2 5.06E-09 
(C3bBb)C3bC5 -> (C3bBb)C3b + 
C5a + C5b 
4.86E-09 
C3bBbC3 -> C3bBb + C3 4.39E-09 
(C3bBb)C3bC5 -> (C3bBb)C3b + 
C5 
2.29E-09 
C3bFBFDP -> C3bFBP + FD 1.28E-09 
C5bC6C7 -> C5bC6 + C7 8.38E-10 
C5bC6C7C8 -> C5bC6C7 + C8 5.62E-10 
TCC -> C5bC6C7C8 + C9 5.02E-10 
C5bC6 -> C5b + C6 3.18E-11 
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Appendix 7 Table of species in the C-ODE model ordered by sensitivity (the effect on the RMSE of the model 
fit). 
Species Sensitivity ( RMSE per 1% increase) 
C5a 0.05161 
C3 0.038944 
FH 0.035733 
C3a 0.03158 
TCC 0.030827 
C1 0.027729 
C1inh 0.025781 
Ba 0.017575 
C4BP 0.016905 
C4 0.013029 
C5 0.004588 
C2 0.004214 
FD 0.003385 
FB 0.002252 
P 0.002102 
FI 0.001433 
C4a 0.001145 
MBL 2.87E-05 
C6 2.85E-05 
C8 3.14E-06 
sCR1 1.68E-06 
C7 1.11E-06 
C9 1.97E-07 
(C3bBb)C3b 0 
(C3bBb)C3bC5 0 
(C3bBb)C3bP 0 
(C3bBb)C3bPC5 0 
(C4bC2a)C3b 0 
(C4bC2a)C3bC5 0 
Bb 0 
C1inhC1 0 
C2a 0 
C2b 0 
C3(H2O) 0 
C3(H2O)Bb 0 
C3(H2O)BbC3 0 
C3(H2O)FB 0 
C3(H2O)FBFD 0 
C3(H2O)FH 0 
C3(H2O)FHFI 0 
C3bBb 0 
C3bBbC3 0 
C3bBbP 0 
C3bBbPC3 0 
C3bP 0 
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C3bFB 0 
C3bFBP 0 
C3bFBFD 0 
C3bFBFDP 0 
C3bFH 0 
C3bFHFI 0 
C4BPC4b 0 
C4BPC4bFI 0 
C4b 0 
C4bC2 0 
C4bC2a 0 
C4bC2aC3 0 
C5b 0 
C5bC6 0 
C5bC6C7 0 
C5bC6C7C8 0 
aC1 0 
aC1C4 0 
aC1C4bC2 0 
aC3b 0 
aMBL 0 
aMBLC1inh 0 
aMBLC4 0 
aMBLC4bC2 0 
dC3(H2O) 0 
dC3b 0 
dC4b 0 
iC3b 0 
sCR1C3b 0 
sCR1C3bFI 0 
sCR1C4b 0 
sCR1C4bFI 0 
 
306 
 
 
Appendix 8 Consent form for participants in the clinical investigation described in Chapter 6.  
 
